<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange
Commission on October 14, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.&nbsp;333-___________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT<BR>
UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>LIFESCI
ACQUISITION II CORP.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;(Exact name of registrant as specified in its charter)</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>6770</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>84-4278203</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of <BR>
incorporation or organization)</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">(Primary Standard Industrial <BR>
Classification Code Number)</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer <BR>
Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>250 W 55th St #3401</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(646) 889-1200<BR>
</B>(Address, including zip code, and telephone number, including area code, of registrant&rsquo;s principal executive&nbsp;offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Andrew McDonald</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>250 W 55th St #3401,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(646) 889-1200<BR>
</B>(Name, address, including zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Copies to:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; padding-bottom: 2.25pt; text-align: center"><B>Mitchell S. Nussbaum,&nbsp;Esq. <BR>
Giovanni Caruso,&nbsp;Esq. <BR>
Loeb&nbsp;&amp; Loeb LLP <BR>
345 Park Avenue <BR>
New York, New York 10154 <BR>
(212) 407-4000 <BR>
(212) 407-4990 &mdash; Facsimile</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="width: 49%; padding-bottom: 2.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Douglas S. Ellenoff,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Stuart Neuhauser,&nbsp;Esq.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ellenoff Grossman&nbsp;&amp; Schole LLP<BR>
        1345 Avenue of the Americas</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10105<BR>
        (212) 370-1300<BR>
        (212) 370-7889 &mdash; Facsimile</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Approximate date
of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If any of the securities
being registered on this Form&nbsp;are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities
Act of 1933 check the following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form&nbsp;is
filed to register additional securities for an offering pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form&nbsp;is
a post-effective amendment filed pursuant to Rule&nbsp;462(c)&nbsp;under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If this Form&nbsp;is
a post-effective amendment filed pursuant to Rule&nbsp;462(d)&nbsp;under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule&nbsp;12b-2 of the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; padding-bottom: 2pt; text-align: justify">Large accelerated filer</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 29%; padding-bottom: 2pt; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 25%; padding-bottom: 2pt; text-align: justify">Accelerated filer</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="width: 23%; padding-bottom: 2pt; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2pt; text-align: justify">Non-accelerated filer</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; text-align: justify">Smaller reporting company</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; text-align: justify">Emerging growth company</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2pt; text-align: justify"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>CALCULATION
OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Title of Each Class&nbsp;of Security being registered</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount <BR> Being Registered</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Proposed<BR> Maximum <BR> Offering<BR> Price per<BR>
 Security<SUP>(1)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Proposed Maximum <BR> Aggregate<BR>
 Offering <BR> Price<SUP>(1)(2)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount of <BR> Registration <BR> Fee</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 47%; padding-left: 9pt; text-indent: -9pt"><FONT STYLE="font-size: 10pt">Common stock, $0.0001 par
    value<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">8,625,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">86,250,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">9,410</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 48%">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right; width: 10%">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; width: 10%">86,250,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right; width: 10%">9,410</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;&nbsp;&nbsp;Estimated solely for the purpose of calculating
the registration fee pursuant to Rule&nbsp;457(o)&nbsp;under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(2)&nbsp;&nbsp;&nbsp;Includes the aggregate of 7,500,000 shares of common stock to
be issued to public stockholders in the public offering, and 1,125,000 shares of common stock which may be issued upon exercise
of a 45-day option granted to the Underwriters to cover over-allotments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section&nbsp;8(a)&nbsp;of the Securities Act of 1933, as amended, or until the Registration Statement shall become
effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Registration Statement contains
a prospectus relating to the initial public offering of shares of common stock of LifeSci Acquisition II Corp. for $10.00 per
share. This Registration Statement also contains a prospectus relating to offer and sales of shares of LifeSci Acquisition II
Corp. common stock in connection with certain market making transactions that may be effected by LifeSci Capital LLC in the
secondary market for 30 days following the date of this prospectus. The complete prospectus relating to the initial public
offering of our common stock (the &ldquo;IPO Prospectus&rdquo;) follows immediately after this Explanatory Note. Following
the IPO Prospectus are certain pages&nbsp;of the prospectus relating solely to such market making transactions (together with
the remainder of the prospectus as modified as indicated below, the &ldquo;Market Making Prospectus&rdquo;), including an
alternate front and back cover page, an alternate table of contents and alternate sections entitled
 &ldquo;Summary&nbsp;&mdash;&nbsp;The Offering,&rdquo; &ldquo;Use of Proceeds&rdquo; and &ldquo;Plan of Distribution.&rdquo;
Each of such alternate pages&nbsp;has been marked &ldquo;Alternate Page&nbsp;for Market Making Prospectus.&rdquo; The Market
Making Prospectus will not include the information in the sections of the IPO Prospectus entitled &ldquo;Risk
Factors&nbsp;&mdash;&nbsp;Our initial stockholders paid nominal purchase price for their founder shares, and, accordingly,
you will experience immediate and substantial dilution from the purchase of our common stock.,&rdquo; &ldquo;Risk
Factors&nbsp;&mdash;&nbsp;The determination of the offering price of our shares of common stock and the size of this offering
is more arbitrary than the pricing of securities and size of an offering of an operating company in a particular industry.
You may have less assurance, therefore, that the offering price of our shares of common stock properly reflects the value of
such shares than you would have in a typical offering of an operating company.,&rdquo; &ldquo;Dilution,&rdquo;
 &ldquo;Capitalization,&rdquo; &ldquo;Use of Proceeds&rdquo; and &ldquo;Underwriting (Conflict of Interest).&rdquo; All other
sections of the IPO Prospectus are to be used in the Market Making Prospectus. A complete version of each of the IPO
Prospectus and the Market Making Prospectus will be filed with the U.S. Securities and Exchange Commission in accordance with
Rule&nbsp;424 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"><B>The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="color: #D2232A"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="width: 54%; padding-bottom: 2.25pt; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; color: #D2232A"><B>SUBJECT&nbsp;TO&nbsp;COMPLETION,&nbsp;DATED&nbsp;OCTOBER
                                         14,&nbsp;2020</B></P> </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIFESCI ACQUISITION II CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7,500,000 SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci Acquisition
II Corp., which we refer to as &ldquo;we,&rdquo; &ldquo;us&rdquo; or &ldquo;our company,&rdquo; is a newly organized blank check
company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock
purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities, which
we refer to throughout this prospectus as our &ldquo;initial business combination.&rdquo; Although we are not limited to a particular
industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that
have their primary operations located in North America in the healthcare industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This is an initial
public offering of our securities. We are offering 7,500,000 shares of common stock at an offering price of $10.00 per share. Unlike
certain other SPAC IPOs, investors in this offering will not receive warrants that would become exercisable following completion
of our initial business combination. We have granted LifeSci Capital LLC (&ldquo;LifeSci Capital&rdquo;), the representative of
the underwriters, a 45-day option to purchase up to an additional 1,125,000 shares of common stock (over and above the 7,500,000
shares referred to above) solely to cover over-allotments, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will provide the holders of our outstanding shares of common
stock that were sold in this offering with the opportunity to redeem their shares of common stock upon the consummation of our
initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust
account described below, including interest (net of taxes payable), divided by the number of then outstanding shares of common
stock that were sold in this offering, which we refer to as our &ldquo;public shares.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have 24 months
to consummate our initial business combination. If we are unable to consummate our initial business combination within the above
time period, we will distribute the aggregate amount then on deposit in the trust account, pro rata to our public stockholders,
by way of the redemption of their shares and thereafter cease all operations except for the purposes of winding up of our affairs,
as further described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci Holdings LLC,
our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo; at $0.90
per warrant for an aggregate purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common stock
at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our
initial business combination and 12 months from the closing of this offering and will expire five years after the effective date
of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement basis
simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that if
the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the trust
account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&nbsp;1,
2020, LifeSci Holdings LLC, our sponsor, purchased 2,156,250 shares, which we refer to herein as &ldquo;founder shares&rdquo; or
 &ldquo;insider shares,&rdquo; for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred
215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder shares include an aggregate
of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters&rsquo; over-allotment option is not
exercised in full or in part, with LifeSci Holdings LLC to forfeit up to 253,125 shares and Chardan Healthcare Investments LLC
to forfeit up to 28,125 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is presently no public market for our common stock. We
intend to apply to have our common stock listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &ldquo;LSAQ&rdquo; on
or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq.
We cannot assure you that our securities will continue to be listed on Nasdaq after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 and will therefore be subject to reduced public
company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Investing in our
securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;18 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Price to Public</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Underwriting<BR>
Discount and<BR>
Commissions<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Proceeds, Before<BR>
Expenses, to us</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 45%"><FONT STYLE="font-size: 10pt"><B>Per share</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">0.20</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 15%; text-align: right"><FONT STYLE="font-size: 10pt">9.80</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">75,000,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,500,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73,500,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 24px">(1)</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Includes $[__] payable to [__] for acting as a qualified independent underwriter. Please see the section titled &ldquo;Underwriting&rdquo; for further information relating to the underwriting arrangements agreed to between us and the underwriters in this offering.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon consummation
of the offering, $10.00 per share sold to the public in this offering (whether or not the over-allotment option has been exercised
in full or part) will be deposited into a United States-based trust account with Continental Stock Transfer&nbsp;&amp;
Trust Company acting as trustee. Except as described in this prospectus, these funds will not be released to us until the earlier
of the completion of our initial business combination and our redemption of the public shares upon our failure to consummate a
business combination within the required period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The underwriters
are offering the shares of common stock on a firm commitment basis. LifeSci Capital LLC, acting as the representative of the underwriters,
expects to deliver the shares of common stock to purchasers on or about <B>[__], </B>2020<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>LifeSci Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[__], 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIFESCI ACQUISITION II CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><B>Page</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 87%"><A HREF="#S1_001">SUMMARY</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><A HREF="#S1_001">1</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_002">SUMMARY FINANCIAL DATA</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_002">17</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_003">RISK FACTORS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_003">18</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_004">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_004">38</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_005">USE OF PROCEEDS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_005">39</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_006">DIVIDEND POLICY</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_006">42</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_007">DILUTION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_007">43</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_008">CAPITALIZATION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_008">44</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_009">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
    OF OPERATIONS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_009">45</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_010">PROPOSED BUSINESS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_010">49</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_011">MANAGEMENT</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_011">66</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_012">PRINCIPAL STOCKHOLDERS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_012">73</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_013">CERTAIN TRANSACTIONS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_013">75</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_014">DESCRIPTION OF SECURITIES</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_014">77</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_015">SECURITIES ELIGIBLE FOR FUTURE SALE</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_015">80</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_016">UNDERWRITING (CONFLICTS OF INTEREST)</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_016">82</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_017">LEGAL MATTERS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_017">87</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#S1_018">EXPERTS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_018">87</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_019">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_019">87</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#S1_020">INDEX TO FINANCIAL STATEMENTS</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><A HREF="#S1_020">F-1</A></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">i</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_001"></A>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>This summary only
highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all
of the information that you should consider in making an investment decision. You should read this entire prospectus carefully,
including the information under &ldquo;Risk Factors&rdquo; and our financial statements and the related notes included elsewhere
in this prospectus, before investing. Unless otherwise stated in this prospectus:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 24px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 24px"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>&ldquo;we,&rdquo; &ldquo;us&rdquo; &ldquo;our&rdquo; or
    &ldquo;our company&rdquo; refers to LifeSci Acquisition II Corp.;</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&ldquo;initial stockholders&rdquo;
    refers to all of our stockholders immediately prior to the date of this prospectus, including our sponsor and officers and
    directors to the extent they hold such shares;</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&ldquo;founder shares&rdquo; refers
    to the 2,156,250 shares of common stock held by our sponsor, our directors, and affiliates of our management team prior to
    this offering (including up to an aggregate of 281,250 shares of common stock subject to forfeiture to the extent that the
    underwriters&rsquo; over-allotment option is not exercised in full or in part);</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><I>&ldquo;private warrants&rdquo; refers
    to the warrants we are selling privately to our sponsor and/or its designees upon consummation of this offering;</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>&ldquo;sponsor&rdquo; refers to LifeSci Holdings LLC,
    an entity affiliated with LifeSci Capital LLC;</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt"><I>the term &ldquo;public stockholders&rdquo;
    means the holders of shares of common stock being sold in this public offering, or &ldquo;public shares,&rdquo; whether they
    are purchased in the public offering or in the aftermarket, including any of our initial stockholders to the extent that they
    purchase such public shares (except that our initial stockholders will not have conversion or tender rights with respect to
    any public shares they own); and</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>the information in this prospectus assumes that the underwriters
    will not exercise their over-allotment option.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Certain financial
information contained in this prospectus has been rounded and, as a result, certain totals shown in this prospectus may not equal
the arithmetic sum of the figures that should otherwise aggregate to those totals.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>You should rely
only on the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide
you with different information. We are not, and the underwriters are not, making an offer of these securities in any jurisdiction
where the offer is not permitted.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a blank check
company formed under the laws of the State of Delaware on December&nbsp;18, 2019. We were formed for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses,
which we refer to throughout this prospectus as our initial business combination. Although there is no restriction or limitation
on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation.
We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology,
digital health, and healthcare services sectors, which aligns with our management team&rsquo;s experience in healthcare investing
and drug development. At the time of preparing this prospectus, we have not identified any specific business combination, nor has
anyone on our behalf initiated or engaged in any substantive discussions, formal or otherwise, related to such a transaction. Our
efforts to date are limited to organizational activities related to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Sponsor and Competitive Advantages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sponsor is an affiliate
of LifeSci Capital LLC, a research-driven investment bank with deep domain expertise in the life sciences, LifeSci Advisors LLC,
an investor relations and public relations company in the life sciences industry with comprehensive solutions to communications
and investor outreach, and LifeSci Venture Management LLC, a corporate venture capital firm that seeks to invest in biotech and
health sectors, collectively &ldquo;LifeSci&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as a boutique investment bank is unique in that it exclusively serves corporate clients that are emerging life science companies
that discover, develop, and commercialize innovative products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as an investor relations and public relations firm is unique in that it provides companies in the life sciences industry
with comprehensive solutions to communications and investor outreach. LifeSci assists companies in increasing visibility within
the investment community and educating investors on opportunities offered by these companies. LifeSci&rsquo;s core capabilities
include non-deal roadshow planning and execution, KOL Events/R&amp;D Days, corporate communications, and public relations through
its affiliate LifeSci Public Relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as a venture capital firm is unique in that it focuses on pre-public institutional rounds of transformational healthcare
companies managed by exceptional founder/entrepreneurs. LifeSci&rsquo;s investment principals have broad-ranging life sciences
experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research,
and bench research - both basic science and applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s team
is comprised of individuals with medical and advanced scientific training and legal and banking experience, enabling a deeply differentiated
approach to research and idea generation. Complementing LifeSci&rsquo;s scientific insight and industry relationships is LifeSci&rsquo;s
business team, whose members include portfolio managers, corporate managers, and investment bankers who actively engage with banks
and academic institutions, cultivating strong relationships and expanding their network of key contacts and syndicate partners.
We believe the well-rounded nature of the team, strengthened by strong ties across industry, academia, banking platforms, and unaffiliated
investor relationships, will enhance our management team&rsquo;s ability to source viable prospective target businesses, capitalize
them, and ensure public-market readiness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent directors
have extensive experience in clinical medicine, development and regulatory, operational, and management leadership within the healthcare
and financial industries. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective
candidates and successfully execute our initial business combination. Following the completion of our initial transaction, we believe
our independent directors will fortify our ongoing operations by providing sound and experienced counsel on potential further acquisitions,
divestitures, corporate strategy, and human resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
management team is equipped with the knowledge, experience, capital and human resources, and sustainable corporate governance practices
to pursue unique opportunities that will offer attractive risk-adjusted returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management team
is led by Andrew McDonald, Co-Founder of LifeSci Advisors and LifeSci Capital, Michael Rice, Co-Founder of LifeSci Advisors and
LifeSci Capital, and David Dobkin, Managing Director of LifeSci Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
company&rsquo;s philosophical alignment with LifeSci, and our ability to leverage the rigorous and comprehensive scientific and
financial analysis that LifeSci is known for, provides us with a strong competitive advantage. LifeSci focuses on dynamic sectors
of healthcare with great potential to transform the healthcare industry: biotechnology, specialty pharmaceuticals, medical devices,
digital health, information technology, and healthcare services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, LifeSci&rsquo;s
investors relations hosted over 1,500 meetings in 27 key regions in the United States and over 500 meetings in 16 key regions throughout
Europe. In 2019, LifeSci&rsquo;s Public Relations group secured over 1,300 media hits for their clients, with more than 100 million
viewers and readers globally, and wrote over 4,000 social media posts. LifeSci Venture&rsquo;s first fund in 2017 has invested
in 12 companies alongside large dedicated healthcare funds and has launched its second fund in the third quarter of 2019. LifeSci&rsquo;s
investment bank has executed over 50 transactions since inception, in which over 50% were repeat or Lead Managed. LifeSci&rsquo;s
investment bank core capabilities include experienced-based investment banking advisory, varied capital raising abilities, industry
insight and accessibility, global institutional coverage and reach, equity research, and client empowerment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci's investor
relations presence has continued to expand year-over-year. In 2019, LifeSci Advisors conducted 4,602 one-on-one non-deal roadshow
(NDR) investor meetings, 140 key opinion leader (KOL) events, 594 meetings with high net worth (HNW) individuals and financial
advisors, and 4,160 one-on-one meetings at the J.P. Morgan healthcare conference (JPM), as compared to 4,105 NDR meetings, 130
KOL events, 568 HNW meetings, and 2,700 one-on-one meetings at JPM in 2018. Additionally, LifeSci's Executive Search group completed
30 board and executive placements in 2019, up from 17 in 2018. LifeSci's client base continues to grow as well, reaching 177 healthcare
client partnerships in 2019, up from 150 in 2018. LifeSci Partners has a global footprint, with offices in cities including New
York, Chicago, Boston, Charlotte, London, Geneva, Paris, and Tel Aviv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Our Board of Directors and Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Andrew McDonald,&nbsp;</B>our
Chief Executive Officer and Board Member, is an experienced healthcare investment professional with expertise in identifying transformative
products and technologies in all stages of development. Andrew has been the Chairman and Chief Executive Officer of LifeSci Acquisition
Corp., a special purpose acquisition company, since June&nbsp;2019. Andrew has served as the Chief Executive Officer of Attune
Pharmaceuticals since March&nbsp;2015 and is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci,
Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008.
From 2004 to 2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment
bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001 to 2004, where
he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal
chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Andrew holds the Series&nbsp;7, 24, 63, 79, 86, and 87 licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Michael Rice,</B>&nbsp;our
Chief Operating Officer and Board Member, has experience in portfolio management, corporate management, investment banking and
capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking
at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity
Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions,
many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America, serving large
hedge funds and private equity healthcare funds. Michael has been the Chief Operating Officer and a director of LifeSci Acquisition
Corp., a special purpose acquisition company, since June&nbsp;2019. Previously, he was a Managing Director at JPMorgan/Hambrecht&nbsp;&amp;
Quist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>David Dobkin</B>,
our Chief Financial Officer and Board Member, is an experienced healthcare capital markets investment banker with a career focused
on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. David
has been the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, since
June&nbsp;2019. David has worked with companies developing a wide range of technologies and brings extensive strategic advisory
and execution capability to his clients. David has experience with both traditional and non-traditional forms of equity and debt
offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across the United States
and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to that, in 2015, David
founded Dobkin&nbsp;&amp; Company, an investment bank tailored for entrepreneur-led companies focused on seed and growth equity
and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf
of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous
experience conducting cross-border transactions. Prior to October&nbsp;2010, David worked for Lazard Fr&egrave;res, one of the
world&rsquo;s preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers
and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Fr&egrave;res, David began his career in in
the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein Perella, David advised healthcare
companies on capital formation as well as strategic alternatives. David conducted graduate research in stem cell bioengineering
and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a B.S.
in Biomedical Engineering, from Columbia University. David holds the Series&nbsp;63, 79, and 82 licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Industry Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
consists of sectors within the economic system providing curative, preventive, rehabilitative, and palliative care for patients.
The industry includes organizations providing such goods and services, as well as the doctors, nurses, and other healthcare employees.
Total healthcare spending in the United States reached nearly $3.5 trillion in 2017 and is expected to grow by an average 5.6 percent
annually over 2016-2025, according to a Centers for Medicare&nbsp;&amp; Medicaid Services report released in February&nbsp;2017.
Total healthcare expenditures are thus expected rise to 19.9 percent of the US Gross Domestic Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare market
globally mirrors a similar trend in the U.S. of an increased contribution to the economy, due to the aging of the global population
and other durable macro dynamics. For example, in good part due to the impact of healthcare on society, life expectancy in the
U.S. increased from 47 years in 1900 to 79 years in 2016. As a disproportionate amount of overall healthcare spending is associated
with diseases of aging, the aging of the global population will continue to drive increased healthcare consumption. In addition,
less developed countries have gone through an unprecedented period of healthcare insurance and infrastructure expansion that has
led the countries to have significantly higher contributions to the global healthcare marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The target universe
of healthcare opportunities is extensive, considering healthcare&rsquo;s overall contribution to the economy. A factor that further
broadens the universe is the high amount of innovation occurring within healthcare. In the wake of the genomics revolution, the
pace of innovation is accelerating. With the streamlining of the externalization of breakthrough science from academic institutions,
particularly in the United States, as mandates shifted from protecting intellectual property to externalizing it, increasing numbers
of potentially disruptive healthcare innovations exist that may be underappreciated or underfunded. Early-stage companies need
capital and advisory services to reach their commercial potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
is primed for new technologies and business models due to the increasing cost of healthcare and due to the increasing pressure
to add value to the system. We believe that lower-value segments of healthcare will be burdened by the pressures of cost cutting,
while companies or segments that deliver superior products and services, with better clinical and non-clinical outcomes, will thrive.
Successful companies will be data driven, consumer focused, operationally efficient and transfer best-in-class standards globally.
Our team will take a holistic approach to investment opportunities and conduct stringent due diligence to screen such companies.
We see opportunities for companies that address global healthcare cost pressures by: succeeding in disruptive innovation, thus
justifying monies spent by delivering cures or other breakthrough outcomes; delivering cost savings to address global healthcare
cost pressures; or providing access to medicines, as the marginal benefits from healthcare spending are highest when providing
goods and services to those who do not already receive them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investment Criteria</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are focused on
companies in disruptive and other value added subsegments of healthcare that have the potential for significant gains in the next
five years. Our ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to
raise money from the private capital markets. The segments we will target include biotechnology, medical technology and digital
health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The focus of our management
team is to create stockholder value by leveraging its experience to efficiently guide an emerging healthcare company towards commercialization.
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in
evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses,
we may deviate from these criteria and guidelines should we see fit to do so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify"><I>Healthcare Company Poised for Rapid Growth</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to primarily seek
to acquire one or more growth businesses with a total equity value of greater than 5 to 10 times the amount of the proceeds of
this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can
benefit from a public listing and new capital for growth to support significant revenue and earnings growth or to advance clinical
programs. We do not intend to acquire a start-up company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify"><I>Niche Leader and Specialized Business with High Growth Potential</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to seek target companies
that have significant and underexploited expansion opportunities in a niche sector. This can be accomplished through a combination
of accelerating organic growth and finding attractive add-on acquisition targets. Our management team has significant experience
in identifying such targets and in helping target management assess the strategic and financial fit. Similarly, our management
has the expertise to assess the likely synergies and a process to help a target integrate acquisitions. Additionally, our management
team has extensive experience assisting healthcare companies raise money as they navigate the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify"><I>Benefits from Being a U.S. Public Company (Value Creation and Marketing Opportunities)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to seek target companies
that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms
and in a manner that leverage our experience. We expect to evaluate a Company based on its potential to successfully achieve regulatory
approval and commercialize its product(s). We also expect to evaluate financial returns based on (i)&nbsp;risk-adjusted peak sales
potential (ii)&nbsp;the potential of pipeline products and the scientific platform (iii)&nbsp;the ability to achieve the system
cost savings, (iv)&nbsp;the ability to accelerate growth via other options, including through the opportunity for follow-on acquisitions
and (v)&nbsp;the prospects for creating value through other value creation initiatives. Potential upside, for example, from the
growth in the target business&rsquo; earnings or an improved capital structure will be weighed against any identified downside
risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><I>&bull;</I></TD>
    <TD STYLE="text-align: justify"><I>Potential Benefit from Globalization Trends and Possession of Competitive Advantages</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Target companies exhibit unrecognized
value or other characteristics that we believe have been misevaluated by the marketplace based on company-specific analyses and
due diligence. For a potential target company, this process will include, among other things, a review and analysis of the company&rsquo;s
capital structure, quality of current or future earnings, preclinical or clinical data, potential for operational improvements,
corporate governance, customers, material contracts, and the industry and trends. We intend to leverage the operational experience
and disciplined investment approach of our team to identify opportunities to unlock value that our experience in complex situations
allows us to pursue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These criteria are
not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based,
to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may
deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Private Placements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&nbsp;1,
2020, our sponsor purchased 2,156,250 shares, which we refer to throughout this prospectus as the &ldquo;founder shares&rdquo;
or &ldquo;insider shares,&rdquo; for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred
215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder shares include an aggregate
of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters&rsquo; over-allotment option is not
exercised in full or in part, so that our initial stockholders will collectively own 20% of our issued and outstanding shares after
this offering (excluding the sale of the private warrants and assuming our initial stockholders do not purchase public shares in
this offering). None of our initial stockholders has indicated any intention to purchase public shares in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The founder shares
are identical to the public shares. However, our initial stockholders have agreed (A)&nbsp;to vote their founder shares in favor
of any proposed business combination, (B)&nbsp;not to propose, or vote in favor of, prior to and unrelated to an initial business
combination, an amendment to our certificate of incorporation that would affect the substance or timing of our redemption obligation
to redeem all public shares if we cannot complete an initial business combination within 24 months of the closing of this offering,
unless we provide public stockholders an opportunity to redeem their public shares in conjunction with any such amendment, (C)&nbsp;not
to redeem any shares, including founder shares into the right to receive cash from the trust account in connection with a stockholder
vote to approve our proposed initial business combination or sell any shares to us in any tender offer in connection with our proposed
initial business combination, and (D)&nbsp;that the founder shares shall not participate in any liquidating distribution upon winding
up if a business combination is not consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On the date of this
prospectus, the founder shares will be placed into an escrow account maintained by Continental Stock Transfer&nbsp;&amp; Trust
Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier
of (i)&nbsp;6 months after the date of the consummation of our initial business combination or (ii)&nbsp;the date on which the
closing price of our shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends,
reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after our initial business
combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6
months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our
initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which
results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property.
During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1)&nbsp;to
any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers,
directors, stockholders, employees and members of our sponsor and its affiliates, (2)&nbsp;amongst initial stockholders or to our
officers, directors and employees, (3)&nbsp;if a holder is an entity, as a distribution to its, partners, stockholders or members
upon its liquidation, (4)&nbsp;by bona fide gift to a member of the holder&rsquo;s immediate family or to a trust, the beneficiary
of which is a holder or a member of a holder&rsquo;s immediate family, for estate planning purposes, (5)&nbsp;by virtue of the
laws of descent and distribution upon death, (6)&nbsp;pursuant to a qualified domestic relations order, (7)&nbsp;by certain pledges
to secure obligations incurred in connection with purchases of our securities, (8)&nbsp;by private sales at prices no greater than
the price at which the shares were originally purchased or (9)&nbsp;for the cancellation of up to 281,250 shares of common stock
subject to forfeiture to the extent that the underwriters&rsquo; over-allotment is not exercised in full or in part or in connection
with the consummation of our initial business combination, in each case (except for clause 9 or with our prior consent) where the
transferee agrees to the terms of the escrow agreement and the insider letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo;
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital.&nbsp;Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants)&nbsp;in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The proceeds from
the private placement of the private warrants will be added to the proceeds of this offering and placed in a trust account in the
United States maintained by Continental Stock Transfer&nbsp;&amp; Trust Company, as trustee. If we do not complete our initial
business combination within 24 months, the proceeds from the sale of the private warrants will be included in the liquidating distribution
to the holders of our public shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The private warrants
will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial
purchasers or their permitted transferees. The private warrants will not be transferable, assignable or saleable until after the
completion of a business combination, subject to the limited exceptions described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If public shares are
purchased by any of our directors, officers or initial stockholders, they will be entitled to funds from the trust account to the
same extent as any public stockholder upon our liquidation but will not have redemption rights related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our executive offices
are located at 250 W. 55th St., #3401, New York, NY 10019, and our telephone number is (646) 889-1200.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In making your decision
on whether to invest in our securities, you should take into account not only the backgrounds of the members of our management
team, but also the special risks we face as a blank check company and the fact that this offering is not being conducted in compliance
with Rule&nbsp;419 promulgated under the Securities Act. You will not be entitled to protections normally afforded to investors
in Rule&nbsp;419 blank check offerings. You should carefully consider these and the other risks set forth in the section below
entitled &ldquo;Risk Factors&rdquo; beginning on page&nbsp;18 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Securities offered</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 68%; text-align: justify"><FONT STYLE="font-size: 10pt">7,500,000 shares of common stock, at $10.00 per share.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Listing of our securities and<BR>
 proposed symbol</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We anticipate the shares of common stock will be listed on Nasdaq under the symbol &ldquo;LSAQ&rdquo;.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We will file a Current Report on Form&nbsp;8-K with the SEC, including an audited balance sheet, promptly upon the consummation of this offering, which is anticipated to take place two business days from the date the shares commence trading. The audited balance sheet will reflect our receipt of the proceeds from the exercise of the over-allotment option if the over-allotment option is exercised on the date of this prospectus. If the over-allotment option is exercised after the date of this prospectus, we will file an amendment to the Form&nbsp;8-K or a new Form&nbsp;8-K to provide updated financial information to reflect the exercise of the over-allotment option. </FONT></TD></TR>

</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Shares of common stock:</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 68%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Number issued and outstanding before<BR>
 this offering</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">2,156,250 shares<SUP>(1)</SUP></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Number to be issued and outstanding after</B></FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">9,375,000 shares<SUP>(2)</SUP></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">This number includes an aggregate of up to 281,250 shares of common stock held by our initial stockholders that are subject to forfeiture if the over-allotment option is not fully exercised by the underwriters.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited. If the over-allotment option is exercised in full, there will be a total of 10,781,250 shares of common stock issued and outstanding.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%; text-align: justify"><B>Offering proceeds to be held in trust</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$75,000,000 of the net proceeds of
        this offering (or $86,250,000 if the over-allotment option is exercised in full), including $2,730,000 (or $2,955,000 if the
        over-allotment option is exercised in full), we will receive from the sale of the private warrants, or $10.00 per share sold
        to the public in this offering will be placed in a trust account in the United States, maintained by Continental
        Stock Transfer&nbsp;&amp; Trust Company, acting as trustee pursuant to an agreement to be signed on the date of this
        prospectus. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full), we will receive from the sale
        of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) be used for offering
        expenses and $750,000 will be used for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth below, the proceeds
        in the trust account will not be released until the earlier of: (1)&nbsp;the completion of an initial business combination within
        the required time period and (2)&nbsp;our redemption of 100% of the outstanding public shares if we have not completed a business
        combination in the required time period. Therefore, unless and until our initial business combination is consummated, the proceeds
        held in the trust account will not be available for our use for any expenses related to this offering or expenses which we may
        incur related to the investigation and selection of a target business and the negotiation of an agreement to acquire a target business.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, there can be released to us,
from time to time, (i)&nbsp;any interest earned on the funds in the trust account that we may need to pay our tax obligations and
(ii)&nbsp;any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working
capital requirements. With this exception, expenses incurred by us may be paid prior to a business combination only from the net
proceeds of this offering not held in the trust account of approximately $750,000 provided, however, that in order to meet our
working capital needs following the consummation of this offering if the funds not held in the trust account are insufficient,
our initial stockholders, officers and directors or their affiliates may, but are not obligated to, loan us funds, from time to
time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory
note. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender&rsquo;s
discretion, up to $500,000 of the notes may be converted upon consummation of our business combination into additional private
warrants at a conversion price of $0.90 per private warrant. Such private warrants will be identical to the private warrants to
be issued at the closing of this offering. Our directors have approved the issuance of the private warrants upon conversion of
such notes, to the extent the holder wishes to so convert them at the time of the consummation of our initial business combination.
If we do not complete a business combination, the loans will only be repaid with funds not held in the trust account, to the extent
available.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%; text-align: justify"><B>Limited payments to insiders</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the consummation of a
business combination, there will be no fees, reimbursements or other cash payments paid to our initial stockholders, officers,
directors or their affiliates prior to, or for any services they render in order to effectuate, the consummation of a business
combination (regardless of the type of transaction that it is) other than:</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 4%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 61%">payment of $10,000 per month to an affiliate of LifeSci Holdings
LLC for office space and related services, subject to deferral as described herein;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 4%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 61%">repayment of loans which may be made by our insiders,
officers, directors or any of its or their affiliates to finance transaction costs in connection with an initial business combination,
the terms of which have not been determined;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 4%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 61%">reimbursement of out-of-pocket expenses incurred by them
in connection with certain activities on our behalf, such as identifying and investigating possible business targets and business
combinations; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35%"></TD><TD STYLE="width: 4%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 61%">repayment upon consummation of our initial business combination
of any loans which may be made by our initial stockholders or their affiliates or our officers and directors to finance transaction
costs in connection with an intended initial business combination.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: justify; width: 30%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; width: 68%">There is no limit on the amount of out-of-pocket
        expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in
        the trust account and the interest income earned on the amounts held in the trust account available to us, such expenses would
        not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve all reimbursements
        and payments made to any initial stockholder or member of our management team, or their respective affiliates, and any reimbursements
        and payments made to members of our audit committee will be reviewed and approved by our board of directors, with any interested
        director abstaining from such review and approval.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><B>Potential revisions to agreements with insiders</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">We could seek to amend certain agreements made by our management team disclosed in this prospectus without the approval of stockholders, although we have no intention to do so. For example, restrictions on our executives relating to the voting of securities owned by them, the agreement of our management team to remain with us until the closing of a business combination, the obligation of our management team to not propose certain changes to our organizational documents or the obligation of the management team and its affiliates to not receive any compensation in connection with a business combination could be modified without obtaining stockholder approval. Although stockholders would not be given the opportunity to redeem their shares in connection with such changes, in no event would we be able to modify the redemption or liquidation rights of our stockholders without permitting our stockholders the right to redeem their shares in connection with any such change. We will not agree to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if such a modification were necessary to complete a business combination).</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%"><B>Stockholder approval of, or tender offer in connection with, initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 68%">W<FONT STYLE="background-color: white">e have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor.</FONT> In connection with any proposed initial business combination, we will either (1)&nbsp;seek stockholder approval of such initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2)&nbsp;provide our public stockholders with the opportunity to sell their public shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that we are unable to satisfy any applicable closing condition set forth in the definitive agreement related to our initial business combination, or we are unable to maintain net tangible assets of at least $5,000,001, we will not consummate such initial business combination. The decision as to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval. If we provide stockholders with the opportunity to sell their shares to us by means of a tender offer, we will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as is required under the SEC&rsquo;s proxy rules. If we seek stockholder approval of our initial business combination, we will consummate the business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the business combination.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%; text-align: justify">We have determined not to consummate any business combination unless we have net tangible assets of at least $5,000,001 upon such consummation in order to avoid being subject to Rule&nbsp;419 promulgated under the Securities Act. However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as we may be required to have a lesser number of shares redeemed) and may force us to seek third party financing which may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination and we may not be able to locate another suitable target within the applicable time period, if at all.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Our initial stockholders have agreed (A)&nbsp;to vote their
founder shares and any public shares in favor of any proposed business combination, (B)&nbsp;not to propose, or vote in favor of,
prior to and unrelated to an initial business combination, an amendment to our certificate of incorporation that would affect the
substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months unless we provide public stockholder an opportunity to redeem their public shares in conjunction with any such
amendment, (C)&nbsp;not to convert any shares (including the founder shares) into the right to receive cash from the trust account
in connection with a stockholder vote to approve our proposed initial business combination or sell any shares to us in a tender
offer in connection with our proposed initial business combination, and (D)&nbsp;that the founder shares shall not participate
in any liquidating distribution upon winding up if a business combination is not consummated. None of our initial stockholders
or their affiliates has indicated any intention to purchase public shares of common stock in the open market or in private transactions.
However, if a significant number of stockholders vote, or indicate an intention to vote, against a proposed business combination,
our initial stockholders, officers, directors or their affiliates could make such purchases in the open market or in private transactions
in order to influence the vote. Our initial stockholders, officers, directors and their affiliates could purchase sufficient shares
so that the initial business combination may be approved without the majority vote of public shares held by non-affiliates. Notwithstanding
the foregoing, our officers, directors, initial stockholders and their affiliates will not make purchases of shares of common stock
if the purchases would violate Section&nbsp;9(a)(2)&nbsp;or Rule&nbsp;10b-5 of the Exchange Act, which are rules&nbsp;designed
to stop potential manipulation of a company&rsquo;s stock or purchasing shares when the buyer is in possession of material non-public
information about the Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><B>Conditions to completing our initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed not to enter into a definitive
agreement regarding an initial business combination without the prior consent of our sponsor.&nbsp;Further, there is no limitation
on our ability to raise funds privately or through loans in connection with our initial business combination. Our initial business
combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of
the value of the trust account (excluding any taxes payable on the income earned on the trust account) at the time of the agreement
to enter into the initial business combination. If we are no longer listed on Nasdaq, we will not be required to satisfy the 80%
test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our board is not able to independently
        determine the fair market value of the target business or businesses, we may obtain an opinion from an independent investment banking
        or accounting firm as to the fair market value of the target business. We will complete our initial business combination only if
        the post-transaction company in which our public stockholders own shares will own or acquire 50% or more of the outstanding voting
        securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
        as an investment company under the Investment Company Act. Even if the post-transaction company owns 50% or more of the voting
        securities of the target, our stockholders prior to the business combination may collectively own a minority interest in the post
        business combination company, depending on valuations ascribed to the target and us in the business combination transaction. If
        less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction
        company, the portion of such business or businesses that is owned or acquired is what will be valued for purposes of the 80% test,
        provided that in the event that the business combination involves more than one target business, the 80% test will be based on
        the aggregate value of all of the target businesses.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Conversion rights</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with any stockholder meeting
        called to approve a proposed initial business combination, each public stockholder will have the right, regardless of whether he,
        she or it is voting for or against such proposed business combination, to demand that we convert his, her or its public shares
        into a <I>pro rata</I> share of the trust account upon consummation of the business combination.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may require public stockholders wishing
        to exercise conversion rights, whether they are a record holder or hold their shares in &ldquo;street name,&rdquo; to either tender
        the certificates they are seeking to convert to our transfer agent or to deliver the shares they are seeking to convert to the
        transfer agent electronically using Depository Trust Company&rsquo;s DWAC (Deposit/Withdrawal At Custodian) System, at the holder&rsquo;s
        option, at any time at or prior to the vote on the business combination. There is a nominal cost associated with this tendering
        process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge
        the tendering broker $45 and it would be up to the broker whether or not to pass this cost on to the converting holder. However,
        this fee would be incurred regardless of whether or not we require holders to deliver their shares prior to the vote on the business
        combination in order to exercise conversion rights. This is because a holder would need to deliver shares to exercise conversion
        rights regardless of the timing of when such delivery must be effectuated. However, in the event we require stockholders to deliver
        their shares prior to the vote on the proposed business combination and the proposed business combination is not consummated, this
        may result in an increased cost to stockholders. The conversion rights will include the requirement that a beneficial holder must
        identify itself in order to validly redeem its shares.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, we may be required
        to give a minimum of only ten days&rsquo; notice for each general meeting. As a result, if we require public stockholders who wish
        to convert their shares of common stock into the right to receive a <I>pro rata</I> portion of the funds in the trust account to
        comply with the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares
        for conversion. Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities
        when they otherwise would not want to.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we require public stockholders who wish
        to convert their shares of common stock to comply with specific delivery requirements for conversion described above and such proposed
        business combination is not consummated, we will promptly return such certificates to the tendering public stockholders.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%"><B>Release of funds in trust account upon closing of our initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify; width: 68%">On the completion of our initial business combination, all amounts held in the trust account will be released to us. We will use these funds to pay amounts due to any public stockholders who exercise their conversion rights as described above under &ldquo;&mdash; Conversion rights&rdquo; to pay all or a portion of the consideration payable to the target or targets or owners of the target or targets of our initial business combination and to pay other expenses associated with our initial business combination. If our initial business combination is paid for using stock or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><B>Liquidation&nbsp;if&nbsp;no&nbsp;business&nbsp;combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">If we are unable to complete our initial business combination
within 24 months from the closing of this offering, we will (i)&nbsp;cease all operations except for the purpose of winding up,
(ii)&nbsp;as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public
shares (including any public shares in this offering or any public shares that our initial stockholders or their affiliates purchased
in this offering or later acquired in the open market or in private transactions), which redemption will completely extinguish
public stockholders&rsquo; rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii)&nbsp;as promptly as reasonably practicable following such redemption, subject to the approval of our
remaining holders of common stock and our board of directors, proceed to commence a voluntary liquidation and thereby a formal
dissolution of the Company, subject (in the case of (ii)&nbsp;and (iii)&nbsp;above) to our obligations to provide for claims of
creditors and the requirements of applicable law.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our redemption of 100%
        of our outstanding public shares for a portion of the funds held in the trust account, each holder will receive a full pro rata
        portion of the amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not
        necessary to pay our taxes payable on such funds.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not have funds sufficient to pay
        or provide for all creditors&rsquo; claims. Although we will seek to have all third parties (including any vendors or other entities
        we engage after this offering) and any prospective target businesses enter into valid and enforceable agreements with us waiving
        any right, title, interest or claim of any kind in or to any monies held in the trust account, there is no guarantee that they
        will execute such agreements. There is also no guarantee that the third parties would not challenge the enforceability of these
        waivers and bring claims against the trust account for monies owed them.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the founder shares and private
warrants will not participate in any redemption distribution with respect to their founder shares and private warrants, but may have
any public shares redeemed upon liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to conclude our initial
        business combination and we expend all of the net proceeds of this offering not deposited in the trust account, without taking
        into account any interest earned on the trust account, we expect that the initial per-share redemption price will be approximately
        $10.00. The proceeds deposited in the trust account could, however, become subject to claims of our creditors that are in preference
        to the claims of our stockholders. Furthermore, our underwriters may seek recourse against the proceeds in the trust account relating
        to any future claims they may have against us. In addition, if we are forced to file a bankruptcy case or an involuntary bankruptcy
        case is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy
        law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our
        stockholders. Therefore, the actual per-share redemption price may be less than approximately $10.00. We will pay the costs of
        any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our sponsor
        has agreed to pay the funds necessary to complete such liquidation and has agreed not to seek repayment for such expenses. We currently
        do not anticipate that such funds will be insufficient.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 30%; text-align: justify"><B>Conflict of Interest</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 68%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LifeSci Capital, the representative of
the underwriters in this offering and an affiliate of certain of our officers and directors, is a beneficial owner of our sponsor,
LifeSci Holdings LLC. As a result, LifeSci Capital is deemed to have a &ldquo;conflict of interest&rdquo; within the meaning of
FINRA Rule&nbsp;5121 (&ldquo;Rule&nbsp;5121&rdquo;). Accordingly, this offering is being made in compliance with the applicable
requirements of Rule&nbsp;5121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rule&nbsp;5121 requires that a &ldquo;qualified
        independent underwriter,&rdquo; as defined in Rule&nbsp;5121, participate in the preparation of the registration statement and
        prospectus and exercise the usual standards of due diligence with respect thereto. [__] has agreed to act as a &ldquo;qualified
        independent underwriter&rdquo; for this offering. [__] will receive $[__] for acting as a qualified independent underwriter. We
        have agreed to indemnify [__] against certain liabilities incurred in connection with acting as a &ldquo;qualified independent
        underwriter,&rdquo; including liabilities under the Securities Act. In addition, no underwriter with a conflict of interest will
        confirm sales to any account over which it exercises discretionary authority without the specific prior written approval of the
        account holder.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a newly formed
company that has conducted no operations and has generated no revenues. Until we complete our initial business combination, we
will have no operations and will generate no operating revenues. In making your decision on whether to invest in our securities,
you should take into account not only the background of our management team, but also the special risks we face as a blank check
company, as well as the fact that this offering is not being conducted in compliance with Rule&nbsp;419 promulgated under the Securities
Act, and, therefore, you will not be entitled to protections normally afforded to investors in Rule&nbsp;419 blank check offerings.
For additional information concerning how Rule&nbsp;419 blank check offerings differ from this offering, please see &ldquo;<I>Proposed
Business &mdash; Comparison to offerings of blank check companies subject to Rule&nbsp;419</I>.&rdquo; You should carefully consider
these and the other risks set forth in the section entitled &ldquo;Risk Factors&rdquo; beginning on page&nbsp;18 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_002"></A>SUMMARY FINANCIAL DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
summarizes the relevant financial data for our business and should be read with our financial statements, which are included in
this prospectus. We have not had any significant operations to date, so only balance sheet data are presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Balance Sheet Data:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left">Working capital (deficit)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(4,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">75,774,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,774,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">29,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Value of shares of common stock subject to possible conversion/tender</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,773,990</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Includes
the $2,730,000 we will receive from the sale of the private warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The &ldquo;as adjusted&rdquo;
information gives effect to the sale of the shares we are offering, including the application of the related gross proceeds and
the payment of the estimated remaining costs from such sale and the repayment of the accrued and other liabilities required to
be repaid such that we have at least $5,000,001 of net tangible assets upon consummation of this offering and upon consummation
of our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The &ldquo;as adjusted&rdquo;
working capital and total assets amounts include the $75,000,000 (without exercise of over-allotment option) to be held in the
trust account, which, except for limited situations described in this prospectus, will be available to us only upon the consummation
of our initial business combination within the time period described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will consummate
our initial business combination only if we have net tangible assets of at least $5,000,001 upon such consummation and a majority
of the outstanding shares of common stock voted are voted in favor of the business combination (if a vote is required or being
obtained).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>An investment in
our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the
other information contained in this prospectus, before making a decision to invest in our shares of common stock. If any of the
following events occur, our business, financial condition and operating results may be materially adversely affected. In that event,
the trading price of our securities could decline, and you could lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are a newly formed blank check company
in the early stage with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve
our business objective.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a recently
formed blank check company with no operating results, and we will not commence operations until obtaining funding through this
offering and consummating our initial business combination. Because we lack an operating history, you have no basis upon which
to evaluate our ability to achieve our business objective of completing our initial business combination with one or more target
businesses. We have no plans, arrangements or understandings with any prospective target business concerning our initial business
combination and may be unable to complete our initial business combination. If we fail to complete our initial business combination,
we will never generate any operating revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The requirement that the target business
or businesses that we acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in the
trust account (excluding any taxes payable) at the time of the execution of a definitive agreement for our initial business combination
may limit the type and number of companies with which we may complete such a business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to Nasdaq
listing rules, the target business or businesses that we acquire must collectively have a fair market value equal to at least 80%
of the balance of the funds in the trust account (excluding any taxes payable) at the time of the execution of a definitive agreement
for our initial business combination. This restriction may limit the type and number of companies that we may complete a business
combination with. If we are unable to locate a target business or businesses that satisfy this fair market value test, we may be
forced to liquidate and you will only be entitled to receive your pro rata portion of the funds in the trust account, which may
be less than $10.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our search for a business combination,
and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the
recent coronavirus (COVID-19) outbreak and the status of debt and equity markets.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The outbreak of the
COVID-19 coronavirus has resulted in a widespread health crisis that has adversely affected the economies and financial markets
worldwide. We may be unable to complete a business combination if continued concerns relating to COVID-19 restrict travel, limit
the ability to have meetings with potential investors, if the target company&rsquo;s personnel, vendors and service providers are
unavailable to negotiate and consummate a transaction in a timely manner, or if COVID-19 causes a prolonged economic downturn.
The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which are highly
uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions
to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 or other matters of global concern
continue for an extensive period of time, our ability to consummate a business combination, or the operations of a target business
with which we ultimately consummate a business combination, may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our ability
to consummate a business combination may be dependent on the ability to raise equity and debt financing which may be impacted by
COVID-19 and other events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our public stockholders may not be afforded
an opportunity to vote on our proposed business combination, which means we may consummate our initial business combination even
though a majority of our public stockholders do not support such a combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a stockholder vote
is not required, we may conduct redemptions via a tender offer. Accordingly, we may consummate our initial business combination
even if holders of a majority of our public shares do not approve the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Your only opportunity to affect the
investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares
from us for cash.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At the time of your
investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of one or more target businesses.
Because our board of directors may consummate our initial business combination without seeking stockholder approval, public stockholders
may not have the right or opportunity to vote on the business combination. Accordingly, your only opportunity to affect the investment
decision regarding a potential business combination may be limited to exercising your redemption rights within the period of time
(which will be at least 20 business days) set forth in our tender offer documents mailed to our public stockholders in which we
describe our business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The ability of our public stockholders
to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which
may make it difficult for us to enter into our initial business combination with a target.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may enter into
a transaction agreement with a prospective target that requires as a closing condition that we have a minimum net worth or a certain
amount of cash. If too many public stockholders exercise their redemption rights, we may not be able to meet such closing condition,
and as a result, would not be able to proceed with the business combination. Furthermore, in no event will we redeem our public
shares in an amount that would cause our net tangible assets to be less than $5,000,001. Consequently, if accepting all properly
submitted redemption requests would cause our net tangible assets to be less than $5,000,001 or such greater amount necessary to
satisfy a closing condition as described above, we would not proceed with such redemption and the related business combination
and may instead search for an alternate business combination. Prospective targets would be aware of these risks and, thus, may
be reluctant to enter into our initial business combination transaction with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The ability of a large number of our
stockholders to exercise redemption rights may not allow us to consummate the most desirable business combination or optimize our
capital structure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
the successful consummation of our business combination, we may redeem up to that number of shares of common stock that would permit
us to maintain net tangible assets of $5,000,001. If our business combination requires us to use substantially all of our cash
to pay the purchase price, the redemption threshold may be further limited. Alternatively, we may need to arrange third party financing
to help fund our business combination in case a larger percentage of stockholders exercise their redemption rights than we expect.
If the acquisition involves the issuance of our shares as consideration, we may be required to issue a higher percentage of our
shares to the target or its stockholders to make up for the failure to satisfy a minimum cash requirement. Raising additional funds
to cover any shortfall may involve dilutive equity financing or incurring indebtedness at higher than desirable levels. This may
limit our ability to effectuate the most attractive business combination available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The requirement that we maintain a minimum
net worth or retain a certain amount of cash could increase the probability that we cannot consummate our business combination
and that you would have to wait for liquidation in order to redeem your shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If, pursuant to the
terms of our proposed business combination, we are required to maintain a minimum net worth or retain a certain amount of cash
in trust in order to consummate the business combination and regardless of whether we proceed with redemptions under the tender
offer or proxy rules, the probability that we cannot consummate our business combination is increased. If we do not consummate
our business combination, you would not receive your pro rata portion of the trust account until we liquidate. If you are in need
of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at
a discount to the pro rata amount in our trust account. In either situation, you may suffer a material loss on your investment
or lose the benefit of funds expected in connection with our redemption until we liquidate or you are able to sell your shares
in the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The requirement that we complete our
initial business combination within 24 months from the closing of this offering may give potential target businesses leverage over
us in negotiating our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any potential target
business with which we enter into negotiations concerning our initial business combination will be aware that we must consummate
our initial business combination within 24 months from the closing of this offering. Consequently, such target businesses may obtain
leverage over us in negotiating our initial business combination, knowing that if we do not complete our initial business combination
with that particular target business, we may be unable to complete our initial business combination with any target business. This
risk will increase as we get closer to the timeframe described above. In addition, we may have limited time to conduct due diligence
and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be able to consummate our
initial business combination within the required time period, in which case we would cease all operations except for the purpose
of winding up and we would redeem our public shares and liquidate.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our sponsor, officers
and directors have agreed that we must complete our initial business combination within 24 months from the closing of this offering.
We may not be able to find a suitable target business and consummate our initial business combination within such time period.
If we are unable to consummate our initial business combination within the required time period, we will, as promptly as reasonably
possible but not more than five business days thereafter (subject to our certificate of incorporation and Delaware law), distribute
the aggregate amount then on deposit in the trust account (net of taxes payable), pro rata to our public stockholders by way of
redemption and cease all operations except for the purposes of winding up of our affairs, as further described herein. This redemption
of public stockholders from the trust account shall be effected as required by function of our certificate of incorporation and
prior to any voluntary winding up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we seek stockholder approval of our
business combination, our sponsor, directors, officers, advisors and their affiliates may elect to purchase shares from stockholders,
in which case they may influence a vote in favor of a proposed business combination that you do not support.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we seek stockholder
approval of our business combination and we do not conduct redemptions in connection with our business combination pursuant to
the tender offer rules, our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated
transactions either prior to or following the consummation of our initial business combination. Such purchases will not be made
if our sponsor, directors, officers, advisors or their affiliates are in possession of any material non-public information that
has not been disclosed to the selling stockholder. Such a purchase would include a contractual acknowledgement that such stockholder,
although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise its
redemption rights. In the event that our sponsor, directors, officers, advisors or their affiliates purchase shares in privately
negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders
would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule&nbsp;10b-18 would apply
to purchases by our sponsor, directors, officers, advisors or their affiliates, then such purchases will comply with Rule&nbsp;10b-18
under the Exchange Act, to the extent it applies, which provides a safe harbor for purchases made under certain conditions, including
with respect to timing, pricing and volume of purchases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The purpose of such
purchases would be to (1)&nbsp;increase the likelihood of obtaining stockholder approval of the business combination or (2)&nbsp;satisfy
a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the
closing of the business combination, where it appears that such requirement would otherwise not be met. This may result in the
consummation of an initial business combination that may not otherwise have been possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchases of shares of common stock
in the open market or in privately negotiated transactions by our sponsor, directors, officers, advisors or their affiliates may
make it difficult for us to maintain the listing of our shares on a national securities exchange following the consummation of
an initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our sponsor, directors,
officers, advisors or their affiliates purchase shares of common stock in the open market or in privately negotiated transactions,
the public &ldquo;float&rdquo; of our shares of common stock and the number of beneficial holders of our securities would both
be reduced, possibly making it difficult to maintain the listing or trading of our securities on a national securities exchange
following consummation of the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You will not have any rights or interests
in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be
forced to sell your public shares, potentially at a loss.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our public stockholders
shall be entitled to receive funds from the trust account only in the event of a redemption to public stockholders prior to any
winding up in the event we do not consummate our initial business combination or our liquidation, if they redeem their shares in
connection with an initial business combination that we consummate or if we seek to amend our certificate of incorporation to affect
the substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months of the closing of this offering. In no other circumstances will a stockholder have any right or interest of any
kind to the funds in the trust account. Accordingly, to liquidate your investment, you may be forced to sell your public shares,
potentially at a loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You will not be entitled to protections
normally afforded to investors of many other blank check companies.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because the net
proceeds of this offering are intended to be used to complete our initial business combination with a target business that
has not been identified, we may be deemed to be a &ldquo;blank check&rdquo; company under the United States securities laws.
However, because we will have net tangible assets in excess of $5,000,000 upon the successful consummation of this offering
and will expect to file a Current Report on Form&nbsp;8-K, including an audited balance sheet demonstrating this fact, we are
exempt from rules&nbsp;promulgated by the SEC to protect investors in blank check companies, such as Rule&nbsp;419.
Accordingly, investors will not be afforded the benefits or protections of those rules. Among other things, this means our
shares will be immediately tradable and we will have a longer period of time to complete our initial business combination
than do companies subject to Rule&nbsp;419. Moreover, offerings subject to Rule&nbsp;419 would prohibit the release of any
interest earned on funds held in the trust account to us. For a more detailed comparison of our offering to offerings that
comply with Rule&nbsp;419, please see &ldquo;Proposed Business &mdash; Comparison of This Offering to Those of Blank Check
Companies Subject to Rule&nbsp;419.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we seek stockholder approval of our
business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a &ldquo;group&rdquo;
of stockholders are deemed to hold in excess of 20% of our shares of common stock, you will lose the ability to redeem all such
shares in excess of 20% of our shares of common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we seek stockholder
approval of our initial business combination and we do not conduct redemptions in connection with our business combination pursuant
to the tender offer rules, our certificate of incorporation provides that a public stockholder, individually or together with any
affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &ldquo;group&rdquo; (as
defined under Section&nbsp;13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than
an aggregate of 20% of the shares sold in this offering. Your inability to redeem more than an aggregate of 20% of the shares sold
in this offering will reduce your influence over our ability to consummate our initial business combination and you could suffer
a material loss on your investment in us if you sell such excess shares in open market transactions. As a result, you will continue
to hold that number of shares exceeding 20% and, in order to dispose of such shares, you would be required to sell your shares
in open market transaction, potentially at a loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the net proceeds of this offering
not being held in the trust account are insufficient to allow us to operate for at least the next 24 months, we may be unable to
complete our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The funds available
to us outside of the trust account may not be sufficient to allow us to operate for at least the next 24 months, assuming that
our initial business combination is not consummated during that time. Of the funds available to us, we could use a portion of the
funds available to us to pay fees to consultants to assist us with our search for a target business. We could also use a portion
of the funds as a down payment or to fund a &ldquo;no-shop&rdquo; provision (a provision in letters of intent designed to keep
target businesses from &ldquo;shopping&rdquo; around for transactions with other companies on terms more favorable to such target
businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so.
If we are unable to fund such down payments or &ldquo;no shop&rdquo; provisions, our ability to close a contemplated transaction
could be impaired. Furthermore, if we entered into a letter of intent where we paid for the right to receive exclusivity from a
target business and were subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might
not have sufficient funds to continue searching for, or conduct due diligence with respect to, a target business. If we are unable
to complete our initial business combination, our public stockholders may only receive a pro rata portion of the amount then in
the trust account (which may be less than $10.00 per share) (whether or not the underwriters&rsquo; over-allotment option is exercised
in full) on our redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Subsequent to our consummation of our
initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if we conduct
thorough due diligence on a target business with which we combine, this diligence may not surface all material issues that may
be present inside a particular target business, that it would be possible to uncover all material issues through a customary amount
of due diligence, or that factors outside of the target business and outside of our control will not later arise. As a result of
these factors, we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment or other
charges that could result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected
risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even
though these charges may be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of
this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may
cause us to violate net worth or other covenants to which we may be subject as a result of assuming pre-existing debt held by a
target business or by virtue of our obtaining post-combination debt financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our directors may decide not to enforce
indemnification obligations against LifeSci Holdings LLC, our sponsor, resulting in a reduction in the amount of funds in the trust
account available for distribution to our public stockholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event that
the proceeds in the trust account are reduced below $10.00 per share (whether or not the underwriters&rsquo; overallotment option
is exercised in full) and LifeSci Holdings LLC, our sponsor, asserts that it is unable to satisfy its obligations or that it has
no indemnification obligations related to a particular claim, our independent directors would determine on our behalf whether to
take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent
directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible
that our independent directors in exercising their business judgment may choose not to do so in any particular instance. If our
independent directors choose not to enforce these indemnification obligations on our behalf, the amount of funds in the trust account
available for distribution to our public stockholders may be reduced below $10.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we are deemed to be an investment
company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities
may be restricted, which may make it difficult for us to complete our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are deemed to
be an investment company under the Investment Company Act, our activities may be restricted, including restrictions on the nature
of our investments and restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial
business combination. In addition, we may have imposed upon us burdensome requirements, including registration as an investment
company, adoption of a specific form of corporate structure and reporting, record keeping, voting, proxy and disclosure requirements
and other rules&nbsp;and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we were deemed
to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses
for which we have not allotted funds and may hinder our ability to consummate our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Changes in laws or regulations, or a
failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to
laws and regulations enacted by national, regional and local governments, in particular, the Securities Exchange and Commission,
or the &ldquo;SEC&rdquo;. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming
and costly. Those laws and regulations and their interpretation and application also may change from time to time and those changes
could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with
applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If we are unable to consummate our initial
business combination, our public stockholders may be forced to wait up to 24 months or longer before redemption from our trust
account.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are unable to
consummate our initial business combination within 24 months from the closing of this offering, we will, as promptly as reasonably
possible but not more than five business days thereafter (subject to our certificate of incorporation and applicable law), distribute
the aggregate amount then on deposit in the trust account (net of taxes payable), pro rata to our public stockholders by way of
redemption and cease all operations except for the purposes of winding up of our affairs by way of a voluntary liquidation, as
further described herein. Any redemption of public stockholders from the trust account shall be effected as required by our certificate
of incorporation prior to our commencing any voluntary liquidation. Except as otherwise described herein, we have no obligation
to return funds to investors prior to the date of any redemption required as a result of our failure to consummate our initial
business combination within the period described above or our liquidation, unless we consummate our initial business combination
prior thereto and only then in cases where investors have sought to redeem their shares of common stock. Only upon any such redemption
of public shares as we are required to effect or any liquidation will public stockholders be entitled to distributions if we are
unable to complete our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The grant of registration rights to
our initial stockholders may make it more difficult to complete our initial business combination, and the future exercise of such
rights may adversely affect the market price of our shares of common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to an agreement
to be entered into on the date of this prospectus, our initial stockholders, our sponsor (and/or our sponsor&rsquo;s designees)
and their permitted transferees can demand that we register the founder shares and the private warrants. We will bear the cost of
registering these securities. The registration and availability of such a significant number of securities for trading in the public
market may have an adverse effect on the market price of our shares of common stock. In addition, the existence of the registration
rights may make our initial business combination more costly or difficult to conclude. This is because the stockholder of the target
business may increase the equity stake they seek in the combined entity or ask for more cash consideration to offset the negative
impact on the market price of our shares of common stock that is expected when the securities owned by our sponsor, holders of
our private warrants or their respective permitted transferees are registered. The Sponsor may not (i)&nbsp;have more than one demand
registration right at our expense, (ii)&nbsp;exercise its demand registration rights more than five (5)&nbsp;years from the effective
date of the registration statement of which this prospectus forms a part, and (iii)&nbsp;exercise its &ldquo;piggy-back&rdquo;
registration rights more than seven (7)&nbsp;years from the effective date of the registration statement of which this prospectus
forms a part, as long as our sponsor or any of its related persons are beneficial owners of private placement warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because we have not selected a particular
business or specific geographic location or any specific target businesses with which to pursue our initial business combination,
you will be unable to ascertain the merits or risks of any particular target business&rsquo; operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we have a
stated focus on certain target businesses in a specific geographic location as indicated elsewhere in this prospectus, we may pursue
acquisition opportunities in any geographic region, but may rely upon our management team&rsquo;s background. While we may pursue
an acquisition opportunity in any business industry or sector, we intend to initially focus on those industries or sectors that
complement our management team&rsquo;s background. Except for the limitations that a target business have a fair market value of
at least 80% of the value of the trust account (excluding any taxes payable) and that we are not permitted to effectuate our initial
business combination with another blank check company or similar company with nominal operations, we will have virtually unrestricted
flexibility in identifying and selecting a prospective acquisition candidate. Because we have not yet identified or approached
any specific target business with respect to our initial business combination, there is no basis to evaluate the possible merits
or risks of any particular target business&rsquo;s operations, results of operations, cash flows, liquidity, financial condition
or prospects. To the extent we consummate our initial business combination, we may be affected by numerous risks inherent in the
business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking
an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially
unstable or a development stage entity. Although our officers and directors will endeavor to evaluate the risks inherent in a particular
target business, we may not properly ascertain or assess all of the significant risk factors or that we will have adequate time
to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control
or reduce the chances that those risks will adversely impact a target business. In addition, investors will be relying on the business
judgment of our board of directors, which will have significant discretion in choosing the standard used to establish the fair
market value of a particular target business. An investment in our shares may not ultimately prove to be more favorable to investors
than a direct investment, if such opportunity were available, in an acquisition target.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may seek investment opportunities
outside our management&rsquo;s area of expertise and our management may not be able to adequately ascertain or assess all significant
risks associated with the target company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is no limitation
on the industry or business sector we may consider when contemplating our initial business combination. We may therefore be presented
with a business combination candidate in an industry unfamiliar to our management team, but determine that such candidate offers
an attractive investment opportunity for our company. In the event we elect to pursue an investment outside of our management&rsquo;s
expertise, our management&rsquo;s experience may not be directly applicable to the target business or their evaluation of its operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Although we identified general criteria
and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business
combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter
into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we have identified
specific criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which
we enter into our initial business combination will not have all of these positive attributes. If we consummate our initial business
combination with a target that does not meet some or all of these guidelines, such combination may not be as successful as a combination
with a business that does meet all of our general criteria and guidelines. In addition, if we announce our initial business combination
with a target that does not meet our general criteria and guidelines, a greater number of stockholders may exercise their redemption
rights, which may make it difficult for us to meet any closing condition with a target business that requires us to have a minimum
net worth or a certain amount of cash. In addition, if stockholder approval of the transaction is required by law or Nasdaq, or
we decide to obtain stockholder approval for business or other legal reasons, it may be more difficult for us to attain stockholder
approval of our initial business combination if the target business does not meet our general criteria and guidelines. If we are
unable to complete our initial business combination, our public stockholders may only receive $10.00 per share or even less (whether
or not the underwriters&rsquo; over-allotment option is exercised in full) on our redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Management&rsquo;s flexibility in identifying
and selecting a prospective acquisition candidate, along with our management&rsquo;s financial interest in consummating our initial
business combination, may lead management to enter into an acquisition agreement that is not in the best interest of our stockholders.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the requirement
that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value
of at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such
initial business combination, we will have virtually unrestricted flexibility in identifying and selecting a prospective acquisition
candidate. Investors will be relying on management&rsquo;s ability to identify business combinations, evaluate their merits, conduct
or monitor diligence and conduct negotiations. Management&rsquo;s flexibility in identifying and selecting a prospective acquisition
candidate, along with management&rsquo;s financial interest in consummating our initial business combination, may lead management
to enter into an acquisition agreement that is not in the best interest of our stockholders, which would be the case if the trading
price of our shares of common stock after giving effect to such business combination was less than the per-share trust liquidation
value that our stockholders would have received if we had dissolved without consummating our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are not required to obtain an opinion
from an independent investment banking firm, and consequently, an independent source may not confirm that the price we are paying
for the business is fair to our stockholders from a financial point of view.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless we consummate
our initial business combination with an affiliated entity, we are not required to obtain an opinion from an independent investment
banking firm that the price we are paying is fair to our stockholders from a financial point of view. If no opinion is obtained,
our stockholders will be relying on the judgment of our board of directors, who will determine fair market value based on standards
generally accepted by the financial community. Such standards used will be disclosed in our tender offer documents or proxy solicitation
materials, as applicable, related to our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Resources could be wasted in researching
acquisitions that are not consummated.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that
the investigation of each specific target business and the negotiation, drafting, and execution of relevant agreements, disclosure
documents, and other instruments will require substantial management time and attention and substantial costs for accountants,
attorneys and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point
for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target
business, we may fail to consummate our initial business combination for any number of reasons including those beyond our control.
Any such event will result in a loss to us of the related costs incurred, which could materially adversely affect subsequent attempts
to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public
stockholders may only receive $10.00 per share or even less (whether or not the underwriters&rsquo; over-allotment option is exercised
in full) on our redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our ability to successfully effect our
initial business combination and to be successful thereafter will be largely dependent upon the efforts of our officers, directors
and key personnel, some of whom may join us following our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our operations are
dependent upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success
depends on the continued service of our officers and directors, at least until we have consummated our initial business combination.
In addition, our officers and directors are not required to commit any specified amount of time to our affairs and, accordingly,
will have conflicts of interest in allocating management time among various business activities, including identifying potential
business combinations and monitoring the related due diligence. We do not have an employment agreement with, or key-man insurance
on the life of, any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers
could have a detrimental effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The role of such persons
in the target business, however, cannot presently be ascertained. Although some of such persons may remain with the target business
in senior management or advisory positions following our initial business combination, it is likely that some or all of the management
of the target business will remain in place. While we intend to closely scrutinize any individuals we engage after our initial
business combination, our assessment of these individuals may not prove to be correct. These individuals may be unfamiliar with
the requirements of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping
them become familiar with such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our key personnel may negotiate employment
or consulting agreements with a target business in connection with a particular business combination. These agreements may provide
for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of
interest in determining whether a particular business combination is the most advantageous.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our key personnel
may be able to remain with us after the consummation of our initial business combination only if they are able to negotiate employment
or consulting agreements in connection with the business combination. Such negotiations would take place simultaneously with the
negotiation of the business combination and could provide for such individuals to receive compensation in the form of cash payments
and/or our securities for services they would render to us after the consummation of the business combination. The personal and
financial interests of such individuals may influence their motivation in identifying and selecting a target business. However,
we believe the ability of such individuals to remain with us after the consummation of our initial business combination will not
be the determining factor in our decision as to whether or not we will proceed with any potential business combination. There is
no certainty, however, that any of our key personnel will remain with us after the consummation of our initial business combination.
Our key personnel may not remain in senior management or advisory positions with us. The determination as to whether any of our
key personnel will remain with us will be made at the time of our initial business combination. In addition, pursuant to an agreement
to be entered into concurrently with the issuance and sale of the securities in this offering, our sponsor, upon consummation of
an initial business combination, will be entitled to nominate three individuals for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may have a limited ability to assess
the management of a prospective target business and, as a result, may effectuate our initial business combination with a target
business whose management may not have the skills, qualifications or abilities to manage a public company.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When evaluating the
desirability of effecting our initial business combination with a prospective target business, our ability to assess the target
business&rsquo; management may be limited due to a lack of time, resources or information. Our assessment of the capabilities of
the target&rsquo;s management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or
abilities we suspected. Should the target&rsquo;s management not possess the skills, qualifications or abilities necessary to manage
a public company, the operations and profitability of the post-combination business may be negatively impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The officers and directors of an acquisition
candidate may resign upon consummation of our initial business combination. The loss of an acquisition target&rsquo;s key personnel
could negatively impact the operations and profitability of our post-combination business.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The role of an acquisition
candidate&rsquo;s key personnel upon the consummation of our initial business combination cannot be ascertained at this time. Although
we contemplate that certain members of an acquisition candidate&rsquo;s management team will remain associated with the acquisition
candidate following our initial business combination, it is possible that some members of the management team of an acquisition
candidate will not wish to remain in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain of our officers and directors
are affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly, may
have conflicts of interest in allocating their time and determining to which entity a particular business opportunity should be
presented.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following the completion
of this offering and until we consummate our business combination, we intend to engage in the business of identifying and combining
with one or more businesses. Certain of our executive officers and directors are affiliated with entities that are engaged in a
similar business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our officers may become
aware of business opportunities which may be appropriate for presentation to us and the other entities to which they owe certain
fiduciary duties. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity
should be presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, some
of our officers and directors are affiliated with LifeSci Capital, which is the underwriter in this offering. Such officers and
directors owe a pre-existing fiduciary duty to LifeSci Capital, meaning that they will present opportunities to LifeSci Capital
prior to presenting them to us, if, for example, a potential target company is open to either raising funds in an offering or engaging
in a transaction with a SPAC. In addition, three of our officers and directors, Andrew McDonald, Michael Rice and David Dobkin
are officers and directors of LifeSci Acquisition Corp., a special purpose acquisition company that is seeking a target. LifeSci
Acquisition Corp. will have priority over us in connection with potential target businesses identified by each of them. These affiliations
may limit the number of potential targets they present to us for purposes of completing a business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any conflict of interest
may not be resolved in our favor and potential target businesses may be presented to another entity prior to its presentation to
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain shares beneficially owned by
our officers and directors will not participate in liquidation distributions and, therefore, our officers and directors may have
a conflict of interest in determining whether a particular target business is appropriate for our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our officers and directors have waived their right to redeem
any shares in connection with our initial business combination, or to receive distributions with respect to their founder shares
upon our liquidation if we are unable to consummate our initial business combination. Accordingly, these securities will be worthless
if we do not consummate our initial business combination. The personal and financial interests of our directors and officers may
influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently,
our directors&rsquo; and officers&rsquo; discretion in identifying and selecting a suitable target business may result in a conflict
of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and
in our stockholders&rsquo; best interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may engage in our initial business
combination with one or more target businesses that have relationships with entities that may be affiliated with our executive
officers, directors or existing holders, which may raise potential conflicts of interest.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not adopted
a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary
or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have
an interest. In light of the involvement of our sponsor, officers and directors with other entities, we may decide to acquire one
or more businesses affiliated with our sponsor, officers and directors. Our directors also serve as officers and board members
for other entities. Our sponsor, officers and directors are not currently aware of any specific opportunities for us to consummate
our initial business combination with any entities with which they are affiliated, and there have been no preliminary discussions
concerning a business combination with any entity or entities. Although we will not be specifically focusing on, or targeting,
any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met
our criteria for our initial business combination as set forth in &ldquo;Proposed Business &mdash; Effecting our initial business
combination &mdash; Selection of a target business and structuring of our initial business combination&rdquo; and such transaction
was approved by a majority of our disinterested directors. Despite our agreement to obtain an opinion from an independent investment
banking firm, or another independent entity that commonly renders valuation opinions on the type of target business we seek to
acquire, regarding the fairness to our stockholders from a financial point of view of a business combination with one or more domestic
or international businesses affiliated with our executive officers, directors or existing holders, potential conflicts of interest
still may exist and, as a result, the terms of the business combination may not be as advantageous to our public stockholders as
they would be absent any conflicts of interest. Our directors have a fiduciary duty to act in the best interests of our stockholders,
whether or not a conflict of interest may exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because our sponsor will lose its entire
initial investment in us if our initial business combination is not consummated and our officers and directors have significant
financial interests in us, a conflict of interest may arise in determining whether a particular acquisition target is appropriate
for our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&nbsp;1,
2020, our sponsor purchased 2,156,250 founder shares for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci
Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder
shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters&rsquo; over-allotment
option is not exercised in full or in part. The founder shares will be worthless if we do not consummate an initial business combination.
In addition, LifeSci Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants (or 3,283,333
warrants if the over-allotment option is exercised in full), or &ldquo;private warrants,&rdquo; at $0.90 per warrant for a total
purchase price of $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full), which will also be worthless if
we do not consummate our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may issue notes or other debt securities,
or otherwise incur substantial debt, to complete our initial business combination, which may adversely affect our financial condition
and thus negatively impact the value of our stockholders&rsquo; investment in us.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we have no
commitments as of the date of this prospectus to issue any notes or other debt securities, or to otherwise incur outstanding debt,
we may choose to incur substantial debt to complete our initial business combination. If we incur any indebtedness without a waiver
from the lender of any right, title, interest or claim of any kind in or to any monies held in the trust account, the incurrence
of debt could have a variety of negative effects, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">default and foreclosure on our assets if our operating revenues after our initial business combination are insufficient to repay our debt obligations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our inability to pay dividends on our shares of common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our shares of common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may only be able to complete one
business combination with the proceeds of this offering, which will cause us to be solely dependent on a single business, which
may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The net proceeds from this offering together with the funds
we will receive from the sale of the private warrants (excluding $750,000 of net proceeds that will not be held in the trust account)
will provide us with approximately $75,000,000 (or approximately $86,250,000 if the underwriters&rsquo; over-allotment option is
exercised in full) that we may use to complete our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may effectuate
our initial business combination with a single target business or multiple target businesses simultaneously. However, we may not
be able to effectuate our initial business combination with more than one target business because of various factors, including
the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the
SEC that present operating results and the financial condition of several target businesses as if they had been operated on a combined
basis. By consummating our initial business combination with only a single entity, our lack of diversification may subject us to
numerous economic, competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit
from the possible spreading of risks or offsetting of losses, unlike other entities, which may have the resources to complete several
business combinations in different industries or different areas of a single industry. Accordingly, the prospects for our success
may be solely dependent upon the performance of a single business, property or asset, or dependent upon the development or market
acceptance of a single or limited number of products or services. This lack of diversification may subject us to numerous economic,
competitive and regulatory developments, any or all of which may have a substantial adverse impact upon the particular industry
in which we may operate subsequent to our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may attempt to simultaneously consummate
business combinations with multiple prospective targets, which may hinder our ability to consummate our initial business combination
and give rise to increased costs and risks that could negatively impact our operations and profitability.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we determine to
simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that
our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make it more
difficult for us, and delay our ability, to complete the initial business combination. With multiple business combinations, we
could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due
diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of
the operations and services or products of the acquired companies in a single operating business. If we are unable to adequately
address these risks, it could negatively impact our profitability and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may attempt to consummate our initial
business combination with a private company about which little information is available.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In pursuing our acquisition
strategy, we may seek to effectuate our initial business combination with a privately held company. By definition, very little
public information exists about private companies, and we could be required to make our decision on whether to pursue a potential
initial business combination on the basis of limited information, which may result in our initial business combination with a company
that is not as profitable as we suspected, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may not be able to maintain control
of a target business after our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may structure our
initial business combination to acquire less than 100% of the equity interests or assets of a target business, but we will only
consummate such business combination if we will become the majority stockholder of the target (or control the target through contractual
arrangements in limited circumstances for regulatory compliance purposes) or are otherwise not required to register as an investment
company under the Investment Company Act or to the extent permitted by law we may acquire interests in a variable interest entity,
in which we may have less than a majority of the voting rights in such entity, but in which we are the primary beneficiary. Even
though we may own a majority interest in the target, our stockholders prior to the business combination may collectively own a
minority interest in the post business combination company, depending on valuations ascribed to the target and us in the business
combination transaction. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange
for all of the outstanding capital stock of a target. In this case, we acquire a 100% controlling interest in the target. However,
as a result of the issuance of a substantial number of new shares, our stockholders immediately prior to such transaction could
own less than a majority of our outstanding shares subsequent to such transaction. In addition, other minority stockholders may
subsequently combine their holdings resulting in a single person or group obtaining a larger share of the company&rsquo;s stock
than we initially acquired. Accordingly, this may make it more likely that we will not be able to maintain our control of the target
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The ability of our public stockholders to exercise their
redemption rights may not allow us to effectuate the most desirable business combination or optimize our capital structure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our initial business
combination requires us to use substantially all of our cash to pay the purchase price, because we will not know how many public
stockholders may exercise redemption rights, we may either need to reserve part of the trust account for possible payment upon
such redemption, or we may need to arrange third party financing to help fund our initial business combination. In the event that
the acquisition involves the issuance of our stock as consideration, we may be required to issue a higher percentage of our stock
to make up for a shortfall in funds. Raising additional funds to cover any shortfall may involve dilutive equity financing or incurring
indebtedness at higher than desirable levels. This may limit our ability to effectuate the most attractive business combination
available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>In connection with any meeting held
to approve an initial business combination, we will offer each public stockholder the option to vote in favor of the proposed business
combination and still seek redemption of his, her or its shares.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
any meeting held to approve an initial business combination, we will offer each public stockholder (but not our initial stockholders,
officers or directors) the right to have his, her or its shares of common stock redeemed for cash (subject to the limitations described
elsewhere in this prospectus) regardless of whether such stockholder votes for or against such proposed business combination; provided
that a stockholder must in fact vote for or against a proposed business combination in order to have his, her or its shares of
common stock redeemed for cash. If a stockholder fails to vote for or against a proposed business combination, that stockholder
would not be able to have his shares of common stock so redeemed. We will consummate our initial business combination only if we
have net tangible assets of at least $5,000,001 upon such consummation and a majority of the outstanding shares of common stock
voted are voted in favor of the business combination. This is different than other similarly structured blank check companies where
stockholders are offered the right to redeem their shares only when they vote against a proposed business combination. This threshold
and the ability to seek redemption while voting in favor of a proposed business combination may make it more likely that we will
consummate our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A public stockholder who fails to vote
either in favor of or against a proposed business combination will not be able to have his shares redeemed for cash.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order for a public
stockholder to have his shares redeemed for cash in connection with any proposed business combination, that public stockholder
must vote either in favor of or against a proposed business combination. If a public stockholder fails to vote in favor of or against
a proposed business combination, whether that stockholder abstains from the vote or simply does not vote, that stockholder would
not be able to have his shares of common stock so redeemed to cash in connection with such business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We will require public stockholders
who wish to redeem their shares of common stock in connection with a proposed business combination or amendment to our certificate
of incorporation to effect the substance or timing of their redemption obligation if we fail to timely complete a business combination
to comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights
prior to the deadline for exercising their rights.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will require our
public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in &ldquo;street
name,&rdquo; to either tender their certificates to our transfer agent prior to the expiration date set forth in the tender offer
documents mailed to such holders, or in the event we distribute proxy materials, up to two business days prior to the vote on the
proposal to approve the business combination or amendment to our certificate of incorporation to affect the substance or timing
of our redemption obligation to redeem all public shares if we cannot complete an initial business combination, or to deliver their
shares to the transfer agent electronically using Depository Trust Company&rsquo;s DWAC (Deposit/Withdrawal At Custodian) System,
at the holder&rsquo;s option. In order to obtain a physical stock certificate, a stockholder&rsquo;s broker and/or clearing broker,
DTC and our transfer agent will need to act to facilitate this request. It is our understanding that stockholders should generally
allot at least two weeks to obtain physical certificates from the transfer agent. However, because we do not have any control over
this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical stock certificate.
While we have been advised that it takes a short time to deliver shares through the DWAC System, this may not be the case. Under
our certificate of incorporation, we are required to provide at least 10 days advance notice of any stockholder meeting, which
would be the minimum amount of time a stockholder would have to determine whether to exercise redemption rights. Accordingly, if
it takes longer than we anticipate for stockholders to deliver their shares, stockholders who wish to redeem may be unable to meet
the deadline for exercising their redemption rights and thus may be unable to redeem their shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Redeeming stockholders may be unable
to sell their securities when they wish to in the event that the proposed business combination is not approved.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will require public
stockholders who wish to redeem their shares of common stock in connection with any proposed business combination to comply with
the delivery requirements discussed above for redemption. If such proposed business combination is not consummated, we will promptly
return such certificates to the tendering public stockholders. Accordingly, investors who attempted to redeem their shares in such
a circumstance will be unable to sell their securities after the failed acquisition until we have returned their securities to
them. The market price for our shares of common stock may decline during this time and you may not be able to sell your securities
when you wish, even while other stockholders that did not seek redemption may be able to sell their securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because of our structure, other companies
may have a competitive advantage and we may not be able to consummate an attractive business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to encounter
intense competition from entities other than blank check companies having a business objective similar to ours, including venture
capital funds, leveraged buyout funds and operating businesses competing for acquisitions. Many of these entities are well established
and have extensive experience in identifying and effecting business combinations directly or through affiliates. Many of these
competitors possess greater technical, human and other resources than we do and our financial resources will be relatively limited
when contrasted with those of many of these competitors. Therefore, our ability to compete in acquiring certain sizable target
businesses may be limited by our available financial resources. This inherent competitive limitation gives others an advantage
in pursuing the acquisition of certain target businesses. Furthermore, seeking stockholder approval of our initial business combination
may delay the consummation of a transaction. Additionally, our rights, and the future dilution they represent (entitling the holders
to receive shares of common stock on consummation of our initial business combination), may not be viewed favorably by certain
target businesses. Any of the foregoing may place us at a competitive disadvantage in successfully negotiating our initial business
combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Certificate of Incorporation contains
provisions that prohibit our engaging in business combinations with interested stockholders in certain circumstances.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have opted out
of Section&nbsp;203 of the Delaware General Corporate Law, or the DGCL. However, our amended and restated certificate of incorporation
contains similar provisions providing that we may not engage in certain &ldquo;business combinations&rdquo; with any &ldquo;interested
stockholder&rdquo; for a three-year period following the time that the stockholder became an interested stockholder, unless</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 48px">&bull;</TD>
    <TD STYLE="text-align: justify">prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 48px">&bull;</TD>
    <TD STYLE="text-align: justify">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 48px">&bull;</TD>
    <TD STYLE="text-align: justify">at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66&frac23;% of the outstanding voting stock that is not owned by the interested stockholder.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a &ldquo;business
combination&rdquo; includes a merger, asset or stock sale or certain other transactions with the interested stockholder. Subject
to certain exceptions, an &ldquo;interested stockholder&rdquo; is a person who, together with that person&rsquo;s affiliates and
associates, owns, or within the previous three years owned, 20% or more of our voting stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under certain circumstances,
this provision will make it more difficult for a person who would be an &ldquo;interested stockholder&rdquo; to effect various
business combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring
our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if
our board of directors approves either the business combination or the transaction which results in the stockholder becoming an
interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make
it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
certificate of incorporation provides that our sponsor and its respective affiliates, any of their respective direct or indirect
transferees of at least 20% of our outstanding common stock and any group as to which such persons are party to, do not constitute
 &ldquo;interested stockholders&rdquo; for purposes of this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may be unable to obtain additional
financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel
us to restructure or abandon a particular business combination. If we are unable to complete our initial business combination,
our public stockholders may only receive $10.00 per share or even less (whether or not the underwriters&rsquo; over-allotment option
is exercised in full) on our redemption.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we believe
that the net proceeds of this offering will be sufficient to allow us to consummate our initial business combination, because
we have not yet identified any prospective target business we cannot ascertain the capital requirements for any particular transaction
or our costs to operate or locate a transaction. If the net proceeds of this offering prove to be insufficient, either because
of the size of our initial business combination, the depletion of the available net proceeds in search of a target business, the
obligation to repurchase for cash a significant number of shares from stockholders who elect redemption in connection with our
initial business combination or the terms of negotiated transactions to purchase shares in connection with our initial business
combination, we may be required to seek additional financing or to abandon the proposed business combination. Financing may not
be available on acceptable terms, if at all. The current economic environment has made it especially difficult for companies to
obtain acquisition financing. To the extent that additional financing proves to be unavailable when needed to consummate our initial
business combination, we would be compelled to either restructure the transaction or abandon that particular initial business
combination and seek an alternative target business candidate. If we are unable to complete our initial business combination,
our public stockholders may only receive $10.00 per share or even less (whether or not the underwriters&rsquo; over-allotment
option is exercised in full) on our redemption. In addition, even if we do not need additional financing to consummate our initial
business combination, we may require such financing to fund the operations or growth of the target business. The failure to secure
additional financing could have a material adverse effect on the continued development or growth of the target business. None
of our officers, directors or stockholders is required to provide any financing to us in connection with or after our initial
business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our sponsor controls a substantial interest
in us and thus may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not
support.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">W<FONT STYLE="background-color: white">e have agreed not to
enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor. Further,
</FONT>upon closing of this offering, our initial stockholders and our sponsor (and/its designees) collectively will own 20% of
our issued and outstanding shares of common stock (assuming they do not purchase any shares in this offering). Accordingly, they
may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including
amendments to our certificate of incorporation. If our sponsor purchases any shares in this offering or if we or our sponsor purchase
any additional shares of common stock in the aftermarket or in privately negotiated transactions, this would increase their control.
Neither our sponsor nor, to our knowledge, any of our officers or directors, has any current intention to purchase additional securities.
Factors that would be considered in making such additional purchases would include consideration of the current trading price of
our shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our initial stockholders paid an aggregate
of $25,000, or approximately $0.012 per founder share and, accordingly, you will experience immediate and substantial dilution
from the purchase of our shares of common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The difference
between the public offering price per share and the pro forma net tangible book value per share after this offering
constitutes the dilution to you and the other investors in this offering. Our initial stockholders acquired the founder
shares at a nominal price, significantly contributing to this dilution. Upon closing of this offering, you and the other
public stockholders will incur an immediate and substantial dilution of approximately 78.2% or $7.82 per share (the
difference between the pro forma net tangible book value per share of $2.18 and the initial offering price of $10.00 per
share immediately upon the closing of this offering), or approximately 80.6% dilution or $8.06 per share (the difference
between the pro forma net tangible book value per share of $1.94 and the initial offering price of $10.00 per share) if the
over-allotment is fully exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The determination of the offering price
of our shares and the size of this offering is more arbitrary than the pricing of securities and size of an offering of an operating
company in a particular industry.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to this offering
there has been no public market for any of our securities. The public offering price of the shares was negotiated between us and
the underwriters. In determining the size of this offering, management held customary organizational meetings with representatives
of the underwriters, both prior to our inception and thereafter, with respect to the state of capital markets, generally, and
the amount the underwriters believed they reasonably could raise on our behalf. Factors considered in determining the size of
this offering, prices and terms of the shares of common stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">the history and prospects of companies whose principal business is the acquisition of other companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">prior offerings of those companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our prospects for acquiring an operating business at attractive values;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a review of debt to equity ratios in leveraged transactions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our capital structure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">an assessment of our management and their experience in identifying operating companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">general conditions of the securities markets at the time of this offering; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">other factors as were deemed relevant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although these factors
were considered, the determination of our offering price is more arbitrary than the pricing of securities of an operating company
in a particular industry since we have no historical operations or financial results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>There is currently no market for our
securities and a market for our securities may not develop, which would adversely affect the liquidity and price of our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of
this prospectus there is currently no market for our securities. Prospective stockholders therefore have no access to information
about prior market history on which to base their investment decision. Following this offering, the price of our securities may
vary significantly due to one or more potential business combinations and general market or economic conditions. Once listed on
Nasdaq, an active trading market for our securities may never develop or, if developed, it may not be sustained. Additionally,
if our securities become delisted from Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated
quotation system for equity securities not listed on a national exchange, the liquidity and price of our securities may be more
limited than if we were listed on Nasdaq or another national exchange. You may be unable to sell your securities unless a market
can be established and sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Once initially listed on Nasdaq, our
securities may not continue to be listed on Nasdaq in the future, which could limit investors&rsquo; ability to make transactions
in our securities and subject us to additional trading restrictions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that
our securities will be initially listed on Nasdaq upon consummation of this offering. However, we cannot assure you of this or
that our securities will continue to be listed on Nasdaq in the future. Additionally, in connection with our business combination,
Nasdaq may require us to file a new initial listing application and meet its initial listing requirements as opposed to its more
lenient continued listing requirements. We cannot assure you that we will be able to meet those initial listing requirements at
that time. If Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a limited availability of market quotations for our securities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a reduced liquidity with respect to our securities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a determination that our shares of common stock are a &ldquo;penny stock&rdquo; which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a limited amount of news and analyst coverage for our company; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">a decreased ability to issue additional securities or obtain additional financing in the future.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because we must furnish our stockholders
with target business financial statements prepared in accordance with U.S. generally accepted accounting principles or international
financial reporting standards, we may lose the ability to complete an otherwise advantageous initial business combination with
some prospective target businesses.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The federal proxy
rules, which require that a proxy statement with respect to a vote on a business combination meeting certain financial significance
tests include historical and/or pro forma financial statement disclosure in periodic reports. These financial statements may be
required to be prepared in accordance with, or be reconciled to, accounting principles generally accepted in the United States
of America, or GAAP, or international financial reporting standards, or IFRS as issued by the International Accounting Standards
Board or the IASB, depending on the circumstances and the historical financial statements may be required to be audited in accordance
with the standards of the Public Company Accounting Oversight Board (United States), or PCAOB. We will include the substantially
the same financial statement disclosure in connection with any tender offer documents we use, whether or not they are required
under the tender offer rules. These financial statement requirements may limit the pool of potential target businesses we may consummate
our initial business combination with because some targets may be unable to provide such statements in time for us to disclose
such statements in accordance with federal proxy rules&nbsp;and complete our initial business combination within the prescribed
time frame.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compliance obligations under the Sarbanes-Oxley
Act of 2002 may make it more difficult for us to effectuate our initial business combination, require substantial financial and
management resources, and increase the time and costs of completing an acquisition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;404 of
the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we evaluate and report on our system of internal controls
beginning with our Annual Report on Form&nbsp;10-K for the year ending June&nbsp;30, 2022. The fact that we are a blank check company
makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to all public companies
because a target company with which we seek to complete our initial business combination may not be in compliance with the provisions
of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal controls of any such entity
to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We are an &ldquo;emerging growth company&rdquo;
and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities
less attractive to investors.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the JOBS Act. We will remain an &ldquo;emerging growth company&rdquo; for up to five years.
However, if our non-convertible debt issued within a three-year period or revenues exceeds $1.07 billion, or the market value of
our shares of common stock that are held by non-affiliates exceeds $700 million on the last day of the second fiscal quarter of
any given fiscal year, we would cease to be an emerging growth company as of the following fiscal year. As an emerging growth company,
we are not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, we have
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and we are exempt
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. Additionally, as an emerging growth company, we have elected to delay the adoption of new or
revised accounting standards that have different effective dates for public and private companies until those standards apply to
private companies. As such, our financial statements may not be comparable to companies that comply with public company effective
dates. We cannot predict if investors will find our shares less attractive because we may rely on these provisions. If some investors
find our shares less attractive as a result, there may be a less active trading market for our shares and our share price may be
more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Further, Section&nbsp;102(b)(1)&nbsp;of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out
of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private
companies are required to adopt the new or revised standard. This may make comparison of our financial statements with another
public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended
transition period difficult or impossible because of the potential differences in accountant standards used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our amended and restated certificate
of incorporation will designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types
of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&rsquo; ability to obtain
a favorable judicial forum for disputes with our company or our company&rsquo;s directors, officers or other employees.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1)&nbsp;derivative
action or proceeding brought on behalf of our company, (2)&nbsp;action asserting a claim of breach of a fiduciary duty owed by
any director, officer, employee or agent of our company to our company or our stockholders, or any claim for aiding and abetting
any such alleged breach, (3)&nbsp;action asserting a claim against our company or any director or officer of our company arising
pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws, or (4)&nbsp;action
asserting a claim against us or any director or officer of our company governed by the internal affairs doctrine except for, as
to each of (1)&nbsp;through (4)&nbsp;above, any claim (a)&nbsp;as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten days following such determination), (b)&nbsp;which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery, or (c)&nbsp;arising under the federal securities laws, including the Securities
Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall concurrently be the sole
and exclusive forums. Notwithstanding the foregoing, the inclusion of such provision in our amended and restated certificate of
incorporation will not be deemed to be a waiver by our stockholders of our obligation to comply with federal securities laws, rules&nbsp;and
regulations, and the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive
forum. Any person or entity purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to
have notice of and to have consented to the forum provisions in our amended and restated certificate of incorporation. If any action
the subject matter of which is within the scope the forum provisions is filed in a court other than a court located within the
State of Delaware (a &ldquo;foreign action&rdquo;) in the name of any stockholder, such stockholder shall be deemed to have consented
to: (x)&nbsp;the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with
any action brought in any such court to enforce the forum provisions (an &ldquo;enforcement action&rdquo;), and (y)&nbsp;having
service of process made upon such stockholder in any such enforcement action by service upon such stockholder&rsquo;s counsel in
the foreign action as agent for such stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This choice-of-forum
provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes with
our company or its directors, officers or other employees, which may discourage such lawsuits. Alternatively, if a court were to
find this provision of our amended and restated certificate of incorporation inapplicable or unenforceable with respect to one
or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters
in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations
and result in a diversion of the time and resources of our management and board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Associated with Acquiring and
Operating a Business outside of the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We may effect our initial business combination
with a company located outside of the United States.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we effect our initial
business combination with a company located outside of the United States, we would be subject to any special considerations or
risks associated with companies operating in the target business&rsquo; home jurisdiction, including any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">rules&nbsp;and regulations or currency redemption or corporate withholding taxes on individuals;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">laws governing the manner in which future business combinations may be effected;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">exchange listing and/or delisting requirements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">tariffs and trade barriers;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">regulations related to customs and import/export matters;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">longer payment cycles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">tax issues, such as tax law changes and variations in tax laws as compared to the United States;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">currency fluctuations and exchange controls;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">rates of inflation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">challenges in collecting accounts receivable;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">cultural and language differences;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">employment regulations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">crime, strikes, riots, civil disturbances, terrorist attacks and wars; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">deterioration of political relations with the United States. We may not be able to adequately address these additional risks. If we were unable to do so, our operations might suffer.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>There are costs and difficulties inherent
in managing cross-border business operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Managing a business,
operations, personnel or assets in another country is challenging and costly. Any management that we may have (whether based abroad
or in the United States) may be inexperienced in cross-border business practices and unaware of significant differences in accounting
rules, legal regimes and labor practices. Even with a seasoned and experienced management team, the costs and difficulties inherent
in managing cross-border business operations, personnel and assets can be significant (and much higher than in a purely domestic
business) and may negatively impact our financial and operational performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Social unrest, acts of terrorism, regime
changes, changes in laws and regulations, political upheaval, or policy changes or enactments may occur in a country in which we
may operate after we effect our initial business combination.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Political events in
another country may significantly affect our business, assets or operations. Social unrest, acts of terrorism, regime changes,
changes in laws and regulations, political upheaval, and policy changes or enactments could negatively impact our business in a
particular country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Many countries have difficult and unpredictable
legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to seek
and enforce legal protections, including with respect to intellectual property and other property rights, or to defend ourselves
with regard to legal actions taken against us in a given country, may be difficult or impossible, which could adversely impact
our operations, assets or financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Rules&nbsp;and regulations
in many countries are often ambiguous or open to differing interpretation by responsible individuals and agencies at the municipal,
state, regional and federal levels. The attitudes and actions of such individuals and agencies are often difficult to predict and
inconsistent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Delay with respect
to the enforcement of particular rules&nbsp;and regulations, including those relating to customs, tax, environmental and labor,
could cause serious disruption to operations abroad and negatively impact our results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If relations between the United States
and foreign governments deteriorate, it could cause potential target businesses or their goods and services to become less attractive.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The relationship between
the United States and foreign governments could be subject to sudden fluctuation and periodic tension. For instance, the United
States may announce its intention to impose quotas on certain imports. Such import quotas may adversely affect political relations
between the two countries and result in retaliatory countermeasures by the foreign government in industries that may affect our
ultimate target business. Changes in political conditions in foreign countries and changes in the state of U.S. relations with
such countries are difficult to predict and could adversely affect our operations or cause potential target businesses or their
goods and services to become less attractive. Because we are not limited to any specific industry, there is no basis for investors
in this offering to evaluate the possible extent of any impact on our ultimate operations if relations are strained between the
United States and a foreign country in which we acquire a target business or move our principal manufacturing or service operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If our management following our initial
business combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar
with such laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following our initial
business combination, our management may resign from their positions as officers or directors of the company and the management
of the target business at the time of the business combination will remain in place. Management of the target business may not
be familiar with United States securities laws. If new management is unfamiliar with our laws, they may have to expend time and
resources becoming familiar with such laws. This could be expensive and time-consuming and could lead to various regulatory issues,
which may adversely affect our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Currency policies may cause a target
business&rsquo; ability to succeed in the international markets to be diminished.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the event we acquire
a non-U.S. target, all revenues and income would likely be received in a foreign currency, the dollar equivalent of our net assets
and distributions, if any, could be adversely affected by reductions in the value of the local currency. The value of the currencies
in our target regions fluctuate and are affected by, among other things, changes in political and economic conditions. Any change
in the relative value of such currency against our reporting currency may affect the attractiveness of any target business or,
following consummation of our initial business combination, our financial condition and results of operations. Additionally, if
a currency appreciates in value against the dollar prior to the consummation of our initial business combination, the cost of a
target business as measured in dollars will increase, which may make it less likely that we are able to consummate such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Because foreign law could govern our
material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Foreign law could
govern our material agreements. The target business may not be able to enforce any of its material agreements or that remedies
will be available outside of such foreign jurisdiction&rsquo;s legal system. The system of laws and the enforcement of existing
laws and contracts in such jurisdiction may not be as certain in implementation and interpretation as in the United States. The
judiciaries in certain foreign countries may be relatively inexperienced in enforcing corporate and commercial law, leading to
a higher than usual degree of uncertainty as to the outcome of any litigation, any such jurisdictions may not favor outsiders or
could be corrupt. As a result, the inability to enforce or obtain a remedy under any of our future agreements could result in a
significant loss of business and business opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_004"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Certain statements
contained in this prospectus, which reflect our current views with respect to future events and financial performance, and any
other statements of a future or forward-looking nature, constitute &ldquo;forward-looking statements&rdquo; for the purpose of
the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management&rsquo;s
expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking
statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo;
and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement
is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our ability to complete our initial business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our potential ability to obtain additional financing to complete our initial business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our pool of prospective target businesses;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">the ability of our officers and directors to generate a number of potential investment opportunities;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">the delisting of our securities from Nasdaq or an inability to have our securities listed on Nasdaq following a business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our public securities&rsquo; potential liquidity and trading;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">the lack of a market for our securities; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32px">&nbsp;</TD>
    <TD STYLE="width: 32px">&bull;</TD>
    <TD STYLE="text-align: justify">our financial performance following this offering.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The forward-looking
statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their
potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results
or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, those factors described under the heading &ldquo;Risk Factors&rdquo; beginning on
page&nbsp;18. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect,
actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required under applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are offering
7,500,000 shares of common stock at a price of $10.00 per share. We estimate that the net proceeds of this offering, together
with the funds we receive from the sale of the private warrants (all of which will be deposited into the trust account), will
be used as set forth in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Without <BR> Over-<BR> Allotment <BR> Option</TD>
<TD STYLE="vertical-align: super; text-align: left; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Over-<BR> Allotment <BR> Option <BR> Exercised</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; font-weight: bold"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Gross proceeds</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="width: 74%; font-size: 10pt; text-align: left">From offering</TD>
<TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="width: 10%; font-size: 10pt; text-align: right">75,000,000</TD>
<TD STYLE="vertical-align: super; width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
<TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="width: 10%; font-size: 10pt; text-align: right">86,250,000</TD>
<TD STYLE="vertical-align: super; width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">From sale of private warrants</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,730,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,955,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Total gross proceeds</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">77,730,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">89,205,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; font-style: italic"><I>Offering expenses<SUP>(1)</SUP></I></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Underwriting discount</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">1,500,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">1,725,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">Initial Trustees&rsquo; fee</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">6,500</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">6,500</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Legal fees and expenses</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">225,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">225,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">Nasdaq listing fee</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">50,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">50,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Printing and engraving expenses</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">20,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">20,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">Accounting fees and expenses</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">40,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">40,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">FINRA filing fee</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">13,438</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">13,438</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">SEC registration fee</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">9,410</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">9,410</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">115,652</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">115,652</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left; padding-left: 0.125in">Total offering expenses</TD>
<TD STYLE="padding-bottom: 2.5pt; font-size: 10pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,980,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="padding-bottom: 2.5pt; font-size: 10pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,205,000</TD>
<TD STYLE="vertical-align: super; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; font-style: italic; text-align: left">Net proceeds</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Held in trust</FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">75,000,000</FONT></TD>
<TD STYLE="vertical-align: middle; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
<TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD>
<TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">86,250,000</FONT></TD>
<TD STYLE="vertical-align: middle; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Not held in trust</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">750,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">750,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.125in">Total net proceeds</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">75,750,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">87,000,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left">Use of net proceeds not held in the trust account<SUP>(3)&nbsp;(4)</SUP></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Legal, accounting and other third party expenses attendant to the search for target businesses and to the due diligence investigation, structuring and negotiation of a business combination</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">$</TD>
<TD STYLE="font-size: 10pt; text-align: right">100,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">13.3</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Due diligence of prospective target businesses by officers, directors and initial&nbsp;stockholders</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">65,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">8.7</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left">Legal and accounting fees relating to SEC reporting obligations</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">60,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">8.0</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Payment of administrative fee to an affiliate of LifeSci Holdings LLC ($10,000 per month for up to 24 months), subject to deferral as described herein</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">240,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="font-size: 10pt; text-align: right">32.0</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
<TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Working capital to cover miscellaneous expenses, D&amp;O insurance, general corporate purposes, liquidation obligations and reserves</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">285,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38.0</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Total</TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">750,000</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></FONT></TD>
<TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD>
<TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">100.0</TD>
<TD STYLE="vertical-align: super; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt"><SUP>%</SUP></FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">A portion of the offering expenses, including the SEC registration fee, the FINRA filing fee, the non-refundable portion of the Nasdaq listing fee and a portion of the legal and audit fees, have been paid from the funds we borrowed from our sponsor. These funds will be repaid out of the proceeds of this offering available to us.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(2)</TD>
    <TD STYLE="text-align: justify">The funds held in the trust account will be used to acquire a target business, to pay holders who wish to convert or sell their shares for a portion of the funds held in the trust account and potentially to pay our expenses relating thereto. Our expenses relating to the acquisition of a target business would either come from the funds held in the trust account or additional funds otherwise available to us outside of the trust account, including cash held by the target business. Any remaining funds will be disbursed to the combined company and be used as working capital to finance the operations of the target business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(3)</TD>
    <TD STYLE="text-align: justify">The amount of proceeds not held in trust will remain constant at $750,000 even if the over-allotment is exercised.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(4)</TD>
    <TD STYLE="text-align: justify">These are estimates only. Our actual expenditures for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level of complexity of that business combination. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would be deducted from our excess working capital.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The payment to an
affiliate of LifeSci Holdings LLC of a monthly fee of $10,000 is for general and administrative services including office space,
utilities and secretarial support. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon
a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses
in connection with our initial business combination. Any such unpaid amount will accrue without interest and be due and payable
no later than the date of the consummation of our initial business combination. This arrangement is being agreed to by an affiliate
of LifeSci Holdings LLC for our benefit. We believe that the fee charged by the affiliate of LifeSci Holdings LLC is at least as
favorable as we could have obtained from an unaffiliated person. This arrangement will terminate upon completion of our initial
business combination or the distribution of the trust account to our public stockholders. Other than the $10,000 per month fee,
no compensation of any kind (including finder&rsquo;s fees, consulting fees or other similar compensation) will be paid to our
insiders, members of our management team or any of our or their respective affiliates, for services rendered to us prior to or
in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However,
such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our
behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business
combinations, as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine
their operations. Since the role of present management after our initial business combination is uncertain, we have no ability
to determine what remuneration, if any, will be paid to those persons after our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A total of
$10.00 per share (whether or not the underwriters&rsquo; over-allotment option is exercised in full) of the net proceeds from
this offering and the sale of the private warrants described in this prospectus will be placed in a trust account in the United
States, maintained by Continental Stock Transfer&nbsp;&amp; Trust Company acting as trustee and will be
invested only in U.S. government treasury bills, notes and bonds with a maturity of 183 days or less or in money market funds
meeting certain conditions under Rule&nbsp;2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries.
Except for all interest income that may be released to us to pay our tax obligations or for working capital purposes
(provided that the funds released for working capital purposes may not exceed $250,000 annually), as discussed below, none of
the funds held in the trust account will be released from the trust account until the earlier of: (i)&nbsp;the consummation
of our initial business combination within 24 months from the closing of this offering and (ii)&nbsp;a redemption to public
stockholders prior to any voluntary winding-up in the event we do not consummate our initial business combination within the
applicable period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The net proceeds held
in the trust account may be used as consideration to pay the sellers of a target business with which we ultimately complete our
initial business combination. If our initial business combination is paid for using shares or debt securities, or not all of the
funds released from the trust account are used for payment of the purchase price in connection with our business combination, we
may apply the cash released from the trust account that is not applied to the purchase price for general corporate purposes, including
for maintenance or expansion of operations of acquired businesses, the payment of principal or interest due on indebtedness incurred
in consummating the initial business combination, to fund the purchase of other companies or for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We believe that amounts
not held in trust will be sufficient to pay the costs and expenses to which such proceeds are allocated. This belief is based on
the fact that while we may begin preliminary due diligence of a target business in connection with an indication of interest, we
intend to undertake in-depth due diligence, depending on the circumstances of the relevant prospective acquisition, only after
we have negotiated and signed a letter of intent or other preliminary agreement that addresses the terms of our initial business
combination. However, if our estimate of the costs of undertaking in-depth due diligence and negotiating our initial business combination
is less than the actual amount necessary to do so, or the amount of interest available to use from the trust account is minimal
as a result of the current interest rate environment, we may be required to raise additional capital, the amount, availability
and cost of which is currently unascertainable. In this event, we could seek such additional capital through loans or additional
investments from members of our management team, but such members of our management team are not under any obligation to advance
funds to, or invest in, us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of
this prospectus, our sponsor has not loaned us any amounts to be used for a portion of the expenses of this offering. Any loans
will be non-interest bearing and payable on the date on which we consummate the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in order
to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor
or our officers and directors may, but are not obligated to, loan us funds as may be required. If we consummate our initial business
combination, we would repay such loaned amounts. The notes would either be paid upon consummation of our initial business combination,
without interest, or, at the lender&rsquo;s discretion, up to $500,000 of the notes may be converted upon consummation of our business
combination into additional private warrants at a conversion price of $0.90 per private warrant. Such private warrants will be
identical to the private warrants to be issued at the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In no event will we
redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001. Furthermore, the redemption
threshold may be further limited by the terms and conditions of our initial business combination. In such case, we would not proceed
with the redemption of our public shares or the business combination, and instead may search for an alternate business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A public stockholder
will be entitled to receive funds from the trust account only upon the earlier to occur of: (i)&nbsp;our consummation of our initial
business combination, and then only in connection with those shares of common stock that such stockholder properly elected to redeem,
subject to the limitations described herein, (ii)&nbsp;the redemption of our public shares if we are unable to consummate our initial
business combination within 24 months following the closing of this offering, subject to applicable law, or (iii)&nbsp;if we seek
to amend our certificate of incorporation to affect the substance or timing of our obligation to redeem all public shares if we
cannot complete an initial business combination within 24 months of the closing of this offering and such amendment is duly approved.
In no other circumstances will a public stockholder have any right or interest of any kind to or in the trust account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our initial stockholders
have agreed to waive their redemption rights with respect to any shares they own in connection with the consummation of our initial
business combination, including their founder shares, public shares and private placement warrants that they have purchased during
or after the offering, if any. In addition, our initial stockholders have agreed to waive their rights to liquidating distributions
with respect to their founder shares and private placement warrants if we fail to consummate our initial business combination within
24 months from the closing of this offering. However, if our initial stockholders acquire public shares in or after this offering,
they will be entitled to receive liquidating distributions with respect to such public shares if we fail to consummate our initial
business combination within the required time period. In addition, we agreed not to enter into a definitive agreement regarding
an initial business combination without the prior consent of our sponsor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_006"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not paid any
cash dividends on our shares of common stock to date and do not intend to pay cash dividends prior to the completion of our initial
business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital
requirements and general financial condition subsequent to completion of our initial business combination. The payment of any cash
dividends subsequent to our initial business combination will be within the discretion of our board of directors at such time and
subject to the Delaware law. In addition, our board of directors is not currently contemplating and does not anticipate declaring
any share dividends in the foreseeable future, except if we increase the size of the offering pursuant to Rule&nbsp;462(b)&nbsp;under
the Securities Act, in which case we will effect a share dividend immediately prior to the consummation of the offering in such
amount as to maintain our initial stockholders&rsquo; ownership at 20% of the issued and outstanding shares of common stock upon
the consummation of this offering (assuming no purchase in this offering and not taking into account ownership of the private warrants).
Further, if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends may
be limited by restrictive covenants we may agree to in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_007"></A>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">The difference between the public offering price per share and the pro forma net tangible book value per share after this offering constitutes
the dilution to investors in this offering. Net tangible book value per share is determined by dividing our net tangible book value, which
is our total tangible assets less total liabilities (including the value of shares of common stock which may be redeemed for cash), by
the number of outstanding shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0 0pt 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At June 30, 2020,
our net tangible book value deficit was $(4,000) or approximately $(0.00) per share. After giving effect to the sale of 7,500,000
shares of common stock we are offering by this prospectus and the proceeds received from the sale of the private warrants, the
deduction of underwriting discounts and estimated expenses of this offering, our pro forma net tangible book value at June 30,
2020 would have been $5,000,010 or $2.18 per share, representing an immediate increase in net tangible book value of $2.18 per
share to the initial stockholders and an immediate dilution of 78.2% per share or $7.82 to new investors not exercising their conversion/tender
rights. For purposes of presentation, our pro forma net tangible book value after this offering is $70,773,990 less than it otherwise
would have been because, if we effect a business combination, the ability of public stockholders to exercise conversion rights
or sell their shares to us in any tender offer may result in the conversion or tender of up to 7,077,399 shares sold in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The
following table illustrates the dilution to the new investors on a per-share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; font: 10pt Times New Roman, Times, Serif">Public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 10%">10.00</TD>
    <TD STYLE="width: 2%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net tangible book value before this offering</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(0.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Increase attributable to new investors, private sales and capital contribution</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2.18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Pro forma net tangible book value after this offering</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2.18</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Dilution to new investors</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">$</TD>
    <TD STYLE="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">7.82</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Percentage of dilution to new investors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">78.2</TD>
    <TD>%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
sets forth information with respect to our initial stockholders and the new investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares Purchased</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total Consideration</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Average<BR>
Price</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial stockholders<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,875,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.01</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New investors</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,500,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80.0</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.97</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">9,375,000</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,025,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100.00</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited as a result thereof.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The pro forma net
tangible book value after the offering is calculated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Numerator:<SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 86%; font-size: 10pt; text-align: left">Net tangible book value before this offering</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(4,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net proceeds from this offering and private placement of private warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">75,750,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Plus: Offering costs accrued or paid in advance and excluded from tangible book value before this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Proceeds held in trust subject to conversion/tender</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(70,773,990</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,000,010</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Denominator:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Shares of common stock issued and outstanding prior to this offering<SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,875,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Shares of common stock to be sold in this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less: Shares subject to conversion/tender</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,077,399</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,297,601</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited by us as a result thereof.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_008"></A>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth our capitalization
at June 30, 2020 and as adjusted to give effect to the sale of our public shares of common stock and the private warrants and the
application of the estimated net proceeds derived from the sale of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June&nbsp;30, 2020</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>As<BR>
 Adjusted<SUP>(1)</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt; width: 72%">Promissory note &ndash; related party<SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right; width: 10%">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of common stock, $0.0001 par value, none and 7,077,399 shares are&nbsp;subject to possible conversion/tender, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,773,990</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares of common stock, $0.0001 par value, 5,000,000 shares authorized (actual); 30,000,000 authorized, as adjusted, 2,156,250 shares issued and outstanding, actual; 2,297,601 shares issued and&nbsp;outstanding<SUP>(3)&nbsp;</SUP>(excluding 7,077,399 shares subject to possible conversion/tender), as adjusted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">230</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,784</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,000,780</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">24,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,000,010</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Total capitalization</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">24,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">75,774,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Includes the $2,730,000 we will receive from the sale of the private warrants.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(2)</TD>
    <TD STYLE="text-align: justify">As of June&nbsp;30, 2020, we had not borrowed any amounts under the promissory note. The loans are non-interest bearing and payable on the date on which we consummate the offering.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(3)</TD>
    <TD STYLE="text-align: justify">Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited as a result thereof.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_009"></A>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL CONDITION AND RESULTS&nbsp;OF&nbsp;OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We were incorporated
on December&nbsp;18, 2019 as a Delaware corporation to serve as a vehicle to effect a merger, share exchange, asset acquisition,
share purchase, recapitalization, reorganization or similar business combination with one or more target businesses. Our efforts
to identify a prospective target business will not be limited to a particular industry or geographic location. We intend to utilize
cash derived from the proceeds of this offering, our securities, debt or a combination of cash, securities and debt, in effecting
a business combination. The issuance of additional shares in our business combination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">may significantly reduce the equity interest of our stockholders;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">may subordinate the rights of holders of common stock if we issue preferred shares with rights senior to those afforded to our shares of common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">will likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our present officers and directors; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">may adversely affect prevailing market prices for our securities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Similarly, if we issue
debt securities, it could result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">default and foreclosure on our assets if our operating revenues after a business combination are insufficient to pay our debt obligations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">acceleration of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation of that covenant;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional financing while such security is outstanding.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As indicated in the
accompanying financial statements, at June&nbsp;30, 2020, we had $25,000 in cash and $28,000 in deferred offering costs. Further,
we expect to continue to incur significant costs in the pursuit of our acquisition plans. Our plans to raise capital or to consummate
our initial business combination may not be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations and Known Trends
or Future Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have neither engaged
in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and
those necessary to prepare for this offering. Following this offering, we will not generate any operating revenues until after
completion of our initial business combination. We will generate non-operating income in the form of interest income on cash and
cash equivalents after this offering. There has been no significant change in our financial or trading position and no material
adverse change has occurred since the date of our audited financial statements. After this offering, we expect to incur increased
expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as
for due diligence expenses. We expect our expenses to increase substantially after the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As indicated in the
accompanying financial statements, at June&nbsp;30, 2020, we had $25,000 in cash and working capital deficit of $4,000. Further,
we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management&rsquo;s
plans to address this uncertainty through this offering are discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our liquidity needs
have been satisfied to date through receipt of $25,000 from the sale of the insider shares and loans from our sponsor. We estimate
that the net proceeds from (1)&nbsp;the sale of the shares in this offering, after deducting offering expenses of approximately
$480,000 and underwriting fees and qualified independent underwriter fees of $1,500,000 (or $1,725,000 if the over-allotment option
is exercised in full) and (2)&nbsp;the sale of the private warrants for a purchase price of $2,730,000 (or $2,955,000 if the over-allotment
option is exercised in full) will be $75,750,000 (or $87,000,000 if the over-allotment option is exercised in full). Of this amount,
$75,000,000 (or $86,250,000 if the over-allotment option is exercised in full) will be held in the trust account. The remaining
$750,000 (whether or not the over-allotment option is exercised in full) will not be held in the trust account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to use substantially
all of the net proceeds of this offering, including the funds held in the trust account, to acquire a target business or businesses
and to pay our expenses relating thereto. To the extent that our share capital is used in whole or in part as consideration to
effect our initial business combination, the remaining proceeds held in the trust account as well as any other net proceeds not
expended will be used as working capital to finance the operations of the target business. Such working capital funds could be
used in a variety of ways including continuing or expanding the target business&rsquo; operations, for strategic acquisitions and
for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses
or finders&rsquo; fees which we had incurred prior to the completion of our initial business combination if the funds available
to us outside of the trust account were insufficient to cover such expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Over the next 24 months
(assuming a business combination is not consummated prior thereto), we will be using the funds held outside of the trust account
for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses,
traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents
and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating
and consummating the business combination. Out of the funds available outside the trust account, we anticipate that we will incur
approximately:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">$100,000 of expenses for the search for target businesses and for the legal, accounting and other third-party expenses attendant to the due diligence investigations, structuring and negotiating of a business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">$65,000 of expenses for the due diligence and investigation of a target business by our officers, directors and initial stockholders;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">$60,000 of expenses in legal and accounting fees relating to our SEC reporting obligations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">$240,000 for the payment of the administrative fee to an affiliate
of LifeSci Holdings LLC, our sponsor (of $10,000 per month for up to 24 months), subject to deferral as described herein; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">$285,000 for general working capital that will be used for miscellaneous expenses, including director and officer liability insurance premiums.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our estimates of
the costs of undertaking in-depth due diligence and negotiating our initial business combination is less than the actual amount
necessary to do so, we may have insufficient funds available to operate our business prior to our initial business combination.
Moreover, we may need to obtain additional financing either to consummate our initial business combination or because we become
obligated to redeem a significant number of our public shares upon consummation of our initial business combination, in which case
we may issue additional securities or incur debt in connection with such business combination. Subject to compliance with applicable
securities laws, we would only consummate such financing simultaneously with the consummation of our initial business combination.
Following our initial business combination, if cash on hand is insufficient, we may need to obtain additional financing in order
to meet our obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci Holdings LLC,
our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo; at $0.90
per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common stock at
an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our initial
business combination and 12 months from the closing of this offering and will expire five years after the effective date of the
registration statement of which this prospectus forms a part. This purchase will take place on a private placement basis simultaneously
with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants, $1,980,000 will
be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that if the over-allotment
option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional number of private
warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the trust account $10.00 per
share sold to the public in this offering. These additional private warrants will be purchased in a private placement that will
occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If needed to finance
transaction costs in connection with searching for a target business or consummating an intended initial business combination,
our initial stockholders, officers, directors or their affiliates may, but are not obligated to, loan us funds as may be required.
In the event that the initial business combination does not close, we may use a portion of the working capital held outside the
trust account to repay such loaned amounts, but no proceeds from our trust account would be used for such repayment. Such loans
would be evidenced by promissory notes. The notes would either be paid upon consummation of our initial business combination, without
interest, or, at the lender&rsquo;s discretion, up to $500,000 of the notes may be converted upon consummation of our business
combination into additional private warrants at a conversion price of $0.90 per private warrant. We believe the purchase price
of these private warrants will approximate the fair value of such private warrants when issued. However, if it is determined, at
the time of issuance, that the fair value of such private warrants exceeds the purchase price, we would record compensation expense
for the excess of the fair value of the private warrants on the day of issuance over the purchase price in accordance with Accounting
Standards Codification (&ldquo;ASC&rdquo;) 718 &mdash; Compensation &mdash; Stock Compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not currently
required to maintain an effective system of internal controls as defined by Section&nbsp;404 of the Sarbanes-Oxley Act. We will
be required to comply with the internal control requirements of the Sarbanes-Oxley Act for the fiscal year ending June&nbsp;30,
2022. As of the date of this prospectus, we have not completed an assessment, nor have our auditors tested our systems, of internal
controls. We expect to assess the internal controls of our target business or businesses prior to the completion of our initial
business combination and, if necessary, to implement and test additional controls as we may determine are necessary in order to
state that we maintain an effective system of internal controls. A target business may not be in compliance with the provisions
of the Sarbanes-Oxley Act regarding the adequacy of internal controls. Target businesses we may consider for our initial business
combination may have internal controls that need improvement in areas such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">staffing for financial, accounting and external reporting areas, including segregation of duties;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">reconciliation of accounts;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">proper recording of expenses and liabilities in the period to which they relate;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">evidence of internal review and approval of accounting transactions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">documentation of processes, assumptions and conclusions underlying significant estimates; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">documentation of accounting policies and procedures.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because it will take
time, management involvement and perhaps outside resources to determine what internal control improvements are necessary for us
to meet regulatory requirements and market expectations for our operation of a target business, we may incur significant expense
in meeting our public reporting responsibilities, particularly in the areas of designing, enhancing, or remediating internal and
disclosure controls. Doing so effectively may also take longer than we expect, thus increasing our exposure to financial fraud
or erroneous financing reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Once our management&rsquo;s
report on internal controls is complete, we will retain our independent auditors to audit and render an opinion on such report
when, or if, required by Section&nbsp;404. The independent auditors may identify additional issues concerning a target business&rsquo;s
internal controls while performing their audit of internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quantitative and Qualitative Disclosures
about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The net proceeds of
this offering, including amounts in the trust account, will be invested in United States government treasury bills, bonds or notes
having a maturity of 183 days or less, or in money market funds meeting the applicable conditions under Rule&nbsp;2a-7 promulgated
under the Investment Company Act of 1940 and that invest solely in U.S. treasuries. Due to the short-term nature of these investments,
we believe there will be no associated material exposure to interest rate risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance Sheet Arrangements; Commitments
and Contractual Obligations; Quarterly Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of the date of
this prospectus, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii)&nbsp;of Regulation S-K and
did not have any commitments or contractual obligations. No unaudited quarterly operating data is included in this prospectus as
we have conducted no operations to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>JOBS Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On April&nbsp;5, 2012,
the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements
for qualifying public companies. We will qualify as an &ldquo;emerging growth company&rdquo; and under the JOBS Act will be allowed
to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies.
We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised
accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As
such, our financial statements may not be comparable to companies that comply with public company effective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_010"></A>PROPOSED BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a blank check
company formed under the laws of the State of Delaware on December&nbsp;18, 2019. We were formed for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses,
which we refer to throughout this prospectus as our initial business combination. Although there is no restriction or limitation
on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation.
We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology,
digital health, and healthcare services sectors, which aligns with our management team&rsquo;s experience in healthcare investing
and drug development. At the time of preparing this prospectus, we have not identified any specific business combination, nor has
anyone on our behalf initiated or engaged in any substantive discussions, formal or otherwise, related to such a transaction. Our
efforts to date are limited to organizational activities related to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Sponsor and Competitive Advantages</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our sponsor is an affiliate
of LifeSci Capital LLC, a research-driven investment bank with deep domain expertise in the life sciences, LifeSci Advisors LLC,
an investor relations and public relations company in the life sciences industry with comprehensive solutions to communications
and investor outreach, and LifeSci Venture Management LLC, a corporate venture capital firm that seeks to invest in biotech and
health sectors, collectively &ldquo;LifeSci&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as a boutique investment bank is unique in that it exclusively serves corporate clients that are emerging life science companies
that discover, develop, and commercialize innovative products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as an investor relations and public relations firm is unique in that it provides companies in the life sciences industry
with comprehensive solutions to communications and investor outreach. LifeSci assists companies in increasing visibility within
the investment community and educating investors on opportunities offered by these companies. LifeSci&rsquo;s core capabilities
include non-deal roadshow planning and execution, KOL Events/R&amp;D Days, corporate communications, and public relations through
its affiliate LifeSci Public Relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s service
model as a venture capital firm is unique in that it focuses on pre-public institutional rounds of transformational healthcare
companies managed by exceptional founder/entrepreneurs. LifeSci&rsquo;s investment principals have broad-ranging life sciences
experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research,
and bench research - both basic science and applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s team
is comprised of individuals with medical and advanced scientific training and legal and banking experience, enabling a deeply differentiated
approach to research and idea generation. Complementing LifeSci&rsquo;s scientific insight and industry relationships is LifeSci&rsquo;s
business team, whose members include portfolio managers, corporate managers, and investment bankers who actively engage with banks
and academic institutions, cultivating strong relationships and expanding their network of key contacts and syndicate partners.
We believe the well-rounded nature of the team, strengthened by strong ties across industry, academia, banking platforms, and unaffiliated
investor relationships, will enhance our management team&rsquo;s ability to source viable prospective target businesses, capitalize
them, and ensure public-market readiness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our independent directors
have extensive experience in clinical medicine, development and regulatory, operational, and management leadership within the healthcare
and financial industries. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective
candidates and successfully execute our initial business combination. Following the completion of our initial transaction, we believe
our independent directors will fortify our ongoing operations by providing sound and experienced counsel on potential further acquisitions,
divestitures, corporate strategy, and human resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
management team is equipped with the knowledge, experience, capital and human resources, and sustainable corporate governance practices
to pursue unique opportunities that will offer attractive risk-adjusted returns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management team
is led by Andrew McDonald, Co-Founder of LifeSci Advisors and LifeSci Capital, Michael Rice, Co-Founder of LifeSci Advisors and
LifeSci Capital and David Dobkin, Managing Director of LifeSci Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
company&rsquo;s philosophical alignment with LifeSci, and our ability to leverage the rigorous and comprehensive scientific and
financial analysis that LifeSci is known for, provides us with a strong competitive advantage. LifeSci focuses on dynamic sectors
of healthcare with great potential to transform the healthcare industry: biotechnology, specialty pharmaceuticals, medical devices,
digital health, information technology, and healthcare services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2018, LifeSci&rsquo;s
investors relations hosted over 1,500 meetings in 27 key regions in the United States and over 500 meetings in 16 key regions throughout
Europe. In 2019, LifeSci&rsquo;s Public Relations group secured over 1,300 media hits for their clients, with more than 100 million
viewers and readers globally, and wrote over 4,000 social media posts. LifeSci Venture&rsquo;s first fund in 2017 has invested
in 12 companies alongside large dedicated healthcare funds and has launched its second fund in the third quarter of 2019. LifeSci&rsquo;s
investment bank has executed over 50 transactions since inception, in which over 50% were repeat or Lead Managed. LifeSci&rsquo;s
investment bank core capabilities include experienced-based investment banking advisory, varied capital raising abilities, industry
insight and accessibility, global institutional coverage and reach, equity research, and client empowerment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LifeSci&rsquo;s investor
relations presence has continued to expand year-over-year. In 2019, LifeSci Advisors conducted 4,602 one-on-one non-deal roadshow
(NDR) investor meetings, 140 key opinion leader (KOL) events, 594 meetings with high net worth (HNW) individuals and financial
advisors, and 4,160 one-on-one meetings at the J.P. Morgan healthcare conference (JPM), as compared to 4,105 NDR meetings, 130
KOL events, 568 HNW meetings, and 2,700 one-on-one meetings at JPM in 2018. Additionally, LifeSci&rsquo;s Executive Search group completed
30 board and executive placements in 2019, up from 17 in 2018. LifeSci&rsquo;s client base continues to grow as well, reaching 177 healthcare
client partnerships in 2019, up from 150 in 2018. LifeSci Partners has a global footprint, with offices in cities including New
York, Chicago, Boston, Charlotte, London, Geneva, Paris, and Tel Aviv.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Industry Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
consists of sectors within the economic system providing curative, preventive, rehabilitative, and palliative care for patients.
The industry includes organizations providing such goods and services, as well as the doctors, nurses, and other healthcare employees.
Total healthcare spending in the United States reached nearly $3.5 trillion in 2017 and is expected to grow by an average 5.6 percent
annually over 2016-2025, according to a Centers for Medicare&nbsp;&amp; Medicaid Services report released in February&nbsp;2017.
Total healthcare expenditures are thus expected rise to 19.9 percent of the US Gross Domestic Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare market
globally mirrors a similar trend in the US of an increased contribution to the economy, due to the aging of the global population
and other durable macro dynamics. For example, in good part due to the impact of healthcare on society, life expectancy in the
U.S. increased from 47 years in 1900 to 79 years in 2016. As a disproportionate amount of overall healthcare spending is associated
with diseases of aging, the aging of the global population will continue to drive increased healthcare consumption. In addition,
less developed countries have gone through an unprecedented period of healthcare insurance and infrastructure expansion that has
led the countries to have significantly higher contributions to the global healthcare marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The target universe
of healthcare opportunities is extensive, considering healthcare&rsquo;s overall contribution to the economy. A factor that further
broadens the universe is the high amount of innovation occurring within healthcare. In the wake of the genomics revolution, the
pace of innovation is accelerating. With the streamlining of the externalization of breakthrough science from academic institutions,
particularly in the United States, as mandates shifted from protecting intellectual property to externalizing it, increasing numbers
of potentially disruptive healthcare innovations exist that may be underappreciated or underfunded. Early-stage companies need
capital and advisory services to reach their commercial potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The healthcare industry
is primed for new technologies and business models due to the increasing cost of healthcare and due to the increasing pressure
to add value to the system. We believe that lower-value segments of healthcare will be burdened by the pressures of cost cutting,
while companies or segments that deliver superior products and services, with better clinical and non-clinical outcomes, will thrive.
Successful companies will be data driven, consumer focused, operationally efficient and transfer best-in-class standards globally.
Our team will take a holistic approach to investment opportunities and conduct stringent due diligence to screen such companies.
We see opportunities for companies that address global healthcare cost pressures by: succeeding in disruptive innovation, thus
justifying monies spent by delivering cures or other breakthrough outcomes; delivering cost savings to address global healthcare
cost pressures; or providing access to medicines, as the marginal benefits from healthcare spending are highest when providing
goods and services to those who do not already receive them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investment Criteria</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are focused on
companies in disruptive and other value-added subsegments of healthcare that have the potential for significant gains in the next
five years. Our ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to
raise money from the private capital markets. The segments we will target include biotechnology, medical technology and digital
health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The focus of our management
team is to create stockholder value by leveraging its experience to efficiently guide an emerging healthcare company towards commercialization.
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in
evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses,
we may deviate from these criteria and guidelines should we see fit to do so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Healthcare
Company Poised for Rapid Growth</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to primarily seek
to acquire one or more growth businesses with a total equity value of greater than 5 to 10 times the amount of the proceeds of
this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can
benefit from a public listing and new capital for growth to support significant revenue and earnings growth or to advance clinical
programs. We do not intend to acquire a start-up company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Niche
Leader and Specialized Business with High Growth Potential</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to seek target companies
that have significant and underexploited expansion opportunities in a niche sector. This can be accomplished through a combination
of accelerating organic growth and finding attractive add-on acquisition targets. Our management team has significant experience
in identifying such targets and in helping target management assess the strategic and financial fit. Similarly, our management
has the expertise to assess the likely synergies and a process to help a target integrate acquisitions. Additionally, our management
team has extensive experience assisting healthcare companies raise money as they navigate the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Benefits
from Being a U.S. Public Company (Value Creation and Marketing Opportunities)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">We intend to seek target companies
that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms
and in a manner that leverage our experience. We expect to evaluate a Company based on its potential to successfully achieve regulatory
approval and commercialize its product(s). We also expect to evaluate financial returns based on (i)&nbsp;risk-adjusted peak sales
potential (ii)&nbsp;the potential of pipeline products and the scientific platform (iii)&nbsp;the ability to achieve the system
cost savings, (iv)&nbsp;the ability to accelerate growth via other options, including through the opportunity for follow-on acquisitions,
and (v)&nbsp;the prospects for creating value through other value creation initiatives. Potential upside, for example, from the
growth in the target business&rsquo; earnings or an improved capital structure, will be weighed against any identified downside
risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><I>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Potential
Benefit from Globalization Trends and Possession of Competitive Advantages</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Target companies exhibit unrecognized
value or other characteristics that we believe have been misevaluated by the marketplace based on our company-specific analyses
and due diligence. For a potential target company, this process will include, among other things, a review and analysis of the
company&rsquo;s capital structure, quality of current or future earnings, preclinical or clinical data, potential for operational
improvements, corporate governance, customers, material contracts, and the industry and trends. We intend to leverage the operational
experience and disciplined investment approach of our team to identify opportunities to unlock value that our experience in complex
situations allows us to pursue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These criteria are
not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based,
to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may
deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effecting a Business Combination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not presently
engaged in, and we will not engage in, any operations for an indefinite period of time following this offering. We intend to effectuate
our initial business combination using cash from the proceeds of this offering and the private placement of the private warrants,
our shares, new debt, or a combination of these, as the consideration to be paid in our initial business combination. We may seek
to consummate our initial business combination with a company or business that may be financially unstable or in its early stages
of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing and
sales), which would subject us to the numerous risks inherent in such companies and businesses, although we will not be permitted
to effectuate our initial business combination with another blank check company or a similar company with nominal operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If our initial business
combination is paid for using shares or debt securities, or not all of the funds released from the trust account are used for payment
of the purchase price in connection with our business combination or used for redemptions of purchases of our common stock, we
may apply the cash released to us from the trust account that is not applied to the purchase price for general corporate purposes,
including for maintenance or expansion of operations of acquired businesses, the payment of principal or interest due on indebtedness
incurred in consummating our initial business combination, to fund the purchase of other companies or for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not identified
any acquisition targets. From the period prior to our formation through the date of this prospectus, there have been no communications,
evaluations or discussions between any of our officers, directors or our sponsor and any of their contacts or relationships regarding
a potential initial business combination. Additionally, we have not engaged or retained any agent or other representative to identify
or locate any suitable acquisition candidate. Subject to the requirement that our initial business combination must be with one
or more target businesses or assets having an aggregate fair market value of at least 80% of the value of the trust account (excluding
any taxes payable) at the time of the agreement to enter into such initial business combination, we have virtually unrestricted
flexibility in identifying and selecting one or more prospective target businesses. Accordingly, there is no current basis for
investors in this offering to evaluate the possible merits or risks of the target business with which we may ultimately complete
our initial business combination. Although our management will assess the risks inherent in a particular target business with which
we may combine, this assessment may not result in our identifying all risks that a target business may encounter. Furthermore,
some of those risks may be outside of our control, meaning that we can do nothing to control or reduce the chances that those risks
will adversely impact a target business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may seek to raise
additional funds through a private offering of debt or equity securities in connection with the consummation of our initial business
combination, and we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts
held in the trust account. Subject to compliance with applicable securities laws, we would consummate such financing only simultaneously
with the consummation of our business combination. In the case of an initial business combination funded with assets other than
the trust account assets, our tender offer documents or proxy materials disclosing the business combination would disclose the
terms of the financing and, only if required by law or Nasdaq, we would seek stockholder approval of such financing. There are
no prohibitions on our ability to raise funds privately or through loans in connection with our initial business combination. At
this time, we are not a party to any arrangement or understanding with any third party with respect to raising any additional funds
through the sale of securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sources of Target Businesses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We anticipate that
target business candidates will be brought to our attention from various unaffiliated sources, including investment bankers, venture
capital funds, private equity groups, leveraged buyout funds, management buyout funds and other members of the financial community.
Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us through calls
or mailings. These sources also may introduce us to target businesses in which they think we may be interested on an unsolicited
basis, since many of these sources will have read this prospectus and know what types of businesses we are targeting. Our officers
and directors, as well as their affiliates, also may bring to our attention target business candidates that they become aware of
through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending
trade shows or conventions. In addition, we expect to receive a number of proprietary deal flow opportunities that would not otherwise
necessarily be available to us as a result of the business relationships of our officers and directors. While we do not presently
anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal
basis, we may engage these firms or other individuals in the future, in which event we may pay a finder&rsquo;s fee, consulting
fee or other compensation to be determined in an arm&rsquo;s length negotiation based on the terms of the transaction. We will
engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not
otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management
determines is in our best interest to pursue. Payment of finder&rsquo;s fees is customarily tied to completion of a transaction,
in which case any such fee will be paid out of the funds held in the trust account. Although some of our officers and directors
may enter into employment or consulting agreements with the acquired business following our initial business combination, the presence
or absence of any such arrangements will not be used as a criterion in our selection process of an acquisition candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not prohibited
from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the
event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would
obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions
on the type of target business we seek to acquire that such an initial business combination is fair to our unaffiliated stockholders
from a financial point of view.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Selection of a Target Business and
Structuring of a Business Combination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the requirement
that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value
of at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such
initial business combination, our management will have virtually unrestricted flexibility in identifying and selecting one or more
prospective target businesses. In any case, we will only consummate an initial business combination in which we become the majority
shareholder of the target (or control the target through contractual arrangements in limited circumstances for regulatory compliance
purposes as discussed below) or are otherwise not required to register as an investment company under the Investment Company Act
or to the extent permitted by law we may acquire interests in a variable interest entity, in which we may have less than a majority
of the voting rights in such entity, but in which we are the primary beneficiary. There is no basis for investors in this offering
to evaluate the possible merits or risks of any target business with which we may ultimately complete our initial business combination.
To the extent we effect our initial business combination with a company or business that may be financially unstable or in its
early stages of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing
and sales), we may be affected by numerous risks inherent in such company or business. Although our management will endeavor to
evaluate the risks inherent in a particular target business, we may not properly ascertain or assess all significant risk factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In evaluating a prospective
target business, we expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent
management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as well as a review
of financial and other information which will be made available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The time required
to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated
with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification
and evaluation of a prospective target business with which a business combination is not ultimately completed will result in our
incurring losses and will reduce the funds we can use to complete another business combination. We will not pay any finders or
consulting fees to members of our management team, or any of their respective affiliates, for services rendered to or in connection
with our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fair Market Value of Target Business
or Businesses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The target business
or businesses or assets with which we effect our initial business combination must have a collective fair market value equal to
at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such initial
business combination. If we acquire less than 100% of one or more target businesses in our initial business combination, the aggregate
fair market value of the portion or portions we acquire must equal at least 80% of the value of the trust account at the time of
the agreement to enter into such initial business combination. However, we will always acquire at least a controlling interest
in a target business. The fair market value of a portion of a target business or assets will likely be calculated by multiplying
the fair market value of the entire business by the percentage of the target we acquire. We may seek to consummate our initial
business combination with an initial target business or businesses with a collective fair market value in excess of the balance
in the trust account. In order to consummate such an initial business combination, we may issue a significant amount of debt, equity
or other securities to the sellers of such business and/or seek to raise additional funds through a private offering of debt, equity
or other securities. If we issue securities in order to consummate such an initial business combination, our stockholders could
end up owning a minority of the combined company&rsquo;s voting securities as there is no requirement that our stockholders own
a certain percentage of our company (or, depending on the structure of the initial business combination, an ultimate parent company
that may be formed) after our business combination. Because we have no specific business combination under consideration, we have
not entered into any such arrangement to issue our debt or equity securities and have no current intention of doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fair market value
of a target business or businesses or assets will be determined by our board of directors based upon standards generally accepted
by the financial community, such as actual and potential gross margins, the values of comparable businesses, earnings and cash
flow, book value, enterprise value and, where appropriate, upon the advice of appraisers or other professional consultants. Investors
will be relying on the business judgment of our board of directors, which will have significant discretion in choosing the standard
used to establish the fair market value of a particular target business. If our board of directors is not able to independently
determine that the target business or assets has a sufficient fair market value to meet the threshold criterion, we will obtain
an opinion from an unaffiliated, independent investment banking firm or another independent entity that commonly renders valuation
opinions on the type of target business we seek to acquire with respect to the satisfaction of such criterion. Notwithstanding
the foregoing, unless we consummate a business combination with an affiliated entity, we are not required to obtain an opinion
from an independent investment banking firm, or another independent entity that commonly renders valuation opinions on the type
of target business we seek to acquire, that the price we are paying is fair to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Lack of Business Diversification</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For an indefinite
period of time after consummation of our initial business combination, the prospects for our success may depend entirely on the
future performance of a single business. Unlike other entities that have the resources to complete business combinations with multiple
entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate
the risks of being in a single line of business. By consummating our initial business combination with only a single entity, our
lack of diversification may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; padding-left: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; padding-left: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify">cause us to depend on the marketing and sale of a single product or limited number of products or services.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Limited Ability to Evaluate the Target&rsquo;s
Management Team</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although we intend
to closely scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial
business combination with that business, our assessment of the target business&rsquo; management may not prove to be correct. The
future role of members of our management team, if any, in the target business cannot presently be stated with any certainty. Consequently,
members of our management team may not become a part of the target&rsquo;s management team, and the future management may not have
the necessary skills, qualifications or abilities to manage a public company. Further, it is also not certain whether one or more
of our directors will remain associated in some capacity with us following our initial business combination. Moreover, members
of our management team may not have significant experience or knowledge relating to the operations of the particular target business.
Our key personnel may not remain in senior management or advisory positions with the combined company. The determination as to
whether any of our key personnel will remain with the combined company will be made at the time of our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Following our initial
business combination, we may seek to recruit additional managers to supplement the incumbent management of the target business.
We may not have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge
or experience necessary to enhance the incumbent management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stockholders May&nbsp;Not Have the
Ability to Approve an Initial Business Combination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with
any proposed business combination, we will either (1)&nbsp;seek stockholder approval of our initial business combination at a meeting
called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for
or against the proposed business combination, into their <I>pro rata</I> share of the aggregate amount then on deposit in the trust
account (net of taxes payable) or (2)&nbsp;provide our public stockholders with the opportunity to sell their public shares to
us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their <I>pro rata</I>
share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations
described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with
us, not to convert any public shares held by them into their <I>pro rata</I> share of the aggregate amount then on deposit in the
trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each stockholder may tender
any or all of his, her or its public shares rather than some <I>pro rata</I> portion of his, her or its shares. The decision as
to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares
to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction and whether the
terms of the transaction would otherwise require us to seek stockholder approval. If we so choose and we are legally permitted
to do so, we have the flexibility to avoid a stockholder vote and allow our stockholders to sell their shares pursuant to Rule&nbsp;13e-4
and Regulation 14E of the Exchange Act which regulate issuer tender offers. In that case, we will file tender offer documents with
the SEC which will contain substantially the same financial and other information about the initial business combination as is
required under the SEC&rsquo;s proxy rules. We will consummate our initial business combination only if we have net tangible assets
of at least $5,000,001 upon such consummation and, solely if we seek stockholder approval, a majority of the issued and outstanding
shares of common stock voted are voted in favor of the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We chose our net tangible
asset threshold of $5,000,001 to ensure that we would avoid being subject to Rule&nbsp;419 promulgated under the Securities Act.
However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital
closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial
business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as
we may be required to have a lesser number of shares converted or sold to us) and may force us to seek third party financing which
may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination
and we may not be able to locate another suitable target within the applicable time period, if at all. Public stockholders may
therefore have to wait 24 months from the closing of this offering in order to be able to receive a <I>pro rata</I> share of the
trust account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our initial stockholders
and our officers and directors have agreed (1)&nbsp;to vote any shares of common stock owned by them in favor of any proposed business
combination, (2)&nbsp;not to convert any shares of common stock in connection with a stockholder vote to approve a proposed initial
business combination and (3)&nbsp;not sell any shares of common stock in any tender in connection with a proposed initial business
combination. As a result, if we sought stockholder approval of a proposed transaction, we would need only 312,501 of our public
shares (or approximately 6.3% of our public shares) to be voted in favor of the transaction in order to have such transaction approved
(assuming that only a quorum was present at the meeting, that the over-allotment option is not exercised and that the initial stockholders
do not purchase any shares in this offering or shares in the after-market).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">None of our officers,
directors, initial stockholders or their affiliates has indicated any intention to purchase shares of common stock in
this offering or from persons in the open market or in private transactions. However, if we hold a meeting to approve a proposed
business combination and a significant number of stockholders vote, or indicate an intention to vote, against such proposed business
combination, our officers, directors, initial stockholders or their affiliates could make such purchases in the open market or
in private transactions in order to influence the vote. Notwithstanding the foregoing, our officers, directors, initial stockholders
and their affiliates will not make purchases of common stock if the purchases would violate Section&nbsp;9(a)(2)&nbsp;or Rule&nbsp;10b-5
of the Exchange Act, which are rules&nbsp;designed to stop potential manipulation of a company&rsquo;s stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Conversion/Tender Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At any meeting called
to approve an initial business combination, public stockholders may seek to convert their public shares, regardless of whether
they vote for or against the proposed business combination, into their <I>pro rata</I> share of the aggregate amount then on deposit
in the trust account, less any taxes then due but not yet paid. Notwithstanding the foregoing, our initial stockholders have agreed,
pursuant to written letter agreements with us, not to convert any public shares held by them into their <I>pro rata</I> share of
the aggregate amount then on deposit in the trust account. If we hold a meeting to approve an initial business combination, a holder
will always have the ability to vote against a proposed business combination and not seek conversion of his shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Alternatively, if
we engage in a tender offer, each public stockholder will be provided the opportunity to sell his public shares to us in such tender
offer. The tender offer rules&nbsp;require us to hold the tender offer open for at least 20 business days. Accordingly, this is
the minimum amount of time we would need to provide holders to determine whether they want to sell their public shares to us in
the tender offer or remain an investor in our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our initial stockholders,
officers and directors will not have conversion rights with respect to any shares of common stock owned by them, directly or indirectly,
whether acquired prior to this offering or purchased by them in this offering or in the aftermarket.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may also require
public stockholders, whether they are a record holder or hold their shares in &ldquo;street name,&rdquo; to either tender their
certificates (if any) to our transfer agent or to deliver their shares to the transfer agent electronically using Depository Trust
Company&rsquo;s DWAC (Deposit/Withdrawal At Custodian) System, at the holder&rsquo;s option, at any time at or prior to the vote
on the business combination. The proxy solicitation materials that we will furnish to stockholders in connection with the vote
for any proposed business combination will indicate whether we are requiring stockholders to satisfy such delivery requirements.
Accordingly, a stockholder would have from the time our proxy statement is mailed through the vote on the business combination
to deliver his shares if he wishes to seek to exercise his conversion rights. Under Delaware law and our bylaws, we are required
to provide at least 10 days&rsquo; advance notice of any stockholder meeting, which would be the minimum amount of time a stockholder
would have to determine whether to exercise conversion rights. As a result, if we require public stockholders who wish to convert
their shares of common stock into the right to receive a <I>pro rata </I>portion of the funds in the trust account to comply with
the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares for conversion.
Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities when they
otherwise would not want to. The conversion rights will include the requirement that a beneficial holder must identify itself in
order to validly redeem its shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is a nominal
cost associated with this tendering process and the act of certificating the shares or delivering them through the DWAC System.
The transfer agent will typically charge the tendering broker $45 and it would be up to the broker whether or not to pass this
cost on to the converting holder. However, this fee would be incurred regardless of whether or not we require holders seeking to
exercise conversion rights. The need to deliver shares is a requirement of exercising conversion rights regardless of the timing
of when such delivery must be effectuated. However, in the event we require stockholders seeking to exercise conversion rights
to deliver their shares prior to the consummation of the proposed business combination and the proposed business combination is
not consummated, this may result in an increased cost to stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any request to convert
or tender such shares once made, may be withdrawn at any time up to the vote on the proposed business combination or expiration
of the tender offer. Furthermore, if a holder of a public share delivered his certificate in connection with an election of their
conversion or tender and subsequently decides prior to the vote on the business combination or the expiration of the tender offer
not to elect to exercise such rights, he may simply request that the transfer agent return the certificate (physically or electronically).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the initial business
combination is not approved or completed for any reason, then our public stockholders who elected to exercise their conversion
or tender rights would not be entitled to convert their shares for the applicable <I>pro rata</I> share of the trust account. In
such case, we will promptly return any shares delivered by public holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation of Trust Account if No
Business Combination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we do not complete
a business combination within 24 months from the closing of this offering, we will (i)&nbsp;cease all operations except for the
purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100%
of the outstanding public shares and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval
of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii)&nbsp;and (iii)&nbsp;above)
to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the Delaware
General Corporation Law, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions
received by them in a dissolution. The pro rata portion of our trust account distributed to our public stockholders upon the redemption
of 100% of our outstanding public shares in the event we do not complete our initial business combination within the required time
period may be considered a liquidation distribution under Delaware law. If the corporation complies with certain procedures set
forth in Section&nbsp;280 of the Delaware General Corporation Law intended to ensure that it makes reasonable provision for all
claims against it, including a 60-day notice period during which any third-party claims can be brought against the corporation,
a 90-day period during which the corporation may reject any claims brought, and an additional 150-day waiting period before any
redemptions are made to stockholders, any liability of stockholders with respect to a redemption is limited to the lesser of such
stockholder&rsquo;s pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder
would be barred after the third anniversary of the dissolution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Furthermore, if the
pro rata portion of our trust account distributed to our public stockholders upon the redemption of 100% of our public shares in
the event we do not complete our initial business combination within the required time period is not considered a liquidation distribution
under Delaware law and such redemption distribution is deemed to be unlawful, then pursuant to Section&nbsp;174 of the Delaware
General Corporation Law, the statute of limitations for claims of creditors could then be six years after the unlawful redemption
distribution, instead of three years, as in the case of a liquidation distribution. It is our intention to redeem our public shares
as soon as reasonably possible following the 24<SUP>th</SUP> month from the closing of this offering and, therefore, we do not
intend to comply with the above procedures. As such, our stockholders could potentially be liable for any claims to the extent
of distributions received by them (but no more) and any liability of our stockholders may extend well beyond the third anniversary
of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because we will not
be complying with Section&nbsp;280 of the Delaware General Corporation Law, Section&nbsp;281(b)&nbsp;of the Delaware General Corporation
Law requires us to adopt a plan, based on facts known to us at such time that will provide for our payment of all existing and
pending claims or claims that may be potentially brought against us within the subsequent 10 years. However, because we are a blank
check company, rather than an operating company, and our operations will be limited to seeking to complete an initial business
combination, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers,&nbsp;etc.) or prospective
target businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will seek to have
all third parties (including any vendors or other entities we engage after this offering) and any prospective target businesses
enter into valid and enforceable agreements with us waiving any right, title, interest or claim of any kind they may have in or
to any monies held in the trust account. The underwriters in this offering will execute such a waiver agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result, the claims
that could be made against us will be limited, thereby lessening the likelihood that any claim would result in any liability extending
to the trust. We therefore believe that any necessary provision for creditors will be reduced and should not have a significant
impact on our ability to distribute the funds in the trust account to our public stockholders. Nevertheless, there is no guarantee
that vendors, service providers and prospective target businesses will execute such agreements. In the event that a potential contracted
party was to refuse to execute such a waiver, we will execute an agreement with that entity only if our management first determines
that we would be unable to obtain, on a reasonable basis, substantially similar services or opportunities from another entity willing
to execute such a waiver. Examples of instances where we may engage a third party that refused to execute a waiver would be the
engagement of a third party consultant who cannot sign such an agreement due to regulatory restrictions, such as our auditors who
are unable to sign due to independence requirements, or whose particular expertise or skills are believed by management to be superior
to those of other consultants that would agree to execute a waiver or a situation in which management does not believe it would
be able to find a provider of required services willing to provide the waiver. There is also no guarantee that, even if they execute
such agreements with us, they will not seek recourse against the trust account. Our insiders have agreed that they will be jointly
and severally liable to us if and to the extent any claims by a vendor for services rendered or products sold to us, or a prospective
target business with which we have discussed entering into a transaction agreement, reduce the amount of funds in the trust account
to below $10.00 per public share, except as to any claims by a third party who executed a valid and enforceable agreement with
us waiving any right, title, interest or claim of any kind they may have in or to any monies held in the trust account and except
as to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under
the Securities Act. Our board of directors has evaluated our insiders&rsquo; financial net worth and believes they will be able
to satisfy any indemnification obligations that may arise. However, our insiders may not be able to satisfy their indemnification
obligations, as we have not required our insiders to retain any assets to provide for their indemnification obligations, nor have
we taken any further steps to ensure that they will be able to satisfy any indemnification obligations that arise. Moreover, our
insiders will not be liable to our public stockholders and instead will only have liability to us. As a result, if we liquidate,
the per-share distribution from the trust account could be less than approximately $10.00 due to claims or potential claims of
creditors. We will distribute to all of our public stockholders, in proportion to their respective equity interests, an aggregate
sum equal to the amount then held in the trust account, inclusive of any interest not previously released to us, (subject to our
obligations under Delaware law to provide for claims of creditors as described below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are unable to
consummate an initial business combination and are forced to redeem 100% of our outstanding public shares for a portion of the
funds held in the trust account, we anticipate notifying the trustee of the trust account to begin liquidating such assets promptly
after such date and anticipate it will take no more than 10 business days to effectuate the redemption of our public shares. Our
insiders have waived their rights to participate in any redemption with respect to their insider shares. We will pay the costs
of any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our insiders
have agreed to pay the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000)
and have agreed not to seek repayment of such expenses. Each holder of public shares will receive a full pro rata portion of the
amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not previously released
to us or necessary to pay our taxes or for working capital purposes up to $250,000 annually. The proceeds deposited in the trust
account could, however, become subject to claims of our creditors that are in preference to the claims of public stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our public stockholders
shall be entitled to receive funds from the trust account only in the event of our failure to complete our initial business combination
in the required time period or if the stockholders seek to have us convert their respective shares of common stock upon a business
combination which is actually completed by us. In no other circumstances shall a stockholder have any right or interest of any
kind to or in the trust account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are forced to
file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not dismissed, the proceeds held in the trust
account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of
third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account,
the per share redemption or conversion amount received by public stockholders may be less than $10.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If, after we distribute
the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition
is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor
and/or bankruptcy laws as either a &ldquo;preferential transfer&rdquo; or a &ldquo;fraudulent conveyance.&rdquo; As a result, a
bankruptcy court could seek to recover all amounts received by our stockholders. In addition, our board of directors may be viewed
as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims
of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. Claims may
be brought against us for these reasons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Certificate of Incorporation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our certificate of
incorporation contains certain requirements and restrictions relating to this offering that will apply to us until the consummation
of our initial business combination. If we hold a stockholder vote to amend any provisions of our certificate of incorporation
relating to stockholder&rsquo;s rights or pre-business combination activity (including the substance or timing within which we
have to complete a business combination), we will provide our public stockholders with the opportunity to redeem their shares of
common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit
in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay
our franchise and income taxes or for working capital purposes up to $250,000 annually, divided by the number of then outstanding
public shares, in connection with any such vote. Our insiders have agreed to waive any conversion rights with respect to any insider
shares and any public shares they may hold in connection with any vote to amend our certificate of incorporation. Specifically,
our certificate of incorporation provides, among other things, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">prior to the consummation of our initial business combination, we shall either (1)&nbsp;seek stockholder approval of our initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their shares of common stock, regardless of whether they vote for or against the proposed business combination, into a portion of the aggregate amount then on deposit in the trust account, or (2)&nbsp;provide our stockholders with the opportunity to sell their shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account, in each case subject to the limitations described herein;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">we will consummate our initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause our net tangible assets to be less than $5,000,001 and a majority of the outstanding shares of common stock voted are voted in favor of the business combination;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">if our initial business combination is not consummated within 24 months of the closing of this offering, then our existence will terminate and we will distribute all amounts in the trust account to all of our public holders of shares of common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">upon the consummation of this offering, $75,000,000, or $86,250,000 if the over-allotment option is exercised in full, shall be placed into the trust account;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">we may not consummate any other business combination, merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar transaction prior to our initial business combination; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">prior to our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (i)&nbsp;receive funds from the trust account or (ii)&nbsp;vote on any initial business combination.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Potential Revisions to Agreements
with Insiders</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each of our insiders
has entered into letter agreements with us pursuant to which each of them has agreed to do certain things relating to us and our
activities prior to a business combination. We could seek to amend these letter agreements without the approval of stockholders,
although we have no intention to do so. In particular:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">Restrictions relating to liquidating the trust account if we failed to consummate a business combination in the time-frames specified above could be amended, but only if we allowed all stockholders to redeem their shares in connection with such amendment;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">Restrictions relating to our insiders being required to vote in favor of a business combination or against any amendments to our organizational documents could be amended to allow our insiders to vote on a transaction as they wished;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">The requirement of members of the management team to remain our officer or director until the closing of a business combination could be amended to allow persons to resign from their positions with us if, for example, the current management team was having difficulty locating a target business and another management team had a potential target business;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">The restrictions on transfer of our securities could be amended to allow transfer to third parties who were not members of our original management team;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">The obligation of our management team to not propose amendments to our organizational documents could be amended to allow them to propose such changes to our stockholders;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">The obligation of insiders to not receive any compensation in connection with a business combination could be modified in order to allow them to receive such compensation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">The requirement to obtain a valuation for any target business affiliated with our insiders, in the event it was too expensive to do so.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as specified
above, stockholders would not be required to be given the opportunity to redeem their shares in connection with such changes. Such
changes could result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD STYLE="text-align: justify">Our having an extended period of time to consummate a business combination (although with less in trust as a certain number of our stockholders would certainly redeem their shares in connection with any such extension);</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD>Our insiders being able to vote against a business combination or in favor of changes to our organizational documents;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD>Our operations being controlled by a new management team that our stockholders did not elect to invest with;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD>Our insiders receiving compensation in connection with a business combination; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 48px; text-align: center">&bull;</TD>
    <TD>Our insiders closing a transaction with one of their affiliates without receiving an independent valuation of such business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will not agree
to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if we believed
such a modification were necessary to complete a business combination). Each of our officers and directors have fiduciary obligations
to us requiring that they act in our best interests and the best interests of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In identifying, evaluating
and selecting a target business for our initial business combination, we may encounter intense competition from other entities
having a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout
funds, and operating businesses seeking strategic acquisitions. Many of these entities are well established and have significant
experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors
possess greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be
limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of
a target business. Furthermore, the requirement that we acquire a target business or businesses having a fair market value equal
to at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into the
business combination, our obligation to pay cash in connection with our public stockholders who exercise their redemption rights may not be viewed favorably by certain
target businesses. Any of these factors may place us at a competitive disadvantage in successfully negotiating our initial business
combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Facilities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will pay to an
affiliate of our sponsor a fee of $10,000 per month for use of office space and certain office and secretarial services. The office
space will be located at 250 W. 55th St., #3401, New York, NY 10019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Employees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We currently have
two executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they intend
to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination.
The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial
business combination and the stage of the business combination process we are in. We do not intend to have any full time employees
prior to the consummation of our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Periodic Reporting and Audited Financial
Statements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have registered
our shares of common stock under the Exchange Act and have reporting obligations, including the requirement
that we file annual, quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual
report will contain financial statements audited and reported on by our independent registered public accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will provide stockholders
with audited financial statements of the prospective target business as part of any proxy solicitation sent to stockholders to
assist them in assessing the target business. In all likelihood, the financial information included in the proxy solicitation materials
will need to be prepared in accordance with U.S. GAAP or IFRS, depending on the circumstances, and the historical financial statements
may be required to be audited in accordance with the standards of the PCAOB. The financial statements may also be required to be
prepared in accordance with U.S. GAAP for the Form&nbsp;8-K announcing the closing of an initial business combination, which would
need to be filed within four business days thereafter. We cannot assure you that any particular target business identified by us
as a potential acquisition candidate will have the necessary financial information. To the extent that this requirement cannot
be met, we may not be able to acquire the proposed target business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will be required
to comply with the internal control requirements of the Sarbanes-Oxley Act beginning for the fiscal year ending June&nbsp;30, 2022.
A target company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls.
The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the
time and costs necessary to complete any such acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an &ldquo;emerging
growth company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act, as modified by the JOBS Act. As such, we are
eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being required to comply with the auditor
attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities
less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may
be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, Section&nbsp;107
of the JOBS Act also provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period
provided in Section&nbsp;7(a)(2)(B)&nbsp;of the Securities Act for complying with new or revised accounting standards. In other
words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will remain an
emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary
of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07 billion, or (c)&nbsp;in
which we are deemed to be a large accelerated filer, which means the market value of our Class&nbsp;A common stock that is held
by non-affiliates exceeds $700 million as of the prior June&nbsp;30<SUP>th</SUP>, and (2)&nbsp;the date on which we have issued
more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to &ldquo;emerging
growth company&rdquo; shall have the meaning associated with it in the JOBS Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is no material
litigation, arbitration or governmental proceeding currently pending against us or any of our officers or directors in their capacity
as such, and we and our officers and directors have not been subject to any such proceeding in the 12 months preceding the date
of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Comparison to Offerings of Blank Check
Companies Subject to Rule&nbsp;419</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
compares and contrasts the terms of our offering and the terms of an offering of blank check companies under Rule&nbsp;419 promulgated
by the SEC assuming that the gross proceeds, underwriting discounts and underwriting expenses for the Rule&nbsp;419 offering are
the same as this offering and that the underwriters will not exercise their over-allotment option. None of the terms of a Rule&nbsp;419
offering will apply to this offering because we will be listed on a national securities exchange, we will have net tangible assets
in excess of $5,000,001 upon the successful consummation of this offering and will file a Current Report on Form&nbsp;8-K, including
an audited balance sheet demonstrating this fact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-top: 10pt; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms of the Offering</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms Under a Rule&nbsp;419 Offering</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><B>Escrow of offering proceeds</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">$75,000,000 of the net offering proceeds and proceeds from the sale of the private warrants
    will be deposited into a trust account in the United States, maintained by Continental Stock Transfer&nbsp;&amp; Trust
    Company, acting as trustee.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">$66,150,000 of the offering proceeds would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; padding-right: 8pt; text-align: justify"><B>Investment of net proceeds</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">The $75,000,000 of the net offering proceeds and proceeds from the sale of
    the private warrants held in trust will only be invested in United States government treasury bills, bonds or notes with a
    maturity of 183 days or less or in money market funds meeting the applicable conditions under Rule&nbsp;2a-7 promulgated
    under the Investment Company Act of 1940 and that invest solely in United States government treasuries.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act of 1940 or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; padding-left: 10pt; text-indent: -10pt"><B>Limitation on fair value or net assets of target business</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">The initial target business that we acquire must have a fair market value equal to at least 80% of the balance in our trust account net of taxes payable at the time of the execution of a definitive agreement for our initial business combination.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">We would be restricted from acquiring a target business unless the fair value of such business or net assets to be acquired represent at least 80% of the maximum offering proceeds.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; text-align: justify"><B>Trading of securities issued</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">The shares may commence trading on or promptly after the date of this prospectus.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">No trading of the shares would be permitted until the completion of a
    business combination. During this period, the securities would be held in the escrow or trust account.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-top: 10pt; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms of the Offering</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms Under a Rule&nbsp;419 Offering</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; text-align: justify"><B>Election to remain an investor</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">We will either (1)&nbsp;give our stockholders the opportunity to vote on the business combination or (2)&nbsp;provide our public stockholders with the opportunity to sell their public shares to us in a tender offer for cash equal to their <I>pro rata</I> share of the aggregate amount then on deposit in the trust account, less taxes. If we hold a meeting to approve a proposed business combination, we will send each stockholder a proxy statement containing information required by the SEC. Under our certificate of incorporation, we must provide at least 10 days advance notice of any meeting of stockholders. Accordingly, this is the minimum amount of time we would need to provide holders to determine whether to exercise their rights to convert their shares into cash at such a meeting or to remain an investor in our company. Alternatively, if we do not hold a meeting and instead conduct a tender offer, we will conduct such tender offer in accordance with the tender offer rules&nbsp;of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as we would have included in a proxy statement. </TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">A prospectus containing information required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company, in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of the post-effective amendment, to decide whether he or she elects to remain a stockholder of the company or require the return of his or her investment. If the company has not received the notification by the end of the 45<SUP>th</SUP> business day, funds and interest or dividends, if any, held in the trust or escrow account would automatically be returned to the stockholder. Unless a sufficient number of investors elect to remain investors, all of the deposited funds in the escrow account must be returned to all investors and none of the securities will be issued.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">The tender offer rules&nbsp;require us to hold the tender offer open for at least 20 business days. Accordingly, this is the minimum amount of time we would need to provide holders to determine whether they want to sell their shares to us in the tender offer or remain an investor in our company.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-top: 10pt; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms of the Offering</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 2%; border-top: black 1pt solid; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 32%; border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><B>Terms Under a Rule
    419 Offering</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><B>Business combination deadline</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">Pursuant to our certificate of incorporation, if we do not complete an initial business combination within 24 months from the consummation of this offering, it will trigger our automatic winding up, dissolution and liquidation.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">If an acquisition has not been consummated within 18 months after the effective date of the initial registration statement, funds held in the trust or escrow account would be returned to investors.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; padding-left: 10pt; text-indent: -10pt"><B>Interest earned on the funds in the trust account</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">There can be released to us, from time to time, (i)&nbsp;any interest earned on the funds in the trust account that we may need to pay our tax obligations and (ii)&nbsp;any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working capital requirements. The remaining interest earned on the funds in the trust account will not be released until the earlier of the completion of a business combination and our entry into liquidation upon failure to effect a business combination within the allotted time.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">All interest earned on the funds in the trust account will be held in trust for the benefit of public stockholders until the earlier of the completion of a business combination and our liquidation upon failure to effect a business combination within the allotted time.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 8pt; padding-left: 10pt; text-indent: -10pt"><B>Release of funds</B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">Except for interest earned on the funds held in the trust account that may be released to us to pay our tax obligations or for working capital purposes (provided that the fund released for working capital purposes may not exceed $250,000 annually), the proceeds held in the trust account will not be released until the earlier of the completion of a business combination (in which case, the proceeds released to us will be net of the funds used to pay converting or tendering stockholders, as the trustee will directly send the appropriate portion of the amount held in trust to the converting or tendering stockholders at the time of the business combination) and the liquidation of our trust account upon failure to effect a business combination within the allotted time.</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-top: 8pt; text-align: justify">The proceeds held in the escrow account would not be released until the earlier of the completion of a business combination or the failure to effect a business combination within the allotted time.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_011"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Directors and Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our current directors, director nominees
and executive officers are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Age</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Position</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt; text-align: justify">Andrew McDonald, Ph.D.</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: center">46</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt; text-align: left">Chairman, Chief Executive Officer and Board Member</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Michael Rice</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">55</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Operating Officer and Board Member</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">David Dobkin</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">41</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Chief Financial Officer and Board Member</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Thomas Wynn</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">51</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Board Member Nominee</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Thomas Mathers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">53</P></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Board Member Nominee</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Elizabeth Barrett</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">58</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Board Member Nominee</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Graham Walmsley</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">33</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Board Member Nominee</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Scott Janssen</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">51</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">Board Member Nominee</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Andrew McDonald</B>,<B>&nbsp;</B>our
Chief Executive Officer and Board Member since June&nbsp;2019, is an experienced healthcare investment professional with expertise
in identifying transformative products and technologies in all stages of development. Andrew has been the Chairman and Chief Executive
Officer of LifeSci Acquisition Corp., a special purpose acquisition company, since June&nbsp;2019. Andrew has served as the Chief
Executive Officer of Attune Pharmaceuticals since March&nbsp;2015 and is a Founding Partner of LifeSci Advisors and LifeSci Capital.
Prior to founding LifeSci in March&nbsp;2010, Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated
life science hedge fund, from 2006 to 2008. From 2004 to 2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst
at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal
chemist at Cytokinetics from 2001 to 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials.
Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine
and completed his B.S. in chemistry at UC Berkeley. Andrew holds the Series&nbsp;7, 24, 63, 79, 86, and 87 licenses. We believe
Andrew is qualified to sit on our board due to his long-running healthcare advisory experience and background as a medicinal chemist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Michael Rice</B>,&nbsp;our
Chief Operating Officer and Board Member since June&nbsp;2019, has experience in portfolio management, corporate management, investment
banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital in March&nbsp;2010, Michael was the co-head
of health care investment banking at Canaccord Adams from April&nbsp;2007 to November&nbsp;2008, where he was involved in debt
and equity financing. Michael was also was a Managing Director at ThinkEquity Partners from April&nbsp;2005 to April&nbsp;2007,
where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions,
many of which were firsts at ThinkEquity. Prior to that, from August&nbsp;2003 to March&nbsp;2005, Michael served as a Managing
Director at Banc of America, serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director
at JPMorgan/Hambrecht&nbsp;&amp; Quist. Michael has been a director of RDD Pharma Ltd. since January&nbsp;2016 and Navidea Biopharmaceuticals
Inc. since May&nbsp;2016. Michael has been the Chief Operating Officer and a director of LifeSci Acquisition Corp., a special purpose
acquisition company, since June&nbsp;2019. Michael received his BA from the University of Maryland. Michael holds the Series&nbsp;7,
24, 63, and 79 licenses. We believe Michael is qualified to sit on our board due to his long-running healthcare advisory experience,
as well as his previous company board positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>David Dobkin</B>,
our Chief Financial Officer and Board Member since June&nbsp;2019, is an experienced healthcare capital markets investment banker
with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial
and strategic goals. David has been the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose
acquisition company, since June&nbsp;2019. David has worked with companies developing a wide range of technologies and brings extensive
strategic advisory and execution capability to his clients. David has experience with both traditional and non-traditional forms
of equity and debt offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across
the United States and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to
that, in 2015, David founded Dobkin&nbsp;&amp; Company, an investment bank tailored for entrepreneur-led companies focused on seed
and growth equity and capital, in 2015. Previously, from 2010 to 2015, David worked in various capacities with the New Zealand
Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic
foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October&nbsp;2010, David
worked for Lazard Fr&egrave;res, one of the world&rsquo;s preeminent financial advisory and asset management firms, where he facilitated
and advised on cross-border mergers and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Fr&egrave;res,
David began his career in in the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein
Perella, David advised healthcare companies on capital formation as well as strategic alternatives. David conducted graduate research
in stem cell bioengineering and received a Master of Science, Biomedical Engineering, from the University of Southern California.
David also received a B.S. in Biomedical Engineering, from Columbia University. David holds the Series&nbsp;63, 79, and 82 licenses.
We believe David is qualified to sit on our board due to his extensive experience in mergers and acquisitions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Thomas Wynn</B>,
who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, has been a portfolio manager at Monashee Investment Management
since 2011. From 1995 to 2011, he co-founded and served as the Managing Director of Leerink Swann LLC, a Boston based healthcare
investment bank. From 1991 to 1995, he worked at Lehman Brothers. Thomas received his B.A from Fairfield University and J.D. from
Suffolk University We believe Thomas is qualified to sit on our board due to long-running experience in healthcare investing and
advisory services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Thomas Mathers</B>,
who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, founded and has been the President and CEO at Allievex Corporation,
a company neurodegenerative diseases, since April&nbsp;2018<B>.</B> He has also been a General Partner at Pappas Ventures V, a
venture capital company, since February&nbsp;2018. Prior to Pappas Capital and Allievex, from June&nbsp;2010 to March&nbsp;2017,
Tom was the President and CEO of CoLucid Pharmaceuticals,&nbsp;Inc. (NASDAQ: CLCD), a biotechnology company founded by Pappas Capital,
which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly&nbsp;&amp; Company acquired
CoLucid in March&nbsp;2017 in an all cash transaction for nearly $1 billion. Prior to CoLucid, he was President and CEO of Peptimmune,&nbsp;Inc.;
President and CEO of Cell Based Delivery,&nbsp;Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic
Development at Genzyme Corporation. Tom currently serves as a Trustee of Butler University and is co-founder and Chairman of D&eacute;clion
Holdings, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases.
He is also a business advisor to the Progeria Research Foundation, and previously served on the Board of Directors for the Biotechnology
Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property,
and regulatory policy. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for
his services as an AH-64 Apache helicopter pilot in the Gulf War. We believe Thomas is qualified to sit on our board due to his
long-running experience in early stage investing and experience on company boards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Graham
Walmsley</B></FONT>, who will become our Board Member on the effective date of the registration statement of which this prospectus
is a part, has been the General Partner of Logos Global Management, LP, a biotechnology-focused investment partnership based in
San Francisco, since August&nbsp;2019. He was a principal at Versant Ventures, a leading healthcare investment firm, from July&nbsp;2016
until August&nbsp;2019. He was the head of Business Development at Jecure Therapeutics, a developer of therapeutics targeting non-alcoholic
steatohepatitis and liver fibrosis from June&nbsp;2017 until March&nbsp;2019. From April&nbsp;2018 to December&nbsp;2018, he was
the Head of Business Development at Pipeline Therapeutics, a developer of neuro-regeneration drugs. From July&nbsp;2012 to June&nbsp;2016,
he was an Affiliated Trainee at Stanford Hospital&nbsp;&amp; Clinics. He is currently a member of the Board of Directors of ALX
Oncology (NASDAQ: ALXO) and Akero Therapeutics (NASDAQ: AKRO). We believe Graham is qualified to sit on our board due to his extensive
experience in biotechnology investing and previous company board positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Elizabeth
Barrett</B></FONT>, who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, is a highly regarded
industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Since January 2019,
Liz has served as President and CEO of UroGen Pharma. Prior to UroGen, from February 2018 to January 2019, Liz was CEO of Novartis Oncology
and a member of the Novartis Executive Committee. She previously was previously at Pfizer Inc. from March 2009 to January 2019, where
she held numerous leadership positions, including Global President of Oncology, President of Global Innovative Pharma for Europe, President
of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, Liz held positions at
Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson &amp;
Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from Saint
Joseph&rsquo;s University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Scott
Janssen</B></FONT>, who will become our Board Member on the effective date of the registration statement of which this
prospectus is a part, has served as Managing Director of LifeSci Associates since June 2020. Previously, he was the Chief
Accounting Officer at CMG Partners from August 2019 to April 2020. Scott has over 25 years of accounting, finance and
operational experience working within and consulting to public and private companies within the life science and technology
space. Scott was a Managing Director of the Connor Group from January 2014 to August 2019 to where he supported his clients
by providing them accounting and operational consulting services. Mr. Janssen spent six years of his career from January 1993
to November 1999 as an auditor with Ernst &amp; Young and Grant Thornton in the Bay Area and Los Angeles. He was a Managing
Director at Connor Group, a consulting firm from January 2014 to August 2019. Scott received a B.S. in Applied Mathematics
from the University of California, Los Angeles. We believe Scott is qualified to sit on our board due to his long-running
experience in accounting and finance consulting roles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number and Terms of Office of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon consummation
of this offering, our board of directors will have 7 members, 4 of whom will be deemed &ldquo;independent&rdquo; under SEC and
Nasdaq rules. Our board of directors will be divided into three classes with only one class of directors being elected in each
year and each class serving a three-year term. The term of office of the first class of directors, consisting of Andrew McDonald,
Michael Rice, and David Dobkin will expire at our first annual meeting of stockholders. The term of office of the second class
of directors, consisting of Thomas Wynn, Thomas Mathers, Graham Walmsley, Elizabeth Barrett and Scott Janssen, will expire at the second annual meeting.
We may not hold an annual meeting of stockholders until after we consummate our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to an agreement
to be entered into concurrently with the issuance and sale of the securities in this offering, our sponsor, upon consummation of
an initial business combination, will be entitled to nominate three individuals for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our officers are appointed
by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our
board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws
provide that our directors may consist of a chairman of the board, and that our officers may consist of chief executive officer,
president, chief financial officer, executive vice president(s), vice president(s), secretary, treasurer and such other officers
as may be determined by the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No executive officer
has received any cash compensation for services rendered to us. Commencing on the date of this prospectus through the completion
of our initial business combination with a target business, we will pay to LifeSci Holdings LLC a fee of $10,000 per month for
providing us with office space and certain office and secretarial services. However, pursuant to the terms of such agreement, we
may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the
trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue
without interest and be due and payable no later than the date of the consummation of our initial business combination. Other than
the $10,000 per month administrative fee, no compensation or fees of any kind, including finder&rsquo;s fees, consulting fees and
other similar fees, will be paid to our insiders or any of the members of our management team, for services rendered prior to or
in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However,
such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our
behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business
combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine
their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the
extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts
held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">After our initial
business combination, members of our management team who remain with us may be paid consulting, management or other fees from the
combined company with any and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation
materials furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of a stockholder
meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to
determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination
in a Current Report on Form&nbsp;8-K, as required by the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Nasdaq listing standards
require that within one year of the listing of our securities on the Nasdaq Capital Market we have at least three independent directors
and that a majority of our board of directors be independent. An &ldquo;independent director&rdquo; is defined generally as a person
other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the
opinion of the company&rsquo;s board of directors, would interfere with the director&rsquo;s exercise of independent judgment in
carrying out the responsibilities of a director. Our Board of Directors had determined that Thomas Wynn, Thomas Mathers, Graham
Walmsley, Elizabeth Barrett and Scott Janssen are &ldquo;independent directors&rdquo; as defined in the Nasdaq listing standards
and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors
are present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will only enter
into a business combination if it is approved by a majority of our independent directors. Additionally, we will only enter into
transactions with our officers and directors and their respective affiliates that are on terms no less favorable to us than could
be obtained from independent parties. Any related-party transactions must be approved by our audit committee and a majority of
disinterested directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective as of the
date of this prospectus, we will establish an audit committee of the board of directors, which will consist of Thomas Wynn, Thomas
Mathers and Elizabeth Barrett, each of whom is an independent director. Thomas Wynn will serve as chairman of the audit committee.
The audit committee&rsquo;s duties, which are specified in our Audit Committee Charter, include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form&nbsp;10-K;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">discussing with management major risk assessment and risk management policies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">monitoring the independence of the independent auditor;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing and approving all related-party transactions;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">inquiring and discussing with management our compliance with applicable laws and regulations;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">appointing or replacing the independent auditor;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">approving reimbursement of expenses incurred by our management team in identifying potential target businesses.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Financial Experts on Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The audit committee
will at all times be composed exclusively of &ldquo;independent directors&rdquo; who are &ldquo;financially literate&rdquo; as
defined under the Nasdaq listing standards. The Nasdaq listing standards define &ldquo;financially literate&rdquo; as being able
to read and understand fundamental financial statements, including a company&rsquo;s balance sheet, income statement and cash flow
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, we must
certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in
finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results
in the individual&rsquo;s financial sophistication. The board of directors has determined that Thomas Wynn qualifies as an &ldquo;audit
committee financial expert,&rdquo; as defined under rules&nbsp;and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Nominating Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective as of the
date of this prospectus, we have established a nominating committee of the board of directors, which will consist of Thomas Mathers,
Graham Walmsley and Scott Janssen each of whom is an independent director under Nasdaq&rsquo;s listing standards. Thomas Mathers
is the Chairperson of the nominating committee. The nominating committee is responsible for overseeing the selection of persons
to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management,
stockholders, investment bankers and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Guidelines for Selecting Director Nominees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The guidelines for
selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24px"></TD><TD STYLE="width: 24px; text-align: left">&bull;</TD><TD STYLE="text-align: justify">should have demonstrated notable or significant achievements
in business, education or public service;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24px"></TD><TD STYLE="width: 24px; text-align: left">&bull;</TD><TD STYLE="text-align: justify">should possess the requisite intelligence, education
and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives
and backgrounds to its deliberations; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 24px"></TD><TD STYLE="width: 24px; text-align: left">&bull;</TD><TD STYLE="text-align: justify">should have the highest ethical standards, a strong sense
of professionalism and intense dedication to serving the interests of the stockholders.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The nominating committee
will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism
in evaluating a person&rsquo;s candidacy for membership on the board of directors. The nominating committee may require certain
skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and
will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating
committee does not distinguish among nominees recommended by stockholders and other persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Upon the effectiveness
of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of
directors consisting of Scott Janssen, Thomas Wynn and Graham Walmsley, each of whom is an independent director. Scott Janssen
will serve as chairman of the compensation committee. We will adopt a compensation committee charter, which will detail the principal
functions of the compensation committee, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing and approving on an annual basis the corporate goals and objectives relevant to our President and Chief Executive Officer&rsquo;s compensation, evaluating our President and Chief Executive Officer&rsquo;s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our President and Chief Executive Officer based on such evaluation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing and approving the compensation of all of our other executive officers;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing our executive compensation policies and plans;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">implementing and administering our incentive compensation equity-based remuneration plans;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">assisting management in complying with our proxy statement and annual report disclosure requirements;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">producing a report on executive compensation to be included in our annual proxy statement; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The charter will also
provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant,
legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of
any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other
adviser, the compensation committee will consider the independence of each such adviser, including the factors required by NASDAQ
and the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Compensation Committee Interlocks and
Insider Participation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may not have a
compensation committee in place prior to the completion of our initial business combination. Any executive compensation matters
that arise prior to the time we have a compensation committee in place will be determined by our independent directors. None of
our directors who currently serve as members of our compensation committee is, or has at any time in the past been, one of our
officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the compensation
committee of any other entity that has one or more executive officers serving on our board of directors. None of our executive
officers currently serves, or in the past year has served, as a member of the board of directors of any other entity that has one
or more executive officers serving on our compensation committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective upon consummation
of this offering, we will adopt a code of ethics that applies to all of our executive officers, directors and employees. The code
of ethics codifies the business and ethical principles that govern all aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conflicts of Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investors should be
aware of the following potential conflicts of interest:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our officers and directors may have conflicts of interest in determining to which entity a particular business opportunity should be presented.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">Unless we consummate our initial business combination, our officers, directors and other insiders will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that such expenses exceed the amount of available proceeds not deposited in the trust account.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">The insider shares beneficially owned by our officers and directors
will be released from escrow only if our initial business combination is successfully completed. Additionally, if we are unable
to complete an initial business combination within the required time frame, our officers and directors will not be entitled to
receive any amounts held in the trust account with respect to any of their insider shares or private warrants. Furthermore, our sponsor
has agreed that the private warrants will not be sold or transferred by it until after we have completed our initial business combination.
For the foregoing reasons, our board may have a conflict of interest in determining whether a particular target business is an
appropriate business with which to effect our initial business combination.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In general, officers
and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities
to a corporation if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">the corporation could financially undertake the opportunity;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">the opportunity is within the corporation&rsquo;s line of business; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify">&bull;</TD>
    <TD STYLE="text-align: justify">it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, as a
result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting
business opportunities meeting the above-listed criteria to multiple entities. Furthermore, our certificate of incorporation provides
that the doctrine of corporate opportunity will not apply with respect to any of our officers or directors in circumstances where
the application of the doctrine would conflict with any fiduciary duties or contractual obligations they may have. In order to
minimize potential conflicts of interest which may arise from multiple affiliations, our officers and directors (other than our
independent directors) have agreed to present to us for our consideration, prior to presentation to any other person or entity,
any suitable opportunity to acquire a target business, until the earlier of: (1)&nbsp;our consummation of an initial business combination
and (2)&nbsp;24 months from the date of this prospectus. This agreement is, however, subject to any pre-existing fiduciary and
contractual obligations such officer or director may from time to time have to another entity. Accordingly, if any of them becomes
aware of a business combination opportunity which is suitable for an entity to which he or she has pre-existing fiduciary or contractual
obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity
to such entity, and only present it to us if such entity rejects the opportunity. We do not believe, however, that the pre-existing
fiduciary duties or contractual obligations of our officers and directors will materially undermine our ability to complete our
business combination because in most cases the affiliated companies are closely held entities controlled by the officer or director
or the nature of the affiliated company&rsquo;s business is such that it is unlikely that a conflict will arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Three of our officers
and directors, Andrew McDonald, Michael Rice and David Dobkin are officers and directors of LifeSci Acquisition Corp., a special
purpose acquisition company that is seeking a target. LifeSci Acquisition Corp. will have priority over us in connection with potential
target businesses identified by each of them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
summarizes the current material pre-existing fiduciary or contractual obligations of our officers, directors and director nominees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 19%; border-bottom: black 1pt solid"><B>Name of Individual</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; white-space: nowrap; width: 25%; border-bottom: black 1pt solid"><B>Name of Affiliated</B><BR>
<B>Company</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 25%; text-align: center"><B>Entity&rsquo;s Business</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 25%; text-align: center"><B>Affiliation</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Andrew McDonald, PhD</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Capital LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Venture Management LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Index Partners LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attune Pharmaceuticals,&nbsp;Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
        LifeSci Acquisition Corp.</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare investment bank</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare investor and public relations firm</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare venture capital firm</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Index provider of healthcare-based stock market indices</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Novel orally administered small molecule<BR>
        therapeutics for the treatment of rare diseases</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Special Purpose Acquisition Company</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Co-Founder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Co-Founder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Partner</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Member</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Co-Founder and Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chairman and Chief Executive Officer</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Michael Rice</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Capital LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Venture Management LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Index Partners LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Acquisition Corp.</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare investment bank</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare investor and public relations firm</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare venture capital firm</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Index provider of healthcare-based stock
        market indices</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Special Purpose Acquisition Company</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Co-Founder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Co-Founder</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Partner</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Member</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Operating Officer and Director</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>David Dobkin</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Capital, LLC</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Acquisition Corp.</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Healthcare investment bank</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Special Purpose Acquisition Company</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Managing Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer and director</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Thomas Wynn</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">Monashee Investment Management</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;Investment management</TD>
    <TD>&nbsp;</TD>
    <TD>Portfolio Manager</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Thomas Mathers</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Allievex Corporation</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pappas Ventures V</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neurodegenerative diseases</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Venture Capital</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President and CEO</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Partner</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Graham Walmsley</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Logos Global Management, LP</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ALX Oncology</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Akero Therapeutics</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biotechnology investment</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cancer treatments</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Non-alcoholic liver disease treatments</P></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Partner</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Elizabeth Barrett</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">UroGen Pharma Ltd. <BR>
Sage Therapeutics Inc.</TD>
    <TD>&nbsp;</TD>
    <TD>Biopharmaceutical company <BR>
Biopharmaceutical company</TD>
    <TD>&nbsp;</TD>
    <TD>President and<BR>
 CEO<BR>
 Director</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="background-color: white">We
have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our
sponsor.&nbsp;Further, </FONT>our insiders, including our officers and directors, have agreed to vote any shares of common stock
held by them in favor of our initial business combination. In addition, they have agreed to waive their respective rights to receive
any amounts held in the trust account with respect to their insider shares and private warrants if we are unable to complete our
initial business combination within the required time frame. If they purchase shares of common stock in this offering or in the
open market, however, they would be entitled to receive their pro rata share of the amounts held in the trust account if we are
unable to complete our initial business combination within the required time frame, but have agreed not to convert such shares
in connection with the consummation of our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All ongoing and future
transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to
be no less favorable to us than are available from unaffiliated third parties. Such transactions will require prior approval by
our audit committee and a majority of our uninterested &ldquo;independent&rdquo; directors, or the members of our board who do
not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel.
We will not enter into any such transaction unless our audit committee and a majority of our disinterested &ldquo;independent&rdquo;
directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with
respect to such a transaction from unaffiliated third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To further minimize
conflicts of interest, we have agreed not to consummate our initial business combination with an entity that is affiliated with
any of our officers, directors or other insiders, unless we have obtained (i)&nbsp;an opinion from an independent investment banking
firm that the business combination is fair to our unaffiliated stockholders from a financial point of view and (ii)&nbsp;the approval
of a majority of our disinterested and independent directors (if we have any at that time). In no event will our insiders or any
of the members of our management team be paid any finder&rsquo;s fee, consulting fee or other similar compensation prior to, or
for any services they render in order to effectuate, the consummation of our initial business combination (regardless of the type
of transaction that it is).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Limitation on Liability and Indemnification
of Directors and Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our certificate of
incorporation provides that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law
as it now exists or may in the future be amended. In addition, our certificate of incorporation provides that our directors will
not be personally liable for monetary damages to us for breaches of their fiduciary duty as directors, unless they violated their
duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful
payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions
as directors. Notwithstanding the foregoing, as set forth in our certificate of incorporation, such indemnification will not extend
to any claims our insiders may make to us to cover any loss that they may sustain as a result of their agreement to pay debts and
obligations to target businesses or vendors or other entities that are owed money by us for services rendered or contracted for
or products sold to us as described elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our bylaws also will
permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions,
regardless of whether Delaware law would permit indemnification. We will purchase a policy of directors&rsquo; and officers&rsquo;
liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in
some circumstances and insures us against our obligations to indemnify the directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These provisions may
discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also
may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder&rsquo;s investment may be adversely
affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these provisions.
We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced
directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to
the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_012"></A>PRINCIPAL STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
sets forth information regarding the beneficial ownership of our shares of common stock as of the date of this prospectus and as
adjusted to reflect the sale of our shares of common stock offered by this prospectus (assuming none of the individuals listed
purchase shares in this offering), by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">each person known by us to be the beneficial owner of more than 5% of our issued and outstanding shares of common stock;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">each of our officers and directors; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">all of our officers and directors as a group.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated,
we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock
beneficially owned by them. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prior to Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>After Offering<SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name and Address of Beneficial Owner<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount <BR>
and Nature of<BR>
Beneficial<BR>
Ownership</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Approximate<BR>
Percentage of <BR>
Outstanding<BR>
Shares of<BR>
Common <BR>
Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount <BR>
and Nature of<BR>
Beneficial<BR>
Ownership</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Approximate<BR>
Percentage of <BR>
Outstanding Shares <BR>
of Common <BR>
Stock</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Andrew McDonald Ph.D.</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,910,625</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">88.6</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,660,500</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">17.7<FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Michael Rice</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,910,625</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">88.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,660,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">David Dobkin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Thomas Wynn</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Thomas Mathers</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Graham Walmsley</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Elizabeth Barrett</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;*</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Scott Janssen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">All officers and directors as a group (7 individuals)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,940,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">90.0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,690,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">LifeSci Holdings LLC<SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,910,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">88.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,660,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Chardan Healthcare Investments LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">215,625</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">10.0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">187,500</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">*</TD>
    <TD STYLE="text-align: justify">Less than 1%.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">Unless otherwise indicated, the business address of each of the individuals is c/o LifeSci Acquisition II Corp., 250 W. 55th St., #3401, New York, NY 10019</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(2)</TD>
    <TD STYLE="text-align: justify">Assumes no exercise of the over-allotment option and, therefore, an aggregate of 281,250 shares of common stock held by our initial stockholders are forfeited.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(3)</TD>
    <TD>Consists of shares of common stock owned by LifeSci Holdings
LLC, for which Michael Rice and Andrew McDonald are the managing members.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(4)</TD>
    <TD STYLE="text-align: justify">Michael Rice and Andrew McDonald are the managing members of
LifeSci Holdings LLC.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Immediately after
this offering, our initial stockholders will beneficially own 20% of the then issued and outstanding shares of common stock (assuming
none of them purchase any shares offered by this prospectus and excluding the private warrants). None of our initial stockholders,
officers and directors has indicated to us that he intends to purchase securities in this offering. Because of the ownership block
held by our initial stockholders, such individuals may be able to effectively exercise control over all matters requiring approval
by our stockholders, including the election of directors and approval of significant corporate transactions other than approval
of our initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the underwriters
do not exercise all or a portion of the over-allotment option, our initial stockholders will have up to an aggregate 281,250 shares
of common stock subject to forfeiture. Only a number of shares necessary to maintain our initial stockholders&rsquo; collective
20% ownership interest in our shares of common stock after giving effect to the offering and the exercise, if any, of the underwriters&rsquo;
over-allotment option will be forfeited and excluding the private warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of the insider
shares issued and outstanding prior to the date of this prospectus will be placed in escrow with Continental Stock Transfer&nbsp;&amp;
Trust Company, as escrow agent, until (1)&nbsp;with respect to 50% of the insider shares, the earlier of six months after the date
of the consummation of our initial business combination and the date on which the closing price of our common stock equals or exceeds
$12.50 per share (as adjusted for share splits, share capitalizations, reorganizations and recapitalizations) for any 20 trading
days within any 30-trading day period commencing after our initial business combination and (2)&nbsp;with respect to the remaining
50% of the insider shares, six months after the date of the consummation of our initial business combination, or earlier, in either
case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar
transaction which results in all of our stockholders having the right to exchange their shares for cash, securities or other property.
Up to 281,250 of the insider shares may also be released from escrow earlier than this date for forfeiture and cancellation if
the over-allotment option is not exercised in full as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During the escrow
period, the holders of these shares will not be able to sell or transfer their securities except (i)&nbsp;for transfers to our
officers, directors or their respective affiliates (including for transfers to an entity&rsquo;s members upon its liquidation),
(ii)&nbsp;to relatives and trusts for estate planning purposes, (iii)&nbsp;by virtue of the laws of descent and distribution upon
death, (iv)&nbsp;pursuant to a qualified domestic relations order, (v)&nbsp;by certain pledges to secure obligations incurred in
connection with purchases of our securities, (vi)&nbsp;by private sales made at or prior to the consummation of a business combination
at prices no greater than the price at which the shares were originally purchased or (vii)&nbsp;to us for no value for cancellation
in connection with the consummation of our initial business combination, in each case (except for clause (vii)) where the transferee
agrees to the terms of the escrow agreement, but will retain all other rights as our stockholders, including, without limitation,
the right to vote their shares of common stock and the right to receive cash dividends, if declared. If dividends are declared
and payable in shares of common stock, such dividends will also be placed in escrow. If we are unable to effect a business combination
and liquidate the trust account, none of our initial stockholders will receive any portion of the liquidation proceeds with respect
to their insider shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo;
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital.&nbsp;Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants)&nbsp;in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
If we do not complete our initial business combination within 24 months from the closing of this offering, the proceeds from the
sale of the private warrants will be included in the liquidating distribution to the holders of our public shares. The private
warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the
initial purchasers or their permitted transferees. The private warrants will not be transferable, assignable or saleable until
after the completion of a business combination, subject to the limited exceptions described above. The private warrants purchased
by our sponsor will not be exercisable more than five years from the commencement of sales of this offering in accordance with
FINRA Rule 5110(g)(8)(A), as long as our sponsor or any of its related persons beneficially own these private warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to meet our
working capital needs following the consummation of this offering, our initial stockholders, officers and directors or their affiliates
may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their
sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of our initial
business combination, without interest, or, at the lender&rsquo;s discretion, up to $500,000 of the notes may be converted upon
consummation of our business combination into additional private warrants at a conversion price of $0.90 per private warrant. Our
directors have approved the issuance of the private warrants upon conversion of such notes, to the extent the holder wishes to
so convert them at the time of the consummation of our initial business combination. If we do not complete a business combination,
the loans will not be repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci Holdings LLC
is our &ldquo;promoter,&rdquo; as that term is defined under the Federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_013"></A>CERTAIN TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On January&nbsp;1,
2020, our sponsor purchased 2,156,250 founder shares for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci
Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder
shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters&rsquo; over-allotment
option is not exercised in full or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the underwriters
do not exercise all or a portion of their over-allotment option, our initial stockholders have agreed that up to an aggregate of
281,250 shares of common stock in proportion to the portion of the over-allotment option that was not exercised are subject to
forfeiture and would be immediately cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the underwriters
determine the size of the offering should be increased (including pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act) or
decreased, a share capitalizations or a contribution back to capital, as applicable, would be effectuated in order to maintain
our initial stockholder&rsquo;s ownership at 20% of the number of shares issued and outstanding after the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo;
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital.&nbsp;Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants)&nbsp;in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
The private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to
be held by the initial purchasers or their permitted transferees. The private warrants will not be transferable, assignable or
saleable until after the completion of a business combination, subject to the limited exceptions described above. The private warrants
purchased by our sponsor will not be exercisable more than five years from the commencement of sales of this offering in accordance
with FINRA Rule 5110(g)(8)(A), as long as our sponsor or any of its related persons beneficially own these private warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order to meet our
working capital needs following the consummation of this offering, our initial stockholders, officers and directors and their respective
affiliates may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable
in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of
our initial business combination, without interest, or, at the lender&rsquo;s discretion, up to $500,000 of the notes may be converted
upon consummation of our business combination into additional private warrants at a conversion price of $0.90 per private warrant.
Our directors have approved the issuance of the private warrants upon conversion of such notes, to the extent the holder wishes
to so convert them at the time of the consummation of our initial business combination. If we do not complete a business combination,
the loans would not be repaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The holders of our
insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants, will be entitled
to registration and stockholder rights pursuant to an agreement to be signed prior to or on the effective date of this offering.
The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders
of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior
to the date on which these shares of common stock are to be released from escrow. In addition, the holders have certain &ldquo;piggy-back&rdquo;
registration rights with respect to registration statements filed subsequent to our consummation of a business combination. <I>We
will bear the expenses incurred in connection with the filing of any such registration statements.</I> Our sponsor and its related
persons may not, with respect to the private warrants purchased by it, (i)&nbsp;have more than one demand registration right at
our expense, (ii)&nbsp;exercise their demand registration rights more than five (5)&nbsp;years from the effective date of the registration
statement of which this prospectus forms a part, and (iii)&nbsp;exercise their &ldquo;piggy-back&rdquo; registration rights more
than seven (7)&nbsp;years from the commencement of sales of the offering as long as our sponsor or any of its related persons are
beneficial owners of private placement warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the registration
rights and stockholder rights agreement our sponsor will be entitled, upon consummation of our initial business combination, to
nominate three individuals for election to our board of directors, which is described under the section of this prospectus entitled
 &ldquo;Description of Securities&mdash;Registration and Stockholder Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will reimburse
our officers and directors for any reasonable out-of-pocket business expenses incurred by them in connection with certain activities
on our behalf such as identifying and investigating possible target businesses and business combinations. There is no limit on
the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available
proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses
would not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve
all reimbursements and payments made to any initial stockholder or member of our management team, or our or their respective affiliates,
and any reimbursements and payments made to members of our audit committee will be reviewed and approved by our Board of Directors,
with any interested director abstaining from such review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No compensation or
fees of any kind, including finder&rsquo;s fees, consulting fees or other similar compensation, will be paid to any of our initial
stockholders, officers or directors who owned our shares of common stock prior to this offering, or to any of their respective
affiliates, prior to or with respect to the business combination (regardless of the type of transaction that it is).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All ongoing and future
transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to
be no less favorable to us than are available from unaffiliated third parties. Such transactions, including the payment of any
compensation, will require prior approval by a majority of our uninterested &ldquo;independent&rdquo; directors (to the extent
we have any) or the members of our board who do not have an interest in the transaction, in either case who had access, at our
expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our disinterested &ldquo;independent&rdquo;
directors (or, if there are no &ldquo;independent&rdquo; directors, our disinterested directors) determine that the terms of such
transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated
third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related Party Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Code of Ethics,
which we will adopt upon consummation of this offering, will require us to avoid, wherever possible, all related party transactions
that could result in actual or potential conflicts of interests, except under guidelines approved by the board of directors (or
the audit committee). Related-party transactions are defined as transactions in which (1)&nbsp;the aggregate amount involved will
or may be expected to exceed $120,000 in any calendar year, (2)&nbsp;we or any of our subsidiaries is a participant, and (3)&nbsp;any
(a)&nbsp;executive officer, director or nominee for election as a director, (b)&nbsp;greater than 5% beneficial owner of our common
stock, or (c)&nbsp;immediate family member, of the persons referred to in clauses (a)&nbsp;and (b), has or will have a direct or
indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity).
A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his
or her work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives
improper personal benefits as a result of his or her position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our audit committee,
pursuant to its written charter, will be responsible for reviewing and approving related-party transactions to the extent we enter
into such transactions. All ongoing and future transactions between us and any of our officers and directors or their respective
affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such
transactions will require prior approval by our audit committee and a majority of our uninterested &ldquo;independent&rdquo; directors,
or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our
attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of
our disinterested &ldquo;independent&rdquo; directors determine that the terms of such transaction are no less favorable to us
than those that would be available to us with respect to such a transaction from unaffiliated third parties. Additionally, we require
each of our directors and executive officers to complete a directors&rsquo; and officers&rsquo; questionnaire that elicits information
about related party transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These procedures are
intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict
of interest on the part of a director, employee or officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To further minimize
potential conflicts of interest, we have agreed not to consummate a business combination with an entity which is affiliated with
any of our initial stockholders unless we obtain an opinion from an independent investment banking firm that the business combination
is fair to our unaffiliated stockholders from a financial point of view. Furthermore, in no event will any of our existing officers,
directors or initial stockholders, or any entity with which they are affiliated, be paid any finder&rsquo;s fee, consulting fee
or other compensation prior to, or for any services they render in order to effectuate, the consummation of a business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_014"></A>DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our amended
certificate of incorporation, our authorized capital stock consists of 30,000,000 shares of common stock, par value $0.0001, and
1,000,000 shares of preferred stock, par value $0.0001. As of the date of this prospectus, 2,156,250 shares of common stock are
issued and outstanding, held our sponsor, our directors, and affiliates of our management team. No preferred shares are issued
or outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our holders of record
of our common stock are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with
any vote held to approve our initial business combination, our insiders, officers and directors, have agreed to vote their respective
shares of common stock owned by them immediately prior to this offering, including both the insider shares and any shares acquired
in this offering or following this offering in the open market, in favor of the proposed business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will consummate
our initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause our
net tangible assets to be less than $5,000,001 and a majority of the outstanding shares of common stock voted are voted in favor
of the business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to our certificate
of incorporation, if we do not consummate our initial business combination within 24 months from the closing of this offering,
we will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not
more than ten business days thereafter, redeem 100% of the outstanding public shares, which redemption will completely extinguish
public stockholders&rsquo; rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the approval of our
remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii)&nbsp;and (iii)&nbsp;above)
to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our insiders
have agreed to waive their rights to share in any distribution with respect to their insider shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our stockholders have
no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the
shares of common stock, except that public stockholders have the right to sell their shares to us in any tender offer or have their
shares of common stock converted to cash equal to their pro rata share of the trust account if they vote on the proposed business
combination and the business combination is completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we hold a stockholder
vote to amend any provisions of our certificate of incorporation relating to stockholder&rsquo;s rights or pre-business combination
activity (including the substance or timing within which we have to complete a business combination), we will provide our public
stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held
in the trust account and not previously released to us to pay our franchise and income taxes or for working capital purposes, divided
by the number of then outstanding public shares, in connection with any such vote. In either of such events, converting stockholders
would be paid their pro rata portion of the trust account promptly following consummation of the business combination or the approval
of the amendment to the certificate of incorporation. If the business combination is not consummated or the amendment is not approved,
stockholders will not be paid such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There are no shares
of preferred stock outstanding. No shares of preferred stock are being issued or registered in this offering. Accordingly, our
board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion,
voting or other rights which could adversely affect the voting power or other rights of the holders of common stock. However, the
underwriting agreement prohibits us, prior to a business combination, from issuing preferred stock which participates in any manner
in the proceeds of the trust account, or which votes as a class with the common stock on our initial business combination. We may
issue some or all of the preferred stock to effect our initial business combination. In addition, the preferred stock could be
utilized as a method of discouraging, delaying or preventing a change in control of us. Although we do not currently intend to
issue any shares of preferred stock, we reserve the right to do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Private Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No warrants are currently
outstanding. Each private warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per
whole share, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of this
offering or the consummation of an initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The private warrants
will not be exercisable more than five years from the commencement of sales of this offering in accordance with FINRA Rule 5110(g)(8)(A),
as long as our sponsor or any of its related persons beneficially own these private warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The exercise price
and number of shares of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in
the event of a share dividend, extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The warrants may be
exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with
the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment
of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant
holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their
warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder
will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have not paid any
cash dividends on our shares of common stock to date and do not intend to pay cash dividends prior to the completion of a business
combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements
and general financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to
a business combination will be within the discretion of our then board of directors. It is the present intention of our board of
directors to retain all earnings, if any, for use in our business operations and, accordingly, our board does not anticipate declaring
any dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transfer agent
for our shares of common stock is Continental Stock Transfer&nbsp;&amp; Trust Company, 1 State
Street, 30th Floor, New York, New York 10004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Anti-Takeover Provisions of Delaware Law and our
Certificate of Incorporation and By-Laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have opted out
of Section&nbsp;203 of the Delaware General Corporate Law, or the DGCL. However, our amended and restated certificate of incorporation
contains similar provisions providing that we may not engage in certain &ldquo;business combinations&rdquo; with any &ldquo;interested
stockholder&rdquo; for a three-year period following the time that the stockholder became an interested stockholder, unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Generally, a &ldquo;business
combination&rdquo; includes a merger, asset or stock sale or certain other transactions resulting in a financial benefit to the
interested stockholder. Subject to certain exceptions, an &ldquo;interested stockholder&rdquo; is a person who, together with that
person&rsquo;s affiliates and associates, owns, or within the previous three years owned, 20% or more of our voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under certain circumstances,
this provision will make it more difficult for a person who would be an &ldquo;interested stockholder&rdquo; to effect various
business combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring
our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if
our board of directors approves either the business combination or the transaction which results in the stockholder becoming an
interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make
it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
certificate of incorporation provides that our sponsor and its respective affiliates, any of their respective direct or indirect
transferees of at least 20% of our outstanding common stock and any group as to which such persons are party to, do not constitute
 &ldquo;interested stockholders&rdquo; for purposes of this provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Special meeting of stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our bylaws provide
that special meetings of our stockholders may be called only by a majority vote of our board of directors, by our chief executive
officer or by our chairman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Advance notice requirements for stockholder proposals and
director nominations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our bylaws provide
that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as
directors at our annual meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder&rsquo;s
notice will need to be delivered to our principal executive offices not later than the close of business on the 90<SUP>th</SUP>
day nor earlier than the opening of business on the 120<SUP>th</SUP> day prior to the scheduled date of the annual meeting of stockholders.
Our bylaws also specify certain requirements as to the form and content of a stockholders&rsquo; meeting. These provisions may
preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Authorized but unissued shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our authorized but
unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized
for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or
discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Exclusive forum for certain lawsuits</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our amended and restated
certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1)&nbsp;derivative
action or proceeding brought on behalf of our company, (2)&nbsp;action asserting a claim of breach of a fiduciary duty owed by
any director, officer, employee or agent of our company to our company or our stockholders, or any claim for aiding and abetting
any such alleged breach, (3)&nbsp;action asserting a claim against our company or any director or officer of our company arising
pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws, or (4)&nbsp;action
asserting a claim against us or any director or officer of our company governed by the internal affairs doctrine except for, as
to each of (1)&nbsp;through (4)&nbsp;above, any claim (A)&nbsp;as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten days following such determination), (B)&nbsp;which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery, or (C)&nbsp;arising under the federal securities laws, including the Securities
Act as to which the Court of Chancery and the federal district court for the District of Delaware shall concurrently be the sole
and exclusive forums. Notwithstanding the foregoing, the inclusion of such provision in our amended and restated certificate of
incorporation will not be deemed to be a waiver by our stockholders of our obligation to comply with federal securities laws, rules&nbsp;and
regulations, and the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive
forum. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in
the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and
officers. Furthermore, the enforceability of choice of forum provisions in other companies&rsquo; certificates of incorporation
has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable
or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_015"></A>SECURITIES ELIGIBLE FOR FUTURE SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Immediately
after this offering, we will have 9,375,000 shares of common stock issued and outstanding, or 10,781,250 shares of common
stock if the over-allotment option is exercised in full. Of these shares, the 7,500,000 shares sold in this offering, or
8,625,000 shares if the over-allotment option is exercised in full, will be freely tradable without restriction or further
registration under the Securities Act, except for any shares purchased by one of our affiliates within the meaning of
Rule&nbsp;144 under the Securities Act. All of the remaining shares are restricted securities under Rule&nbsp;144, in that
they were issued in private transactions not involving a public offering. All of those shares will not be transferable except
in limited circumstances described elsewhere in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Rule&nbsp;144</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A person who has beneficially
owned restricted shares of common stock for at least six months would be entitled to sell their securities provided that (i)&nbsp;such
person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale
and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale. Persons
who have beneficially owned restricted shares of common stock for at least six months but who are our affiliates at the time of,
or any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would
be entitled to sell within any three-month period a number of shares that does not exceed the greater of either of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">1% of the number of shares of common stock then issued and outstanding, which will equal 93,750 shares immediately after this offering (or 107,812 shares) if the over-allotment option is exercised in full); and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">The average weekly trading volume of the shares of common stock during the four calendar weeks preceding the filing of a notice on Form&nbsp;144 with respect to the sale.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Sales under Rule&nbsp;144
are also limited by manner of sale provisions and notice requirements and to the availability of current public information about
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Restrictions on the Use of Rule&nbsp;144 by Shell Companies
or Former Shell Companies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Historically, the
SEC staff had taken the position that Rule&nbsp;144 is not available for the resale of securities initially issued by companies
that are, or previously were, blank check companies, like us. The SEC has codified and expanded this position in the amendments
discussed above by prohibiting the use of Rule&nbsp;144 for resale of securities issued by any shell companies (other than business
combination related shell companies) or any issuer that has been at any time previously a shell company. The SEC has provided an
important exception to this prohibition, however, if the following conditions are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the issuer of the securities that was formerly a shell company has ceased to be a shell company;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form&nbsp;8-K reports; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">at least one year has elapsed from the time that the issuer filed current Form&nbsp;10 type information with the SEC reflecting its status as an entity that is not a shell company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result, it is
likely that pursuant to Rule&nbsp;144, our initial stockholders will be able to sell their insider shares freely without registration
one year after we have completed our initial business combination assuming they are not an affiliate of ours at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Registration and Stockholder Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The holders of our
insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants, will be entitled
to registration and stockholder rights pursuant to an agreement to be signed prior to or on the effective date of this offering.
The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders
of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior
to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the private warrants
can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders
have certain &ldquo;piggy-back&rdquo; registration rights with respect to registration statements filed subsequent to our consummation
of a business combination. <I>We will bear the expenses incurred in connection with the filing of any such registration statements.</I>
Our sponsor and its related persons may not, with respect to the private warrants purchased by it, (i)&nbsp;have more than one
demand registration right at our expense, (ii)&nbsp;exercise their demand registration rights more than five (5)&nbsp;years from
the effective date of the registration statement of which this prospectus forms a part, and (iii)&nbsp;exercise their &ldquo;piggy-back&rdquo;
registration rights more than seven (7)&nbsp;years from the effective date of the registration statement of which this prospectus
forms a part, as long as our sponsor or any of its related persons are beneficial owners of private placement warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, pursuant
to the registration and stockholder rights agreement, our sponsor, upon consummation of an initial business combination, will be
entitled to nominate three individuals for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_016"></A>UNDERWRITING (CONFLICTS OF INTEREST)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to offer
our securities described in this prospectus through the underwriters named below. LifeSci Capital is the representative for the
underwriters. We have entered into an underwriting agreement with the representative. Subject to the terms and conditions of the
underwriting agreement, each of the underwriters has severally agreed to purchase from us the number of shares listed next to its
name in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Underwriter</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of
    Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">LifeSci Capital</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">[__]</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">[__]</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">[__]</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; padding-bottom: 2.5pt">Total</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7,500,000</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A copy of the underwriting
agreement has been filed as an exhibit to the registration statement of which this prospectus forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing of our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our shares of common
stock will be quoted on Nasdaq under the symbol &ldquo;LSAQ&rdquo;. Our shares will be listed on Nasdaq on or promptly after the
effective date of the registration statement. We cannot guarantee that our securities will continue to be listed on Nasdaq after
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Over-allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have granted the
underwriters an option to buy up to 1,125,000 additional shares. The underwriters may exercise this option solely for the purpose
of covering over-allotments, if any, made in connection with this offering. The underwriters have 45 days from the date of this
prospectus to exercise this option. If the underwriters exercise this option, they will each purchase additional shares approximately
in proportion to the amounts specified in the table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Commissions and Discounts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shares sold by the
underwriters to the public will initially be offered at the offering price set forth on the cover of this prospectus. The underwriters
will be entitled to a cash underwriting discount of $1,500,000 (or $1,725,000 if the over-allotment option is exercised in full).
[__] will receive $[__], payable out of the cash underwriting discount of $1,500,000 (or $1,725,000 if the over-allotment option
is exercised in full), for acting as a qualified independent underwriter. Any shares sold by the underwriters to securities dealers
may be sold at a discount of up to [$0.08] per share from the public offering price. If all of the shares are not sold at the initial
public offering price, the representative may change the offering price and the other selling terms. Upon execution of the underwriting
agreement, the underwriters will be obligated to purchase the shares at the prices and upon the terms stated therein, and, as a
result, will thereafter bear any risk associated with changing the offering price to the public or other selling terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The underwriters have
agreed to reimburse certain of our expenses. We have agreed to reimburse the underwriters for all expenses and fees related to
the review by FINRA, which will not exceed $25,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table
shows the per share and total underwriting discounts and commissions we will pay to the underwriters assuming both no exercise
and full exercise of the underwriters&rsquo; over-allotment option to purchase up to an additional 1,125,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Business Combination Marketing Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have engaged LifeSci
Capital as an advisor in connection with our business combination to assist us in holding meetings with our shareholders to discuss
the potential business combination and the target business&rsquo; attributes, introduce us to potential investors that are interested
in purchasing our securities in connection with our initial business combination, assist us in obtaining shareholder approval for
the business combination and assist us with our press releases and public filings in connection with the business combination.
We will pay LifeSci Capital a cash fee for such services upon the consummation of our initial business combination in an amount
equal to 3.5% of the gross proceeds of this offering (exclusive of any applicable finders&rsquo; fees which might become payable);
provided that up to 33% of the fee may be allocated in our sole discretion to other third parties who are investment banks or financial
advisory firms not participating in this offering that assist us in identifying and consummating an initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, we will
pay LifeSci Capital a cash fee equal to 1.0% of the total consideration payable in the proposed business combination if it introduces
us to the target business with which we complete a business combination; provided that the foregoing fee will not be paid prior
to the date that is 60 days from the effective date of the registration statement of which this prospectus forms a part, unless
FINRA determines that such payment would not be deemed underwriters&rsquo; compensation in connection with this offering pursuant
to FINRA Rule 5110.01(b)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Share</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Without <BR>
Over-allotment</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>With <BR>
Over-allotment</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Public offering price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">10.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">75,000,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">86,250,000</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Discount and qualified independent underwriter fees<SUP>(1)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,500,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,725,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Proceeds before expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">73,500,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">84,525,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">(1)</TD>
    <TD STYLE="text-align: justify">The offering expenses are estimated at $480,000.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pricing of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have been advised
by the representative that the underwriters propose to offer the shares to the public at the offering price set forth on the cover
page&nbsp;of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Prior to this offering
there has been no public market for any of our securities. The public offering price of the shares was negotiated between us and
the representative. Factors considered in determining the prices and terms of the shares include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the history and prospects of companies whose principal business is the acquisition of other companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">prior offerings of those companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our prospects for acquiring an operating business at attractive values;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">our capital structure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the per share amount of net proceeds being placed into the trust account;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">an assessment of our management and their experience in identifying operating companies;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">general conditions of the securities markets at the time of the offering; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">other factors as were deemed relevant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">However, although
these factors were considered, the determination of our offering price is more arbitrary than the pricing of securities for an
operating company in a particular industry since the underwriters are unable to compare our financial results and prospects with
those of public companies operating in the same industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Regulatory Restrictions on Purchase of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Rules&nbsp;of the
SEC may limit the ability of the underwriters to bid for or purchase our shares before the distribution of the shares is completed.
However, the underwriters may engage in the following activities in accordance with the rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">Stabilizing Transactions. The underwriters may make bids or
purchases for the purpose of preventing or retarding a decline in the price of our common stock, as long as stabilizing bids do
not exceed the offering price of $10.00 and the underwriters comply with all other applicable rules.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">Over-Allotments and Syndicate Coverage Transactions.&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may create a short position in our common stock by selling more of our shares than are set forth on the cover page&nbsp;of
this prospectus up to the amount of the over-allotment option. This is known as a covered short position. The underwriters may
also create a short position in our common stock by selling more of our shares than are set forth on the cover page&nbsp;of this
prospectus and the shares allowed by the over-allotment option. This is known as a naked short position. If the underwriters create
a short position during the offering, the representative may engage in syndicate covering transactions by purchasing our shares
in the open market. The representative may also elect to reduce any short position by exercising all or part of the over-allotment
option. Determining what method to use in reducing the short position depends on how the shares trade in the aftermarket following
the offering. If the share price drops following the offering, the short position is usually covered with shares purchased by the
underwriters in the aftermarket. However, the underwriters may cover a short position by exercising the over-allotment option even
if the share price drops following the offering. If the share price rises after the offering, then the over-allotment option is
used to cover the short position. If the short position is more than the over-allotment option, the naked short must be covered
by purchases in the aftermarket, which could be at prices above the offering price.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">Penalty Bids. The representative may reclaim a selling concession
from a syndicate member when the shares originally sold by the syndicate member are purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Stabilization and
syndicate covering transactions may cause the price of our securities to be higher than they would be in the absence of these transactions.
The imposition of a penalty bid might also have an effect on the prices of our securities if it discourages resales of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither we nor the
underwriters make any representation or prediction as to the effect that the transactions described above may have on the price
of our securities. These transactions may occur on Nasdaq, in the over-the-counter market or on any trading market. If any of these
transactions are commenced, they may be discontinued without notice at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conflicts of Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci Holdings LLC,
our sponsor, is an affiliate of LifeSci Capital LLC, the representative of the underwriters in this offering, and certain of our
officers and directors are affiliated with LifeSci Capital LLC. As a result, LifeSci Capital LLC is deemed to have a &ldquo;conflict
of interest&rdquo; within the meaning of Rule&nbsp;5121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Accordingly, this
offering is being made in compliance with the applicable requirements of Rule&nbsp;5121. Rule&nbsp;5121 requires that a &ldquo;qualified
independent underwriter,&rdquo; as defined in Rule&nbsp;5121, participate in the preparation of the registration statement and
prospectus and exercise the usual standards of due diligence with respect thereto. [__] has agreed to act as a &ldquo;qualified
independent underwriter&rdquo; for this offering. [__] will receive $[__] for acting as a qualified independent underwriter. We
have agreed to indemnify [__] against certain liabilities incurred in connection with acting as a &ldquo;qualified independent
underwriter,&rdquo; including liabilities under the Securities Act. In addition, no underwriter with a conflict of interest will
confirm sales to any account over which it exercises discretionary authority without the specific prior written approval of the
account holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other Terms</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as set forth
above, we are not under any contractual obligation to engage any of the underwriters to provide any services for us after this
offering, and have no present intent to do so. However, any of the underwriters may, among other things, introduce us to potential
target businesses or assist us in raising additional capital, as needs may arise in the future. If any underwriter provides services
to us after this offering, we may pay the underwriter fair and reasonable fees that would be determined at that time in an arm&rsquo;s
length negotiation; provided that no agreement will be entered into with the underwriter and no fees for such services will be
paid to the underwriter prior to the date which is 90 days after the date of this prospectus, unless FINRA determines that such
payment would not be deemed underwriter&rsquo;s compensation in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo;
at $0.90 per warrant for a total purchase price of $2,730,000. The private warrants will become exercisable on the later of the
completion of our initial business combination and 12 months from the closing of this offering and will expire five years after
the effective date of the registration statement of which this prospectus forms a part. Each private warrant is exercisable for
one (1) share of common stock at an exercise price of $11.50 per warrant. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital.&nbsp;Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants)&nbsp;in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The private warrants
have been deemed compensation by FINRA and are therefore subject to a 360-day lock-up, including the 180-day lock-up pursuant to
Rule&nbsp;5110(e)(1)&nbsp;of the FINRA Manual from the commencement of sales of the offering. Pursuant to FINRA Rule&nbsp;5110(e)(1),
these securities will not be sold during the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject
of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities
by any person for a period of 360 days immediately following the effective date of the registration statement of which this prospectus
forms a part or commencement of sales of the public offering, except to any underwriter and selected dealer participating in the
offering and their bona fide officers, partners, registered persons and affiliates provided that all securities so transferred
remain subject to the lockup restriction above for the remainder of the time period. We have granted the holders of private warrants
the registration rights as described under the section &ldquo;Securities Eligible for Future Sale &mdash; Registration and Stockholder
Rights.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have agreed to
indemnify the underwriters against some liabilities, including civil liabilities under the Securities Act, or to contribute to
payments the underwriters may be required to make in this respect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Resale Restrictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We intend to distribute
our securities in the Province of Ontario, Canada (the &ldquo;Canadian Offering Jurisdiction&rdquo;) by way of a private placement
and exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in such Canadian
Offering Jurisdiction. Any resale of our securities in Canada must be made under applicable securities laws that will vary depending
on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary
exemption granted by the applicable Canadian securities regulatory authority. Canadian resale restrictions in some circumstances
may apply to resales of interests made outside of Canada. Canadian purchasers are advised to seek legal advice prior to any resale
of our securities. We may never be a &ldquo;reporting issuer&rdquo;, as such term is defined under applicable Canadian securities
legislation, in any province or territory of Canada in which our securities will be offered and there currently is no public market
for any of the securities in Canada, and one may never develop. Canadian investors are advised that we have no intention to file
a prospectus or similar document with any securities regulatory authority in Canada qualifying the resale of the securities to
the public in any province or territory in Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representations of Purchasers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A Canadian purchaser
will be required to represent to us and the dealer from whom the purchase confirmation is received that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the purchaser is entitled under applicable provincial securities laws to purchase our securities without the benefit of a prospectus qualified under those securities laws;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">where required by law, that the purchaser is purchasing as principal and not as agent;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the purchaser has reviewed the text above under Resale Restrictions; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">&bull;</TD>
    <TD STYLE="text-align: justify">the purchaser acknowledges and consents to the provision of specified information concerning its purchase of our securities to the regulatory authority that by law is entitled to collect the information.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Rights of Action &mdash; Ontario Purchasers Only</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under Ontario securities
legislation, certain purchasers who purchase a security offered by this prospectus during the period of distribution will have
a statutory right of action for damages, or while still the owner of our securities, for rescission against us in the event that
this prospectus contains a misrepresentation without regard to whether the purchaser relied on the misrepresentation. The right
of action for damages is exercisable not later than the earlier of 180 days from the date the purchaser first had knowledge of
the facts giving rise to the cause of action and three years from the date on which payment is made for our securities. The right
of action for rescission is exercisable not later than 180 days from the date on which payment is made for our securities. If a
purchaser elects to exercise the right of action for rescission, the purchaser will have no right of action for damages against
us. In no case will the amount recoverable in any action exceed the price at which our securities were offered to the purchaser
and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, we will have no liability.
In the case of an action for damages, we will not be liable for all or any portion of the damages that are proven to not represent
the depreciation in value of our securities as a result of the misrepresentation relied upon. These rights are in addition to,
and without derogation from, any other rights or remedies available at law to an Ontario purchaser. The foregoing is a summary
of the rights available to an Ontario purchaser. Ontario purchasers should refer to the complete text of the relevant statutory
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforcement of Legal Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All of our directors
and officers as well as the experts named herein are located outside of Canada and, as a result, it may not be possible for Canadian
purchasers to effect service of process within Canada upon us or those persons. All of our assets and the assets of those persons
are located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada
or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Collection of Personal Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a Canadian purchaser
is resident in or otherwise subject to the securities laws of the Province of Ontario, the Purchaser authorizes the indirect collection
of personal information pertaining to the Canadian purchaser by the Ontario Securities Commission (the &ldquo;OSC&rdquo;) and each
Canadian purchaser will be required to acknowledge and agree that the Canadian purchaser has been notified by us (i)&nbsp;of the
delivery to the OSC of personal information pertaining to the Canadian purchaser, including, without limitation, the full name,
residential address and telephone number of the Canadian purchaser, the number and type of securities purchased and the total purchase
price paid in respect of the securities, (ii)&nbsp;that this information is being collected indirectly by the OSC under the authority
granted to it in securities legislation, (iii)&nbsp;that this information is being collected for the purposes of the administration
and enforcement of the securities legislation of Ontario, and (iv)&nbsp;that the title, business address and business telephone
number of the public official in Ontario who can answer questions about the OSC&rsquo;s indirect collection of the information
is the Administrative Assistant to the Director of Corporate Finance, the Ontario Securities Commission, Suite&nbsp;1903, Box 5520,
Queen Street West, Toronto, Ontario, M5H 3S8, Telephone: (416) 593-8086, Facsimile: (416) 593-8252.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_017"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Loeb&nbsp;&amp; Loeb
LLP, is acting as United States counsel in connection with the registration of our securities under the Securities Act and will
pass on the validity of the securities offered in the prospectus. Ellenoff Grossman&nbsp;&amp; Schole LLP, is acting as counsel
for the underwriters in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_018"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
of LifeSci Acquisition II Corp. as of June&nbsp;30, 2020, and for the period from December&nbsp;18, 2019 (inception) through June&nbsp;30,
2020 appearing in this prospectus have been audited by WithumSmith+Brown,&nbsp;PC, independent registered public accounting firm,
as set forth in their report thereon, appearing elsewhere in this prospectus, and are included in reliance on such report given
on the authority of such firm as an experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_019"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have filed with
the SEC a registration statement on Form&nbsp;S-1, which includes exhibits, schedules and amendments, under the Securities Act,
with respect to this offering of our securities. Although this prospectus, which forms a part of the registration statement, contains
all material information included in the registration statement, parts of the registration statement have been omitted as permitted
by rules&nbsp;and regulations of the SEC. We refer you to the registration statement and its exhibits for further information about
us, our securities and this offering. The registration statement and its exhibits, as well as our other reports filed with the
SEC, can be inspected and copied at the SEC&rsquo;s public reference room at 100 F Street, N.E., Washington, D.C. 20549. The public
may obtain information about the operation of the public reference room by calling the SEC at 1-800-SEC-0330. In addition, the
SEC maintains a web site at <I>http://www.sec.gov</I> which contains the Form&nbsp;S-1 and other reports, proxy and information
statements and information regarding issuers that file electronically with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_020"></A>LIFESCI ACQUISITION II CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><B>Page</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left"><A HREF="#S1_021">Report of Independent Registered Public Accounting Firm</A></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: center"><A HREF="#S1_021"><FONT>F-2</FONT></A></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Financial Statements:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#S1_022">Balance Sheet</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#S1_022"><FONT>F-3</FONT></A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><A HREF="#S1_023">Statement of Operations</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#S1_023"><FONT>F-4</FONT></A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#S1_024">Statement of Changes in Stockholder&rsquo;s Equity</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#S1_024"><FONT>F-5</FONT></A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left"><A HREF="#S1_025">Statement of Cash Flows</A></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><A HREF="#S1_025"><FONT>F-6</FONT></A></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Notes to Financial Statements</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><FONT>F-7</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 93; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_021"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Stockholder and the Board of Directors
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LifeSci Acquisition II Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheet of LifeSci Acquisition II Corp. (the &quot;Company&quot;) as of June&nbsp;30, 2020, the related statements of operations,
changes in stockholder&rsquo;s equity and cash flows for the period from December&nbsp;18, 2019 (inception) through June&nbsp;30,
2020, and the related notes (collectively referred to as the &quot;financial statements&quot;). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of June&nbsp;30, 2020, and the results of its
operations and its cash flows for the period from December&nbsp;18, 2019 (inception) through June&nbsp;30, 2020, in conformity
with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules&nbsp;and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ WithumSmith+Brown, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company's auditor
since 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October 14, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_022"></A>LIFESCI ACQUISITION II CORP.<BR>
BALANCE SHEET<BR STYLE="clear: both">
JUNE 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">ASSETS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; width: 87%; font-size: 10pt; text-align: left">Current asset &ndash; cash</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">25,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Deferred offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">53,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDER&rsquo;S EQUITY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left">Accrued expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">28,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">29,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Commitments and Contingencies</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Stockholder&rsquo;s Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Common stock, $0.0001 par value; 5,000,000 shares authorized; 2,156,250 shares issued and outstanding <SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">216</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,784</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholder&rsquo;s Equity</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">24,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDER&rsquo;S EQUITY</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">53,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 94%; text-align: justify">Includes up to 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral
part of these financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_023"></A>LIFESCI ACQUISITION II CORP.<BR>
STATEMENT OF OPERATIONS<BR STYLE="clear: both">
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Formation and operating costs</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Weighted average shares outstanding, basic and diluted <SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,875,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per common share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 94%; text-align: justify">Excludes an aggregate of up to 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral
part of these financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_024"></A>LIFESCI ACQUISITION II CORP.<BR>
STATEMENT OF CHANGES IN STOCKHOLDER&rsquo;S EQUITY<BR STYLE="clear: both">
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Common&nbsp;Stock</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Additional<BR> Paid-in</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Total<BR> Stockholder&rsquo;s</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Balance &ndash; December&nbsp;18, 2019 (inception)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 35%; font-size: 10pt; text-align: left">Issuance of common stock to Sponsor <SUP>(1)</SUP></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,156,250</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">216</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">24,784</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">25,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance - June&nbsp;30, 2020</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,156,250</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">216</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">24,784</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">24,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">(1)</TD>
    <TD STYLE="width: 95%; text-align: justify">Includes 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral
part of these financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="S1_025"></A>LIFESCI ACQUISITION II CORP.<BR>
STATEMENT OF CASH FLOWS<BR STYLE="clear: both">
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(1,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; font-size: 10pt; text-align: left; padding-bottom: 1pt">Accrued expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from issuance of common stock to Sponsor</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">25,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Net Change in Cash</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">25,000</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Cash &ndash; Beginning of period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Cash &ndash; End of period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">25,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Non-cash investing and financing activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Deferred offering costs included in accrued offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">28,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral
part of these financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 1 &mdash; Description of Organization and Business Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LifeSci Acquisition II Corp. (the &ldquo;Company&rdquo;)
was incorporated in Delaware on December&nbsp;18, 2019. The Company was formed for the purpose of entering into a merger, share
exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or
more businesses or entities that the Company has not yet identified (a &ldquo;Business Combination&rdquo;). Although the Company
is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends
to focus on businesses operating in North America in the healthcare industry. The Company is an early stage and emerging growth
company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June&nbsp;30, 2020, the Company had
not commenced any operations. All activity through June&nbsp;30, 2020 relates to the Company&rsquo;s formation and the proposed
initial public offering (&ldquo;Proposed Public Offering&rdquo;), which is described below. The Company will not generate any operating
revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income
in the form of interest income from the proceeds derived from the Proposed Public Offering. The Company has selected June&nbsp;30
as its fiscal year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s ability to commence
operations is contingent upon obtaining adequate financial resources through a Proposed Public Offering of 7,500,000 shares of
common stock (or 8,625,000 shares if the underwriters&rsquo; over-allotment option is exercised in full) (the &ldquo;Shares&rdquo;)
at $10.00 per Share, which is discussed in Note 3, and the sale of 3,033,333 warrants (or 3,283,333 warrants if the underwriters&rsquo;
over-allotment option is exercised in full (the &ldquo;Private Warrants&rdquo;) at a price of $0.90 per warrant in a private placement,
in a private placement to LifeSci Holdings, LLC (the &ldquo;Sponsor&rdquo;), an entity affiliated LifeSci Capital LLC, that will
close simultaneously with the Proposed Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s management has broad
discretion with respect to the specific application of the net proceeds of the Proposed Public Offering and the sale of the Private
Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
The Company&rsquo;s initial Business Combination must be with one or more target businesses that together have a fair market value
equal to at least 80% of the balance in the Trust Account (as defined below)  (net
of amounts previously released to the Company to pay its tax obligations and for working capital purposes, subject to an annual
limit of $250,000) at the time of the signing an agreement to enter into a Business Combination. The Company will only complete
a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities
of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an
investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act. There is no assurance that
the Company will be able to successfully effect a Business Combination. Upon the closing of the Proposed Public Offering, management
has agreed that $10.00 per Share sold in the Proposed Public Offering and the proceeds from the sale of the Private Warrants will
be held in a trust account (&ldquo;Trust Account&rdquo;) and invested in U.S. government securities, within the meaning set forth
in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 183 days or less or in any open-ended investment company
that holds itself out as a money market fund meeting the conditions of Rule&nbsp;2a-7 of the Investment Company Act, as determined
by the Company, until the earlier of: (i)&nbsp;the consummation of a Business Combination or (ii)&nbsp;the distribution of the
funds in the Trust Account as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will provide its stockholders with the opportunity
to redeem all or a portion of their Shares sold in the Proposed Public Offering (the &ldquo;Public Shares&rdquo;) upon the completion
of a Business Combination either (i)&nbsp;in connection with a stockholder meeting called to approve the Business Combination or
(ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination
or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their
shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus
any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations
or for working capital purposes). The common stock subject
to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Proposed Public
Offering, in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 480 &ldquo;Distinguishing Liabilities
from Equity.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will proceed with a Business
Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and,
if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.
If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal
reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant
to the tender offer rules&nbsp;of the Securities and Exchange Commission (&ldquo;SEC&rdquo;), and file tender offer documents with
the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transaction is required by law,
or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares
in conjunction with a proxy solicitation pursuant to the proxy rules&nbsp;and not pursuant to the tender offer rules. If the Company
seeks stockholder approval in connection with a Business Combination, the Sponsor and other initial stockholders (collectively,
the &ldquo;Initial Stockholders&rdquo;) have agreed to (a)&nbsp;vote their Founder Shares (as defined in Note 5),  and any Public Shares held by them in favor of a Business Combination and (b)&nbsp;not to convert any shares
(including Founder Shares) in connection with a stockholder vote to approve a Business Combination or sell any such shares to the
Company in a tender offer in connection with a Business Combination. Additionally, each public stockholder may elect to redeem
their Public Shares irrespective of whether they vote for or against the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, if the Company
seeks stockholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender offer
rules, a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting
in concert or as a &ldquo;group&rdquo; (as defined in Section&nbsp;13(d)(3)&nbsp;of the Securities Exchange Act of 1934, as amended
(the &ldquo;Exchange Act&rdquo;)), will be restricted from redeeming their shares with respect to more than an aggregate of 20%
of the Public Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will have until 24 months from
the closing of the Proposed Public Offering to consummate a Business Combination (the &ldquo;Combination Period&rdquo;). If the
Company is unable to complete a Business Combination within the Combination Period, the Company will (i)&nbsp;cease all operations
except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but no more than five business days thereafter,
redeem 100% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit
in the Trust Account, including interest earned (net of taxes payable), divided by the number of then outstanding Public Shares,
which redemption will completely extinguish public stockholders&rsquo; rights as stockholders (including the right to receive further
liquidation distributions, if any), subject to applicable law, and (iii)&nbsp;as promptly as reasonably possible following such
redemption, subject to the approval of the remaining stockholders and the Company&rsquo;s board of directors, proceed to commence
a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for
claims of creditors and the requirements of applicable law. The proceeds deposited in the Trust Account could, however, become
subject to claims of creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and Chardan Healthcare Investments
LLC have agreed to (i)&nbsp;waive their redemption rights with respect to Founder Shares and any Public Shares
they may acquire during or after the Proposed Public Offering in connection with the consummation of a Business Combination, (ii)&nbsp;to
waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares
if the Company fails to consummate a Business Combination within the Combination Period and (iii)&nbsp;not to propose an amendment
to the Company&rsquo;s Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company&rsquo;s
obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides
the public stockholders an opportunity to redeem their Public Shares in conjunction with any such amendment. However, the Sponsor
will be entitled to liquidating distributions with respect to any Public Shares acquired if the Company fails to consummate a Business
Combination or liquidates within the Combination Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to protect the amounts held in
the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services
rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into
a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per share, except as to any claims by
a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account
or to any claims under the Company&rsquo;s indemnity of the underwriters of the Proposed Public Offering against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). Moreover, in the event
that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company&rsquo;s
independent registered public accounting firm), prospective target businesses or other entities with which the Company does business,
execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust
Account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Going Concern Consideration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not have sufficient liquidity
to meet its anticipated obligations over the next year from the date of the issuance of these financial statements. In connection
with the Company&rsquo;s assessment of going concern considerations in accordance with FASB&rsquo;s Accounting Standards Update
(&ldquo;ASU&rdquo;) 2014-15, &ldquo;Disclosures of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern,&rdquo;
management has determined that the Company has access to funds from the Sponsor that are sufficient to fund the working capital
needs of the Company until the earlier of the consummation of the Proposed Public Offering or one year from the issuance of these
financial statements (see Note 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &mdash; Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements are
presented in in conformity with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;) and
pursuant to the rules&nbsp;and regulations of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Emerging Growth Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is an &ldquo;emerging growth
company,&rdquo; as defined in Section&nbsp;2(a)&nbsp;of the Securities Act, as modified by the Jumpstart Our Business Startups
Act of 2012 (the &ldquo;JOBS Act&rdquo;), and it may take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, Section&nbsp;102(b)(1)&nbsp;of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt
out of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of the Company&rsquo;s financial statements with
another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using
the extended transition period difficult or impossible because of the potential differences in accounting standards used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with GAAP requires the Company&rsquo;s management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of expenses during the reporting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents
as of June&nbsp;30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Deferred Offering Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Deferred offering costs consist of legal,
accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Proposed
Public Offering and that will be charged to stockholder&rsquo;s equity upon the completion of the Proposed Public Offering. Should
the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will
be charged to operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the accounting
and reporting requirements of ASC Topic 740 &ldquo;Income Taxes,&rdquo; which requires an asset and liability approach to financial
accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on
enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 740 prescribes a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken
in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination
by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax
expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June&nbsp;30, 2020. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation
from its position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company may be subject to potential
examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include
questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal,
state and city tax laws. The Company&rsquo;s management does not expect that the total amount of unrecognized tax benefits will
materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since
inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for income taxes was deemed
to be de minimis for the period from December&nbsp;18, 2019 (inception) through June&nbsp;30, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Loss Per Common Share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net loss per share is computed by dividing
net loss by the weighted average number of shares of common stock outstanding during the period, excluding shares of common stock
subject to forfeiture by the Sponsor. Weighted average shares were reduced for the effect of an aggregate of 281,250 shares of
common stock that are subject to forfeiture if the over-allotment option is not exercised by the underwriters (see Note 7). At
June&nbsp;30, 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or
converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the
same as basic loss per share for the period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Concentration of Credit Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may
exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management
believes the Company is not exposed to significant risks on such account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Fair Value of Financial Instruments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of the Company&rsquo;s assets
and liabilities, which qualify as financial instruments under ASC 820, &ldquo;Fair Value Measurement,&rdquo; approximates the carrying
amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&rsquo;s
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 3 &mdash; Public Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Proposed Public Offering, the Company will offer
for sale 7,500,000 Shares (or 8,625,000 Shares if the underwriters&rsquo; over-allotment option is exercised in full), at a purchase
price of $10.00 per Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 4 &mdash; Private Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Proposed Public
Offering, the Sponsor is expected to purchase an aggregate of 3,033,333 Private Warrants (or 3,283,333 Private Warrants if the
over-allotment option is exercised in full) at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,730,000,
or $2,955,000, in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. Each Private
Warrant is exercisable to purchase  one share of common stock at an exercise price of $11.50 per warrant. per share.
If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private
Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be
no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 5 &mdash; Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Founder Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January&nbsp;1, 2020, the Company issued
an aggregate of 2,156,250 shares of common stock (the &ldquo;Founder Shares&rdquo;) to the Sponsor for an aggregate purchase price
of $25,000.  On September 30, 2020, LifeSci Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our
sponsor. The founder shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters&rsquo;
over-allotment option is not exercised in full or in part, with LifeSci Holdings LLC to forfeit up to 253,125 shares and Chardan Healthcare
Investments LLC to forfeit up to 28,125 shares. so that the Sponsor will
collectively own approximately 20% of the Company&rsquo;s issued and outstanding shares after the Proposed Public Offering (assuming
the Sponsor does not purchase any Public Shares in the Proposed Public Offering).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Sponsor and Chardan Healthcare Investments
LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold
or released from escrow until the earlier of (i)&nbsp;six months after the date of the consummation of a Business Combination or
(ii)&nbsp;the date on which the closing price of the Company&rsquo;s shares of common stock equals or exceeds $12.50 per share
(as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading
day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned,
sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either
case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other
similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash,
securities or other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Promissory Note &mdash; Related Party</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;19, 2020, the Company issued
an unsecured promissory note to the Sponsor (the &ldquo;Promissory Note&rdquo;), pursuant to which the Company may borrow up to
an aggregate principal amount of $175,000. The Promissory Note is non-interest bearing and is payable within 15 days of the Sponsor
providing the Company with written notice of demand. As of June&nbsp;30, 2020, there were no amounts outstanding under the Promissory
Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Administrative Support Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to enter into an agreement,
commencing on the effective date of the Proposed Public Offering through the earlier of the Company&rsquo;s consummation of a Business
Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and
secretarial support.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Loans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to finance transaction costs in
connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company&rsquo;s officers and directors
may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required (&ldquo;Working Capital
Loans&rdquo;). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon
consummation of a Business Combination, without interest or, at the lender&rsquo;s discretion, up to $500,000 of such Working Capital
Loans may be converted into shares of the post Business Combination entity at a price of $0.90 per warrant. In the event that a
Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the
Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of June&nbsp;30,
2020, no Working Capital Loans were outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &mdash; Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks and Uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management is currently evaluating the
impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have
a negative effect on the Company&rsquo;s financial position, results of its operations, close of the Proposed Public Offering and/or
search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty. _</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration and Stockholder Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the Founder Shares and the
Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will
be entitled to registration and stockholder rights pursuant to a registration and stockholder rights agreement to be signed prior
to or on the effective date of the Proposed Public Offering. The holders of a majority of these securities are entitled to make
up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise
these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be
released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any
time after the Company consummates a Business Combination. In addition, the holders have certain &ldquo;piggy-back&rdquo; registration
rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will
bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons
may not, with respect to the Private Warrants purchased by it, (i)&nbsp;have more than one demand registration right at the Company&rsquo;s
expense, (ii)&nbsp;exercise their demand registration rights more than five (5)&nbsp;years from the effective date of the registration
statement of the Proposed Public Offering, and (iii)&nbsp;exercise their &ldquo;piggy-back&rdquo; registration rights more than
seven (7)&nbsp;years from the effective date of the Proposed Public Offering, as long as the Sponsor or any of its related persons
are beneficial owners of Private Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Underwriting Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company will grant the underwriters a 45-day option from
the date of the Proposed Public Offering to purchase up to 1,125,000 additional Shares to cover over-allotments, if any, at the
Proposed Public Offering price less the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters will be entitled to a cash underwriting discount
of $0.20 per Share, or $1,500,000 in the aggregate (or $1,725,000 if the over-allotment option is exercised in full), payable upon
the closing of the Proposed Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &mdash; Stockholder&rsquo;s Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Common
Stock</I></B></FONT> &mdash; The Company is authorized to issue 5,000,000 shares of common stock with a par value of $0.0001 per
share. The Company plans on filing an Amended and Restated Certificate of Incorporation prior to the closing date of the Proposed
Public Offering such that the Company will increase the number of shares of common stock authorized to be issued. Holders of the
Company&rsquo;s common stock are entitled to one vote for each share. At June&nbsp;30, 2020, there were 2,156,250 shares of common
stock issued and outstanding, of which 281,250 shares are subject to forfeiture to the extent that the underwriters&rsquo; over-allotment
option is not exercised in full so that the Sponsor will own 20% of the issued and outstanding shares after the Proposed Public
Offering (assuming the Sponsor do not purchase any Public Shares in the Proposed Public Offering).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Warrants
</I></B></FONT>&mdash;The Private Warrants will become exercisable at any time commencing on the later of (1)&nbsp;one year after
the closing of the Proposed Public Offering or (2)&nbsp;the consummation of a Business Combination; provided that the Company has
an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants
and a current prospectus relating to such shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Private Warrants purchased by the Sponsor
will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Proposed
Public Offering, in accordance with FINRA Rule&nbsp;5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially
own these Private Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &mdash; Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to October 14, 2020, the date that the financial
statements were available to be issued. Based upon this review, the Company did not identify
any subsequent events, other than described in Note 5, that would have required adjustment or disclosure in the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until [&middot;], 2020 (25 days after the
date of this prospectus), all dealers that buy, sell or trade our shares of common stock, whether or not participating in this
offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No dealer, salesperson or any other person
is authorized to give any information or make any representations in connection with this offering other than those contained in
this prospectus and, if given or made, the information or representations must not be relied upon as having been authorized by
us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any security other than the securities
offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by anyone in any jurisdiction
in which the offer or solicitation is not authorized or is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LifeSci Acquisition II Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7,500,000 Shares of Common Stock</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager</I></B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LifeSci Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[__], 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 105 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #D2232A"><B>The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 45%; padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="color: #D2232A"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="width: 54%; padding-bottom: 2.25pt; text-align: right"><FONT STYLE="color: #D2232A"><B>SUBJECT&nbsp;TO&nbsp;COMPLETION,&nbsp;DATED&nbsp;
    OCTOBER 14,&nbsp;2020 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIFESCI ACQUISITION II CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>7,500,000 SHARES OF COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus has
been prepared for and will be used by LifeSci Capital (&ldquo;LifeSci&rdquo;) in connection with offers and sales of our shares
of common stock in certain market making transactions effected from time to time for 30 days following the date of this prospectus.
These transactions may occur in the open market or may be privately negotiated at prevailing market prices at the time of sales,
at prices related thereto or at negotiated prices. We will not receive any proceeds of such transactions. LifeSci has no obligation
to make a market in our shares, and may discontinue such activities at any time without notice, at its sole discretion. All such
transactions with respect to our securities that are made pursuant to a prospectus after the date of this prospectus are being
made solely pursuant to this prospectus, as it may be supplemented from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There is presently
no public market for our common stock. We intend to apply to have our common stock listed on the Nasdaq Capital Market, or Nasdaq,
under the symbol &ldquo;LSAQ&rdquo; on or promptly after the date of this prospectus. We cannot guarantee that our securities will
be approved for listing on Nasdaq. We cannot assure you that our securities will continue to be listed on Nasdaq after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are an &ldquo;emerging
growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 and will therefore be subject to reduced public
company reporting requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Investing in our
securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;18 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager</I></B>&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>LifeSci Capital</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[__], 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 106; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIFESCI ACQUISITION II CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Page</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-size: 10pt">SUMMARY</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">SUMMARY FINANCIAL DATA</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">17</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">RISK FACTORS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">18</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">38</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">USE OF PROCEEDS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">39</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">DIVIDEND POLICY</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">45</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">PROPOSED BUSINESS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">49</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">MANAGEMENT</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">66</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">PRINCIPAL STOCKHOLDERS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">73</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">CERTAIN TRANSACTIONS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">77</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">SECURITIES ELIGIBLE FOR FUTURE SALE</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">82</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">84</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">LEGAL MATTERS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">EXPERTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">WHERE YOU CAN FIND ADDITIONAL INFORMATION</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">INDEX TO FINANCIAL STATEMENTS</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">F-1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In making your decision
on whether to invest in our securities, you should take into account not only the backgrounds of the members of our management
team, but also the special risks we face as a blank check company and the fact that this offering is not being conducted in compliance
with Rule&nbsp;419 promulgated under the Securities Act. You will not be entitled to protections normally afforded to investors
in Rule&nbsp;419 blank check offerings. You should carefully consider these and the other risks set forth in the section below
entitled &ldquo;Risk Factors&rdquo; beginning on page&nbsp;18 of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Listing of our securities and proposed symbol</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 65%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">We anticipate that the shares of common stock will be listed on Nasdaq under the symbol &ldquo;LSAQ&rdquo;.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: justify"><B>Offering proceeds to be held in trust</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%; padding-bottom: 2.25pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$75,000,000 of the net proceeds of
        this offering (or $86,250,000 if the over-allotment option is exercised in full), including $2,730,000 (or $2,955,000 if the
        over-allotment option is exercised in full) we will receive from the sale of the private warrants, or $10.00 per share sold
        to the public in this offering will be placed in a trust account in the United States, maintained by Continental
        Stock Transfer&nbsp;&amp; Trust Company, acting as trustee pursuant to an agreement to be signed on the date of this
        prospectus. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full) we will receive from the sale
        of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) be used for offering
        expenses and $750,000 will be used for working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as set forth below, the proceeds
        in the trust account will not be released until the earlier of: (1)&nbsp;the completion of an initial business combination within
        the required time period and (2)&nbsp;our redemption of 100% of the outstanding public shares if we have not completed a business
        combination in the required time period. Therefore, unless and until our initial business combination is consummated, the proceeds
        held in the trust account will not be available for our use for any expenses related to this offering or expenses which we may
        incur related to the investigation and selection of a target business and the negotiation of an agreement to acquire a target business.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Notwithstanding the foregoing, there can be released to us,
from time to time, (i)&nbsp;any interest earned on the funds in the trust account that we may need to pay our tax obligations and
(ii)&nbsp;any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working
capital requirements. With this exception, expenses incurred by us may be paid prior to a business combination only from the net
proceeds of this offering not held in the trust account of approximately $750,000 provided, however, that in order to meet our
working capital needs following the consummation of this offering if the funds not held in the trust account are insufficient,
our initial stockholders, officers and directors or their affiliates may, but are not obligated to, loan us funds, from time to
time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory
note. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender&rsquo;s
discretion, up to $500,000 of the notes may be converted upon consummation of our business combination into additional private
warrants at a conversion price of $0.90 per private warrant. Such private warrants will be identical to the private warrants to
be issued at the closing of this offering. Our directors have approved the issuance of the private warrants upon conversion of
such notes, to the extent the holder wishes to so convert them at the time of the consummation of our initial business combination.
If we do not complete a business combination, the loans will only be repaid with funds not held in the trust account, to the extent
available.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: justify"><B>Limited payments to insiders</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to the consummation of a
business combination, there will be no fees, reimbursements or other cash payments paid to our initial stockholders, officers,
directors or their affiliates prior to, or for any services they render in order to effectuate, the consummation of a business
combination (regardless of the type of transaction that it is) other than:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;payment of $10,000 per month to an affiliate of LifeSci Holdings
LLC for office space and related services, subject to deferral as described herein;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;repayment
        of loans which may be made by our insiders, officers, directors or any of its or their affiliates to finance transaction costs
        in connection with an initial business combination, the terms of which have not been determined;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reimbursement
        of out-of-pocket expenses incurred by them in connection with certain activities on our behalf, such as identifying and investigating
        possible business targets and business combinations; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;repayment
        upon consummation of our initial business combination of any loans which may be made by our initial stockholders or their affiliates
        or our officers and directors to finance transaction costs in connection with an intended initial business combination.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no limit on the amount of out-of-pocket
        expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in
        the trust account and the interest income earned on the amounts held in the trust account available to us, such expenses would
        not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve all reimbursements
        and payments made to any initial stockholder or member of our management team, or their respective affiliates, and any reimbursements
        and payments made to members of our audit committee will be reviewed and approved by our board of directors, with any interested
        director abstaining from such review and approval.</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><B>Potential revisions to agreements with insiders</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">We could seek to amend certain agreements made by our management team disclosed in this prospectus without the approval of stockholders, although we have no intention to do so. For example, restrictions on our executives relating to the voting of securities owned by them, the agreement of our management team to remain with us until the closing of a business combination, the obligation of our management team to not propose certain changes to our organizational documents or the obligation of the management team and its affiliates to not receive any compensation in connection with a business combination could be modified without obtaining stockholder approval. Although stockholders would not be given the opportunity to redeem their shares in connection with such changes, in no event would we be able to modify the redemption or liquidation rights of our stockholders without permitting our stockholders the right to redeem their shares in connection with any such change. We will not agree to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if such a modification were necessary to complete a business combination).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%"><B>Stockholder approval of, or tender offer in connection with, initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0">W<FONT STYLE="background-color: white">e have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor.</FONT> In connection with any proposed initial business combination, we will either (1)&nbsp;seek stockholder approval of such initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2)&nbsp;provide our public stockholders with the opportunity to sell their public shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that we are unable to satisfy any applicable closing condition set forth in the definitive agreement related to our initial business combination, or we are unable to maintain net tangible assets of at least $5,000,001, we will not consummate such initial business combination. The decision as to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval. If we provide stockholders with the opportunity to sell their shares to us by means of a tender offer, we will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as is required under the SEC&rsquo;s proxy rules. If we seek stockholder approval of our initial business combination, we will consummate the business combination only if a majority of the outstanding shares of common stock voted are</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">voted in favor of the business combination.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%; text-align: justify">We have determined not to consummate any business combination unless we have net tangible assets of at least $5,000,001 upon such consummation in order to avoid being subject to Rule&nbsp;419 promulgated under the Securities Act. However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as we may be required to have a lesser number of shares redeemed) and may force us to seek third party financing which may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination and we may not be able to locate another suitable target within the applicable time period, if at all.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">Our initial stockholders have agreed (A)&nbsp;to vote their
founder shares and any public shares in favor of any proposed business combination, (B)&nbsp;not to propose, or vote in favor of,
prior to and unrelated to an initial business combination, an amendment to our certificate of incorporation that would affect the
substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months unless we provide public stockholder an opportunity to redeem their public shares in conjunction with any such
amendment, (C)&nbsp;not to convert any shares (including the founder shares) into the right to receive cash from the trust account
in connection with a stockholder vote to approve our proposed initial business combination or sell any shares to us in a tender
offer in connection with our proposed initial business combination, and (D)&nbsp;that the founder shares shall not participate
in any liquidating distribution upon winding up if a business combination is not consummated. None of our initial stockholders
or their affiliates has indicated any intention to purchase public shares in this offering or shares of common stock in the open
market or in private transactions. However, if a significant number of stockholders vote, or indicate an intention to vote, against
a proposed business combination, our initial stockholders, officers, directors or their affiliates could make such purchases in
the open market or in private transactions in order to influence the vote. Our initial stockholders, officers, directors and their
affiliates could purchase sufficient shares so that the initial business combination may be approved without the majority vote
of public shares held by non-affiliates. Notwithstanding the foregoing, our officers, directors, initial stockholders and their
affiliates will not make purchases of shares of common stock if the purchases would violate Section&nbsp;9(a)(2)&nbsp;or Rule&nbsp;10b-5
of the Exchange Act, which are rules&nbsp;designed to stop potential manipulation of a company&rsquo;s stock or purchasing shares
when the buyer is in possession of material non-public information about the Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%"><B>Conditions to completing our initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed not to enter into a definitive
agreement regarding an initial business combination without the prior consent of our sponsor.&nbsp;Further, there is no limitation
on our ability to raise funds privately or through loans in connection with our initial business combination. Our initial business
combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of
the value of the trust account (excluding any taxes payable on the income earned on the trust account) at the time of the agreement
to enter into the initial business combination. If we are no longer listed on Nasdaq, we will not be required to satisfy the 80%
test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our board is not able to independently
        determine the fair market value of the target business or businesses, we may obtain an opinion from an independent investment banking
        or accounting firm as to the fair market value of the target business. We will complete our initial business combination only if
        the post-transaction company in which our public stockholders own shares will own or acquire 50% or more of the outstanding voting
        securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
        as an investment company under the Investment Company Act. Even if the post-transaction company owns 50% or more of the voting
        securities of the target, our stockholders prior to the business combination may collectively own a minority interest in the post
        business combination company, depending on valuations ascribed to the target and us in the business combination transaction. If
        less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction
        company, the portion of such business or businesses that is owned or acquired is what will be valued for purposes of the 80% test,
        provided that in the event that the business combination involves more than one target business, the 80% test will be based on
        the aggregate value of all of the target businesses.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Conversion rights</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with any stockholder meeting
        called to approve a proposed initial business combination, each public stockholder will have the right, regardless of whether he,
        she or it is voting for or against such proposed business combination, to demand that we convert his, her or its public shares
        into a <I>pro rata</I> share of the trust account upon consummation of the business combination.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may require public stockholders wishing
        to exercise conversion rights, whether they are a record holder or hold their shares in &ldquo;street name,&rdquo; to either tender
        the certificates they are seeking to convert to our transfer agent or to deliver the shares they are seeking to convert to the
        transfer agent electronically using Depository Trust Company&rsquo;s DWAC (Deposit/Withdrawal At Custodian) System, at the holder&rsquo;s
        option, at any time at or prior to the vote on the business combination. There is a nominal cost associated with this tendering
        process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge
        the tendering broker $45 and it would be up to the broker whether or not to pass this cost on to the converting holder. However,
        this fee would be incurred regardless of whether or not we require holders to deliver their shares prior to the vote on the business
        combination in order to exercise conversion rights. This is because a holder would need to deliver shares to exercise conversion
        rights regardless of the timing of when such delivery must be effectuated. However, in the event we require stockholders to deliver
        their shares prior to the vote on the proposed business combination and the proposed business combination is not consummated, this
        may result in an increased cost to stockholders. The conversion rights will include the requirement that a beneficial holder must
        identify itself in order to validly redeem its shares.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Delaware law, we may be required
        to give a minimum of only ten days&rsquo; notice for each general meeting. As a result, if we require public stockholders who wish
        to convert their shares of common stock into the right to receive a <I>pro rata</I> portion of the funds in the trust account to
        comply with the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares
        for conversion. Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities
        when they otherwise would not want to.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we require public stockholders who wish
        to convert their shares of common stock to comply with specific delivery requirements for conversion described above and such proposed
        business combination is not consummated, we will promptly return such certificates to the tendering public stockholders.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%"><B>Release of funds in trust account upon closing of our initial business combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%; text-align: justify">On the completion of our initial business combination, all amounts held in the trust account will be released to us. We will use these funds to pay amounts due to any public stockholders who exercise their conversion rights as described above under &ldquo;&mdash; Conversion rights&rdquo; to pay all or a portion of the consideration payable to the target or targets or owners of the target or targets of our initial business combination and to pay other expenses associated with our initial business combination. If our initial business combination is paid for using stock or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><B>Liquidation&nbsp;if&nbsp;no&nbsp;business&nbsp;combination</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">If we are unable to complete our initial business combination
within 24 months from the closing of this offering, we will (i)&nbsp;cease all operations except for the purpose of winding up,
(ii)&nbsp;as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public
shares (including any public shares in this offering or any public shares that our initial stockholders or their affiliates purchased
in this offering or later acquired in the open market or in private transactions), which redemption will completely extinguish
public stockholders&rsquo; rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii)&nbsp;as promptly as reasonably practicable following such redemption, subject to the approval of our
remaining holders of common stock and our board of directors, proceed to commence a voluntary liquidation and thereby a formal
dissolution of the Company, subject (in the case of (ii)&nbsp;and (iii)&nbsp;above) to our obligations to provide for claims of
creditors and the requirements of applicable law.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%; padding-top: 10pt; padding-bottom: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with our redemption of 100%
        of our outstanding public shares for a portion of the funds held in the trust account, each holder will receive a full pro rata
        portion of the amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not
        necessary to pay our taxes payable on such funds. </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not have funds sufficient to pay
        or provide for all creditors&rsquo; claims. Although we will seek to have all third parties (including any vendors or other entities
        we engage after this offering) and any prospective target businesses enter into valid and enforceable agreements with us waiving
        any right, title, interest or claim of any kind in or to any monies held in the trust account, there is no guarantee that they
        will execute such agreements. There is also no guarantee that the third parties would not challenge the enforceability of these
        waivers and bring claims against the trust account for monies owed them.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of the founder shares, private warrants will not
participate in any redemption distribution with respect to their founder shares, private warrants, but may have any public shares
redeemed upon liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are unable to conclude our initial
        business combination and we expend all of the net proceeds of this offering not deposited in the trust account, without taking
        into account any interest earned on the trust account, we expect that the initial per-share redemption price will be approximately
        $10.00. The proceeds deposited in the trust account could, however, become subject to claims of our creditors that are in preference
        to the claims of our stockholders. Furthermore, our underwriters may seek recourse against the proceeds in the trust account relating
        to any future claims they may have against us. In addition, if we are forced to file a bankruptcy case or an involuntary bankruptcy
        case is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy
        law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our
        stockholders. Therefore, the actual per-share redemption price may be less than approximately $10.00. We will pay the costs of
        any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our sponsor
        has agreed to pay the funds necessary to complete such liquidation and has agreed not to seek repayment for such expenses. We currently
        do not anticipate that such funds will be insufficient.</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: justify"><B>Afilliation</B></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 65%; text-align: justify">LifeSci owns shares of our common stock. Additionally, certain
of our initial stockholders, officers and directors are affiliated with LifeSci.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is delivered in connection with the offer and
sale of our shares of common stock by LifeSci in certain market making transactions. We will not receive any of the proceeds from
these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus has
been prepared for use by LifeSci in connection with offers and sales of our common stock in certain market making transactions
effected from time to time for 30 days following the date of this prospectus. LifeSci may act as principals in these transactions.
These sales will be made at prevailing market prices at the time of sale, at prices related thereto or at negotiated prices. We
will not receive any of the proceeds of these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci, through our
sponsor, owns 1,910,625 shares of common stock (88.6% of our outstanding shares of common stock). Additionally officers and directors
of LifeSci own shares of common stock. In addition, LifeSci Holdings LLC, our sponsor, has committed to purchase from us an aggregate
of 3,033,333 warrants (or 3,283,333 warrants if the over-allotment option is exercised in full), or &ldquo;private warrants,&rdquo;
at $0.90 per warrant for a total purchase price of $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full).
The private warrants will become exercisable on the later of the completion of our initial business combination and 12 months from
the closing of this offering and will expire five years after the effective date of the registration statement of which this prospectus
forms a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We agreed to file
a &ldquo;market making&rdquo; prospectus in order to allow LiefSci to engage in market making activities for our shares for 30
days following the date of this prospectus. LifeSci acted as sole book-running manager in our recently completed initial public
offering of securities. Purchases and sales in the open market by LifeSci may include short sales, purchases to cover short positions,
which may include purchases pursuant to the over-allotment option and stabilizing purchases, in accordance with Regulation M under
the Exchange Act. Purchases to cover short positions and stabilizing purchases, as well as other purchases by LifeSci for its own
account, may have the effect of preventing or retarding a decline in the market price of the shares. It may also cause the price
of the shares to be higher than the price that would otherwise exist in the open market in the absence of these transactions. LifeSci
may conduct these transactions in the over-the-counter market or otherwise. If LifeSci commences any of these transactions, it
may discontinue them at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have been advised by LifeSci that, following our initial
public offering, it intends to engage in market making transactions for our common stock as permitted by applicable laws and regulations.
However, LifeSci is not obligated to do so and LifeSci may discontinue its market making activities at any time without notice.
In addition, such market making activity will be subject to the limits imposed by the Securities Act and the Exchange Act. Accordingly,
no assurance can be given as to the liquidity of the trading market for our common stock, that you will be able to sell any of
our shares held by you at a particular time or that the prices that you receive when you sell will be favorable. See &ldquo;Risk
Factors&nbsp;&mdash;&nbsp;There is currently no market for our securities and a market for our securities may not develop, which
would adversely affect the liquidity and price of our securities.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have agreed to
indemnify LifeSci in our initial public offering against certain liabilities, including liabilities under the Securities Act, or
to contribute to payments LifeSci may be required to make because of any of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are not under any
contractual obligation to engage LifeSci to provide any services for us after our initial public offering, and have no present
intent to do so. However, LifeSci may introduce us to potential target businesses or assist us in raising additional capital in
the future. If LifeSci provides services to us in the future, we may pay LifeSci fair and reasonable fees that would be determined
at that time in an arm&rsquo;s length negotiation; provided that no agreement will be entered into with LifeSci and no fees for
such services will be paid to LifeSci prior to the date that is 90 days from the date of this prospectus, unless FINRA determines
that such payment would not be deemed underwriters&rsquo; compensation in connection with our initial public offering and we may
pay LifeSci or any entity with which it is affiliated a finder&rsquo;s fee or other compensation for services rendered to us in
connection with the completion of an initial business combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">LifeSci and its affiliates
may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our
affiliates, for which it may in the future receive, customary fees and commissions for any such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, in the
ordinary course of its business activities, LifeSci and its affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for its own
account and for the accounts of its customers. Such investments and securities activities may involve securities and/or instruments
of ours or our affiliates. LifeSci and its affiliates may also make investment recommendations and/or publish or express independent
research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until
[</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT>], 2020 (25 days after the date of this prospectus), all dealers that
buy, sell or trade our shares of common stock, whether or not participating in this offering, may be required to deliver a prospectus.
This is in addition to the dealers&rsquo; obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No dealer, salesperson
or any other person is authorized to give any information or make any representations in connection with this offering other than
those contained in this prospectus and, if given or made, the information or representations must not be relied upon as having
been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any security other
than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by anyone
in any jurisdiction in which the offer or solicitation is not authorized or is unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LifeSci Acquisition II Corp.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7,500,000
Shares of Common Stock</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0 auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Sole Book-Running Manager</I></B>&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LifeSci Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>[__], 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">A-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 13. Other Expenses of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The estimated expenses
payable by us in connection with the offering described in this registration statement (other than the underwriting discount and
commissions) will be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Trustees&rsquo; fee</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,500</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC Registration Fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,410</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA filing fee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,438</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq listing fees</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing and engraving expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">225,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,652</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">480,000</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our certificate of
incorporation provides that all directors, officers, employees and agents of the registrant shall be entitled to be indemnified
by us to the fullest extent permitted by Section&nbsp;145 of the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;145 of
the Delaware General Corporation Law concerning indemnification of officers, directors, employees and agents is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Section&nbsp;145.
Indemnification of officers, directors, employees and agents; insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a)&nbsp;A corporation
shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the
right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted
in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&rsquo;s conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere
or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the
person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had reasonable cause to believe that the person&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b)&nbsp;A corporation
shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the
person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against
expenses (including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement
of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed
to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of
Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication
of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 119; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c)&nbsp;To the extent
that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any
action, suit or proceeding referred to in subsections (a)&nbsp;and (b)&nbsp;of this section, or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys&rsquo; fees) actually and reasonably
incurred by such person in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d)&nbsp;Any indemnification
under subsections (a)&nbsp;and (b)&nbsp;of this section (unless ordered by a court) shall be made by the corporation only as authorized
in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is
proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a)&nbsp;and
(b)&nbsp;of this section. Such determination shall be made, with respect to a person who is a director or officer at the time of
such determination, (1)&nbsp;by a majority vote of the directors who are not parties to such action, suit or proceeding, even though
less than a quorum, or (2)&nbsp;by a committee of such directors designated by majority vote of such directors, even though less
than a quorum, or (3)&nbsp;if there are no such directors, or if such directors so direct, by independent legal counsel in a written
opinion, or (4)&nbsp;by the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e)&nbsp;Expenses
(including attorneys&rsquo; fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative
action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding
upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys&rsquo;
fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if
any, as the corporation deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f)&nbsp;The indemnification
and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive
of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement,
vote of stockholders or disinterested directors or otherwise, both as to action in such person&rsquo;s official capacity and as
to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under
a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such provision
after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action,
suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of
such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g)&nbsp;A corporation
shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of such person&rsquo;s status as such, whether or not the corporation would
have the power to indemnify such person against such liability under this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(h)&nbsp;For purposes
of this section, references to &ldquo;the corporation&rdquo; shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence
had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person
who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as
such person would have with respect to such constituent corporation if its separate existence had continued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i)&nbsp;For purposes
of this section, references to &ldquo;other enterprises&rdquo; shall include employee benefit plans; references to &ldquo;fines&rdquo;
shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to &ldquo;serving
at the request of the corporation&rdquo; shall include any service as a director, officer, employee or agent of the corporation
which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit
plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to
be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner
 &ldquo;not opposed to the best interests of the corporation&rdquo; as referred to in this section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(j)&nbsp;The indemnification
and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized
or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit
of the heirs, executors and administrators of such a person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(k)&nbsp;The Court
of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification
brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court
of Chancery may summarily determine a corporation&rsquo;s obligation to advance expenses (including attorneys&rsquo; fees).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant
to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In accordance with
Section&nbsp;102(b)(7)&nbsp;of the DGCL, our certificate of incorporation, will provide that no director shall be personally liable
to us or any of our stockholders for monetary damages resulting from breaches of their fiduciary duty as directors, except to the
extent such limitation on or exemption from liability is not permitted under the DGCL unless they violated their duty of loyalty
to the Company or its stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments
of dividends, unlawful stock purchases or unlawful redemptions, or derived improper personal benefit from their actions as directors.
The effect of this provision of our certificate of incorporation is to eliminate our rights and those of our stockholders (through
stockholders&rsquo; derivative suits on our behalf) to recover monetary damages against a director for breach of the fiduciary
duty of care as a director, including breaches resulting from negligent or grossly negligent behavior, except, as restricted by
Section&nbsp;102(b)(7)&nbsp;of the DGCL. However, this provision does not limit or eliminate our rights or the rights of any stockholder
to seek non-monetary relief, such as an injunction or rescission, in the event of a breach of a director&rsquo;s duty of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the DGCL is amended
to authorize corporate action further eliminating or limiting the liability of directors, then, in accordance with our certificate
of incorporation, the liability of our directors to us or our stockholders will be eliminated or limited to the fullest extent
authorized by the DGCL, as so amended. Any repeal or amendment of provisions of our certificate of incorporation limiting or eliminating
the liability of directors, whether by our stockholders or by changes in law, or the adoption of any other provisions inconsistent
therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits
us to further limit or eliminate the liability of directors on a retroactive basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our certificate of
incorporation will also provide that we will, to the fullest extent authorized or permitted by applicable law, indemnify our current
and former officers and directors, as well as those persons who, while directors or officers of our corporation, are or were serving
as directors, officers, employees or agents of another entity, trust or other enterprise, including service with respect to an
employee benefit plan, in connection with any threatened, pending or completed proceeding, whether civil, criminal, administrative
or investigative, against all expense, liability and loss (including, without limitation, attorney&rsquo;s fees, judgments, fines,
ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred or suffered by any such person in connection
with any such proceeding. Notwithstanding the foregoing, a person eligible for indemnification pursuant to our certificate of incorporation
will be indemnified by us in connection with a proceeding initiated by such person only if such proceeding was authorized by our
board of directors, except for proceedings to enforce rights to indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The right to indemnification
conferred by our certificate of incorporation is a contract right that includes the right to be paid by us the expenses incurred
in defending or otherwise participating in any proceeding referenced above in advance of its final disposition, provided, however,
that if the DGCL requires, an advancement of expenses incurred by our officer or director (solely in the capacity as an officer
or director of our corporation) will be made only upon delivery to us of an undertaking, by or on behalf of such officer or director,
to repay all amounts so advanced if it is ultimately determined that such person is not entitled to be indemnified for such expenses
under our certificate of incorporation or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights to indemnification
and advancement of expenses will not be deemed exclusive of any other rights which any person covered by our certificate of incorporation
may have or hereafter acquire under law, our certificate of incorporation, our bylaws, an agreement, vote of stockholders or disinterested
directors, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any repeal or amendment
of provisions of our certificate of incorporation affecting indemnification rights, whether by our stockholders or by changes in
law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only,
except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis,
and will not in any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or
adoption of such inconsistent provision with respect to any act or omission occurring prior to such repeal or amendment or adoption
of such inconsistent provision. Our certificate of incorporation will also permit us, to the extent and in the manner authorized
or permitted by law, to indemnify and to advance expenses to persons other that those specifically covered by our certificate of
incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our bylaws, which
we intend to adopt immediately prior to the closing of this offering, include the provisions relating to advancement of expenses
and indemnification rights consistent with those set forth in our certificate of incorporation. In addition, our bylaws provide
for a right of indemnity to bring a suit in the event a claim for indemnification or advancement of expenses is not paid in full
by us within a specified period of time. Our bylaws also permit us to purchase and maintain insurance, at our expense, to protect
us and/or any director, officer, employee or agent of our corporation or another entity, trust or other enterprise against any
expense, liability or loss, whether or not we would have the power to indemnify such person against such expense, liability or
loss under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any repeal or amendment
of provisions of our bylaws affecting indemnification rights, whether by our board of directors, stockholders or by changes in
applicable law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective
only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive
basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with respect to any act
or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will enter into
indemnity agreements with each of our officers and directors a form of which is filed as Exhibit&nbsp;10.6 to this Registration
Statement. These agreements will require us to indemnify these individuals to the fullest extent permitted under Delaware law and
to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the Underwriting
Agreement filed as Exhibit&nbsp;1.1 to this Registration Statement, we have agreed to indemnify the Underwriters and the Underwriters
have agreed to indemnify us against certain civil liabilities that may be incurred in connection with this offering, including
certain liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 3%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 93%">On January&nbsp;1, 2020, our sponsor purchased 2,156,250 shares,
which we refer to herein as &ldquo;founder shares&rdquo; or &ldquo;insider shares,&rdquo; for an aggregate purchase price of $25,000.
On September 30, 2020, LifeSci Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor
in our sponsor. The founder shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that
the underwriters&rsquo; over-allotment option is not exercised in full or in part. Because these offers and sales were made to
a single purchaser in a transaction not involving a public offering, the shares were issued in reliance on the exemption from registration
contained in Section&nbsp;4(a)(2)&nbsp;of the Securities Act.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 3%; text-align: left">&bull;</TD><TD STYLE="text-align: justify; width: 93%"><FONT STYLE="font-family: Times New Roman, Times, Serif">LifeSci Holdings LLC, our sponsor,
has committed to purchase from us an aggregate of 3,033,333 warrants, or &ldquo;private warrants,&rdquo; at $0.90 per warrant for
a total purchase price of $2,730,000. </FONT>Each private warrant is exercisable for one (1) share of common stock at an exercise
price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our initial business
combination and 12 months from the closing of this offering and will expire five years after the effective date of the registration
statement of which this prospectus forms a part. This purchase will take place on a private placement basis simultaneously with
the consummation of this offering. Our sponsor has also agreed that if the over-allotment option is exercised by the underwriters,
it will purchase from us at a price of $0.90 per warrant an additional number of private warrants (up to a maximum of 250,000 private
warrants) in an amount that is necessary to maintain in the trust account $10.00 per share sold to the public in this offering.
These additional private warrants will be purchased in a private placement that will occur simultaneously with the purchase of
shares resulting from the exercise of the over-allotment option. Because this offer and sale is being made to a single purchaser,
the sale does not involve a public offering and is being made in reliance on the exemption from registration contained in Section&nbsp;4(a)(2)&nbsp;of
the Securities Act. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full) we will receive from the
sale of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) will be used for offering
expenses and $750,000 will be used for working capital.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No underwriting discounts
or commissions were paid with respect to such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 16. Exhibits and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following exhibits are filed as part of this Registration Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-right: 3pt; padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; border-top: black 1pt solid; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="width: 92%; border-top: black 1pt solid; border-bottom: black 1pt solid; padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Underwriting Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Business Combination Marketing Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Amended and Restated Certificate of Incorporation.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Common Stock Certificate.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant Agreement. </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Opinion of Loeb&nbsp;&amp; Loeb LLP.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Letter Agreement among the Registrant, LifeSci Holdings LLC and the Company&rsquo;s officers, directors and stockholders.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Investment Management Trust Agreement between Continental Stock Transfer&nbsp;&amp; Trust Company and the Registrant.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Escrow Agreement between the Registrant, Continental Stock Transfer&nbsp;&amp; Trust Company and the Initial Stockholders.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Registration Rights Agreement among the Registrant and the Initial Stockholders and Continental Stock Transfer&nbsp;&amp; Trust Company.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Agreement, dated January&nbsp;1, 2020, between the Registrant and LifeSci Holdings LLC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Private Placement Warrant Subscription Agreement between the Registrant and LifeSci Holdings LLC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Administrative Support Agreement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Code of Ethics.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><A HREF="tm2025441d2_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></A></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><A HREF="tm2025441d2_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of WithumSmith+Brown, P.C.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Loeb&nbsp;&amp; Loeb LLP (included in Exhibit&nbsp;5.2).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page&nbsp;of the original filing hereof).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Audit Committee Charter.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Nominating Committee Charter.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Compensation Committee Charter.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.4*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Thomas Wynn.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.5*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Thomas Mathers.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.6*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Graham Walmsley.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.7*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Elizabeth Barrett.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.8*</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Scott Janssen.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be filed
by amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 3%; text-align: left">(a)</TD><TD STYLE="text-align: justify; width: 93%">The undersigned registrant hereby undertakes to provide
to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered
in such names as required by the underwriter to permit prompt delivery to each purchaser.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 3%; text-align: left">(b)</TD><TD STYLE="text-align: justify; width: 93%">Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such
issue.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;For the purpose
of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule&nbsp;430C, each
prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;as part of a registration statement relating to an offering, other than registration
statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;For the purpose
of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of an undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule&nbsp;424;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned
registrant;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned registrant hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%; text-align: left">(1)</TD><TD STYLE="text-align: justify; width: 85%">For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon
Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1)&nbsp;or (4)&nbsp;or
497(h)&nbsp;under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 10%"></TD><TD STYLE="width: 5%; text-align: left">(2)</TD><TD STYLE="text-align: justify; width: 85%">For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New York, on the 14th day of October, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><B>LIFESCI ACQUISITION II CORP.</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 46%">/s/ Andrew McDonald</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Andrew McDonald</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">KNOW ALL MEN BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Andrew McDonald his or her true and lawful attorney-in-fact,
with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities
to sign any and all amendments including post-effective amendments to this registration statement, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and
confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: black 1pt solid; width: 28%; border-bottom: black 1pt solid"><B>Name</B></TD>
    <TD STYLE="border-top: black 1pt solid; white-space: nowrap; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; width: 50%; border-bottom: black 1pt solid; text-align: center"><B>Position</B></TD>
    <TD STYLE="border-top: black 1pt solid; white-space: nowrap; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; width: 20%; border-bottom: black 1pt solid; text-align: center"><B>Date</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">/s/ Andrew McDonald</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>Chairman and Chief Operating Officer</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 14, 2020</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Andrew McDonald</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>(Principal executive officer) and Director</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">/s/ David Dobkin&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>Chief Financial Officer (Principal financial and</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 14, 2020</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>David Dobkin</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>accounting officer), Head of Strategy and Director</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid">/s/ Michael Rice</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>Chief Operating Officer (Principal financial and Director</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">October 14, 2020</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Michael Rice</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 125; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "S-1", "sequence": "1", "filename": "tm2025441d2_s1.htm", "description": "FORM S-1", "secsgml_size_bytes": 967071}]
{"company-data": {"conformed-name": "Lifesci Acquisition II Corp.", "cik": "0001819113", "assigned-sic": "6770", "irs-number": "844278203", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-1", "act": "33", "file-number": "333-249480", "film-number": "201239701"}, "business-address": {"street1": "250 W 55TH ST.", "street2": "#3401", "city": "NEW YORK", "state": "NY", "zip": "10019", "phone": "6468891200"}, "mail-address": {"street1": "250 W 55TH ST.", "street2": "#3401", "city": "NEW YORK", "state": "NY", "zip": "10019"}}
As filed with the Securities and Exchange
Commission on October 14, 2020
Registration No. 333-___________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933
LIFESCI
ACQUISITION II CORP.
(Exact name of registrant as specified in its charter)
Delaware
6770
84-4278203
(State or other jurisdiction of
incorporation or organization)
(Primary Standard Industrial
Classification Code Number)
(I.R.S. Employer
Identification Number)
250 W 55th St #3401
New York, NY 10019
(646) 889-1200
(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)
Andrew McDonald
Chief Executive Officer
250 W 55th St #3401,
New York, NY 10019
(646) 889-1200
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Mitchell S. Nussbaum, Esq.
Giovanni Caruso, Esq.
Loeb & Loeb LLP
345 Park Avenue
New York, New York 10154
(212) 407-4000
(212) 407-4990 — Facsimile
Douglas S. Ellenoff, Esq.
Stuart Neuhauser, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105
(212) 370-1300
(212) 370-7889 — Facsimile
Approximate date
of commencement of proposed sale to the public:
As soon as practicable after the effective date of this offering.
If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933 check the following box.
¨
If this Form is
filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.
¨
If this Form is
a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
If this Form is
a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.
¨
Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting
company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
x
Smaller reporting company
x
Emerging growth company
x
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
¨
CALCULATION
OF REGISTRATION FEE
Title of Each Class of Security being registered
Amount
Being Registered
Proposed
Maximum
Offering
Price per
Security
(1)
Proposed Maximum
Aggregate
Offering
Price
(1)(2)
Amount of
Registration
Fee
Common stock, $0.0001 par
    value
(2)
8,625,000
$
10.00
$
86,250,000
$
9,410
Total
$
86,250,000
$
9,410
(1)   Estimated solely for the purpose of calculating
the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended.
(2)   Includes the aggregate of 7,500,000 shares of common stock to
be issued to public stockholders in the public offering, and 1,125,000 shares of common stock which may be issued upon exercise
of a 45-day option granted to the Underwriters to cover over-allotments.
The Registrant
hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in
accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become
effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
EXPLANATORY NOTE
This Registration Statement contains
a prospectus relating to the initial public offering of shares of common stock of LifeSci Acquisition II Corp. for $10.00 per
share. This Registration Statement also contains a prospectus relating to offer and sales of shares of LifeSci Acquisition II
Corp. common stock in connection with certain market making transactions that may be effected by LifeSci Capital LLC in the
secondary market for 30 days following the date of this prospectus. The complete prospectus relating to the initial public
offering of our common stock (the "IPO Prospectus") follows immediately after this Explanatory Note. Following
the IPO Prospectus are certain pages of the prospectus relating solely to such market making transactions (together with
the remainder of the prospectus as modified as indicated below, the "Market Making Prospectus"), including an
alternate front and back cover page, an alternate table of contents and alternate sections entitled
 "Summary — The Offering," "Use of Proceeds" and "Plan of Distribution."
Each of such alternate pages has been marked "Alternate Page for Market Making Prospectus." The Market
Making Prospectus will not include the information in the sections of the IPO Prospectus entitled "Risk
Factors — Our initial stockholders paid nominal purchase price for their founder shares, and, accordingly,
you will experience immediate and substantial dilution from the purchase of our common stock.," "Risk
Factors — The determination of the offering price of our shares of common stock and the size of this offering
is more arbitrary than the pricing of securities and size of an offering of an operating company in a particular industry.
You may have less assurance, therefore, that the offering price of our shares of common stock properly reflects the value of
such shares than you would have in a typical offering of an operating company.," "Dilution,"
 "Capitalization," "Use of Proceeds" and "Underwriting (Conflict of Interest)." All other
sections of the IPO Prospectus are to be used in the Market Making Prospectus. A complete version of each of the IPO
Prospectus and the Market Making Prospectus will be filed with the U.S. Securities and Exchange Commission in accordance with
Rule 424 under the Securities Act.
The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION, DATED OCTOBER
                                         14, 2020
$75,000,000
LIFESCI ACQUISITION II CORP.
7,500,000 SHARES OF COMMON STOCK
LifeSci Acquisition
II Corp., which we refer to as "we," "us" or "our company," is a newly organized blank check
company incorporated in Delaware and formed for the purpose of entering into a merger, share exchange, asset acquisition, stock
purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities, which
we refer to throughout this prospectus as our "initial business combination." Although we are not limited to a particular
industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that
have their primary operations located in North America in the healthcare industry.
This is an initial
public offering of our securities. We are offering 7,500,000 shares of common stock at an offering price of $10.00 per share. Unlike
certain other SPAC IPOs, investors in this offering will not receive warrants that would become exercisable following completion
of our initial business combination. We have granted LifeSci Capital LLC ("LifeSci Capital"), the representative of
the underwriters, a 45-day option to purchase up to an additional 1,125,000 shares of common stock (over and above the 7,500,000
shares referred to above) solely to cover over-allotments, if any.
We will provide the holders of our outstanding shares of common
stock that were sold in this offering with the opportunity to redeem their shares of common stock upon the consummation of our
initial business combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust
account described below, including interest (net of taxes payable), divided by the number of then outstanding shares of common
stock that were sold in this offering, which we refer to as our "public shares."
We have 24 months
to consummate our initial business combination. If we are unable to consummate our initial business combination within the above
time period, we will distribute the aggregate amount then on deposit in the trust account, pro rata to our public stockholders,
by way of the redemption of their shares and thereafter cease all operations except for the purposes of winding up of our affairs,
as further described herein.
LifeSci Holdings LLC,
our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants," at $0.90
per warrant for an aggregate purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common stock
at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our
initial business combination and 12 months from the closing of this offering and will expire five years after the effective date
of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement basis
simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that if
the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the trust
account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
On January 1,
2020, LifeSci Holdings LLC, our sponsor, purchased 2,156,250 shares, which we refer to herein as "founder shares" or
 "insider shares," for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred
215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder shares include an aggregate
of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters' over-allotment option is not
exercised in full or in part, with LifeSci Holdings LLC to forfeit up to 253,125 shares and Chardan Healthcare Investments LLC
to forfeit up to 28,125 shares.
There is presently no public market for our common stock. We
intend to apply to have our common stock listed on the Nasdaq Capital Market, or Nasdaq, under the symbol "LSAQ" on
or promptly after the date of this prospectus. We cannot guarantee that our securities will be approved for listing on Nasdaq.
We cannot assure you that our securities will continue to be listed on Nasdaq after this offering.
We are an "emerging
growth company" as defined in the Jumpstart Our Business Startups Act of 2012 and will therefore be subject to reduced public
company reporting requirements.
Investing in our
securities involves a high degree of risk. See "Risk Factors" beginning on page 18 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Price to Public
Underwriting
Discount and
Commissions
(1)
Proceeds, Before
Expenses, to us
Per share
$
10.00
$
0.20
$
9.80
Total
$
75,000,000
$
1,500,000
$
73,500,000
(1)
Includes $[__] payable to [__] for acting as a qualified independent underwriter. Please see the section titled "Underwriting" for further information relating to the underwriting arrangements agreed to between us and the underwriters in this offering.
Upon consummation
of the offering, $10.00 per share sold to the public in this offering (whether or not the over-allotment option has been exercised
in full or part) will be deposited into a United States-based trust account with Continental Stock Transfer &
Trust Company acting as trustee. Except as described in this prospectus, these funds will not be released to us until the earlier
of the completion of our initial business combination and our redemption of the public shares upon our failure to consummate a
business combination within the required period.
The underwriters
are offering the shares of common stock on a firm commitment basis. LifeSci Capital LLC, acting as the representative of the underwriters,
expects to deliver the shares of common stock to purchasers on or about
[__],
2020
.
Sole Book-Running Manager
LifeSci Capital
[__], 2020
LIFESCI ACQUISITION II CORP.
TABLE OF CONTENTS
Page
SUMMARY
1
SUMMARY FINANCIAL DATA
17
RISK FACTORS
18
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
38
USE OF PROCEEDS
39
DIVIDEND POLICY
42
DILUTION
43
CAPITALIZATION
44
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
    OF OPERATIONS
45
PROPOSED BUSINESS
49
MANAGEMENT
66
PRINCIPAL STOCKHOLDERS
73
CERTAIN TRANSACTIONS
75
DESCRIPTION OF SECURITIES
77
SECURITIES ELIGIBLE FOR FUTURE SALE
80
UNDERWRITING (CONFLICTS OF INTEREST)
82
LEGAL MATTERS
87
EXPERTS
87
WHERE YOU CAN FIND ADDITIONAL INFORMATION
87
INDEX TO FINANCIAL STATEMENTS
F-1
i
SUMMARY
This summary only
highlights the more detailed information appearing elsewhere in this prospectus. As this is a summary, it does not contain all
of the information that you should consider in making an investment decision. You should read this entire prospectus carefully,
including the information under "Risk Factors" and our financial statements and the related notes included elsewhere
in this prospectus, before investing. Unless otherwise stated in this prospectus:
•
"we," "us" "our" or
    "our company" refers to LifeSci Acquisition II Corp.;
•
"initial stockholders"
    refers to all of our stockholders immediately prior to the date of this prospectus, including our sponsor and officers and
    directors to the extent they hold such shares;
•
"founder shares" refers
    to the 2,156,250 shares of common stock held by our sponsor, our directors, and affiliates of our management team prior to
    this offering (including up to an aggregate of 281,250 shares of common stock subject to forfeiture to the extent that the
    underwriters' over-allotment option is not exercised in full or in part);
•
"private warrants" refers
    to the warrants we are selling privately to our sponsor and/or its designees upon consummation of this offering;
•
"sponsor" refers to LifeSci Holdings LLC,
    an entity affiliated with LifeSci Capital LLC;
•
the term "public stockholders"
    means the holders of shares of common stock being sold in this public offering, or "public shares," whether they
    are purchased in the public offering or in the aftermarket, including any of our initial stockholders to the extent that they
    purchase such public shares (except that our initial stockholders will not have conversion or tender rights with respect to
    any public shares they own); and
•
the information in this prospectus assumes that the underwriters
    will not exercise their over-allotment option.
Certain financial
information contained in this prospectus has been rounded and, as a result, certain totals shown in this prospectus may not equal
the arithmetic sum of the figures that should otherwise aggregate to those totals.
You should rely
only on the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide
you with different information. We are not, and the underwriters are not, making an offer of these securities in any jurisdiction
where the offer is not permitted.
General
We are a blank check
company formed under the laws of the State of Delaware on December 18, 2019. We were formed for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses,
which we refer to throughout this prospectus as our initial business combination. Although there is no restriction or limitation
on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation.
We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology,
digital health, and healthcare services sectors, which aligns with our management team's experience in healthcare investing
and drug development. At the time of preparing this prospectus, we have not identified any specific business combination, nor has
anyone on our behalf initiated or engaged in any substantive discussions, formal or otherwise, related to such a transaction. Our
efforts to date are limited to organizational activities related to this offering.
1
Our Sponsor and Competitive Advantages
Our sponsor is an affiliate
of LifeSci Capital LLC, a research-driven investment bank with deep domain expertise in the life sciences, LifeSci Advisors LLC,
an investor relations and public relations company in the life sciences industry with comprehensive solutions to communications
and investor outreach, and LifeSci Venture Management LLC, a corporate venture capital firm that seeks to invest in biotech and
health sectors, collectively "LifeSci".
LifeSci's service
model as a boutique investment bank is unique in that it exclusively serves corporate clients that are emerging life science companies
that discover, develop, and commercialize innovative products.
LifeSci's service
model as an investor relations and public relations firm is unique in that it provides companies in the life sciences industry
with comprehensive solutions to communications and investor outreach. LifeSci assists companies in increasing visibility within
the investment community and educating investors on opportunities offered by these companies. LifeSci's core capabilities
include non-deal roadshow planning and execution, KOL Events/R&D Days, corporate communications, and public relations through
its affiliate LifeSci Public Relations.
LifeSci's service
model as a venture capital firm is unique in that it focuses on pre-public institutional rounds of transformational healthcare
companies managed by exceptional founder/entrepreneurs. LifeSci's investment principals have broad-ranging life sciences
experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research,
and bench research - both basic science and applied.
LifeSci's team
is comprised of individuals with medical and advanced scientific training and legal and banking experience, enabling a deeply differentiated
approach to research and idea generation. Complementing LifeSci's scientific insight and industry relationships is LifeSci's
business team, whose members include portfolio managers, corporate managers, and investment bankers who actively engage with banks
and academic institutions, cultivating strong relationships and expanding their network of key contacts and syndicate partners.
We believe the well-rounded nature of the team, strengthened by strong ties across industry, academia, banking platforms, and unaffiliated
investor relationships, will enhance our management team's ability to source viable prospective target businesses, capitalize
them, and ensure public-market readiness.
Our independent directors
have extensive experience in clinical medicine, development and regulatory, operational, and management leadership within the healthcare
and financial industries. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective
candidates and successfully execute our initial business combination. Following the completion of our initial transaction, we believe
our independent directors will fortify our ongoing operations by providing sound and experienced counsel on potential further acquisitions,
divestitures, corporate strategy, and human resources.
We believe that our
management team is equipped with the knowledge, experience, capital and human resources, and sustainable corporate governance practices
to pursue unique opportunities that will offer attractive risk-adjusted returns.
Our management team
is led by Andrew McDonald, Co-Founder of LifeSci Advisors and LifeSci Capital, Michael Rice, Co-Founder of LifeSci Advisors and
LifeSci Capital, and David Dobkin, Managing Director of LifeSci Capital.
We believe that our
company's philosophical alignment with LifeSci, and our ability to leverage the rigorous and comprehensive scientific and
financial analysis that LifeSci is known for, provides us with a strong competitive advantage. LifeSci focuses on dynamic sectors
of healthcare with great potential to transform the healthcare industry: biotechnology, specialty pharmaceuticals, medical devices,
digital health, information technology, and healthcare services.
In 2018, LifeSci's
investors relations hosted over 1,500 meetings in 27 key regions in the United States and over 500 meetings in 16 key regions throughout
Europe. In 2019, LifeSci's Public Relations group secured over 1,300 media hits for their clients, with more than 100 million
viewers and readers globally, and wrote over 4,000 social media posts. LifeSci Venture's first fund in 2017 has invested
in 12 companies alongside large dedicated healthcare funds and has launched its second fund in the third quarter of 2019. LifeSci's
investment bank has executed over 50 transactions since inception, in which over 50% were repeat or Lead Managed. LifeSci's
investment bank core capabilities include experienced-based investment banking advisory, varied capital raising abilities, industry
insight and accessibility, global institutional coverage and reach, equity research, and client empowerment.
LifeSci's investor
relations presence has continued to expand year-over-year. In 2019, LifeSci Advisors conducted 4,602 one-on-one non-deal roadshow
(NDR) investor meetings, 140 key opinion leader (KOL) events, 594 meetings with high net worth (HNW) individuals and financial
advisors, and 4,160 one-on-one meetings at the J.P. Morgan healthcare conference (JPM), as compared to 4,105 NDR meetings, 130
KOL events, 568 HNW meetings, and 2,700 one-on-one meetings at JPM in 2018. Additionally, LifeSci's Executive Search group completed
30 board and executive placements in 2019, up from 17 in 2018. LifeSci's client base continues to grow as well, reaching 177 healthcare
client partnerships in 2019, up from 150 in 2018. LifeSci Partners has a global footprint, with offices in cities including New
York, Chicago, Boston, Charlotte, London, Geneva, Paris, and Tel Aviv.
2
Our Board of Directors and Management
Andrew McDonald,
our
Chief Executive Officer and Board Member, is an experienced healthcare investment professional with expertise in identifying transformative
products and technologies in all stages of development. Andrew has been the Chairman and Chief Executive Officer of LifeSci Acquisition
Corp., a special purpose acquisition company, since June 2019. Andrew has served as the Chief Executive Officer of Attune
Pharmaceuticals since March 2015 and is a Founding Partner of LifeSci Advisors and LifeSci Capital. Prior to founding LifeSci,
Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008.
From 2004 to 2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment
bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001 to 2004, where
he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal
chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at UC Berkeley.
Andrew holds the Series 7, 24, 63, 79, 86, and 87 licenses.
Michael Rice,
our
Chief Operating Officer and Board Member, has experience in portfolio management, corporate management, investment banking and
capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking
at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at ThinkEquity
Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions,
many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America, serving large
hedge funds and private equity healthcare funds. Michael has been the Chief Operating Officer and a director of LifeSci Acquisition
Corp., a special purpose acquisition company, since June 2019. Previously, he was a Managing Director at JPMorgan/Hambrecht &
Quist.
David Dobkin
,
our Chief Financial Officer and Board Member, is an experienced healthcare capital markets investment banker with a career focused
on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. David
has been the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose acquisition company, since
June 2019. David has worked with companies developing a wide range of technologies and brings extensive strategic advisory
and execution capability to his clients. David has experience with both traditional and non-traditional forms of equity and debt
offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across the United States
and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to that, in 2015, David
founded Dobkin & Company, an investment bank tailored for entrepreneur-led companies focused on seed and growth equity
and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf
of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous
experience conducting cross-border transactions. Prior to October 2010, David worked for Lazard Frères, one of the
world's preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers
and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Frères, David began his career in in
the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein Perella, David advised healthcare
companies on capital formation as well as strategic alternatives. David conducted graduate research in stem cell bioengineering
and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a B.S.
in Biomedical Engineering, from Columbia University. David holds the Series 63, 79, and 82 licenses.
3
Industry Opportunity
The healthcare industry
consists of sectors within the economic system providing curative, preventive, rehabilitative, and palliative care for patients.
The industry includes organizations providing such goods and services, as well as the doctors, nurses, and other healthcare employees.
Total healthcare spending in the United States reached nearly $3.5 trillion in 2017 and is expected to grow by an average 5.6 percent
annually over 2016-2025, according to a Centers for Medicare & Medicaid Services report released in February 2017.
Total healthcare expenditures are thus expected rise to 19.9 percent of the US Gross Domestic Product.
The healthcare market
globally mirrors a similar trend in the U.S. of an increased contribution to the economy, due to the aging of the global population
and other durable macro dynamics. For example, in good part due to the impact of healthcare on society, life expectancy in the
U.S. increased from 47 years in 1900 to 79 years in 2016. As a disproportionate amount of overall healthcare spending is associated
with diseases of aging, the aging of the global population will continue to drive increased healthcare consumption. In addition,
less developed countries have gone through an unprecedented period of healthcare insurance and infrastructure expansion that has
led the countries to have significantly higher contributions to the global healthcare marketplace.
The target universe
of healthcare opportunities is extensive, considering healthcare's overall contribution to the economy. A factor that further
broadens the universe is the high amount of innovation occurring within healthcare. In the wake of the genomics revolution, the
pace of innovation is accelerating. With the streamlining of the externalization of breakthrough science from academic institutions,
particularly in the United States, as mandates shifted from protecting intellectual property to externalizing it, increasing numbers
of potentially disruptive healthcare innovations exist that may be underappreciated or underfunded. Early-stage companies need
capital and advisory services to reach their commercial potential.
The healthcare industry
is primed for new technologies and business models due to the increasing cost of healthcare and due to the increasing pressure
to add value to the system. We believe that lower-value segments of healthcare will be burdened by the pressures of cost cutting,
while companies or segments that deliver superior products and services, with better clinical and non-clinical outcomes, will thrive.
Successful companies will be data driven, consumer focused, operationally efficient and transfer best-in-class standards globally.
Our team will take a holistic approach to investment opportunities and conduct stringent due diligence to screen such companies.
We see opportunities for companies that address global healthcare cost pressures by: succeeding in disruptive innovation, thus
justifying monies spent by delivering cures or other breakthrough outcomes; delivering cost savings to address global healthcare
cost pressures; or providing access to medicines, as the marginal benefits from healthcare spending are highest when providing
goods and services to those who do not already receive them.
4
Investment Criteria
We are focused on
companies in disruptive and other value added subsegments of healthcare that have the potential for significant gains in the next
five years. Our ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to
raise money from the private capital markets. The segments we will target include biotechnology, medical technology and digital
health.
The focus of our management
team is to create stockholder value by leveraging its experience to efficiently guide an emerging healthcare company towards commercialization.
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in
evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses,
we may deviate from these criteria and guidelines should we see fit to do so:
•
Healthcare Company Poised for Rapid Growth
We intend to primarily seek
to acquire one or more growth businesses with a total equity value of greater than 5 to 10 times the amount of the proceeds of
this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can
benefit from a public listing and new capital for growth to support significant revenue and earnings growth or to advance clinical
programs. We do not intend to acquire a start-up company.
•
Niche Leader and Specialized Business with High Growth Potential
We intend to seek target companies
that have significant and underexploited expansion opportunities in a niche sector. This can be accomplished through a combination
of accelerating organic growth and finding attractive add-on acquisition targets. Our management team has significant experience
in identifying such targets and in helping target management assess the strategic and financial fit. Similarly, our management
has the expertise to assess the likely synergies and a process to help a target integrate acquisitions. Additionally, our management
team has extensive experience assisting healthcare companies raise money as they navigate the regulatory approval process.
•
Benefits from Being a U.S. Public Company (Value Creation and Marketing Opportunities)
We intend to seek target companies
that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms
and in a manner that leverage our experience. We expect to evaluate a Company based on its potential to successfully achieve regulatory
approval and commercialize its product(s). We also expect to evaluate financial returns based on (i) risk-adjusted peak sales
potential (ii) the potential of pipeline products and the scientific platform (iii) the ability to achieve the system
cost savings, (iv) the ability to accelerate growth via other options, including through the opportunity for follow-on acquisitions
and (v) the prospects for creating value through other value creation initiatives. Potential upside, for example, from the
growth in the target business' earnings or an improved capital structure will be weighed against any identified downside
risks.
5
•
Potential Benefit from Globalization Trends and Possession of Competitive Advantages
Target companies exhibit unrecognized
value or other characteristics that we believe have been misevaluated by the marketplace based on company-specific analyses and
due diligence. For a potential target company, this process will include, among other things, a review and analysis of the company's
capital structure, quality of current or future earnings, preclinical or clinical data, potential for operational improvements,
corporate governance, customers, material contracts, and the industry and trends. We intend to leverage the operational experience
and disciplined investment approach of our team to identify opportunities to unlock value that our experience in complex situations
allows us to pursue.
These criteria are
not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based,
to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may
deem relevant.
Private Placements
On January 1,
2020, our sponsor purchased 2,156,250 shares, which we refer to throughout this prospectus as the "founder shares"
or "insider shares," for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci Holdings LLC transferred
215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder shares include an aggregate
of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters' over-allotment option is not
exercised in full or in part, so that our initial stockholders will collectively own 20% of our issued and outstanding shares after
this offering (excluding the sale of the private warrants and assuming our initial stockholders do not purchase public shares in
this offering). None of our initial stockholders has indicated any intention to purchase public shares in this offering.
The founder shares
are identical to the public shares. However, our initial stockholders have agreed (A) to vote their founder shares in favor
of any proposed business combination, (B) not to propose, or vote in favor of, prior to and unrelated to an initial business
combination, an amendment to our certificate of incorporation that would affect the substance or timing of our redemption obligation
to redeem all public shares if we cannot complete an initial business combination within 24 months of the closing of this offering,
unless we provide public stockholders an opportunity to redeem their public shares in conjunction with any such amendment, (C) not
to redeem any shares, including founder shares into the right to receive cash from the trust account in connection with a stockholder
vote to approve our proposed initial business combination or sell any shares to us in any tender offer in connection with our proposed
initial business combination, and (D) that the founder shares shall not participate in any liquidating distribution upon winding
up if a business combination is not consummated.
On the date of this
prospectus, the founder shares will be placed into an escrow account maintained by Continental Stock Transfer & Trust
Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier
of (i) 6 months after the date of the consummation of our initial business combination or (ii) the date on which the
closing price of our shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends,
reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after our initial business
combination and the remaining 50% of the founder shares will not be transferred, assigned, sold or released from escrow until 6
months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our
initial business combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which
results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property.
During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to
any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers,
directors, stockholders, employees and members of our sponsor and its affiliates, (2) amongst initial stockholders or to our
officers, directors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members
upon its liquidation, (4) by bona fide gift to a member of the holder's immediate family or to a trust, the beneficiary
of which is a holder or a member of a holder's immediate family, for estate planning purposes, (5) by virtue of the
laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges
to secure obligations incurred in connection with purchases of our securities, (8) by private sales at prices no greater than
the price at which the shares were originally purchased or (9) for the cancellation of up to 281,250 shares of common stock
subject to forfeiture to the extent that the underwriters' over-allotment is not exercised in full or in part or in connection
with the consummation of our initial business combination, in each case (except for clause 9 or with our prior consent) where the
transferee agrees to the terms of the escrow agreement and the insider letter.
6
In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants,"
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
The proceeds from
the private placement of the private warrants will be added to the proceeds of this offering and placed in a trust account in the
United States maintained by Continental Stock Transfer & Trust Company, as trustee. If we do not complete our initial
business combination within 24 months, the proceeds from the sale of the private warrants will be included in the liquidating distribution
to the holders of our public shares.
The private warrants
will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial
purchasers or their permitted transferees. The private warrants will not be transferable, assignable or saleable until after the
completion of a business combination, subject to the limited exceptions described above.
If public shares are
purchased by any of our directors, officers or initial stockholders, they will be entitled to funds from the trust account to the
same extent as any public stockholder upon our liquidation but will not have redemption rights related thereto.
Our executive offices
are located at 250 W. 55th St., #3401, New York, NY 10019, and our telephone number is (646) 889-1200.
7
The Offering
In making your decision
on whether to invest in our securities, you should take into account not only the backgrounds of the members of our management
team, but also the special risks we face as a blank check company and the fact that this offering is not being conducted in compliance
with Rule 419 promulgated under the Securities Act. You will not be entitled to protections normally afforded to investors
in Rule 419 blank check offerings. You should carefully consider these and the other risks set forth in the section below
entitled "Risk Factors" beginning on page 18 of this prospectus.
Securities offered
7,500,000 shares of common stock, at $10.00 per share.
Listing of our securities and
proposed symbol
We anticipate the shares of common stock will be listed on Nasdaq under the symbol "LSAQ".
We will file a Current Report on Form 8-K with the SEC, including an audited balance sheet, promptly upon the consummation of this offering, which is anticipated to take place two business days from the date the shares commence trading. The audited balance sheet will reflect our receipt of the proceeds from the exercise of the over-allotment option if the over-allotment option is exercised on the date of this prospectus. If the over-allotment option is exercised after the date of this prospectus, we will file an amendment to the Form 8-K or a new Form 8-K to provide updated financial information to reflect the exercise of the over-allotment option.
8
Shares of common stock:
Number issued and outstanding before
this offering
2,156,250 shares
(1)
Number to be issued and outstanding after
9,375,000 shares
(2)
(1)
This number includes an aggregate of up to 281,250 shares of common stock held by our initial stockholders that are subject to forfeiture if the over-allotment option is not fully exercised by the underwriters.
(2)
Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited. If the over-allotment option is exercised in full, there will be a total of 10,781,250 shares of common stock issued and outstanding.
9
Offering proceeds to be held in trust
$75,000,000 of the net proceeds of
        this offering (or $86,250,000 if the over-allotment option is exercised in full), including $2,730,000 (or $2,955,000 if the
        over-allotment option is exercised in full), we will receive from the sale of the private warrants, or $10.00 per share sold
        to the public in this offering will be placed in a trust account in the United States, maintained by Continental
        Stock Transfer & Trust Company, acting as trustee pursuant to an agreement to be signed on the date of this
        prospectus. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full), we will receive from the sale
        of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) be used for offering
        expenses and $750,000 will be used for working capital.
Except as set forth below, the proceeds
        in the trust account will not be released until the earlier of: (1) the completion of an initial business combination within
        the required time period and (2) our redemption of 100% of the outstanding public shares if we have not completed a business
        combination in the required time period. Therefore, unless and until our initial business combination is consummated, the proceeds
        held in the trust account will not be available for our use for any expenses related to this offering or expenses which we may
        incur related to the investigation and selection of a target business and the negotiation of an agreement to acquire a target business.
Notwithstanding the foregoing, there can be released to us,
from time to time, (i) any interest earned on the funds in the trust account that we may need to pay our tax obligations and
(ii) any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working
capital requirements. With this exception, expenses incurred by us may be paid prior to a business combination only from the net
proceeds of this offering not held in the trust account of approximately $750,000 provided, however, that in order to meet our
working capital needs following the consummation of this offering if the funds not held in the trust account are insufficient,
our initial stockholders, officers and directors or their affiliates may, but are not obligated to, loan us funds, from time to
time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory
note. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender's
discretion, up to $500,000 of the notes may be converted upon consummation of our business combination into additional private
warrants at a conversion price of $0.90 per private warrant. Such private warrants will be identical to the private warrants to
be issued at the closing of this offering. Our directors have approved the issuance of the private warrants upon conversion of
such notes, to the extent the holder wishes to so convert them at the time of the consummation of our initial business combination.
If we do not complete a business combination, the loans will only be repaid with funds not held in the trust account, to the extent
available.
10
Limited payments to insiders
Prior to the consummation of a
business combination, there will be no fees, reimbursements or other cash payments paid to our initial stockholders, officers,
directors or their affiliates prior to, or for any services they render in order to effectuate, the consummation of a business
combination (regardless of the type of transaction that it is) other than:
•
payment of $10,000 per month to an affiliate of LifeSci Holdings
LLC for office space and related services, subject to deferral as described herein;
•
repayment of loans which may be made by our insiders,
officers, directors or any of its or their affiliates to finance transaction costs in connection with an initial business combination,
the terms of which have not been determined;
•
reimbursement of out-of-pocket expenses incurred by them
in connection with certain activities on our behalf, such as identifying and investigating possible business targets and business
combinations; and
•
repayment upon consummation of our initial business combination
of any loans which may be made by our initial stockholders or their affiliates or our officers and directors to finance transaction
costs in connection with an intended initial business combination.
There is no limit on the amount of out-of-pocket
        expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in
        the trust account and the interest income earned on the amounts held in the trust account available to us, such expenses would
        not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve all reimbursements
        and payments made to any initial stockholder or member of our management team, or their respective affiliates, and any reimbursements
        and payments made to members of our audit committee will be reviewed and approved by our board of directors, with any interested
        director abstaining from such review and approval.
Potential revisions to agreements with insiders
We could seek to amend certain agreements made by our management team disclosed in this prospectus without the approval of stockholders, although we have no intention to do so. For example, restrictions on our executives relating to the voting of securities owned by them, the agreement of our management team to remain with us until the closing of a business combination, the obligation of our management team to not propose certain changes to our organizational documents or the obligation of the management team and its affiliates to not receive any compensation in connection with a business combination could be modified without obtaining stockholder approval. Although stockholders would not be given the opportunity to redeem their shares in connection with such changes, in no event would we be able to modify the redemption or liquidation rights of our stockholders without permitting our stockholders the right to redeem their shares in connection with any such change. We will not agree to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if such a modification were necessary to complete a business combination).
11
Stockholder approval of, or tender offer in connection with, initial business combination
W
e have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor.
In connection with any proposed initial business combination, we will either (1) seek stockholder approval of such initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2) provide our public stockholders with the opportunity to sell their public shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that we are unable to satisfy any applicable closing condition set forth in the definitive agreement related to our initial business combination, or we are unable to maintain net tangible assets of at least $5,000,001, we will not consummate such initial business combination. The decision as to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval. If we provide stockholders with the opportunity to sell their shares to us by means of a tender offer, we will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as is required under the SEC's proxy rules. If we seek stockholder approval of our initial business combination, we will consummate the business combination only if a majority of the outstanding shares of common stock voted are voted in favor of the business combination.
12
We have determined not to consummate any business combination unless we have net tangible assets of at least $5,000,001 upon such consummation in order to avoid being subject to Rule 419 promulgated under the Securities Act. However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as we may be required to have a lesser number of shares redeemed) and may force us to seek third party financing which may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination and we may not be able to locate another suitable target within the applicable time period, if at all.
Our initial stockholders have agreed (A) to vote their
founder shares and any public shares in favor of any proposed business combination, (B) not to propose, or vote in favor of,
prior to and unrelated to an initial business combination, an amendment to our certificate of incorporation that would affect the
substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months unless we provide public stockholder an opportunity to redeem their public shares in conjunction with any such
amendment, (C) not to convert any shares (including the founder shares) into the right to receive cash from the trust account
in connection with a stockholder vote to approve our proposed initial business combination or sell any shares to us in a tender
offer in connection with our proposed initial business combination, and (D) that the founder shares shall not participate
in any liquidating distribution upon winding up if a business combination is not consummated. None of our initial stockholders
or their affiliates has indicated any intention to purchase public shares of common stock in the open market or in private transactions.
However, if a significant number of stockholders vote, or indicate an intention to vote, against a proposed business combination,
our initial stockholders, officers, directors or their affiliates could make such purchases in the open market or in private transactions
in order to influence the vote. Our initial stockholders, officers, directors and their affiliates could purchase sufficient shares
so that the initial business combination may be approved without the majority vote of public shares held by non-affiliates. Notwithstanding
the foregoing, our officers, directors, initial stockholders and their affiliates will not make purchases of shares of common stock
if the purchases would violate Section 9(a)(2) or Rule 10b-5 of the Exchange Act, which are rules designed
to stop potential manipulation of a company's stock or purchasing shares when the buyer is in possession of material non-public
information about the Company.
13
Conditions to completing our initial business combination
We have agreed not to enter into a definitive
agreement regarding an initial business combination without the prior consent of our sponsor. Further, there is no limitation
on our ability to raise funds privately or through loans in connection with our initial business combination. Our initial business
combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of
the value of the trust account (excluding any taxes payable on the income earned on the trust account) at the time of the agreement
to enter into the initial business combination. If we are no longer listed on Nasdaq, we will not be required to satisfy the 80%
test.
If our board is not able to independently
        determine the fair market value of the target business or businesses, we may obtain an opinion from an independent investment banking
        or accounting firm as to the fair market value of the target business. We will complete our initial business combination only if
        the post-transaction company in which our public stockholders own shares will own or acquire 50% or more of the outstanding voting
        securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
        as an investment company under the Investment Company Act. Even if the post-transaction company owns 50% or more of the voting
        securities of the target, our stockholders prior to the business combination may collectively own a minority interest in the post
        business combination company, depending on valuations ascribed to the target and us in the business combination transaction. If
        less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction
        company, the portion of such business or businesses that is owned or acquired is what will be valued for purposes of the 80% test,
        provided that in the event that the business combination involves more than one target business, the 80% test will be based on
        the aggregate value of all of the target businesses.
Conversion rights
In connection with any stockholder meeting
        called to approve a proposed initial business combination, each public stockholder will have the right, regardless of whether he,
        she or it is voting for or against such proposed business combination, to demand that we convert his, her or its public shares
        into a
pro rata
share of the trust account upon consummation of the business combination.
We may require public stockholders wishing
        to exercise conversion rights, whether they are a record holder or hold their shares in "street name," to either tender
        the certificates they are seeking to convert to our transfer agent or to deliver the shares they are seeking to convert to the
        transfer agent electronically using Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) System, at the holder's
        option, at any time at or prior to the vote on the business combination. There is a nominal cost associated with this tendering
        process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge
        the tendering broker $45 and it would be up to the broker whether or not to pass this cost on to the converting holder. However,
        this fee would be incurred regardless of whether or not we require holders to deliver their shares prior to the vote on the business
        combination in order to exercise conversion rights. This is because a holder would need to deliver shares to exercise conversion
        rights regardless of the timing of when such delivery must be effectuated. However, in the event we require stockholders to deliver
        their shares prior to the vote on the proposed business combination and the proposed business combination is not consummated, this
        may result in an increased cost to stockholders. The conversion rights will include the requirement that a beneficial holder must
        identify itself in order to validly redeem its shares.
Under Delaware law, we may be required
        to give a minimum of only ten days' notice for each general meeting. As a result, if we require public stockholders who wish
        to convert their shares of common stock into the right to receive a
pro rata
portion of the funds in the trust account to
        comply with the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares
        for conversion. Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities
        when they otherwise would not want to.
If we require public stockholders who wish
        to convert their shares of common stock to comply with specific delivery requirements for conversion described above and such proposed
        business combination is not consummated, we will promptly return such certificates to the tendering public stockholders.
Release of funds in trust account upon closing of our initial business combination
On the completion of our initial business combination, all amounts held in the trust account will be released to us. We will use these funds to pay amounts due to any public stockholders who exercise their conversion rights as described above under "— Conversion rights" to pay all or a portion of the consideration payable to the target or targets or owners of the target or targets of our initial business combination and to pay other expenses associated with our initial business combination. If our initial business combination is paid for using stock or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.
Liquidation if no business combination
If we are unable to complete our initial business combination
within 24 months from the closing of this offering, we will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public
shares (including any public shares in this offering or any public shares that our initial stockholders or their affiliates purchased
in this offering or later acquired in the open market or in private transactions), which redemption will completely extinguish
public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of our
remaining holders of common stock and our board of directors, proceed to commence a voluntary liquidation and thereby a formal
dissolution of the Company, subject (in the case of (ii) and (iii) above) to our obligations to provide for claims of
creditors and the requirements of applicable law.
14
In connection with our redemption of 100%
        of our outstanding public shares for a portion of the funds held in the trust account, each holder will receive a full pro rata
        portion of the amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not
        necessary to pay our taxes payable on such funds.
We may not have funds sufficient to pay
        or provide for all creditors' claims. Although we will seek to have all third parties (including any vendors or other entities
        we engage after this offering) and any prospective target businesses enter into valid and enforceable agreements with us waiving
        any right, title, interest or claim of any kind in or to any monies held in the trust account, there is no guarantee that they
        will execute such agreements. There is also no guarantee that the third parties would not challenge the enforceability of these
        waivers and bring claims against the trust account for monies owed them.
The holders of the founder shares and private
warrants will not participate in any redemption distribution with respect to their founder shares and private warrants, but may have
any public shares redeemed upon liquidation.
If we are unable to conclude our initial
        business combination and we expend all of the net proceeds of this offering not deposited in the trust account, without taking
        into account any interest earned on the trust account, we expect that the initial per-share redemption price will be approximately
        $10.00. The proceeds deposited in the trust account could, however, become subject to claims of our creditors that are in preference
        to the claims of our stockholders. Furthermore, our underwriters may seek recourse against the proceeds in the trust account relating
        to any future claims they may have against us. In addition, if we are forced to file a bankruptcy case or an involuntary bankruptcy
        case is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy
        law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our
        stockholders. Therefore, the actual per-share redemption price may be less than approximately $10.00. We will pay the costs of
        any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our sponsor
        has agreed to pay the funds necessary to complete such liquidation and has agreed not to seek repayment for such expenses. We currently
        do not anticipate that such funds will be insufficient.
15
Conflict of Interest
LifeSci Capital, the representative of
the underwriters in this offering and an affiliate of certain of our officers and directors, is a beneficial owner of our sponsor,
LifeSci Holdings LLC. As a result, LifeSci Capital is deemed to have a "conflict of interest" within the meaning of
FINRA Rule 5121 ("Rule 5121"). Accordingly, this offering is being made in compliance with the applicable
requirements of Rule 5121.
Rule 5121 requires that a "qualified
        independent underwriter," as defined in Rule 5121, participate in the preparation of the registration statement and
        prospectus and exercise the usual standards of due diligence with respect thereto. [__] has agreed to act as a "qualified
        independent underwriter" for this offering. [__] will receive $[__] for acting as a qualified independent underwriter. We
        have agreed to indemnify [__] against certain liabilities incurred in connection with acting as a "qualified independent
        underwriter," including liabilities under the Securities Act. In addition, no underwriter with a conflict of interest will
        confirm sales to any account over which it exercises discretionary authority without the specific prior written approval of the
        account holder.
RISKS
We are a newly formed
company that has conducted no operations and has generated no revenues. Until we complete our initial business combination, we
will have no operations and will generate no operating revenues. In making your decision on whether to invest in our securities,
you should take into account not only the background of our management team, but also the special risks we face as a blank check
company, as well as the fact that this offering is not being conducted in compliance with Rule 419 promulgated under the Securities
Act, and, therefore, you will not be entitled to protections normally afforded to investors in Rule 419 blank check offerings.
For additional information concerning how Rule 419 blank check offerings differ from this offering, please see "
Proposed
Business — Comparison to offerings of blank check companies subject to Rule 419
." You should carefully consider
these and the other risks set forth in the section entitled "Risk Factors" beginning on page 18 of this prospectus.
16
SUMMARY FINANCIAL DATA
The following table
summarizes the relevant financial data for our business and should be read with our financial statements, which are included in
this prospectus. We have not had any significant operations to date, so only balance sheet data are presented.
June 30, 2020
Actual
As Adjusted
Balance Sheet Data:
Working capital (deficit)
$
(4,000
)
$
75,774,000
Total assets
53,000
75,774,000
Total liabilities
29,000
—
Value of shares of common stock subject to possible conversion/tender
—
70,773,990
Stockholders' equity
24,000
5,000,010
(1)           Includes
the $2,730,000 we will receive from the sale of the private warrants.
The "as adjusted"
information gives effect to the sale of the shares we are offering, including the application of the related gross proceeds and
the payment of the estimated remaining costs from such sale and the repayment of the accrued and other liabilities required to
be repaid such that we have at least $5,000,001 of net tangible assets upon consummation of this offering and upon consummation
of our initial business combination.
The "as adjusted"
working capital and total assets amounts include the $75,000,000 (without exercise of over-allotment option) to be held in the
trust account, which, except for limited situations described in this prospectus, will be available to us only upon the consummation
of our initial business combination within the time period described in this prospectus.
We will consummate
our initial business combination only if we have net tangible assets of at least $5,000,001 upon such consummation and a majority
of the outstanding shares of common stock voted are voted in favor of the business combination (if a vote is required or being
obtained).
17
RISK FACTORS
An investment in
our securities involves a high degree of risk. You should consider carefully all of the risks described below, together with the
other information contained in this prospectus, before making a decision to invest in our shares of common stock. If any of the
following events occur, our business, financial condition and operating results may be materially adversely affected. In that event,
the trading price of our securities could decline, and you could lose all or part of your investment.
We are a newly formed blank check company
in the early stage with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve
our business objective.
We are a recently
formed blank check company with no operating results, and we will not commence operations until obtaining funding through this
offering and consummating our initial business combination. Because we lack an operating history, you have no basis upon which
to evaluate our ability to achieve our business objective of completing our initial business combination with one or more target
businesses. We have no plans, arrangements or understandings with any prospective target business concerning our initial business
combination and may be unable to complete our initial business combination. If we fail to complete our initial business combination,
we will never generate any operating revenues.
The requirement that the target business
or businesses that we acquire must collectively have a fair market value equal to at least 80% of the balance of the funds in the
trust account (excluding any taxes payable) at the time of the execution of a definitive agreement for our initial business combination
may limit the type and number of companies with which we may complete such a business combination.
Pursuant to Nasdaq
listing rules, the target business or businesses that we acquire must collectively have a fair market value equal to at least 80%
of the balance of the funds in the trust account (excluding any taxes payable) at the time of the execution of a definitive agreement
for our initial business combination. This restriction may limit the type and number of companies that we may complete a business
combination with. If we are unable to locate a target business or businesses that satisfy this fair market value test, we may be
forced to liquidate and you will only be entitled to receive your pro rata portion of the funds in the trust account, which may
be less than $10.00 per share.
Our search for a business combination,
and any target business with which we ultimately consummate a business combination, may be materially adversely affected by the
recent coronavirus (COVID-19) outbreak and the status of debt and equity markets.
The outbreak of the
COVID-19 coronavirus has resulted in a widespread health crisis that has adversely affected the economies and financial markets
worldwide. We may be unable to complete a business combination if continued concerns relating to COVID-19 restrict travel, limit
the ability to have meetings with potential investors, if the target company's personnel, vendors and service providers are
unavailable to negotiate and consummate a transaction in a timely manner, or if COVID-19 causes a prolonged economic downturn.
The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which are highly
uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions
to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 or other matters of global concern
continue for an extensive period of time, our ability to consummate a business combination, or the operations of a target business
with which we ultimately consummate a business combination, may be materially adversely affected.
In addition, our ability
to consummate a business combination may be dependent on the ability to raise equity and debt financing which may be impacted by
COVID-19 and other events.
Our public stockholders may not be afforded
an opportunity to vote on our proposed business combination, which means we may consummate our initial business combination even
though a majority of our public stockholders do not support such a combination.
If a stockholder vote
is not required, we may conduct redemptions via a tender offer. Accordingly, we may consummate our initial business combination
even if holders of a majority of our public shares do not approve the business combination.
Your only opportunity to affect the
investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares
from us for cash.
At the time of your
investment in us, you will not be provided with an opportunity to evaluate the specific merits or risks of one or more target businesses.
Because our board of directors may consummate our initial business combination without seeking stockholder approval, public stockholders
may not have the right or opportunity to vote on the business combination. Accordingly, your only opportunity to affect the investment
decision regarding a potential business combination may be limited to exercising your redemption rights within the period of time
(which will be at least 20 business days) set forth in our tender offer documents mailed to our public stockholders in which we
describe our business combination.
The ability of our public stockholders
to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which
may make it difficult for us to enter into our initial business combination with a target.
We may enter into
a transaction agreement with a prospective target that requires as a closing condition that we have a minimum net worth or a certain
amount of cash. If too many public stockholders exercise their redemption rights, we may not be able to meet such closing condition,
and as a result, would not be able to proceed with the business combination. Furthermore, in no event will we redeem our public
shares in an amount that would cause our net tangible assets to be less than $5,000,001. Consequently, if accepting all properly
submitted redemption requests would cause our net tangible assets to be less than $5,000,001 or such greater amount necessary to
satisfy a closing condition as described above, we would not proceed with such redemption and the related business combination
and may instead search for an alternate business combination. Prospective targets would be aware of these risks and, thus, may
be reluctant to enter into our initial business combination transaction with us.
18
The ability of a large number of our
stockholders to exercise redemption rights may not allow us to consummate the most desirable business combination or optimize our
capital structure.
In connection with
the successful consummation of our business combination, we may redeem up to that number of shares of common stock that would permit
us to maintain net tangible assets of $5,000,001. If our business combination requires us to use substantially all of our cash
to pay the purchase price, the redemption threshold may be further limited. Alternatively, we may need to arrange third party financing
to help fund our business combination in case a larger percentage of stockholders exercise their redemption rights than we expect.
If the acquisition involves the issuance of our shares as consideration, we may be required to issue a higher percentage of our
shares to the target or its stockholders to make up for the failure to satisfy a minimum cash requirement. Raising additional funds
to cover any shortfall may involve dilutive equity financing or incurring indebtedness at higher than desirable levels. This may
limit our ability to effectuate the most attractive business combination available to us.
The requirement that we maintain a minimum
net worth or retain a certain amount of cash could increase the probability that we cannot consummate our business combination
and that you would have to wait for liquidation in order to redeem your shares.
If, pursuant to the
terms of our proposed business combination, we are required to maintain a minimum net worth or retain a certain amount of cash
in trust in order to consummate the business combination and regardless of whether we proceed with redemptions under the tender
offer or proxy rules, the probability that we cannot consummate our business combination is increased. If we do not consummate
our business combination, you would not receive your pro rata portion of the trust account until we liquidate. If you are in need
of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at
a discount to the pro rata amount in our trust account. In either situation, you may suffer a material loss on your investment
or lose the benefit of funds expected in connection with our redemption until we liquidate or you are able to sell your shares
in the open market.
The requirement that we complete our
initial business combination within 24 months from the closing of this offering may give potential target businesses leverage over
us in negotiating our initial business combination.
Any potential target
business with which we enter into negotiations concerning our initial business combination will be aware that we must consummate
our initial business combination within 24 months from the closing of this offering. Consequently, such target businesses may obtain
leverage over us in negotiating our initial business combination, knowing that if we do not complete our initial business combination
with that particular target business, we may be unable to complete our initial business combination with any target business. This
risk will increase as we get closer to the timeframe described above. In addition, we may have limited time to conduct due diligence
and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive investigation.
We may not be able to consummate our
initial business combination within the required time period, in which case we would cease all operations except for the purpose
of winding up and we would redeem our public shares and liquidate.
Our sponsor, officers
and directors have agreed that we must complete our initial business combination within 24 months from the closing of this offering.
We may not be able to find a suitable target business and consummate our initial business combination within such time period.
If we are unable to consummate our initial business combination within the required time period, we will, as promptly as reasonably
possible but not more than five business days thereafter (subject to our certificate of incorporation and Delaware law), distribute
the aggregate amount then on deposit in the trust account (net of taxes payable), pro rata to our public stockholders by way of
redemption and cease all operations except for the purposes of winding up of our affairs, as further described herein. This redemption
of public stockholders from the trust account shall be effected as required by function of our certificate of incorporation and
prior to any voluntary winding up.
19
If we seek stockholder approval of our
business combination, our sponsor, directors, officers, advisors and their affiliates may elect to purchase shares from stockholders,
in which case they may influence a vote in favor of a proposed business combination that you do not support.
If we seek stockholder
approval of our business combination and we do not conduct redemptions in connection with our business combination pursuant to
the tender offer rules, our sponsor, directors, officers, advisors or their affiliates may purchase shares in privately negotiated
transactions either prior to or following the consummation of our initial business combination. Such purchases will not be made
if our sponsor, directors, officers, advisors or their affiliates are in possession of any material non-public information that
has not been disclosed to the selling stockholder. Such a purchase would include a contractual acknowledgement that such stockholder,
although still the record holder of our shares is no longer the beneficial owner thereof and therefore agrees not to exercise its
redemption rights. In the event that our sponsor, directors, officers, advisors or their affiliates purchase shares in privately
negotiated transactions from public stockholders who have already elected to exercise their redemption rights, such selling stockholders
would be required to revoke their prior elections to redeem their shares. It is intended that, if Rule 10b-18 would apply
to purchases by our sponsor, directors, officers, advisors or their affiliates, then such purchases will comply with Rule 10b-18
under the Exchange Act, to the extent it applies, which provides a safe harbor for purchases made under certain conditions, including
with respect to timing, pricing and volume of purchases.
The purpose of such
purchases would be to (1) increase the likelihood of obtaining stockholder approval of the business combination or (2) satisfy
a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash at the
closing of the business combination, where it appears that such requirement would otherwise not be met. This may result in the
consummation of an initial business combination that may not otherwise have been possible.
Purchases of shares of common stock
in the open market or in privately negotiated transactions by our sponsor, directors, officers, advisors or their affiliates may
make it difficult for us to maintain the listing of our shares on a national securities exchange following the consummation of
an initial business combination.
If our sponsor, directors,
officers, advisors or their affiliates purchase shares of common stock in the open market or in privately negotiated transactions,
the public "float" of our shares of common stock and the number of beneficial holders of our securities would both
be reduced, possibly making it difficult to maintain the listing or trading of our securities on a national securities exchange
following consummation of the business combination.
You will not have any rights or interests
in funds from the trust account, except under certain limited circumstances. To liquidate your investment, therefore, you may be
forced to sell your public shares, potentially at a loss.
Our public stockholders
shall be entitled to receive funds from the trust account only in the event of a redemption to public stockholders prior to any
winding up in the event we do not consummate our initial business combination or our liquidation, if they redeem their shares in
connection with an initial business combination that we consummate or if we seek to amend our certificate of incorporation to affect
the substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months of the closing of this offering. In no other circumstances will a stockholder have any right or interest of any
kind to the funds in the trust account. Accordingly, to liquidate your investment, you may be forced to sell your public shares,
potentially at a loss.
You will not be entitled to protections
normally afforded to investors of many other blank check companies.
Because the net
proceeds of this offering are intended to be used to complete our initial business combination with a target business that
has not been identified, we may be deemed to be a "blank check" company under the United States securities laws.
However, because we will have net tangible assets in excess of $5,000,000 upon the successful consummation of this offering
and will expect to file a Current Report on Form 8-K, including an audited balance sheet demonstrating this fact, we are
exempt from rules promulgated by the SEC to protect investors in blank check companies, such as Rule 419.
Accordingly, investors will not be afforded the benefits or protections of those rules. Among other things, this means our
shares will be immediately tradable and we will have a longer period of time to complete our initial business combination
than do companies subject to Rule 419. Moreover, offerings subject to Rule 419 would prohibit the release of any
interest earned on funds held in the trust account to us. For a more detailed comparison of our offering to offerings that
comply with Rule 419, please see "Proposed Business — Comparison of This Offering to Those of Blank Check
Companies Subject to Rule 419."
20
If we seek stockholder approval of our
business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a "group"
of stockholders are deemed to hold in excess of 20% of our shares of common stock, you will lose the ability to redeem all such
shares in excess of 20% of our shares of common stock.
If we seek stockholder
approval of our initial business combination and we do not conduct redemptions in connection with our business combination pursuant
to the tender offer rules, our certificate of incorporation provides that a public stockholder, individually or together with any
affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a "group" (as
defined under Section 13 of the Exchange Act), will be restricted from seeking redemption rights with respect to more than
an aggregate of 20% of the shares sold in this offering. Your inability to redeem more than an aggregate of 20% of the shares sold
in this offering will reduce your influence over our ability to consummate our initial business combination and you could suffer
a material loss on your investment in us if you sell such excess shares in open market transactions. As a result, you will continue
to hold that number of shares exceeding 20% and, in order to dispose of such shares, you would be required to sell your shares
in open market transaction, potentially at a loss.
If the net proceeds of this offering
not being held in the trust account are insufficient to allow us to operate for at least the next 24 months, we may be unable to
complete our initial business combination.
The funds available
to us outside of the trust account may not be sufficient to allow us to operate for at least the next 24 months, assuming that
our initial business combination is not consummated during that time. Of the funds available to us, we could use a portion of the
funds available to us to pay fees to consultants to assist us with our search for a target business. We could also use a portion
of the funds as a down payment or to fund a "no-shop" provision (a provision in letters of intent designed to keep
target businesses from "shopping" around for transactions with other companies on terms more favorable to such target
businesses) with respect to a particular proposed business combination, although we do not have any current intention to do so.
If we are unable to fund such down payments or "no shop" provisions, our ability to close a contemplated transaction
could be impaired. Furthermore, if we entered into a letter of intent where we paid for the right to receive exclusivity from a
target business and were subsequently required to forfeit such funds (whether as a result of our breach or otherwise), we might
not have sufficient funds to continue searching for, or conduct due diligence with respect to, a target business. If we are unable
to complete our initial business combination, our public stockholders may only receive a pro rata portion of the amount then in
the trust account (which may be less than $10.00 per share) (whether or not the underwriters' over-allotment option is exercised
in full) on our redemption.
Subsequent to our consummation of our
initial business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges.
Even if we conduct
thorough due diligence on a target business with which we combine, this diligence may not surface all material issues that may
be present inside a particular target business, that it would be possible to uncover all material issues through a customary amount
of due diligence, or that factors outside of the target business and outside of our control will not later arise. As a result of
these factors, we may be forced to later write-down or write-off assets, restructure our operations, or incur impairment or other
charges that could result in our reporting losses. Even if our due diligence successfully identifies certain risks, unexpected
risks may arise and previously known risks may materialize in a manner not consistent with our preliminary risk analysis. Even
though these charges may be non-cash items and not have an immediate impact on our liquidity, the fact that we report charges of
this nature could contribute to negative market perceptions about us or our securities. In addition, charges of this nature may
cause us to violate net worth or other covenants to which we may be subject as a result of assuming pre-existing debt held by a
target business or by virtue of our obtaining post-combination debt financing.
Our directors may decide not to enforce
indemnification obligations against LifeSci Holdings LLC, our sponsor, resulting in a reduction in the amount of funds in the trust
account available for distribution to our public stockholders.
In the event that
the proceeds in the trust account are reduced below $10.00 per share (whether or not the underwriters' overallotment option
is exercised in full) and LifeSci Holdings LLC, our sponsor, asserts that it is unable to satisfy its obligations or that it has
no indemnification obligations related to a particular claim, our independent directors would determine on our behalf whether to
take legal action against our sponsor to enforce its indemnification obligations. While we currently expect that our independent
directors would take legal action on our behalf against our sponsor to enforce its indemnification obligations to us, it is possible
that our independent directors in exercising their business judgment may choose not to do so in any particular instance. If our
independent directors choose not to enforce these indemnification obligations on our behalf, the amount of funds in the trust account
available for distribution to our public stockholders may be reduced below $10.00 per share.
21
If we are deemed to be an investment
company under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities
may be restricted, which may make it difficult for us to complete our initial business combination.
If we are deemed to
be an investment company under the Investment Company Act, our activities may be restricted, including restrictions on the nature
of our investments and restrictions on the issuance of securities, each of which may make it difficult for us to complete our initial
business combination. In addition, we may have imposed upon us burdensome requirements, including registration as an investment
company, adoption of a specific form of corporate structure and reporting, record keeping, voting, proxy and disclosure requirements
and other rules and regulations.
If we were deemed
to be subject to the Investment Company Act, compliance with these additional regulatory burdens would require additional expenses
for which we have not allotted funds and may hinder our ability to consummate our initial business combination.
Changes in laws or regulations, or a
failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations.
We are subject to
laws and regulations enacted by national, regional and local governments, in particular, the Securities Exchange and Commission,
or the "SEC". Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming
and costly. Those laws and regulations and their interpretation and application also may change from time to time and those changes
could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with
applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of
operations.
If we are unable to consummate our initial
business combination, our public stockholders may be forced to wait up to 24 months or longer before redemption from our trust
account.
If we are unable to
consummate our initial business combination within 24 months from the closing of this offering, we will, as promptly as reasonably
possible but not more than five business days thereafter (subject to our certificate of incorporation and applicable law), distribute
the aggregate amount then on deposit in the trust account (net of taxes payable), pro rata to our public stockholders by way of
redemption and cease all operations except for the purposes of winding up of our affairs by way of a voluntary liquidation, as
further described herein. Any redemption of public stockholders from the trust account shall be effected as required by our certificate
of incorporation prior to our commencing any voluntary liquidation. Except as otherwise described herein, we have no obligation
to return funds to investors prior to the date of any redemption required as a result of our failure to consummate our initial
business combination within the period described above or our liquidation, unless we consummate our initial business combination
prior thereto and only then in cases where investors have sought to redeem their shares of common stock. Only upon any such redemption
of public shares as we are required to effect or any liquidation will public stockholders be entitled to distributions if we are
unable to complete our initial business combination.
The grant of registration rights to
our initial stockholders may make it more difficult to complete our initial business combination, and the future exercise of such
rights may adversely affect the market price of our shares of common stock.
Pursuant to an agreement
to be entered into on the date of this prospectus, our initial stockholders, our sponsor (and/or our sponsor's designees)
and their permitted transferees can demand that we register the founder shares and the private warrants. We will bear the cost of
registering these securities. The registration and availability of such a significant number of securities for trading in the public
market may have an adverse effect on the market price of our shares of common stock. In addition, the existence of the registration
rights may make our initial business combination more costly or difficult to conclude. This is because the stockholder of the target
business may increase the equity stake they seek in the combined entity or ask for more cash consideration to offset the negative
impact on the market price of our shares of common stock that is expected when the securities owned by our sponsor, holders of
our private warrants or their respective permitted transferees are registered. The Sponsor may not (i) have more than one demand
registration right at our expense, (ii) exercise its demand registration rights more than five (5) years from the effective
date of the registration statement of which this prospectus forms a part, and (iii) exercise its "piggy-back"
registration rights more than seven (7) years from the effective date of the registration statement of which this prospectus
forms a part, as long as our sponsor or any of its related persons are beneficial owners of private placement warrants.
22
Because we have not selected a particular
business or specific geographic location or any specific target businesses with which to pursue our initial business combination,
you will be unable to ascertain the merits or risks of any particular target business' operations.
Although we have a
stated focus on certain target businesses in a specific geographic location as indicated elsewhere in this prospectus, we may pursue
acquisition opportunities in any geographic region, but may rely upon our management team's background. While we may pursue
an acquisition opportunity in any business industry or sector, we intend to initially focus on those industries or sectors that
complement our management team's background. Except for the limitations that a target business have a fair market value of
at least 80% of the value of the trust account (excluding any taxes payable) and that we are not permitted to effectuate our initial
business combination with another blank check company or similar company with nominal operations, we will have virtually unrestricted
flexibility in identifying and selecting a prospective acquisition candidate. Because we have not yet identified or approached
any specific target business with respect to our initial business combination, there is no basis to evaluate the possible merits
or risks of any particular target business's operations, results of operations, cash flows, liquidity, financial condition
or prospects. To the extent we consummate our initial business combination, we may be affected by numerous risks inherent in the
business operations with which we combine. For example, if we combine with a financially unstable business or an entity lacking
an established record of sales or earnings, we may be affected by the risks inherent in the business and operations of a financially
unstable or a development stage entity. Although our officers and directors will endeavor to evaluate the risks inherent in a particular
target business, we may not properly ascertain or assess all of the significant risk factors or that we will have adequate time
to complete due diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control
or reduce the chances that those risks will adversely impact a target business. In addition, investors will be relying on the business
judgment of our board of directors, which will have significant discretion in choosing the standard used to establish the fair
market value of a particular target business. An investment in our shares may not ultimately prove to be more favorable to investors
than a direct investment, if such opportunity were available, in an acquisition target.
We may seek investment opportunities
outside our management's area of expertise and our management may not be able to adequately ascertain or assess all significant
risks associated with the target company.
There is no limitation
on the industry or business sector we may consider when contemplating our initial business combination. We may therefore be presented
with a business combination candidate in an industry unfamiliar to our management team, but determine that such candidate offers
an attractive investment opportunity for our company. In the event we elect to pursue an investment outside of our management's
expertise, our management's experience may not be directly applicable to the target business or their evaluation of its operations.
Although we identified general criteria
and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business
combination with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter
into our initial business combination may not have attributes entirely consistent with our general criteria and guidelines.
Although we have identified
specific criteria and guidelines for evaluating prospective target businesses, it is possible that a target business with which
we enter into our initial business combination will not have all of these positive attributes. If we consummate our initial business
combination with a target that does not meet some or all of these guidelines, such combination may not be as successful as a combination
with a business that does meet all of our general criteria and guidelines. In addition, if we announce our initial business combination
with a target that does not meet our general criteria and guidelines, a greater number of stockholders may exercise their redemption
rights, which may make it difficult for us to meet any closing condition with a target business that requires us to have a minimum
net worth or a certain amount of cash. In addition, if stockholder approval of the transaction is required by law or Nasdaq, or
we decide to obtain stockholder approval for business or other legal reasons, it may be more difficult for us to attain stockholder
approval of our initial business combination if the target business does not meet our general criteria and guidelines. If we are
unable to complete our initial business combination, our public stockholders may only receive $10.00 per share or even less (whether
or not the underwriters' over-allotment option is exercised in full) on our redemption.
23
Management's flexibility in identifying
and selecting a prospective acquisition candidate, along with our management's financial interest in consummating our initial
business combination, may lead management to enter into an acquisition agreement that is not in the best interest of our stockholders.
Subject to the requirement
that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value
of at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such
initial business combination, we will have virtually unrestricted flexibility in identifying and selecting a prospective acquisition
candidate. Investors will be relying on management's ability to identify business combinations, evaluate their merits, conduct
or monitor diligence and conduct negotiations. Management's flexibility in identifying and selecting a prospective acquisition
candidate, along with management's financial interest in consummating our initial business combination, may lead management
to enter into an acquisition agreement that is not in the best interest of our stockholders, which would be the case if the trading
price of our shares of common stock after giving effect to such business combination was less than the per-share trust liquidation
value that our stockholders would have received if we had dissolved without consummating our initial business combination.
We are not required to obtain an opinion
from an independent investment banking firm, and consequently, an independent source may not confirm that the price we are paying
for the business is fair to our stockholders from a financial point of view.
Unless we consummate
our initial business combination with an affiliated entity, we are not required to obtain an opinion from an independent investment
banking firm that the price we are paying is fair to our stockholders from a financial point of view. If no opinion is obtained,
our stockholders will be relying on the judgment of our board of directors, who will determine fair market value based on standards
generally accepted by the financial community. Such standards used will be disclosed in our tender offer documents or proxy solicitation
materials, as applicable, related to our initial business combination.
Resources could be wasted in researching
acquisitions that are not consummated.
We anticipate that
the investigation of each specific target business and the negotiation, drafting, and execution of relevant agreements, disclosure
documents, and other instruments will require substantial management time and attention and substantial costs for accountants,
attorneys and others. If we decide not to complete a specific initial business combination, the costs incurred up to that point
for the proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target
business, we may fail to consummate our initial business combination for any number of reasons including those beyond our control.
Any such event will result in a loss to us of the related costs incurred, which could materially adversely affect subsequent attempts
to locate and acquire or merge with another business. If we are unable to complete our initial business combination, our public
stockholders may only receive $10.00 per share or even less (whether or not the underwriters' over-allotment option is exercised
in full) on our redemption.
Our ability to successfully effect our
initial business combination and to be successful thereafter will be largely dependent upon the efforts of our officers, directors
and key personnel, some of whom may join us following our initial business combination.
Our operations are
dependent upon a relatively small group of individuals and, in particular, our officers and directors. We believe that our success
depends on the continued service of our officers and directors, at least until we have consummated our initial business combination.
In addition, our officers and directors are not required to commit any specified amount of time to our affairs and, accordingly,
will have conflicts of interest in allocating management time among various business activities, including identifying potential
business combinations and monitoring the related due diligence. We do not have an employment agreement with, or key-man insurance
on the life of, any of our directors or officers. The unexpected loss of the services of one or more of our directors or officers
could have a detrimental effect on us.
The role of such persons
in the target business, however, cannot presently be ascertained. Although some of such persons may remain with the target business
in senior management or advisory positions following our initial business combination, it is likely that some or all of the management
of the target business will remain in place. While we intend to closely scrutinize any individuals we engage after our initial
business combination, our assessment of these individuals may not prove to be correct. These individuals may be unfamiliar with
the requirements of operating a company regulated by the SEC, which could cause us to have to expend time and resources helping
them become familiar with such requirements.
24
Our key personnel may negotiate employment
or consulting agreements with a target business in connection with a particular business combination. These agreements may provide
for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of
interest in determining whether a particular business combination is the most advantageous.
Our key personnel
may be able to remain with us after the consummation of our initial business combination only if they are able to negotiate employment
or consulting agreements in connection with the business combination. Such negotiations would take place simultaneously with the
negotiation of the business combination and could provide for such individuals to receive compensation in the form of cash payments
and/or our securities for services they would render to us after the consummation of the business combination. The personal and
financial interests of such individuals may influence their motivation in identifying and selecting a target business. However,
we believe the ability of such individuals to remain with us after the consummation of our initial business combination will not
be the determining factor in our decision as to whether or not we will proceed with any potential business combination. There is
no certainty, however, that any of our key personnel will remain with us after the consummation of our initial business combination.
Our key personnel may not remain in senior management or advisory positions with us. The determination as to whether any of our
key personnel will remain with us will be made at the time of our initial business combination. In addition, pursuant to an agreement
to be entered into concurrently with the issuance and sale of the securities in this offering, our sponsor, upon consummation of
an initial business combination, will be entitled to nominate three individuals for election to our board of directors.
We may have a limited ability to assess
the management of a prospective target business and, as a result, may effectuate our initial business combination with a target
business whose management may not have the skills, qualifications or abilities to manage a public company.
When evaluating the
desirability of effecting our initial business combination with a prospective target business, our ability to assess the target
business' management may be limited due to a lack of time, resources or information. Our assessment of the capabilities of
the target's management, therefore, may prove to be incorrect and such management may lack the skills, qualifications or
abilities we suspected. Should the target's management not possess the skills, qualifications or abilities necessary to manage
a public company, the operations and profitability of the post-combination business may be negatively impacted.
The officers and directors of an acquisition
candidate may resign upon consummation of our initial business combination. The loss of an acquisition target's key personnel
could negatively impact the operations and profitability of our post-combination business.
The role of an acquisition
candidate's key personnel upon the consummation of our initial business combination cannot be ascertained at this time. Although
we contemplate that certain members of an acquisition candidate's management team will remain associated with the acquisition
candidate following our initial business combination, it is possible that some members of the management team of an acquisition
candidate will not wish to remain in place.
Certain of our officers and directors
are affiliated with entities engaged in business activities similar to those intended to be conducted by us and, accordingly, may
have conflicts of interest in allocating their time and determining to which entity a particular business opportunity should be
presented.
Following the completion
of this offering and until we consummate our business combination, we intend to engage in the business of identifying and combining
with one or more businesses. Certain of our executive officers and directors are affiliated with entities that are engaged in a
similar business.
Our officers may become
aware of business opportunities which may be appropriate for presentation to us and the other entities to which they owe certain
fiduciary duties. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity
should be presented.
For example, some
of our officers and directors are affiliated with LifeSci Capital, which is the underwriter in this offering. Such officers and
directors owe a pre-existing fiduciary duty to LifeSci Capital, meaning that they will present opportunities to LifeSci Capital
prior to presenting them to us, if, for example, a potential target company is open to either raising funds in an offering or engaging
in a transaction with a SPAC. In addition, three of our officers and directors, Andrew McDonald, Michael Rice and David Dobkin
are officers and directors of LifeSci Acquisition Corp., a special purpose acquisition company that is seeking a target. LifeSci
Acquisition Corp. will have priority over us in connection with potential target businesses identified by each of them. These affiliations
may limit the number of potential targets they present to us for purposes of completing a business combination.
Any conflict of interest
may not be resolved in our favor and potential target businesses may be presented to another entity prior to its presentation to
us.
25
Certain shares beneficially owned by
our officers and directors will not participate in liquidation distributions and, therefore, our officers and directors may have
a conflict of interest in determining whether a particular target business is appropriate for our initial business combination.
Our officers and directors have waived their right to redeem
any shares in connection with our initial business combination, or to receive distributions with respect to their founder shares
upon our liquidation if we are unable to consummate our initial business combination. Accordingly, these securities will be worthless
if we do not consummate our initial business combination. The personal and financial interests of our directors and officers may
influence their motivation in timely identifying and selecting a target business and completing a business combination. Consequently,
our directors' and officers' discretion in identifying and selecting a suitable target business may result in a conflict
of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate and
in our stockholders' best interest.
We may engage in our initial business
combination with one or more target businesses that have relationships with entities that may be affiliated with our executive
officers, directors or existing holders, which may raise potential conflicts of interest.
We have not adopted
a policy that expressly prohibits our directors, officers, security holders or affiliates from having a direct or indirect pecuniary
or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have
an interest. In light of the involvement of our sponsor, officers and directors with other entities, we may decide to acquire one
or more businesses affiliated with our sponsor, officers and directors. Our directors also serve as officers and board members
for other entities. Our sponsor, officers and directors are not currently aware of any specific opportunities for us to consummate
our initial business combination with any entities with which they are affiliated, and there have been no preliminary discussions
concerning a business combination with any entity or entities. Although we will not be specifically focusing on, or targeting,
any transaction with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met
our criteria for our initial business combination as set forth in "Proposed Business — Effecting our initial business
combination — Selection of a target business and structuring of our initial business combination" and such transaction
was approved by a majority of our disinterested directors. Despite our agreement to obtain an opinion from an independent investment
banking firm, or another independent entity that commonly renders valuation opinions on the type of target business we seek to
acquire, regarding the fairness to our stockholders from a financial point of view of a business combination with one or more domestic
or international businesses affiliated with our executive officers, directors or existing holders, potential conflicts of interest
still may exist and, as a result, the terms of the business combination may not be as advantageous to our public stockholders as
they would be absent any conflicts of interest. Our directors have a fiduciary duty to act in the best interests of our stockholders,
whether or not a conflict of interest may exist.
Because our sponsor will lose its entire
initial investment in us if our initial business combination is not consummated and our officers and directors have significant
financial interests in us, a conflict of interest may arise in determining whether a particular acquisition target is appropriate
for our initial business combination.
On January 1,
2020, our sponsor purchased 2,156,250 founder shares for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci
Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder
shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters' over-allotment
option is not exercised in full or in part. The founder shares will be worthless if we do not consummate an initial business combination.
In addition, LifeSci Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants (or 3,283,333
warrants if the over-allotment option is exercised in full), or "private warrants," at $0.90 per warrant for a total
purchase price of $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full), which will also be worthless if
we do not consummate our initial business combination.
26
We may issue notes or other debt securities,
or otherwise incur substantial debt, to complete our initial business combination, which may adversely affect our financial condition
and thus negatively impact the value of our stockholders' investment in us.
Although we have no
commitments as of the date of this prospectus to issue any notes or other debt securities, or to otherwise incur outstanding debt,
we may choose to incur substantial debt to complete our initial business combination. If we incur any indebtedness without a waiver
from the lender of any right, title, interest or claim of any kind in or to any monies held in the trust account, the incurrence
of debt could have a variety of negative effects, including:
•
default and foreclosure on our assets if our operating revenues after our initial business combination are insufficient to repay our debt obligations;
•
acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;
•
our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand;
•
our inability to obtain necessary additional financing if the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding;
•
our inability to pay dividends on our shares of common stock;
•
using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our shares of common stock if declared, expenses, capital expenditures, acquisitions and other general corporate purposes;
•
limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;
•
increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and
•
limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.
We may only be able to complete one
business combination with the proceeds of this offering, which will cause us to be solely dependent on a single business, which
may have a limited number of products or services. This lack of diversification may negatively impact our operations and profitability.
The net proceeds from this offering together with the funds
we will receive from the sale of the private warrants (excluding $750,000 of net proceeds that will not be held in the trust account)
will provide us with approximately $75,000,000 (or approximately $86,250,000 if the underwriters' over-allotment option is
exercised in full) that we may use to complete our initial business combination.
We may effectuate
our initial business combination with a single target business or multiple target businesses simultaneously. However, we may not
be able to effectuate our initial business combination with more than one target business because of various factors, including
the existence of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the
SEC that present operating results and the financial condition of several target businesses as if they had been operated on a combined
basis. By consummating our initial business combination with only a single entity, our lack of diversification may subject us to
numerous economic, competitive and regulatory developments. Further, we would not be able to diversify our operations or benefit
from the possible spreading of risks or offsetting of losses, unlike other entities, which may have the resources to complete several
business combinations in different industries or different areas of a single industry. Accordingly, the prospects for our success
may be solely dependent upon the performance of a single business, property or asset, or dependent upon the development or market
acceptance of a single or limited number of products or services. This lack of diversification may subject us to numerous economic,
competitive and regulatory developments, any or all of which may have a substantial adverse impact upon the particular industry
in which we may operate subsequent to our initial business combination.
27
We may attempt to simultaneously consummate
business combinations with multiple prospective targets, which may hinder our ability to consummate our initial business combination
and give rise to increased costs and risks that could negatively impact our operations and profitability.
If we determine to
simultaneously acquire several businesses that are owned by different sellers, we will need for each of such sellers to agree that
our purchase of its business is contingent on the simultaneous closings of the other business combinations, which may make it more
difficult for us, and delay our ability, to complete the initial business combination. With multiple business combinations, we
could also face additional risks, including additional burdens and costs with respect to possible multiple negotiations and due
diligence investigations (if there are multiple sellers) and the additional risks associated with the subsequent assimilation of
the operations and services or products of the acquired companies in a single operating business. If we are unable to adequately
address these risks, it could negatively impact our profitability and results of operations.
We may attempt to consummate our initial
business combination with a private company about which little information is available.
In pursuing our acquisition
strategy, we may seek to effectuate our initial business combination with a privately held company. By definition, very little
public information exists about private companies, and we could be required to make our decision on whether to pursue a potential
initial business combination on the basis of limited information, which may result in our initial business combination with a company
that is not as profitable as we suspected, if at all.
We may not be able to maintain control
of a target business after our initial business combination.
We may structure our
initial business combination to acquire less than 100% of the equity interests or assets of a target business, but we will only
consummate such business combination if we will become the majority stockholder of the target (or control the target through contractual
arrangements in limited circumstances for regulatory compliance purposes) or are otherwise not required to register as an investment
company under the Investment Company Act or to the extent permitted by law we may acquire interests in a variable interest entity,
in which we may have less than a majority of the voting rights in such entity, but in which we are the primary beneficiary. Even
though we may own a majority interest in the target, our stockholders prior to the business combination may collectively own a
minority interest in the post business combination company, depending on valuations ascribed to the target and us in the business
combination transaction. For example, we could pursue a transaction in which we issue a substantial number of new shares in exchange
for all of the outstanding capital stock of a target. In this case, we acquire a 100% controlling interest in the target. However,
as a result of the issuance of a substantial number of new shares, our stockholders immediately prior to such transaction could
own less than a majority of our outstanding shares subsequent to such transaction. In addition, other minority stockholders may
subsequently combine their holdings resulting in a single person or group obtaining a larger share of the company's stock
than we initially acquired. Accordingly, this may make it more likely that we will not be able to maintain our control of the target
business.
28
The ability of our public stockholders to exercise their
redemption rights may not allow us to effectuate the most desirable business combination or optimize our capital structure.
If our initial business
combination requires us to use substantially all of our cash to pay the purchase price, because we will not know how many public
stockholders may exercise redemption rights, we may either need to reserve part of the trust account for possible payment upon
such redemption, or we may need to arrange third party financing to help fund our initial business combination. In the event that
the acquisition involves the issuance of our stock as consideration, we may be required to issue a higher percentage of our stock
to make up for a shortfall in funds. Raising additional funds to cover any shortfall may involve dilutive equity financing or incurring
indebtedness at higher than desirable levels. This may limit our ability to effectuate the most attractive business combination
available to us.
29
In connection with any meeting held
to approve an initial business combination, we will offer each public stockholder the option to vote in favor of the proposed business
combination and still seek redemption of his, her or its shares.
In connection with
any meeting held to approve an initial business combination, we will offer each public stockholder (but not our initial stockholders,
officers or directors) the right to have his, her or its shares of common stock redeemed for cash (subject to the limitations described
elsewhere in this prospectus) regardless of whether such stockholder votes for or against such proposed business combination; provided
that a stockholder must in fact vote for or against a proposed business combination in order to have his, her or its shares of
common stock redeemed for cash. If a stockholder fails to vote for or against a proposed business combination, that stockholder
would not be able to have his shares of common stock so redeemed. We will consummate our initial business combination only if we
have net tangible assets of at least $5,000,001 upon such consummation and a majority of the outstanding shares of common stock
voted are voted in favor of the business combination. This is different than other similarly structured blank check companies where
stockholders are offered the right to redeem their shares only when they vote against a proposed business combination. This threshold
and the ability to seek redemption while voting in favor of a proposed business combination may make it more likely that we will
consummate our initial business combination.
A public stockholder who fails to vote
either in favor of or against a proposed business combination will not be able to have his shares redeemed for cash.
In order for a public
stockholder to have his shares redeemed for cash in connection with any proposed business combination, that public stockholder
must vote either in favor of or against a proposed business combination. If a public stockholder fails to vote in favor of or against
a proposed business combination, whether that stockholder abstains from the vote or simply does not vote, that stockholder would
not be able to have his shares of common stock so redeemed to cash in connection with such business combination.
We will require public stockholders
who wish to redeem their shares of common stock in connection with a proposed business combination or amendment to our certificate
of incorporation to effect the substance or timing of their redemption obligation if we fail to timely complete a business combination
to comply with specific requirements for redemption that may make it more difficult for them to exercise their redemption rights
prior to the deadline for exercising their rights.
We will require our
public stockholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in "street
name," to either tender their certificates to our transfer agent prior to the expiration date set forth in the tender offer
documents mailed to such holders, or in the event we distribute proxy materials, up to two business days prior to the vote on the
proposal to approve the business combination or amendment to our certificate of incorporation to affect the substance or timing
of our redemption obligation to redeem all public shares if we cannot complete an initial business combination, or to deliver their
shares to the transfer agent electronically using Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) System,
at the holder's option. In order to obtain a physical stock certificate, a stockholder's broker and/or clearing broker,
DTC and our transfer agent will need to act to facilitate this request. It is our understanding that stockholders should generally
allot at least two weeks to obtain physical certificates from the transfer agent. However, because we do not have any control over
this process or over the brokers or DTC, it may take significantly longer than two weeks to obtain a physical stock certificate.
While we have been advised that it takes a short time to deliver shares through the DWAC System, this may not be the case. Under
our certificate of incorporation, we are required to provide at least 10 days advance notice of any stockholder meeting, which
would be the minimum amount of time a stockholder would have to determine whether to exercise redemption rights. Accordingly, if
it takes longer than we anticipate for stockholders to deliver their shares, stockholders who wish to redeem may be unable to meet
the deadline for exercising their redemption rights and thus may be unable to redeem their shares.
30
Redeeming stockholders may be unable
to sell their securities when they wish to in the event that the proposed business combination is not approved.
We will require public
stockholders who wish to redeem their shares of common stock in connection with any proposed business combination to comply with
the delivery requirements discussed above for redemption. If such proposed business combination is not consummated, we will promptly
return such certificates to the tendering public stockholders. Accordingly, investors who attempted to redeem their shares in such
a circumstance will be unable to sell their securities after the failed acquisition until we have returned their securities to
them. The market price for our shares of common stock may decline during this time and you may not be able to sell your securities
when you wish, even while other stockholders that did not seek redemption may be able to sell their securities.
Because of our structure, other companies
may have a competitive advantage and we may not be able to consummate an attractive business combination.
We expect to encounter
intense competition from entities other than blank check companies having a business objective similar to ours, including venture
capital funds, leveraged buyout funds and operating businesses competing for acquisitions. Many of these entities are well established
and have extensive experience in identifying and effecting business combinations directly or through affiliates. Many of these
competitors possess greater technical, human and other resources than we do and our financial resources will be relatively limited
when contrasted with those of many of these competitors. Therefore, our ability to compete in acquiring certain sizable target
businesses may be limited by our available financial resources. This inherent competitive limitation gives others an advantage
in pursuing the acquisition of certain target businesses. Furthermore, seeking stockholder approval of our initial business combination
may delay the consummation of a transaction. Additionally, our rights, and the future dilution they represent (entitling the holders
to receive shares of common stock on consummation of our initial business combination), may not be viewed favorably by certain
target businesses. Any of the foregoing may place us at a competitive disadvantage in successfully negotiating our initial business
combination.
Our Certificate of Incorporation contains
provisions that prohibit our engaging in business combinations with interested stockholders in certain circumstances.
We have opted out
of Section 203 of the Delaware General Corporate Law, or the DGCL. However, our amended and restated certificate of incorporation
contains similar provisions providing that we may not engage in certain "business combinations" with any "interested
stockholder" for a three-year period following the time that the stockholder became an interested stockholder, unless
•
prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
•
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or
•
at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66⅔% of the outstanding voting stock that is not owned by the interested stockholder.
Generally, a "business
combination" includes a merger, asset or stock sale or certain other transactions with the interested stockholder. Subject
to certain exceptions, an "interested stockholder" is a person who, together with that person's affiliates and
associates, owns, or within the previous three years owned, 20% or more of our voting stock
Under certain circumstances,
this provision will make it more difficult for a person who would be an "interested stockholder" to effect various
business combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring
our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if
our board of directors approves either the business combination or the transaction which results in the stockholder becoming an
interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make
it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.
31
Our amended and restated
certificate of incorporation provides that our sponsor and its respective affiliates, any of their respective direct or indirect
transferees of at least 20% of our outstanding common stock and any group as to which such persons are party to, do not constitute
 "interested stockholders" for purposes of this provision.
We may be unable to obtain additional
financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel
us to restructure or abandon a particular business combination. If we are unable to complete our initial business combination,
our public stockholders may only receive $10.00 per share or even less (whether or not the underwriters' over-allotment option
is exercised in full) on our redemption.
Although we believe
that the net proceeds of this offering will be sufficient to allow us to consummate our initial business combination, because
we have not yet identified any prospective target business we cannot ascertain the capital requirements for any particular transaction
or our costs to operate or locate a transaction. If the net proceeds of this offering prove to be insufficient, either because
of the size of our initial business combination, the depletion of the available net proceeds in search of a target business, the
obligation to repurchase for cash a significant number of shares from stockholders who elect redemption in connection with our
initial business combination or the terms of negotiated transactions to purchase shares in connection with our initial business
combination, we may be required to seek additional financing or to abandon the proposed business combination. Financing may not
be available on acceptable terms, if at all. The current economic environment has made it especially difficult for companies to
obtain acquisition financing. To the extent that additional financing proves to be unavailable when needed to consummate our initial
business combination, we would be compelled to either restructure the transaction or abandon that particular initial business
combination and seek an alternative target business candidate. If we are unable to complete our initial business combination,
our public stockholders may only receive $10.00 per share or even less (whether or not the underwriters' over-allotment
option is exercised in full) on our redemption. In addition, even if we do not need additional financing to consummate our initial
business combination, we may require such financing to fund the operations or growth of the target business. The failure to secure
additional financing could have a material adverse effect on the continued development or growth of the target business. None
of our officers, directors or stockholders is required to provide any financing to us in connection with or after our initial
business combination.
Our sponsor controls a substantial interest
in us and thus may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not
support.
W
e have agreed not to
enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor. Further,
upon closing of this offering, our initial stockholders and our sponsor (and/its designees) collectively will own 20% of
our issued and outstanding shares of common stock (assuming they do not purchase any shares in this offering). Accordingly, they
may exert a substantial influence on actions requiring a stockholder vote, potentially in a manner that you do not support, including
amendments to our certificate of incorporation. If our sponsor purchases any shares in this offering or if we or our sponsor purchase
any additional shares of common stock in the aftermarket or in privately negotiated transactions, this would increase their control.
Neither our sponsor nor, to our knowledge, any of our officers or directors, has any current intention to purchase additional securities.
Factors that would be considered in making such additional purchases would include consideration of the current trading price of
our shares of common stock.
Our initial stockholders paid an aggregate
of $25,000, or approximately $0.012 per founder share and, accordingly, you will experience immediate and substantial dilution
from the purchase of our shares of common stock.
The difference
between the public offering price per share and the pro forma net tangible book value per share after this offering
constitutes the dilution to you and the other investors in this offering. Our initial stockholders acquired the founder
shares at a nominal price, significantly contributing to this dilution. Upon closing of this offering, you and the other
public stockholders will incur an immediate and substantial dilution of approximately 78.2% or $7.82 per share (the
difference between the pro forma net tangible book value per share of $2.18 and the initial offering price of $10.00 per
share immediately upon the closing of this offering), or approximately 80.6% dilution or $8.06 per share (the difference
between the pro forma net tangible book value per share of $1.94 and the initial offering price of $10.00 per share) if the
over-allotment is fully exercised.
32
The determination of the offering price
of our shares and the size of this offering is more arbitrary than the pricing of securities and size of an offering of an operating
company in a particular industry.
Prior to this offering
there has been no public market for any of our securities. The public offering price of the shares was negotiated between us and
the underwriters. In determining the size of this offering, management held customary organizational meetings with representatives
of the underwriters, both prior to our inception and thereafter, with respect to the state of capital markets, generally, and
the amount the underwriters believed they reasonably could raise on our behalf. Factors considered in determining the size of
this offering, prices and terms of the shares of common stock:
•
the history and prospects of companies whose principal business is the acquisition of other companies;
•
prior offerings of those companies;
•
our prospects for acquiring an operating business at attractive values;
•
a review of debt to equity ratios in leveraged transactions;
•
our capital structure;
•
an assessment of our management and their experience in identifying operating companies;
•
general conditions of the securities markets at the time of this offering; and
•
other factors as were deemed relevant.
Although these factors
were considered, the determination of our offering price is more arbitrary than the pricing of securities of an operating company
in a particular industry since we have no historical operations or financial results.
There is currently no market for our
securities and a market for our securities may not develop, which would adversely affect the liquidity and price of our securities.
As of the date of
this prospectus there is currently no market for our securities. Prospective stockholders therefore have no access to information
about prior market history on which to base their investment decision. Following this offering, the price of our securities may
vary significantly due to one or more potential business combinations and general market or economic conditions. Once listed on
Nasdaq, an active trading market for our securities may never develop or, if developed, it may not be sustained. Additionally,
if our securities become delisted from Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated
quotation system for equity securities not listed on a national exchange, the liquidity and price of our securities may be more
limited than if we were listed on Nasdaq or another national exchange. You may be unable to sell your securities unless a market
can be established and sustained.
Once initially listed on Nasdaq, our
securities may not continue to be listed on Nasdaq in the future, which could limit investors' ability to make transactions
in our securities and subject us to additional trading restrictions.
We anticipate that
our securities will be initially listed on Nasdaq upon consummation of this offering. However, we cannot assure you of this or
that our securities will continue to be listed on Nasdaq in the future. Additionally, in connection with our business combination,
Nasdaq may require us to file a new initial listing application and meet its initial listing requirements as opposed to its more
lenient continued listing requirements. We cannot assure you that we will be able to meet those initial listing requirements at
that time. If Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences,
including:
•
a limited availability of market quotations for our securities;
•
a reduced liquidity with respect to our securities;
•
a determination that our shares of common stock are a "penny stock" which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;
•
a limited amount of news and analyst coverage for our company; and
•
a decreased ability to issue additional securities or obtain additional financing in the future.
33
Because we must furnish our stockholders
with target business financial statements prepared in accordance with U.S. generally accepted accounting principles or international
financial reporting standards, we may lose the ability to complete an otherwise advantageous initial business combination with
some prospective target businesses.
The federal proxy
rules, which require that a proxy statement with respect to a vote on a business combination meeting certain financial significance
tests include historical and/or pro forma financial statement disclosure in periodic reports. These financial statements may be
required to be prepared in accordance with, or be reconciled to, accounting principles generally accepted in the United States
of America, or GAAP, or international financial reporting standards, or IFRS as issued by the International Accounting Standards
Board or the IASB, depending on the circumstances and the historical financial statements may be required to be audited in accordance
with the standards of the Public Company Accounting Oversight Board (United States), or PCAOB. We will include the substantially
the same financial statement disclosure in connection with any tender offer documents we use, whether or not they are required
under the tender offer rules. These financial statement requirements may limit the pool of potential target businesses we may consummate
our initial business combination with because some targets may be unable to provide such statements in time for us to disclose
such statements in accordance with federal proxy rules and complete our initial business combination within the prescribed
time frame.
Compliance obligations under the Sarbanes-Oxley
Act of 2002 may make it more difficult for us to effectuate our initial business combination, require substantial financial and
management resources, and increase the time and costs of completing an acquisition.
Section 404 of
the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we evaluate and report on our system of internal controls
beginning with our Annual Report on Form 10-K for the year ending June 30, 2022. The fact that we are a blank check company
makes compliance with the requirements of the Sarbanes-Oxley Act particularly burdensome on us as compared to all public companies
because a target company with which we seek to complete our initial business combination may not be in compliance with the provisions
of the Sarbanes-Oxley Act regarding adequacy of its internal controls. The development of the internal controls of any such entity
to achieve compliance with the Sarbanes-Oxley Act may increase the time and costs necessary to complete any such acquisition.
We are an "emerging growth company"
and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our securities
less attractive to investors.
We are an "emerging
growth company," as defined in the JOBS Act. We will remain an "emerging growth company" for up to five years.
However, if our non-convertible debt issued within a three-year period or revenues exceeds $1.07 billion, or the market value of
our shares of common stock that are held by non-affiliates exceeds $700 million on the last day of the second fiscal quarter of
any given fiscal year, we would cease to be an emerging growth company as of the following fiscal year. As an emerging growth company,
we are not being required to comply with the auditor attestation requirements of section 404 of the Sarbanes-Oxley Act, we have
reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and we are exempt
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. Additionally, as an emerging growth company, we have elected to delay the adoption of new or
revised accounting standards that have different effective dates for public and private companies until those standards apply to
private companies. As such, our financial statements may not be comparable to companies that comply with public company effective
dates. We cannot predict if investors will find our shares less attractive because we may rely on these provisions. If some investors
find our shares less attractive as a result, there may be a less active trading market for our shares and our share price may be
more volatile.
Further, Section 102(b)(1) of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out
of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private
companies are required to adopt the new or revised standard. This may make comparison of our financial statements with another
public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended
transition period difficult or impossible because of the potential differences in accountant standards used.
34
Our amended and restated certificate
of incorporation will designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types
of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders' ability to obtain
a favorable judicial forum for disputes with our company or our company's directors, officers or other employees.
Our amended and restated
certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1) derivative
action or proceeding brought on behalf of our company, (2) action asserting a claim of breach of a fiduciary duty owed by
any director, officer, employee or agent of our company to our company or our stockholders, or any claim for aiding and abetting
any such alleged breach, (3) action asserting a claim against our company or any director or officer of our company arising
pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws, or (4) action
asserting a claim against us or any director or officer of our company governed by the internal affairs doctrine except for, as
to each of (1) through (4) above, any claim (a) as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten days following such determination), (b) which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery, or (c) arising under the federal securities laws, including the Securities
Act, as to which the Court of Chancery and the federal district court for the District of Delaware shall concurrently be the sole
and exclusive forums. Notwithstanding the foregoing, the inclusion of such provision in our amended and restated certificate of
incorporation will not be deemed to be a waiver by our stockholders of our obligation to comply with federal securities laws, rules and
regulations, and the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive
forum. Any person or entity purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to
have notice of and to have consented to the forum provisions in our amended and restated certificate of incorporation. If any action
the subject matter of which is within the scope the forum provisions is filed in a court other than a court located within the
State of Delaware (a "foreign action") in the name of any stockholder, such stockholder shall be deemed to have consented
to: (x) the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with
any action brought in any such court to enforce the forum provisions (an "enforcement action"), and (y) having
service of process made upon such stockholder in any such enforcement action by service upon such stockholder's counsel in
the foreign action as agent for such stockholder.
This choice-of-forum
provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with
our company or its directors, officers or other employees, which may discourage such lawsuits. Alternatively, if a court were to
find this provision of our amended and restated certificate of incorporation inapplicable or unenforceable with respect to one
or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters
in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations
and result in a diversion of the time and resources of our management and board of directors.
35
Risks Associated with Acquiring and
Operating a Business outside of the United States
We may effect our initial business combination
with a company located outside of the United States.
If we effect our initial
business combination with a company located outside of the United States, we would be subject to any special considerations or
risks associated with companies operating in the target business' home jurisdiction, including any of the following:
•
rules and regulations or currency redemption or corporate withholding taxes on individuals;
•
laws governing the manner in which future business combinations may be effected;
•
exchange listing and/or delisting requirements;
•
tariffs and trade barriers;
•
regulations related to customs and import/export matters;
•
longer payment cycles;
•
tax issues, such as tax law changes and variations in tax laws as compared to the United States;
•
currency fluctuations and exchange controls;
•
rates of inflation;
•
challenges in collecting accounts receivable;
•
cultural and language differences;
•
employment regulations;
•
crime, strikes, riots, civil disturbances, terrorist attacks and wars; and
•
deterioration of political relations with the United States. We may not be able to adequately address these additional risks. If we were unable to do so, our operations might suffer.
There are costs and difficulties inherent
in managing cross-border business operations.
Managing a business,
operations, personnel or assets in another country is challenging and costly. Any management that we may have (whether based abroad
or in the United States) may be inexperienced in cross-border business practices and unaware of significant differences in accounting
rules, legal regimes and labor practices. Even with a seasoned and experienced management team, the costs and difficulties inherent
in managing cross-border business operations, personnel and assets can be significant (and much higher than in a purely domestic
business) and may negatively impact our financial and operational performance.
Social unrest, acts of terrorism, regime
changes, changes in laws and regulations, political upheaval, or policy changes or enactments may occur in a country in which we
may operate after we effect our initial business combination.
Political events in
another country may significantly affect our business, assets or operations. Social unrest, acts of terrorism, regime changes,
changes in laws and regulations, political upheaval, and policy changes or enactments could negatively impact our business in a
particular country.
Many countries have difficult and unpredictable
legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience.
Our ability to seek
and enforce legal protections, including with respect to intellectual property and other property rights, or to defend ourselves
with regard to legal actions taken against us in a given country, may be difficult or impossible, which could adversely impact
our operations, assets or financial condition.
36
Rules and regulations
in many countries are often ambiguous or open to differing interpretation by responsible individuals and agencies at the municipal,
state, regional and federal levels. The attitudes and actions of such individuals and agencies are often difficult to predict and
inconsistent.
Delay with respect
to the enforcement of particular rules and regulations, including those relating to customs, tax, environmental and labor,
could cause serious disruption to operations abroad and negatively impact our results.
If relations between the United States
and foreign governments deteriorate, it could cause potential target businesses or their goods and services to become less attractive.
The relationship between
the United States and foreign governments could be subject to sudden fluctuation and periodic tension. For instance, the United
States may announce its intention to impose quotas on certain imports. Such import quotas may adversely affect political relations
between the two countries and result in retaliatory countermeasures by the foreign government in industries that may affect our
ultimate target business. Changes in political conditions in foreign countries and changes in the state of U.S. relations with
such countries are difficult to predict and could adversely affect our operations or cause potential target businesses or their
goods and services to become less attractive. Because we are not limited to any specific industry, there is no basis for investors
in this offering to evaluate the possible extent of any impact on our ultimate operations if relations are strained between the
United States and a foreign country in which we acquire a target business or move our principal manufacturing or service operations.
If our management following our initial
business combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar
with such laws.
Following our initial
business combination, our management may resign from their positions as officers or directors of the company and the management
of the target business at the time of the business combination will remain in place. Management of the target business may not
be familiar with United States securities laws. If new management is unfamiliar with our laws, they may have to expend time and
resources becoming familiar with such laws. This could be expensive and time-consuming and could lead to various regulatory issues,
which may adversely affect our operations.
Currency policies may cause a target
business' ability to succeed in the international markets to be diminished.
In the event we acquire
a non-U.S. target, all revenues and income would likely be received in a foreign currency, the dollar equivalent of our net assets
and distributions, if any, could be adversely affected by reductions in the value of the local currency. The value of the currencies
in our target regions fluctuate and are affected by, among other things, changes in political and economic conditions. Any change
in the relative value of such currency against our reporting currency may affect the attractiveness of any target business or,
following consummation of our initial business combination, our financial condition and results of operations. Additionally, if
a currency appreciates in value against the dollar prior to the consummation of our initial business combination, the cost of a
target business as measured in dollars will increase, which may make it less likely that we are able to consummate such transaction.
Because foreign law could govern our
material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere.
Foreign law could
govern our material agreements. The target business may not be able to enforce any of its material agreements or that remedies
will be available outside of such foreign jurisdiction's legal system. The system of laws and the enforcement of existing
laws and contracts in such jurisdiction may not be as certain in implementation and interpretation as in the United States. The
judiciaries in certain foreign countries may be relatively inexperienced in enforcing corporate and commercial law, leading to
a higher than usual degree of uncertainty as to the outcome of any litigation, any such jurisdictions may not favor outsiders or
could be corrupt. As a result, the inability to enforce or obtain a remedy under any of our future agreements could result in a
significant loss of business and business opportunities.
37
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
Certain statements
contained in this prospectus, which reflect our current views with respect to future events and financial performance, and any
other statements of a future or forward-looking nature, constitute "forward-looking statements" for the purpose of
the federal securities laws. Our forward-looking statements include, but are not limited to, statements regarding our or our management's
expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking
statements. The words "anticipate," "believe," "continue," "could," "estimate,"
 "expect," "intends," "may," "might," "plan," "possible,"
 "potential," "predict," "project," "should," "will," "would"
and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement
is not forward-looking. Forward-looking statements in this prospectus may include, for example, statements about:
•
our ability to complete our initial business combination;
•
our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
•
our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;
•
our potential ability to obtain additional financing to complete our initial business combination;
•
our pool of prospective target businesses;
•
the ability of our officers and directors to generate a number of potential investment opportunities;
•
the delisting of our securities from Nasdaq or an inability to have our securities listed on Nasdaq following a business combination;
•
our public securities' potential liquidity and trading;
•
the lack of a market for our securities; or
•
our financial performance following this offering.
The forward-looking
statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their
potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements
involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results
or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" beginning on
page 18. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect,
actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation
to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except
as may be required under applicable securities laws.
38
USE OF PROCEEDS
We are offering
7,500,000 shares of common stock at a price of $10.00 per share. We estimate that the net proceeds of this offering, together
with the funds we receive from the sale of the private warrants (all of which will be deposited into the trust account), will
be used as set forth in the following table:
Without
Over-
Allotment
Option
Over-
Allotment
Option
Exercised
Gross proceeds
From offering
$
75,000,000
$
86,250,000
From sale of private warrants
2,730,000
2,955,000
Total gross proceeds
$
77,730,000
$
89,205,000
Offering expenses
(1)
Underwriting discount
$
1,500,000
$
1,725,000
Initial Trustees' fee
6,500
6,500
Legal fees and expenses
225,000
225,000
Nasdaq listing fee
50,000
50,000
Printing and engraving expenses
20,000
20,000
Accounting fees and expenses
40,000
40,000
FINRA filing fee
13,438
13,438
SEC registration fee
9,410
9,410
Miscellaneous expenses
115,652
115,652
Total offering expenses
$
1,980,000
$
2,205,000
Net proceeds
Held in trust
$
75,000,000
(2)
$
86,250,000
(2)
Not held in trust
750,000
750,000
Total net proceeds
$
75,750,000
$
87,000,000
Use of net proceeds not held in the trust account
(3) (4)
Legal, accounting and other third party expenses attendant to the search for target businesses and to the due diligence investigation, structuring and negotiation of a business combination
$
100,000
13.3
%
Due diligence of prospective target businesses by officers, directors and initial stockholders
65,000
8.7
%
Legal and accounting fees relating to SEC reporting obligations
60,000
8.0
%
Payment of administrative fee to an affiliate of LifeSci Holdings LLC ($10,000 per month for up to 24 months), subject to deferral as described herein
240,000
32.0
%
Working capital to cover miscellaneous expenses, D&O insurance, general corporate purposes, liquidation obligations and reserves
285,000
38.0
%
Total
$
750,000
100.0
%
(1)
A portion of the offering expenses, including the SEC registration fee, the FINRA filing fee, the non-refundable portion of the Nasdaq listing fee and a portion of the legal and audit fees, have been paid from the funds we borrowed from our sponsor. These funds will be repaid out of the proceeds of this offering available to us.
(2)
The funds held in the trust account will be used to acquire a target business, to pay holders who wish to convert or sell their shares for a portion of the funds held in the trust account and potentially to pay our expenses relating thereto. Our expenses relating to the acquisition of a target business would either come from the funds held in the trust account or additional funds otherwise available to us outside of the trust account, including cash held by the target business. Any remaining funds will be disbursed to the combined company and be used as working capital to finance the operations of the target business.
39
(3)
The amount of proceeds not held in trust will remain constant at $750,000 even if the over-allotment is exercised.
(4)
These are estimates only. Our actual expenditures for some or all of these items may differ from the estimates set forth herein. For example, we may incur greater legal and accounting expenses than our current estimates in connection with negotiating and structuring our initial business combination based upon the level of complexity of that business combination. We do not anticipate any change in our intended use of proceeds, other than fluctuations among the current categories of allocated expenses, which fluctuations, to the extent they exceed current estimates for any specific category of expenses, would be deducted from our excess working capital.
The payment to an
affiliate of LifeSci Holdings LLC of a monthly fee of $10,000 is for general and administrative services including office space,
utilities and secretarial support. However, pursuant to the terms of such agreement, we may delay payment of such monthly fee upon
a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses
in connection with our initial business combination. Any such unpaid amount will accrue without interest and be due and payable
no later than the date of the consummation of our initial business combination. This arrangement is being agreed to by an affiliate
of LifeSci Holdings LLC for our benefit. We believe that the fee charged by the affiliate of LifeSci Holdings LLC is at least as
favorable as we could have obtained from an unaffiliated person. This arrangement will terminate upon completion of our initial
business combination or the distribution of the trust account to our public stockholders. Other than the $10,000 per month fee,
no compensation of any kind (including finder's fees, consulting fees or other similar compensation) will be paid to our
insiders, members of our management team or any of our or their respective affiliates, for services rendered to us prior to or
in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However,
such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our
behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business
combinations, as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine
their operations. Since the role of present management after our initial business combination is uncertain, we have no ability
to determine what remuneration, if any, will be paid to those persons after our initial business combination.
A total of
$10.00 per share (whether or not the underwriters' over-allotment option is exercised in full) of the net proceeds from
this offering and the sale of the private warrants described in this prospectus will be placed in a trust account in the United
States, maintained by Continental Stock Transfer & Trust Company acting as trustee and will be
invested only in U.S. government treasury bills, notes and bonds with a maturity of 183 days or less or in money market funds
meeting certain conditions under Rule 2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries.
Except for all interest income that may be released to us to pay our tax obligations or for working capital purposes
(provided that the funds released for working capital purposes may not exceed $250,000 annually), as discussed below, none of
the funds held in the trust account will be released from the trust account until the earlier of: (i) the consummation
of our initial business combination within 24 months from the closing of this offering and (ii) a redemption to public
stockholders prior to any voluntary winding-up in the event we do not consummate our initial business combination within the
applicable period.
The net proceeds held
in the trust account may be used as consideration to pay the sellers of a target business with which we ultimately complete our
initial business combination. If our initial business combination is paid for using shares or debt securities, or not all of the
funds released from the trust account are used for payment of the purchase price in connection with our business combination, we
may apply the cash released from the trust account that is not applied to the purchase price for general corporate purposes, including
for maintenance or expansion of operations of acquired businesses, the payment of principal or interest due on indebtedness incurred
in consummating the initial business combination, to fund the purchase of other companies or for working capital.
We believe that amounts
not held in trust will be sufficient to pay the costs and expenses to which such proceeds are allocated. This belief is based on
the fact that while we may begin preliminary due diligence of a target business in connection with an indication of interest, we
intend to undertake in-depth due diligence, depending on the circumstances of the relevant prospective acquisition, only after
we have negotiated and signed a letter of intent or other preliminary agreement that addresses the terms of our initial business
combination. However, if our estimate of the costs of undertaking in-depth due diligence and negotiating our initial business combination
is less than the actual amount necessary to do so, or the amount of interest available to use from the trust account is minimal
as a result of the current interest rate environment, we may be required to raise additional capital, the amount, availability
and cost of which is currently unascertainable. In this event, we could seek such additional capital through loans or additional
investments from members of our management team, but such members of our management team are not under any obligation to advance
funds to, or invest in, us.
40
As of the date of
this prospectus, our sponsor has not loaned us any amounts to be used for a portion of the expenses of this offering. Any loans
will be non-interest bearing and payable on the date on which we consummate the offering.
In addition, in order
to finance transaction costs in connection with an intended initial business combination, our sponsor or an affiliate of our sponsor
or our officers and directors may, but are not obligated to, loan us funds as may be required. If we consummate our initial business
combination, we would repay such loaned amounts. The notes would either be paid upon consummation of our initial business combination,
without interest, or, at the lender's discretion, up to $500,000 of the notes may be converted upon consummation of our business
combination into additional private warrants at a conversion price of $0.90 per private warrant. Such private warrants will be
identical to the private warrants to be issued at the closing of this offering.
In no event will we
redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001. Furthermore, the redemption
threshold may be further limited by the terms and conditions of our initial business combination. In such case, we would not proceed
with the redemption of our public shares or the business combination, and instead may search for an alternate business combination.
A public stockholder
will be entitled to receive funds from the trust account only upon the earlier to occur of: (i) our consummation of our initial
business combination, and then only in connection with those shares of common stock that such stockholder properly elected to redeem,
subject to the limitations described herein, (ii) the redemption of our public shares if we are unable to consummate our initial
business combination within 24 months following the closing of this offering, subject to applicable law, or (iii) if we seek
to amend our certificate of incorporation to affect the substance or timing of our obligation to redeem all public shares if we
cannot complete an initial business combination within 24 months of the closing of this offering and such amendment is duly approved.
In no other circumstances will a public stockholder have any right or interest of any kind to or in the trust account.
Our initial stockholders
have agreed to waive their redemption rights with respect to any shares they own in connection with the consummation of our initial
business combination, including their founder shares, public shares and private placement warrants that they have purchased during
or after the offering, if any. In addition, our initial stockholders have agreed to waive their rights to liquidating distributions
with respect to their founder shares and private placement warrants if we fail to consummate our initial business combination within
24 months from the closing of this offering. However, if our initial stockholders acquire public shares in or after this offering,
they will be entitled to receive liquidating distributions with respect to such public shares if we fail to consummate our initial
business combination within the required time period. In addition, we agreed not to enter into a definitive agreement regarding
an initial business combination without the prior consent of our sponsor.
41
DIVIDEND POLICY
We have not paid any
cash dividends on our shares of common stock to date and do not intend to pay cash dividends prior to the completion of our initial
business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital
requirements and general financial condition subsequent to completion of our initial business combination. The payment of any cash
dividends subsequent to our initial business combination will be within the discretion of our board of directors at such time and
subject to the Delaware law. In addition, our board of directors is not currently contemplating and does not anticipate declaring
any share dividends in the foreseeable future, except if we increase the size of the offering pursuant to Rule 462(b) under
the Securities Act, in which case we will effect a share dividend immediately prior to the consummation of the offering in such
amount as to maintain our initial stockholders' ownership at 20% of the issued and outstanding shares of common stock upon
the consummation of this offering (assuming no purchase in this offering and not taking into account ownership of the private warrants).
Further, if we incur any indebtedness in connection with our initial business combination, our ability to declare dividends may
be limited by restrictive covenants we may agree to in connection therewith.
42
DILUTION
The difference between the public offering price per share and the pro forma net tangible book value per share after this offering constitutes
the dilution to investors in this offering. Net tangible book value per share is determined by dividing our net tangible book value, which
is our total tangible assets less total liabilities (including the value of shares of common stock which may be redeemed for cash), by
the number of outstanding shares of common stock.
At June 30, 2020,
our net tangible book value deficit was $(4,000) or approximately $(0.00) per share. After giving effect to the sale of 7,500,000
shares of common stock we are offering by this prospectus and the proceeds received from the sale of the private warrants, the
deduction of underwriting discounts and estimated expenses of this offering, our pro forma net tangible book value at June 30,
2020 would have been $5,000,010 or $2.18 per share, representing an immediate increase in net tangible book value of $2.18 per
share to the initial stockholders and an immediate dilution of 78.2% per share or $7.82 to new investors not exercising their conversion/tender
rights. For purposes of presentation, our pro forma net tangible book value after this offering is $70,773,990 less than it otherwise
would have been because, if we effect a business combination, the ability of public stockholders to exercise conversion rights
or sell their shares to us in any tender offer may result in the conversion or tender of up to 7,077,399 shares sold in this offering.
The
following table illustrates the dilution to the new investors on a per-share basis:
Public offering price
$
10.00
Net tangible book value before this offering
$
(0.00
)
Increase attributable to new investors, private sales and capital contribution
2.18
Pro forma net tangible book value after this offering
2.18
Dilution to new investors
$
7.82
Percentage of dilution to new investors
78.2
%
The following table
sets forth information with respect to our initial stockholders and the new investors:
Shares Purchased
Total Consideration
Average
Price
Number
Percentage
Amount
Percentage
Per Share
Initial stockholders
(1)
1,875,000
20.0
%
$
25,000
0.03
%
$
0.01
New investors
7,500,000
80.0
%
75,000,000
99.97
%
$
10.00
9,375,000
100.00
%
$
75,025,000
100.00
%
(1)
Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited as a result thereof.
The pro forma net
tangible book value after the offering is calculated as follows:
Numerator:
(1)
Net tangible book value before this offering
$
(4,000
)
Net proceeds from this offering and private placement of private warrants
75,750,000
Plus: Offering costs accrued or paid in advance and excluded from tangible book value before this offering
28,000
Less: Proceeds held in trust subject to conversion/tender
(70,773,990
)
$
5,000,010
Denominator:
Shares of common stock issued and outstanding prior to this offering
(1)
1,875,000
Shares of common stock to be sold in this offering
7,500,000
Less: Shares subject to conversion/tender
(7,077,399
)
2,297,601
(1)
Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited by us as a result thereof.
43
CAPITALIZATION
The following table sets forth our capitalization
at June 30, 2020 and as adjusted to give effect to the sale of our public shares of common stock and the private warrants and the
application of the estimated net proceeds derived from the sale of such securities.
June 30, 2020
Actual
As
Adjusted
(1)
Promissory note – related party
(2)
$
—
$
—
Shares of common stock, $0.0001 par value, none and 7,077,399 shares are subject to possible conversion/tender, respectively
—
70,773,990
Shares of common stock, $0.0001 par value, 5,000,000 shares authorized (actual); 30,000,000 authorized, as adjusted, 2,156,250 shares issued and outstanding, actual; 2,297,601 shares issued and outstanding
(3)
(excluding 7,077,399 shares subject to possible conversion/tender), as adjusted
216
230
Additional paid-in capital
24,784
5,000,780
Accumulated deficit
(1,000
)
(1,000
)
Total stockholders' equity
24,000
5,000,010
Total capitalization
$
24,000
$
75,774,000
(1)
Includes the $2,730,000 we will receive from the sale of the private warrants.
(2)
As of June 30, 2020, we had not borrowed any amounts under the promissory note. The loans are non-interest bearing and payable on the date on which we consummate the offering.
(3)
Assumes the over-allotment option has not been exercised and an aggregate of 281,250 shares of common stock held by our initial stockholders have been forfeited as a result thereof.
44
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
We were incorporated
on December 18, 2019 as a Delaware corporation to serve as a vehicle to effect a merger, share exchange, asset acquisition,
share purchase, recapitalization, reorganization or similar business combination with one or more target businesses. Our efforts
to identify a prospective target business will not be limited to a particular industry or geographic location. We intend to utilize
cash derived from the proceeds of this offering, our securities, debt or a combination of cash, securities and debt, in effecting
a business combination. The issuance of additional shares in our business combination:
•
may significantly reduce the equity interest of our stockholders;
•
may subordinate the rights of holders of common stock if we issue preferred shares with rights senior to those afforded to our shares of common stock;
•
will likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our present officers and directors; and
•
may adversely affect prevailing market prices for our securities.
Similarly, if we issue
debt securities, it could result in:
•
default and foreclosure on our assets if our operating revenues after a business combination are insufficient to pay our debt obligations;
•
acceleration of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation of that covenant;
•
our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand; and
•
our inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional financing while such security is outstanding.
As indicated in the
accompanying financial statements, at June 30, 2020, we had $25,000 in cash and $28,000 in deferred offering costs. Further,
we expect to continue to incur significant costs in the pursuit of our acquisition plans. Our plans to raise capital or to consummate
our initial business combination may not be successful.
Results of Operations and Known Trends
or Future Events
We have neither engaged
in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities and
those necessary to prepare for this offering. Following this offering, we will not generate any operating revenues until after
completion of our initial business combination. We will generate non-operating income in the form of interest income on cash and
cash equivalents after this offering. There has been no significant change in our financial or trading position and no material
adverse change has occurred since the date of our audited financial statements. After this offering, we expect to incur increased
expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as
for due diligence expenses. We expect our expenses to increase substantially after the closing of this offering.
Liquidity and Capital Resources
As indicated in the
accompanying financial statements, at June 30, 2020, we had $25,000 in cash and working capital deficit of $4,000. Further,
we have incurred and expect to continue to incur significant costs in pursuit of our financing and acquisition plans. Management's
plans to address this uncertainty through this offering are discussed below.
45
Our liquidity needs
have been satisfied to date through receipt of $25,000 from the sale of the insider shares and loans from our sponsor. We estimate
that the net proceeds from (1) the sale of the shares in this offering, after deducting offering expenses of approximately
$480,000 and underwriting fees and qualified independent underwriter fees of $1,500,000 (or $1,725,000 if the over-allotment option
is exercised in full) and (2) the sale of the private warrants for a purchase price of $2,730,000 (or $2,955,000 if the over-allotment
option is exercised in full) will be $75,750,000 (or $87,000,000 if the over-allotment option is exercised in full). Of this amount,
$75,000,000 (or $86,250,000 if the over-allotment option is exercised in full) will be held in the trust account. The remaining
$750,000 (whether or not the over-allotment option is exercised in full) will not be held in the trust account.
We intend to use substantially
all of the net proceeds of this offering, including the funds held in the trust account, to acquire a target business or businesses
and to pay our expenses relating thereto. To the extent that our share capital is used in whole or in part as consideration to
effect our initial business combination, the remaining proceeds held in the trust account as well as any other net proceeds not
expended will be used as working capital to finance the operations of the target business. Such working capital funds could be
used in a variety of ways including continuing or expanding the target business' operations, for strategic acquisitions and
for marketing, research and development of existing or new products. Such funds could also be used to repay any operating expenses
or finders' fees which we had incurred prior to the completion of our initial business combination if the funds available
to us outside of the trust account were insufficient to cover such expenses.
Over the next 24 months
(assuming a business combination is not consummated prior thereto), we will be using the funds held outside of the trust account
for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses,
traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents
and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating
and consummating the business combination. Out of the funds available outside the trust account, we anticipate that we will incur
approximately:
•
$100,000 of expenses for the search for target businesses and for the legal, accounting and other third-party expenses attendant to the due diligence investigations, structuring and negotiating of a business combination;
•
$65,000 of expenses for the due diligence and investigation of a target business by our officers, directors and initial stockholders;
•
$60,000 of expenses in legal and accounting fees relating to our SEC reporting obligations;
•
$240,000 for the payment of the administrative fee to an affiliate
of LifeSci Holdings LLC, our sponsor (of $10,000 per month for up to 24 months), subject to deferral as described herein; and
•
$285,000 for general working capital that will be used for miscellaneous expenses, including director and officer liability insurance premiums.
If our estimates of
the costs of undertaking in-depth due diligence and negotiating our initial business combination is less than the actual amount
necessary to do so, we may have insufficient funds available to operate our business prior to our initial business combination.
Moreover, we may need to obtain additional financing either to consummate our initial business combination or because we become
obligated to redeem a significant number of our public shares upon consummation of our initial business combination, in which case
we may issue additional securities or incur debt in connection with such business combination. Subject to compliance with applicable
securities laws, we would only consummate such financing simultaneously with the consummation of our initial business combination.
Following our initial business combination, if cash on hand is insufficient, we may need to obtain additional financing in order
to meet our obligations.
Related Party Transactions
LifeSci Holdings LLC,
our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants," at $0.90
per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common stock at
an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our initial
business combination and 12 months from the closing of this offering and will expire five years after the effective date of the
registration statement of which this prospectus forms a part. This purchase will take place on a private placement basis simultaneously
with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants, $1,980,000 will
be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that if the over-allotment
option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional number of private
warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the trust account $10.00 per
share sold to the public in this offering. These additional private warrants will be purchased in a private placement that will
occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
46
If needed to finance
transaction costs in connection with searching for a target business or consummating an intended initial business combination,
our initial stockholders, officers, directors or their affiliates may, but are not obligated to, loan us funds as may be required.
In the event that the initial business combination does not close, we may use a portion of the working capital held outside the
trust account to repay such loaned amounts, but no proceeds from our trust account would be used for such repayment. Such loans
would be evidenced by promissory notes. The notes would either be paid upon consummation of our initial business combination, without
interest, or, at the lender's discretion, up to $500,000 of the notes may be converted upon consummation of our business
combination into additional private warrants at a conversion price of $0.90 per private warrant. We believe the purchase price
of these private warrants will approximate the fair value of such private warrants when issued. However, if it is determined, at
the time of issuance, that the fair value of such private warrants exceeds the purchase price, we would record compensation expense
for the excess of the fair value of the private warrants on the day of issuance over the purchase price in accordance with Accounting
Standards Codification ("ASC") 718 — Compensation — Stock Compensation.
Controls and Procedures
We are not currently
required to maintain an effective system of internal controls as defined by Section 404 of the Sarbanes-Oxley Act. We will
be required to comply with the internal control requirements of the Sarbanes-Oxley Act for the fiscal year ending June 30,
2022. As of the date of this prospectus, we have not completed an assessment, nor have our auditors tested our systems, of internal
controls. We expect to assess the internal controls of our target business or businesses prior to the completion of our initial
business combination and, if necessary, to implement and test additional controls as we may determine are necessary in order to
state that we maintain an effective system of internal controls. A target business may not be in compliance with the provisions
of the Sarbanes-Oxley Act regarding the adequacy of internal controls. Target businesses we may consider for our initial business
combination may have internal controls that need improvement in areas such as:
•
staffing for financial, accounting and external reporting areas, including segregation of duties;
•
reconciliation of accounts;
•
proper recording of expenses and liabilities in the period to which they relate;
•
evidence of internal review and approval of accounting transactions;
•
documentation of processes, assumptions and conclusions underlying significant estimates; and
•
documentation of accounting policies and procedures.
Because it will take
time, management involvement and perhaps outside resources to determine what internal control improvements are necessary for us
to meet regulatory requirements and market expectations for our operation of a target business, we may incur significant expense
in meeting our public reporting responsibilities, particularly in the areas of designing, enhancing, or remediating internal and
disclosure controls. Doing so effectively may also take longer than we expect, thus increasing our exposure to financial fraud
or erroneous financing reporting.
Once our management's
report on internal controls is complete, we will retain our independent auditors to audit and render an opinion on such report
when, or if, required by Section 404. The independent auditors may identify additional issues concerning a target business's
internal controls while performing their audit of internal control over financial reporting.
47
Quantitative and Qualitative Disclosures
about Market Risk
The net proceeds of
this offering, including amounts in the trust account, will be invested in United States government treasury bills, bonds or notes
having a maturity of 183 days or less, or in money market funds meeting the applicable conditions under Rule 2a-7 promulgated
under the Investment Company Act of 1940 and that invest solely in U.S. treasuries. Due to the short-term nature of these investments,
we believe there will be no associated material exposure to interest rate risk.
Off-Balance Sheet Arrangements; Commitments
and Contractual Obligations; Quarterly Results
As of the date of
this prospectus, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and
did not have any commitments or contractual obligations. No unaudited quarterly operating data is included in this prospectus as
we have conducted no operations to date.
JOBS Act
On April 5, 2012,
the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements
for qualifying public companies. We will qualify as an "emerging growth company" and under the JOBS Act will be allowed
to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies.
We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised
accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As
such, our financial statements may not be comparable to companies that comply with public company effective dates.
48
PROPOSED BUSINESS
Introduction
We are a blank check
company formed under the laws of the State of Delaware on December 18, 2019. We were formed for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses,
which we refer to throughout this prospectus as our initial business combination. Although there is no restriction or limitation
on what industry our target operates in, it is our intention to pursue prospective targets that are focused on healthcare innovation.
We anticipate targeting companies domiciled in North America or Europe that are developing assets in the biopharma, medical technology,
digital health, and healthcare services sectors, which aligns with our management team's experience in healthcare investing
and drug development. At the time of preparing this prospectus, we have not identified any specific business combination, nor has
anyone on our behalf initiated or engaged in any substantive discussions, formal or otherwise, related to such a transaction. Our
efforts to date are limited to organizational activities related to this offering.
Our Sponsor and Competitive Advantages
Our sponsor is an affiliate
of LifeSci Capital LLC, a research-driven investment bank with deep domain expertise in the life sciences, LifeSci Advisors LLC,
an investor relations and public relations company in the life sciences industry with comprehensive solutions to communications
and investor outreach, and LifeSci Venture Management LLC, a corporate venture capital firm that seeks to invest in biotech and
health sectors, collectively "LifeSci".
LifeSci's service
model as a boutique investment bank is unique in that it exclusively serves corporate clients that are emerging life science companies
that discover, develop, and commercialize innovative products.
LifeSci's service
model as an investor relations and public relations firm is unique in that it provides companies in the life sciences industry
with comprehensive solutions to communications and investor outreach. LifeSci assists companies in increasing visibility within
the investment community and educating investors on opportunities offered by these companies. LifeSci's core capabilities
include non-deal roadshow planning and execution, KOL Events/R&D Days, corporate communications, and public relations through
its affiliate LifeSci Public Relations.
LifeSci's service
model as a venture capital firm is unique in that it focuses on pre-public institutional rounds of transformational healthcare
companies managed by exceptional founder/entrepreneurs. LifeSci's investment principals have broad-ranging life sciences
experience including public and private investing, deal structuring, investment banking, equity capital markets, equity research,
and bench research - both basic science and applied.
LifeSci's team
is comprised of individuals with medical and advanced scientific training and legal and banking experience, enabling a deeply differentiated
approach to research and idea generation. Complementing LifeSci's scientific insight and industry relationships is LifeSci's
business team, whose members include portfolio managers, corporate managers, and investment bankers who actively engage with banks
and academic institutions, cultivating strong relationships and expanding their network of key contacts and syndicate partners.
We believe the well-rounded nature of the team, strengthened by strong ties across industry, academia, banking platforms, and unaffiliated
investor relationships, will enhance our management team's ability to source viable prospective target businesses, capitalize
them, and ensure public-market readiness.
49
Our independent directors
have extensive experience in clinical medicine, development and regulatory, operational, and management leadership within the healthcare
and financial industries. We believe that their breadth of experience will bolster our ability to thoroughly evaluate prospective
candidates and successfully execute our initial business combination. Following the completion of our initial transaction, we believe
our independent directors will fortify our ongoing operations by providing sound and experienced counsel on potential further acquisitions,
divestitures, corporate strategy, and human resources.
We believe that our
management team is equipped with the knowledge, experience, capital and human resources, and sustainable corporate governance practices
to pursue unique opportunities that will offer attractive risk-adjusted returns.
Our management team
is led by Andrew McDonald, Co-Founder of LifeSci Advisors and LifeSci Capital, Michael Rice, Co-Founder of LifeSci Advisors and
LifeSci Capital and David Dobkin, Managing Director of LifeSci Capital.
We believe that our
company's philosophical alignment with LifeSci, and our ability to leverage the rigorous and comprehensive scientific and
financial analysis that LifeSci is known for, provides us with a strong competitive advantage. LifeSci focuses on dynamic sectors
of healthcare with great potential to transform the healthcare industry: biotechnology, specialty pharmaceuticals, medical devices,
digital health, information technology, and healthcare services.
In 2018, LifeSci's
investors relations hosted over 1,500 meetings in 27 key regions in the United States and over 500 meetings in 16 key regions throughout
Europe. In 2019, LifeSci's Public Relations group secured over 1,300 media hits for their clients, with more than 100 million
viewers and readers globally, and wrote over 4,000 social media posts. LifeSci Venture's first fund in 2017 has invested
in 12 companies alongside large dedicated healthcare funds and has launched its second fund in the third quarter of 2019. LifeSci's
investment bank has executed over 50 transactions since inception, in which over 50% were repeat or Lead Managed. LifeSci's
investment bank core capabilities include experienced-based investment banking advisory, varied capital raising abilities, industry
insight and accessibility, global institutional coverage and reach, equity research, and client empowerment.
LifeSci's investor
relations presence has continued to expand year-over-year. In 2019, LifeSci Advisors conducted 4,602 one-on-one non-deal roadshow
(NDR) investor meetings, 140 key opinion leader (KOL) events, 594 meetings with high net worth (HNW) individuals and financial
advisors, and 4,160 one-on-one meetings at the J.P. Morgan healthcare conference (JPM), as compared to 4,105 NDR meetings, 130
KOL events, 568 HNW meetings, and 2,700 one-on-one meetings at JPM in 2018. Additionally, LifeSci's Executive Search group completed
30 board and executive placements in 2019, up from 17 in 2018. LifeSci's client base continues to grow as well, reaching 177 healthcare
client partnerships in 2019, up from 150 in 2018. LifeSci Partners has a global footprint, with offices in cities including New
York, Chicago, Boston, Charlotte, London, Geneva, Paris, and Tel Aviv.
Industry Opportunity
The healthcare industry
consists of sectors within the economic system providing curative, preventive, rehabilitative, and palliative care for patients.
The industry includes organizations providing such goods and services, as well as the doctors, nurses, and other healthcare employees.
Total healthcare spending in the United States reached nearly $3.5 trillion in 2017 and is expected to grow by an average 5.6 percent
annually over 2016-2025, according to a Centers for Medicare & Medicaid Services report released in February 2017.
Total healthcare expenditures are thus expected rise to 19.9 percent of the US Gross Domestic Product.
50
The healthcare market
globally mirrors a similar trend in the US of an increased contribution to the economy, due to the aging of the global population
and other durable macro dynamics. For example, in good part due to the impact of healthcare on society, life expectancy in the
U.S. increased from 47 years in 1900 to 79 years in 2016. As a disproportionate amount of overall healthcare spending is associated
with diseases of aging, the aging of the global population will continue to drive increased healthcare consumption. In addition,
less developed countries have gone through an unprecedented period of healthcare insurance and infrastructure expansion that has
led the countries to have significantly higher contributions to the global healthcare marketplace.
The target universe
of healthcare opportunities is extensive, considering healthcare's overall contribution to the economy. A factor that further
broadens the universe is the high amount of innovation occurring within healthcare. In the wake of the genomics revolution, the
pace of innovation is accelerating. With the streamlining of the externalization of breakthrough science from academic institutions,
particularly in the United States, as mandates shifted from protecting intellectual property to externalizing it, increasing numbers
of potentially disruptive healthcare innovations exist that may be underappreciated or underfunded. Early-stage companies need
capital and advisory services to reach their commercial potential.
The healthcare industry
is primed for new technologies and business models due to the increasing cost of healthcare and due to the increasing pressure
to add value to the system. We believe that lower-value segments of healthcare will be burdened by the pressures of cost cutting,
while companies or segments that deliver superior products and services, with better clinical and non-clinical outcomes, will thrive.
Successful companies will be data driven, consumer focused, operationally efficient and transfer best-in-class standards globally.
Our team will take a holistic approach to investment opportunities and conduct stringent due diligence to screen such companies.
We see opportunities for companies that address global healthcare cost pressures by: succeeding in disruptive innovation, thus
justifying monies spent by delivering cures or other breakthrough outcomes; delivering cost savings to address global healthcare
cost pressures; or providing access to medicines, as the marginal benefits from healthcare spending are highest when providing
goods and services to those who do not already receive them.
51
Investment Criteria
We are focused on
companies in disruptive and other value-added subsegments of healthcare that have the potential for significant gains in the next
five years. Our ideal company will be institutionally backed, with a high-quality management team and a demonstrated ability to
raise money from the private capital markets. The segments we will target include biotechnology, medical technology and digital
health.
The focus of our management
team is to create stockholder value by leveraging its experience to efficiently guide an emerging healthcare company towards commercialization.
Consistent with our strategy, we have identified the following general criteria and guidelines that we believe are important in
evaluating prospective target businesses. While we intend to use these criteria and guidelines in evaluating prospective businesses,
we may deviate from these criteria and guidelines should we see fit to do so:
•
Healthcare
Company Poised for Rapid Growth
We intend to primarily seek
to acquire one or more growth businesses with a total equity value of greater than 5 to 10 times the amount of the proceeds of
this offering. We believe that there are a substantial number of potential target businesses with appropriate valuations that can
benefit from a public listing and new capital for growth to support significant revenue and earnings growth or to advance clinical
programs. We do not intend to acquire a start-up company.
•
Niche
Leader and Specialized Business with High Growth Potential
We intend to seek target companies
that have significant and underexploited expansion opportunities in a niche sector. This can be accomplished through a combination
of accelerating organic growth and finding attractive add-on acquisition targets. Our management team has significant experience
in identifying such targets and in helping target management assess the strategic and financial fit. Similarly, our management
has the expertise to assess the likely synergies and a process to help a target integrate acquisitions. Additionally, our management
team has extensive experience assisting healthcare companies raise money as they navigate the regulatory approval process.
52
•
Benefits
from Being a U.S. Public Company (Value Creation and Marketing Opportunities)
We intend to seek target companies
that should offer attractive risk-adjusted equity returns for our stockholders. We intend to seek to acquire a target on terms
and in a manner that leverage our experience. We expect to evaluate a Company based on its potential to successfully achieve regulatory
approval and commercialize its product(s). We also expect to evaluate financial returns based on (i) risk-adjusted peak sales
potential (ii) the potential of pipeline products and the scientific platform (iii) the ability to achieve the system
cost savings, (iv) the ability to accelerate growth via other options, including through the opportunity for follow-on acquisitions,
and (v) the prospects for creating value through other value creation initiatives. Potential upside, for example, from the
growth in the target business' earnings or an improved capital structure, will be weighed against any identified downside
risks.
•         Potential
Benefit from Globalization Trends and Possession of Competitive Advantages
Target companies exhibit unrecognized
value or other characteristics that we believe have been misevaluated by the marketplace based on our company-specific analyses
and due diligence. For a potential target company, this process will include, among other things, a review and analysis of the
company's capital structure, quality of current or future earnings, preclinical or clinical data, potential for operational
improvements, corporate governance, customers, material contracts, and the industry and trends. We intend to leverage the operational
experience and disciplined investment approach of our team to identify opportunities to unlock value that our experience in complex
situations allows us to pursue.
These criteria are
not intended to be exhaustive. Any evaluation relating to the merits of a particular initial business combination may be based,
to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may
deem relevant.
Effecting a Business Combination
General
We are not presently
engaged in, and we will not engage in, any operations for an indefinite period of time following this offering. We intend to effectuate
our initial business combination using cash from the proceeds of this offering and the private placement of the private warrants,
our shares, new debt, or a combination of these, as the consideration to be paid in our initial business combination. We may seek
to consummate our initial business combination with a company or business that may be financially unstable or in its early stages
of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing and
sales), which would subject us to the numerous risks inherent in such companies and businesses, although we will not be permitted
to effectuate our initial business combination with another blank check company or a similar company with nominal operations.
If our initial business
combination is paid for using shares or debt securities, or not all of the funds released from the trust account are used for payment
of the purchase price in connection with our business combination or used for redemptions of purchases of our common stock, we
may apply the cash released to us from the trust account that is not applied to the purchase price for general corporate purposes,
including for maintenance or expansion of operations of acquired businesses, the payment of principal or interest due on indebtedness
incurred in consummating our initial business combination, to fund the purchase of other companies or for working capital.
We have not identified
any acquisition targets. From the period prior to our formation through the date of this prospectus, there have been no communications,
evaluations or discussions between any of our officers, directors or our sponsor and any of their contacts or relationships regarding
a potential initial business combination. Additionally, we have not engaged or retained any agent or other representative to identify
or locate any suitable acquisition candidate. Subject to the requirement that our initial business combination must be with one
or more target businesses or assets having an aggregate fair market value of at least 80% of the value of the trust account (excluding
any taxes payable) at the time of the agreement to enter into such initial business combination, we have virtually unrestricted
flexibility in identifying and selecting one or more prospective target businesses. Accordingly, there is no current basis for
investors in this offering to evaluate the possible merits or risks of the target business with which we may ultimately complete
our initial business combination. Although our management will assess the risks inherent in a particular target business with which
we may combine, this assessment may not result in our identifying all risks that a target business may encounter. Furthermore,
some of those risks may be outside of our control, meaning that we can do nothing to control or reduce the chances that those risks
will adversely impact a target business.
53
We may seek to raise
additional funds through a private offering of debt or equity securities in connection with the consummation of our initial business
combination, and we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts
held in the trust account. Subject to compliance with applicable securities laws, we would consummate such financing only simultaneously
with the consummation of our business combination. In the case of an initial business combination funded with assets other than
the trust account assets, our tender offer documents or proxy materials disclosing the business combination would disclose the
terms of the financing and, only if required by law or Nasdaq, we would seek stockholder approval of such financing. There are
no prohibitions on our ability to raise funds privately or through loans in connection with our initial business combination. At
this time, we are not a party to any arrangement or understanding with any third party with respect to raising any additional funds
through the sale of securities or otherwise.
Sources of Target Businesses
We anticipate that
target business candidates will be brought to our attention from various unaffiliated sources, including investment bankers, venture
capital funds, private equity groups, leveraged buyout funds, management buyout funds and other members of the financial community.
Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us through calls
or mailings. These sources also may introduce us to target businesses in which they think we may be interested on an unsolicited
basis, since many of these sources will have read this prospectus and know what types of businesses we are targeting. Our officers
and directors, as well as their affiliates, also may bring to our attention target business candidates that they become aware of
through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending
trade shows or conventions. In addition, we expect to receive a number of proprietary deal flow opportunities that would not otherwise
necessarily be available to us as a result of the business relationships of our officers and directors. While we do not presently
anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal
basis, we may engage these firms or other individuals in the future, in which event we may pay a finder's fee, consulting
fee or other compensation to be determined in an arm's length negotiation based on the terms of the transaction. We will
engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not
otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management
determines is in our best interest to pursue. Payment of finder's fees is customarily tied to completion of a transaction,
in which case any such fee will be paid out of the funds held in the trust account. Although some of our officers and directors
may enter into employment or consulting agreements with the acquired business following our initial business combination, the presence
or absence of any such arrangements will not be used as a criterion in our selection process of an acquisition candidate.
We are not prohibited
from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the
event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would
obtain an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions
on the type of target business we seek to acquire that such an initial business combination is fair to our unaffiliated stockholders
from a financial point of view.
Selection of a Target Business and
Structuring of a Business Combination
Subject to the requirement
that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value
of at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such
initial business combination, our management will have virtually unrestricted flexibility in identifying and selecting one or more
prospective target businesses. In any case, we will only consummate an initial business combination in which we become the majority
shareholder of the target (or control the target through contractual arrangements in limited circumstances for regulatory compliance
purposes as discussed below) or are otherwise not required to register as an investment company under the Investment Company Act
or to the extent permitted by law we may acquire interests in a variable interest entity, in which we may have less than a majority
of the voting rights in such entity, but in which we are the primary beneficiary. There is no basis for investors in this offering
to evaluate the possible merits or risks of any target business with which we may ultimately complete our initial business combination.
To the extent we effect our initial business combination with a company or business that may be financially unstable or in its
early stages of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing
and sales), we may be affected by numerous risks inherent in such company or business. Although our management will endeavor to
evaluate the risks inherent in a particular target business, we may not properly ascertain or assess all significant risk factors.
In evaluating a prospective
target business, we expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent
management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as well as a review
of financial and other information which will be made available to us.
54
The time required
to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated
with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification
and evaluation of a prospective target business with which a business combination is not ultimately completed will result in our
incurring losses and will reduce the funds we can use to complete another business combination. We will not pay any finders or
consulting fees to members of our management team, or any of their respective affiliates, for services rendered to or in connection
with our initial business combination.
Fair Market Value of Target Business
or Businesses
The target business
or businesses or assets with which we effect our initial business combination must have a collective fair market value equal to
at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into such initial
business combination. If we acquire less than 100% of one or more target businesses in our initial business combination, the aggregate
fair market value of the portion or portions we acquire must equal at least 80% of the value of the trust account at the time of
the agreement to enter into such initial business combination. However, we will always acquire at least a controlling interest
in a target business. The fair market value of a portion of a target business or assets will likely be calculated by multiplying
the fair market value of the entire business by the percentage of the target we acquire. We may seek to consummate our initial
business combination with an initial target business or businesses with a collective fair market value in excess of the balance
in the trust account. In order to consummate such an initial business combination, we may issue a significant amount of debt, equity
or other securities to the sellers of such business and/or seek to raise additional funds through a private offering of debt, equity
or other securities. If we issue securities in order to consummate such an initial business combination, our stockholders could
end up owning a minority of the combined company's voting securities as there is no requirement that our stockholders own
a certain percentage of our company (or, depending on the structure of the initial business combination, an ultimate parent company
that may be formed) after our business combination. Because we have no specific business combination under consideration, we have
not entered into any such arrangement to issue our debt or equity securities and have no current intention of doing so.
The fair market value
of a target business or businesses or assets will be determined by our board of directors based upon standards generally accepted
by the financial community, such as actual and potential gross margins, the values of comparable businesses, earnings and cash
flow, book value, enterprise value and, where appropriate, upon the advice of appraisers or other professional consultants. Investors
will be relying on the business judgment of our board of directors, which will have significant discretion in choosing the standard
used to establish the fair market value of a particular target business. If our board of directors is not able to independently
determine that the target business or assets has a sufficient fair market value to meet the threshold criterion, we will obtain
an opinion from an unaffiliated, independent investment banking firm or another independent entity that commonly renders valuation
opinions on the type of target business we seek to acquire with respect to the satisfaction of such criterion. Notwithstanding
the foregoing, unless we consummate a business combination with an affiliated entity, we are not required to obtain an opinion
from an independent investment banking firm, or another independent entity that commonly renders valuation opinions on the type
of target business we seek to acquire, that the price we are paying is fair to our stockholders.
Lack of Business Diversification
For an indefinite
period of time after consummation of our initial business combination, the prospects for our success may depend entirely on the
future performance of a single business. Unlike other entities that have the resources to complete business combinations with multiple
entities in one or several industries, it is probable that we will not have the resources to diversify our operations and mitigate
the risks of being in a single line of business. By consummating our initial business combination with only a single entity, our
lack of diversification may:
•
subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after our initial business combination, and
•
cause us to depend on the marketing and sale of a single product or limited number of products or services.
55
Limited Ability to Evaluate the Target's
Management Team
Although we intend
to closely scrutinize the management of a prospective target business when evaluating the desirability of effecting our initial
business combination with that business, our assessment of the target business' management may not prove to be correct. The
future role of members of our management team, if any, in the target business cannot presently be stated with any certainty. Consequently,
members of our management team may not become a part of the target's management team, and the future management may not have
the necessary skills, qualifications or abilities to manage a public company. Further, it is also not certain whether one or more
of our directors will remain associated in some capacity with us following our initial business combination. Moreover, members
of our management team may not have significant experience or knowledge relating to the operations of the particular target business.
Our key personnel may not remain in senior management or advisory positions with the combined company. The determination as to
whether any of our key personnel will remain with the combined company will be made at the time of our initial business combination.
Following our initial
business combination, we may seek to recruit additional managers to supplement the incumbent management of the target business.
We may not have the ability to recruit additional managers, or that additional managers will have the requisite skills, knowledge
or experience necessary to enhance the incumbent management.
Stockholders May Not Have the
Ability to Approve an Initial Business Combination
In connection with
any proposed business combination, we will either (1) seek stockholder approval of our initial business combination at a meeting
called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for
or against the proposed business combination, into their
pro rata
share of the aggregate amount then on deposit in the trust
account (net of taxes payable) or (2) provide our public stockholders with the opportunity to sell their public shares to
us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their
pro rata
share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations
described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with
us, not to convert any public shares held by them into their
pro rata
share of the aggregate amount then on deposit in the
trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each stockholder may tender
any or all of his, her or its public shares rather than some
pro rata
portion of his, her or its shares. The decision as
to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares
to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction and whether the
terms of the transaction would otherwise require us to seek stockholder approval. If we so choose and we are legally permitted
to do so, we have the flexibility to avoid a stockholder vote and allow our stockholders to sell their shares pursuant to Rule 13e-4
and Regulation 14E of the Exchange Act which regulate issuer tender offers. In that case, we will file tender offer documents with
the SEC which will contain substantially the same financial and other information about the initial business combination as is
required under the SEC's proxy rules. We will consummate our initial business combination only if we have net tangible assets
of at least $5,000,001 upon such consummation and, solely if we seek stockholder approval, a majority of the issued and outstanding
shares of common stock voted are voted in favor of the business combination.
We chose our net tangible
asset threshold of $5,000,001 to ensure that we would avoid being subject to Rule 419 promulgated under the Securities Act.
However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital
closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial
business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as
we may be required to have a lesser number of shares converted or sold to us) and may force us to seek third party financing which
may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination
and we may not be able to locate another suitable target within the applicable time period, if at all. Public stockholders may
therefore have to wait 24 months from the closing of this offering in order to be able to receive a
pro rata
share of the
trust account.
Our initial stockholders
and our officers and directors have agreed (1) to vote any shares of common stock owned by them in favor of any proposed business
combination, (2) not to convert any shares of common stock in connection with a stockholder vote to approve a proposed initial
business combination and (3) not sell any shares of common stock in any tender in connection with a proposed initial business
combination. As a result, if we sought stockholder approval of a proposed transaction, we would need only 312,501 of our public
shares (or approximately 6.3% of our public shares) to be voted in favor of the transaction in order to have such transaction approved
(assuming that only a quorum was present at the meeting, that the over-allotment option is not exercised and that the initial stockholders
do not purchase any shares in this offering or shares in the after-market).
56
None of our officers,
directors, initial stockholders or their affiliates has indicated any intention to purchase shares of common stock in
this offering or from persons in the open market or in private transactions. However, if we hold a meeting to approve a proposed
business combination and a significant number of stockholders vote, or indicate an intention to vote, against such proposed business
combination, our officers, directors, initial stockholders or their affiliates could make such purchases in the open market or
in private transactions in order to influence the vote. Notwithstanding the foregoing, our officers, directors, initial stockholders
and their affiliates will not make purchases of common stock if the purchases would violate Section 9(a)(2) or Rule 10b-5
of the Exchange Act, which are rules designed to stop potential manipulation of a company's stock.
Conversion/Tender Rights
At any meeting called
to approve an initial business combination, public stockholders may seek to convert their public shares, regardless of whether
they vote for or against the proposed business combination, into their
pro rata
share of the aggregate amount then on deposit
in the trust account, less any taxes then due but not yet paid. Notwithstanding the foregoing, our initial stockholders have agreed,
pursuant to written letter agreements with us, not to convert any public shares held by them into their
pro rata
share of
the aggregate amount then on deposit in the trust account. If we hold a meeting to approve an initial business combination, a holder
will always have the ability to vote against a proposed business combination and not seek conversion of his shares.
Alternatively, if
we engage in a tender offer, each public stockholder will be provided the opportunity to sell his public shares to us in such tender
offer. The tender offer rules require us to hold the tender offer open for at least 20 business days. Accordingly, this is
the minimum amount of time we would need to provide holders to determine whether they want to sell their public shares to us in
the tender offer or remain an investor in our company.
Our initial stockholders,
officers and directors will not have conversion rights with respect to any shares of common stock owned by them, directly or indirectly,
whether acquired prior to this offering or purchased by them in this offering or in the aftermarket.
We may also require
public stockholders, whether they are a record holder or hold their shares in "street name," to either tender their
certificates (if any) to our transfer agent or to deliver their shares to the transfer agent electronically using Depository Trust
Company's DWAC (Deposit/Withdrawal At Custodian) System, at the holder's option, at any time at or prior to the vote
on the business combination. The proxy solicitation materials that we will furnish to stockholders in connection with the vote
for any proposed business combination will indicate whether we are requiring stockholders to satisfy such delivery requirements.
Accordingly, a stockholder would have from the time our proxy statement is mailed through the vote on the business combination
to deliver his shares if he wishes to seek to exercise his conversion rights. Under Delaware law and our bylaws, we are required
to provide at least 10 days' advance notice of any stockholder meeting, which would be the minimum amount of time a stockholder
would have to determine whether to exercise conversion rights. As a result, if we require public stockholders who wish to convert
their shares of common stock into the right to receive a
pro rata
portion of the funds in the trust account to comply with
the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares for conversion.
Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities when they
otherwise would not want to. The conversion rights will include the requirement that a beneficial holder must identify itself in
order to validly redeem its shares.
There is a nominal
cost associated with this tendering process and the act of certificating the shares or delivering them through the DWAC System.
The transfer agent will typically charge the tendering broker $45 and it would be up to the broker whether or not to pass this
cost on to the converting holder. However, this fee would be incurred regardless of whether or not we require holders seeking to
exercise conversion rights. The need to deliver shares is a requirement of exercising conversion rights regardless of the timing
of when such delivery must be effectuated. However, in the event we require stockholders seeking to exercise conversion rights
to deliver their shares prior to the consummation of the proposed business combination and the proposed business combination is
not consummated, this may result in an increased cost to stockholders.
57
Any request to convert
or tender such shares once made, may be withdrawn at any time up to the vote on the proposed business combination or expiration
of the tender offer. Furthermore, if a holder of a public share delivered his certificate in connection with an election of their
conversion or tender and subsequently decides prior to the vote on the business combination or the expiration of the tender offer
not to elect to exercise such rights, he may simply request that the transfer agent return the certificate (physically or electronically).
If the initial business
combination is not approved or completed for any reason, then our public stockholders who elected to exercise their conversion
or tender rights would not be entitled to convert their shares for the applicable
pro rata
share of the trust account. In
such case, we will promptly return any shares delivered by public holders.
Liquidation of Trust Account if No
Business Combination
If we do not complete
a business combination within 24 months from the closing of this offering, we will (i) cease all operations except for the
purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100%
of the outstanding public shares and (iii) as promptly as reasonably possible following such redemption, subject to the approval
of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above)
to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
Under the Delaware
General Corporation Law, stockholders may be held liable for claims by third parties against a corporation to the extent of distributions
received by them in a dissolution. The pro rata portion of our trust account distributed to our public stockholders upon the redemption
of 100% of our outstanding public shares in the event we do not complete our initial business combination within the required time
period may be considered a liquidation distribution under Delaware law. If the corporation complies with certain procedures set
forth in Section 280 of the Delaware General Corporation Law intended to ensure that it makes reasonable provision for all
claims against it, including a 60-day notice period during which any third-party claims can be brought against the corporation,
a 90-day period during which the corporation may reject any claims brought, and an additional 150-day waiting period before any
redemptions are made to stockholders, any liability of stockholders with respect to a redemption is limited to the lesser of such
stockholder's pro rata share of the claim or the amount distributed to the stockholder, and any liability of the stockholder
would be barred after the third anniversary of the dissolution.
Furthermore, if the
pro rata portion of our trust account distributed to our public stockholders upon the redemption of 100% of our public shares in
the event we do not complete our initial business combination within the required time period is not considered a liquidation distribution
under Delaware law and such redemption distribution is deemed to be unlawful, then pursuant to Section 174 of the Delaware
General Corporation Law, the statute of limitations for claims of creditors could then be six years after the unlawful redemption
distribution, instead of three years, as in the case of a liquidation distribution. It is our intention to redeem our public shares
as soon as reasonably possible following the 24
th
month from the closing of this offering and, therefore, we do not
intend to comply with the above procedures. As such, our stockholders could potentially be liable for any claims to the extent
of distributions received by them (but no more) and any liability of our stockholders may extend well beyond the third anniversary
of such date.
Because we will not
be complying with Section 280 of the Delaware General Corporation Law, Section 281(b) of the Delaware General Corporation
Law requires us to adopt a plan, based on facts known to us at such time that will provide for our payment of all existing and
pending claims or claims that may be potentially brought against us within the subsequent 10 years. However, because we are a blank
check company, rather than an operating company, and our operations will be limited to seeking to complete an initial business
combination, the only likely claims to arise would be from our vendors (such as lawyers, investment bankers, etc.) or prospective
target businesses.
We will seek to have
all third parties (including any vendors or other entities we engage after this offering) and any prospective target businesses
enter into valid and enforceable agreements with us waiving any right, title, interest or claim of any kind they may have in or
to any monies held in the trust account. The underwriters in this offering will execute such a waiver agreement.
58
As a result, the claims
that could be made against us will be limited, thereby lessening the likelihood that any claim would result in any liability extending
to the trust. We therefore believe that any necessary provision for creditors will be reduced and should not have a significant
impact on our ability to distribute the funds in the trust account to our public stockholders. Nevertheless, there is no guarantee
that vendors, service providers and prospective target businesses will execute such agreements. In the event that a potential contracted
party was to refuse to execute such a waiver, we will execute an agreement with that entity only if our management first determines
that we would be unable to obtain, on a reasonable basis, substantially similar services or opportunities from another entity willing
to execute such a waiver. Examples of instances where we may engage a third party that refused to execute a waiver would be the
engagement of a third party consultant who cannot sign such an agreement due to regulatory restrictions, such as our auditors who
are unable to sign due to independence requirements, or whose particular expertise or skills are believed by management to be superior
to those of other consultants that would agree to execute a waiver or a situation in which management does not believe it would
be able to find a provider of required services willing to provide the waiver. There is also no guarantee that, even if they execute
such agreements with us, they will not seek recourse against the trust account. Our insiders have agreed that they will be jointly
and severally liable to us if and to the extent any claims by a vendor for services rendered or products sold to us, or a prospective
target business with which we have discussed entering into a transaction agreement, reduce the amount of funds in the trust account
to below $10.00 per public share, except as to any claims by a third party who executed a valid and enforceable agreement with
us waiving any right, title, interest or claim of any kind they may have in or to any monies held in the trust account and except
as to any claims under our indemnity of the underwriters of this offering against certain liabilities, including liabilities under
the Securities Act. Our board of directors has evaluated our insiders' financial net worth and believes they will be able
to satisfy any indemnification obligations that may arise. However, our insiders may not be able to satisfy their indemnification
obligations, as we have not required our insiders to retain any assets to provide for their indemnification obligations, nor have
we taken any further steps to ensure that they will be able to satisfy any indemnification obligations that arise. Moreover, our
insiders will not be liable to our public stockholders and instead will only have liability to us. As a result, if we liquidate,
the per-share distribution from the trust account could be less than approximately $10.00 due to claims or potential claims of
creditors. We will distribute to all of our public stockholders, in proportion to their respective equity interests, an aggregate
sum equal to the amount then held in the trust account, inclusive of any interest not previously released to us, (subject to our
obligations under Delaware law to provide for claims of creditors as described below).
If we are unable to
consummate an initial business combination and are forced to redeem 100% of our outstanding public shares for a portion of the
funds held in the trust account, we anticipate notifying the trustee of the trust account to begin liquidating such assets promptly
after such date and anticipate it will take no more than 10 business days to effectuate the redemption of our public shares. Our
insiders have waived their rights to participate in any redemption with respect to their insider shares. We will pay the costs
of any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our insiders
have agreed to pay the funds necessary to complete such liquidation (currently anticipated to be no more than approximately $15,000)
and have agreed not to seek repayment of such expenses. Each holder of public shares will receive a full pro rata portion of the
amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not previously released
to us or necessary to pay our taxes or for working capital purposes up to $250,000 annually. The proceeds deposited in the trust
account could, however, become subject to claims of our creditors that are in preference to the claims of public stockholders.
Our public stockholders
shall be entitled to receive funds from the trust account only in the event of our failure to complete our initial business combination
in the required time period or if the stockholders seek to have us convert their respective shares of common stock upon a business
combination which is actually completed by us. In no other circumstances shall a stockholder have any right or interest of any
kind to or in the trust account.
If we are forced to
file a bankruptcy case or an involuntary bankruptcy case is filed against us which is not dismissed, the proceeds held in the trust
account could be subject to applicable bankruptcy law, and may be included in our bankruptcy estate and subject to the claims of
third parties with priority over the claims of our stockholders. To the extent any bankruptcy claims deplete the trust account,
the per share redemption or conversion amount received by public stockholders may be less than $10.00.
If, after we distribute
the proceeds in the trust account to our public stockholders, we file a bankruptcy petition or an involuntary bankruptcy petition
is filed against us that is not dismissed, any distributions received by stockholders could be viewed under applicable debtor/creditor
and/or bankruptcy laws as either a "preferential transfer" or a "fraudulent conveyance." As a result, a
bankruptcy court could seek to recover all amounts received by our stockholders. In addition, our board of directors may be viewed
as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us to claims
of punitive damages, by paying public stockholders from the trust account prior to addressing the claims of creditors. Claims may
be brought against us for these reasons.
59
Certificate of Incorporation
Our certificate of
incorporation contains certain requirements and restrictions relating to this offering that will apply to us until the consummation
of our initial business combination. If we hold a stockholder vote to amend any provisions of our certificate of incorporation
relating to stockholder's rights or pre-business combination activity (including the substance or timing within which we
have to complete a business combination), we will provide our public stockholders with the opportunity to redeem their shares of
common stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit
in the trust account, including interest earned on the funds held in the trust account and not previously released to us to pay
our franchise and income taxes or for working capital purposes up to $250,000 annually, divided by the number of then outstanding
public shares, in connection with any such vote. Our insiders have agreed to waive any conversion rights with respect to any insider
shares and any public shares they may hold in connection with any vote to amend our certificate of incorporation. Specifically,
our certificate of incorporation provides, among other things, that:
•
prior to the consummation of our initial business combination, we shall either (1) seek stockholder approval of our initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their shares of common stock, regardless of whether they vote for or against the proposed business combination, into a portion of the aggregate amount then on deposit in the trust account, or (2) provide our stockholders with the opportunity to sell their shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account, in each case subject to the limitations described herein;
•
we will consummate our initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause our net tangible assets to be less than $5,000,001 and a majority of the outstanding shares of common stock voted are voted in favor of the business combination;
•
if our initial business combination is not consummated within 24 months of the closing of this offering, then our existence will terminate and we will distribute all amounts in the trust account to all of our public holders of shares of common stock;
•
upon the consummation of this offering, $75,000,000, or $86,250,000 if the over-allotment option is exercised in full, shall be placed into the trust account;
•
we may not consummate any other business combination, merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar transaction prior to our initial business combination; and
•
prior to our initial business combination, we may not issue additional shares of capital stock that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote on any initial business combination.
Potential Revisions to Agreements
with Insiders
Each of our insiders
has entered into letter agreements with us pursuant to which each of them has agreed to do certain things relating to us and our
activities prior to a business combination. We could seek to amend these letter agreements without the approval of stockholders,
although we have no intention to do so. In particular:
•
Restrictions relating to liquidating the trust account if we failed to consummate a business combination in the time-frames specified above could be amended, but only if we allowed all stockholders to redeem their shares in connection with such amendment;
•
Restrictions relating to our insiders being required to vote in favor of a business combination or against any amendments to our organizational documents could be amended to allow our insiders to vote on a transaction as they wished;
•
The requirement of members of the management team to remain our officer or director until the closing of a business combination could be amended to allow persons to resign from their positions with us if, for example, the current management team was having difficulty locating a target business and another management team had a potential target business;
60
•
The restrictions on transfer of our securities could be amended to allow transfer to third parties who were not members of our original management team;
•
The obligation of our management team to not propose amendments to our organizational documents could be amended to allow them to propose such changes to our stockholders;
•
The obligation of insiders to not receive any compensation in connection with a business combination could be modified in order to allow them to receive such compensation;
•
The requirement to obtain a valuation for any target business affiliated with our insiders, in the event it was too expensive to do so.
Except as specified
above, stockholders would not be required to be given the opportunity to redeem their shares in connection with such changes. Such
changes could result in:
•
Our having an extended period of time to consummate a business combination (although with less in trust as a certain number of our stockholders would certainly redeem their shares in connection with any such extension);
•
Our insiders being able to vote against a business combination or in favor of changes to our organizational documents;
•
Our operations being controlled by a new management team that our stockholders did not elect to invest with;
•
Our insiders receiving compensation in connection with a business combination; and
•
Our insiders closing a transaction with one of their affiliates without receiving an independent valuation of such business.
We will not agree
to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if we believed
such a modification were necessary to complete a business combination). Each of our officers and directors have fiduciary obligations
to us requiring that they act in our best interests and the best interests of our stockholders.
Competition
In identifying, evaluating
and selecting a target business for our initial business combination, we may encounter intense competition from other entities
having a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout
funds, and operating businesses seeking strategic acquisitions. Many of these entities are well established and have significant
experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors
possess greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be
limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of
a target business. Furthermore, the requirement that we acquire a target business or businesses having a fair market value equal
to at least 80% of the value of the trust account (excluding any taxes payable) at the time of the agreement to enter into the
business combination, our obligation to pay cash in connection with our public stockholders who exercise their redemption rights may not be viewed favorably by certain
target businesses. Any of these factors may place us at a competitive disadvantage in successfully negotiating our initial business
combination.
Facilities
We will pay to an
affiliate of our sponsor a fee of $10,000 per month for use of office space and certain office and secretarial services. The office
space will be located at 250 W. 55th St., #3401, New York, NY 10019.
61
Employees
We currently have
two executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they intend
to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination.
The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial
business combination and the stage of the business combination process we are in. We do not intend to have any full time employees
prior to the consummation of our initial business combination.
Periodic Reporting and Audited Financial
Statements
We have registered
our shares of common stock under the Exchange Act and have reporting obligations, including the requirement
that we file annual, quarterly and current reports with the SEC. In accordance with the requirements of the Exchange Act, our annual
report will contain financial statements audited and reported on by our independent registered public accountants.
We will provide stockholders
with audited financial statements of the prospective target business as part of any proxy solicitation sent to stockholders to
assist them in assessing the target business. In all likelihood, the financial information included in the proxy solicitation materials
will need to be prepared in accordance with U.S. GAAP or IFRS, depending on the circumstances, and the historical financial statements
may be required to be audited in accordance with the standards of the PCAOB. The financial statements may also be required to be
prepared in accordance with U.S. GAAP for the Form 8-K announcing the closing of an initial business combination, which would
need to be filed within four business days thereafter. We cannot assure you that any particular target business identified by us
as a potential acquisition candidate will have the necessary financial information. To the extent that this requirement cannot
be met, we may not be able to acquire the proposed target business.
We will be required
to comply with the internal control requirements of the Sarbanes-Oxley Act beginning for the fiscal year ending June 30, 2022.
A target company may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy of their internal controls.
The development of the internal controls of any such entity to achieve compliance with the Sarbanes-Oxley Act may increase the
time and costs necessary to complete any such acquisition.
We are an "emerging
growth company," as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act. As such, we are
eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not "emerging growth companies" including, but not limited to, not being required to comply with the auditor
attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive
compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities
less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may
be more volatile.
In addition, Section 107
of the JOBS Act also provides that an "emerging growth company" can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other
words, an "emerging growth company" can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.
We will remain an
emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary
of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in
which we are deemed to be a large accelerated filer, which means the market value of our Class A common stock that is held
by non-affiliates exceeds $700 million as of the prior June 30
th
, and (2) the date on which we have issued
more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to "emerging
growth company" shall have the meaning associated with it in the JOBS Act.
62
Legal Proceedings
There is no material
litigation, arbitration or governmental proceeding currently pending against us or any of our officers or directors in their capacity
as such, and we and our officers and directors have not been subject to any such proceeding in the 12 months preceding the date
of this prospectus.
Comparison to Offerings of Blank Check
Companies Subject to Rule 419
The following table
compares and contrasts the terms of our offering and the terms of an offering of blank check companies under Rule 419 promulgated
by the SEC assuming that the gross proceeds, underwriting discounts and underwriting expenses for the Rule 419 offering are
the same as this offering and that the underwriters will not exercise their over-allotment option. None of the terms of a Rule 419
offering will apply to this offering because we will be listed on a national securities exchange, we will have net tangible assets
in excess of $5,000,001 upon the successful consummation of this offering and will file a Current Report on Form 8-K, including
an audited balance sheet demonstrating this fact.
Terms of the Offering
Terms Under a Rule 419 Offering
Escrow of offering proceeds
$75,000,000 of the net offering proceeds and proceeds from the sale of the private warrants
    will be deposited into a trust account in the United States, maintained by Continental Stock Transfer & Trust
    Company, acting as trustee.
$66,150,000 of the offering proceeds would be required to be deposited into either an escrow account with an insured depositary institution or in a separate bank account established by a broker-dealer in which the broker-dealer acts as trustee for persons having the beneficial interests in the account.
Investment of net proceeds
The $75,000,000 of the net offering proceeds and proceeds from the sale of
    the private warrants held in trust will only be invested in United States government treasury bills, bonds or notes with a
    maturity of 183 days or less or in money market funds meeting the applicable conditions under Rule 2a-7 promulgated
    under the Investment Company Act of 1940 and that invest solely in United States government treasuries.
Proceeds could be invested only in specified securities such as a money market fund meeting conditions of the Investment Company Act of 1940 or in securities that are direct obligations of, or obligations guaranteed as to principal or interest by, the United States.
Limitation on fair value or net assets of target business
The initial target business that we acquire must have a fair market value equal to at least 80% of the balance in our trust account net of taxes payable at the time of the execution of a definitive agreement for our initial business combination.
We would be restricted from acquiring a target business unless the fair value of such business or net assets to be acquired represent at least 80% of the maximum offering proceeds.
Trading of securities issued
The shares may commence trading on or promptly after the date of this prospectus.
No trading of the shares would be permitted until the completion of a
    business combination. During this period, the securities would be held in the escrow or trust account.
63
Terms of the Offering
Terms Under a Rule 419 Offering
Election to remain an investor
We will either (1) give our stockholders the opportunity to vote on the business combination or (2) provide our public stockholders with the opportunity to sell their public shares to us in a tender offer for cash equal to their
pro rata
share of the aggregate amount then on deposit in the trust account, less taxes. If we hold a meeting to approve a proposed business combination, we will send each stockholder a proxy statement containing information required by the SEC. Under our certificate of incorporation, we must provide at least 10 days advance notice of any meeting of stockholders. Accordingly, this is the minimum amount of time we would need to provide holders to determine whether to exercise their rights to convert their shares into cash at such a meeting or to remain an investor in our company. Alternatively, if we do not hold a meeting and instead conduct a tender offer, we will conduct such tender offer in accordance with the tender offer rules of the SEC and file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as we would have included in a proxy statement.
A prospectus containing information required by the SEC would be sent to each investor. Each investor would be given the opportunity to notify the company, in writing, within a period of no less than 20 business days and no more than 45 business days from the effective date of the post-effective amendment, to decide whether he or she elects to remain a stockholder of the company or require the return of his or her investment. If the company has not received the notification by the end of the 45
th
business day, funds and interest or dividends, if any, held in the trust or escrow account would automatically be returned to the stockholder. Unless a sufficient number of investors elect to remain investors, all of the deposited funds in the escrow account must be returned to all investors and none of the securities will be issued.
The tender offer rules require us to hold the tender offer open for at least 20 business days. Accordingly, this is the minimum amount of time we would need to provide holders to determine whether they want to sell their shares to us in the tender offer or remain an investor in our company.
64
Terms of the Offering
Terms Under a Rule
    419 Offering
Business combination deadline
Pursuant to our certificate of incorporation, if we do not complete an initial business combination within 24 months from the consummation of this offering, it will trigger our automatic winding up, dissolution and liquidation.
If an acquisition has not been consummated within 18 months after the effective date of the initial registration statement, funds held in the trust or escrow account would be returned to investors.
Interest earned on the funds in the trust account
There can be released to us, from time to time, (i) any interest earned on the funds in the trust account that we may need to pay our tax obligations and (ii) any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working capital requirements. The remaining interest earned on the funds in the trust account will not be released until the earlier of the completion of a business combination and our entry into liquidation upon failure to effect a business combination within the allotted time.
All interest earned on the funds in the trust account will be held in trust for the benefit of public stockholders until the earlier of the completion of a business combination and our liquidation upon failure to effect a business combination within the allotted time.
Release of funds
Except for interest earned on the funds held in the trust account that may be released to us to pay our tax obligations or for working capital purposes (provided that the fund released for working capital purposes may not exceed $250,000 annually), the proceeds held in the trust account will not be released until the earlier of the completion of a business combination (in which case, the proceeds released to us will be net of the funds used to pay converting or tendering stockholders, as the trustee will directly send the appropriate portion of the amount held in trust to the converting or tendering stockholders at the time of the business combination) and the liquidation of our trust account upon failure to effect a business combination within the allotted time.
The proceeds held in the escrow account would not be released until the earlier of the completion of a business combination or the failure to effect a business combination within the allotted time.
65
MANAGEMENT
Directors and Executive Officers
Our current directors, director nominees
and executive officers are as follows:
Name
Age
Position
Andrew McDonald, Ph.D.
46
Chairman, Chief Executive Officer and Board Member
Michael Rice
55
Chief Operating Officer and Board Member
David Dobkin
41
Chief Financial Officer and Board Member
Thomas Wynn
51
Board Member Nominee
Thomas Mathers
53
Board Member Nominee
Elizabeth Barrett
58
Board Member Nominee
Graham Walmsley
33
Board Member Nominee
Scott Janssen
51
Board Member Nominee
Andrew McDonald
,
our
Chief Executive Officer and Board Member since June 2019, is an experienced healthcare investment professional with expertise
in identifying transformative products and technologies in all stages of development. Andrew has been the Chairman and Chief Executive
Officer of LifeSci Acquisition Corp., a special purpose acquisition company, since June 2019. Andrew has served as the Chief
Executive Officer of Attune Pharmaceuticals since March 2015 and is a Founding Partner of LifeSci Advisors and LifeSci Capital.
Prior to founding LifeSci in March 2010, Andrew served as senior biotechnology analyst at Great Point Partners, a dedicated
life science hedge fund, from 2006 to 2008. From 2004 to 2006, Andrew was Head of Healthcare Research and a Biotechnology Analyst
at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal
chemist at Cytokinetics from 2001 to 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials.
Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine
and completed his B.S. in chemistry at UC Berkeley. Andrew holds the Series 7, 24, 63, 79, 86, and 87 licenses. We believe
Andrew is qualified to sit on our board due to his long-running healthcare advisory experience and background as a medicinal chemist.
Michael Rice
, our
Chief Operating Officer and Board Member since June 2019, has experience in portfolio management, corporate management, investment
banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital in March 2010, Michael was the co-head
of health care investment banking at Canaccord Adams from April 2007 to November 2008, where he was involved in debt
and equity financing. Michael was also was a Managing Director at ThinkEquity Partners from April 2005 to April 2007,
where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions,
many of which were firsts at ThinkEquity. Prior to that, from August 2003 to March 2005, Michael served as a Managing
Director at Banc of America, serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director
at JPMorgan/Hambrecht & Quist. Michael has been a director of RDD Pharma Ltd. since January 2016 and Navidea Biopharmaceuticals
Inc. since May 2016. Michael has been the Chief Operating Officer and a director of LifeSci Acquisition Corp., a special purpose
acquisition company, since June 2019. Michael received his BA from the University of Maryland. Michael holds the Series 7,
24, 63, and 79 licenses. We believe Michael is qualified to sit on our board due to his long-running healthcare advisory experience,
as well as his previous company board positions.
David Dobkin
,
our Chief Financial Officer and Board Member since June 2019, is an experienced healthcare capital markets investment banker
with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial
and strategic goals. David has been the Chief Financial Officer and a director of LifeSci Acquisition Corp., a special purpose
acquisition company, since June 2019. David has worked with companies developing a wide range of technologies and brings extensive
strategic advisory and execution capability to his clients. David has experience with both traditional and non-traditional forms
of equity and debt offerings in both the U.S. and abroad. He is a regular speaker on growth capital formation at conferences across
the United States and Canada. Prior to joining LifeSci Capital, David was a Managing Director at Boustead Securities. Prior to
that, in 2015, David founded Dobkin & Company, an investment bank tailored for entrepreneur-led companies focused on seed
and growth equity and capital, in 2015. Previously, from 2010 to 2015, David worked in various capacities with the New Zealand
Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic
foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October 2010, David
worked for Lazard Frères, one of the world's preeminent financial advisory and asset management firms, where he facilitated
and advised on cross-border mergers and acquisitions transactions in excess of $2.5 billion. Prior to joining for Lazard Frères,
David began his career in in the Healthcare investment banking group for Wasserstein Perella based in New York. At Wasserstein
Perella, David advised healthcare companies on capital formation as well as strategic alternatives. David conducted graduate research
in stem cell bioengineering and received a Master of Science, Biomedical Engineering, from the University of Southern California.
David also received a B.S. in Biomedical Engineering, from Columbia University. David holds the Series 63, 79, and 82 licenses.
We believe David is qualified to sit on our board due to his extensive experience in mergers and acquisitions.
66
Thomas Wynn
,
who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, has been a portfolio manager at Monashee Investment Management
since 2011. From 1995 to 2011, he co-founded and served as the Managing Director of Leerink Swann LLC, a Boston based healthcare
investment bank. From 1991 to 1995, he worked at Lehman Brothers. Thomas received his B.A from Fairfield University and J.D. from
Suffolk University We believe Thomas is qualified to sit on our board due to long-running experience in healthcare investing and
advisory services.
Thomas Mathers
,
who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, founded and has been the President and CEO at Allievex Corporation,
a company neurodegenerative diseases, since April 2018
.
He has also been a General Partner at Pappas Ventures V, a
venture capital company, since February 2018. Prior to Pappas Capital and Allievex, from June 2010 to March 2017,
Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a biotechnology company founded by Pappas Capital,
which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired
CoLucid in March 2017 in an all cash transaction for nearly $1 billion. Prior to CoLucid, he was President and CEO of Peptimmune, Inc.;
President and CEO of Cell Based Delivery, Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic
Development at Genzyme Corporation. Tom currently serves as a Trustee of Butler University and is co-founder and Chairman of Déclion
Holdings, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases.
He is also a business advisor to the Progeria Research Foundation, and previously served on the Board of Directors for the Biotechnology
Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property,
and regulatory policy. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for
his services as an AH-64 Apache helicopter pilot in the Gulf War. We believe Thomas is qualified to sit on our board due to his
long-running experience in early stage investing and experience on company boards.
Graham
Walmsley
, who will become our Board Member on the effective date of the registration statement of which this prospectus
is a part, has been the General Partner of Logos Global Management, LP, a biotechnology-focused investment partnership based in
San Francisco, since August 2019. He was a principal at Versant Ventures, a leading healthcare investment firm, from July 2016
until August 2019. He was the head of Business Development at Jecure Therapeutics, a developer of therapeutics targeting non-alcoholic
steatohepatitis and liver fibrosis from June 2017 until March 2019. From April 2018 to December 2018, he was
the Head of Business Development at Pipeline Therapeutics, a developer of neuro-regeneration drugs. From July 2012 to June 2016,
he was an Affiliated Trainee at Stanford Hospital & Clinics. He is currently a member of the Board of Directors of ALX
Oncology (NASDAQ: ALXO) and Akero Therapeutics (NASDAQ: AKRO). We believe Graham is qualified to sit on our board due to his extensive
experience in biotechnology investing and previous company board positions.
Elizabeth
Barrett
, who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, is a highly regarded
industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Since January 2019,
Liz has served as President and CEO of UroGen Pharma. Prior to UroGen, from February 2018 to January 2019, Liz was CEO of Novartis Oncology
and a member of the Novartis Executive Committee. She previously was previously at Pfizer Inc. from March 2009 to January 2019, where
she held numerous leadership positions, including Global President of Oncology, President of Global Innovative Pharma for Europe, President
of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, Liz held positions at
Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson &
Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from Saint
Joseph's University.
Scott
Janssen
, who will become our Board Member on the effective date of the registration statement of which this
prospectus is a part, has served as Managing Director of LifeSci Associates since June 2020. Previously, he was the Chief
Accounting Officer at CMG Partners from August 2019 to April 2020. Scott has over 25 years of accounting, finance and
operational experience working within and consulting to public and private companies within the life science and technology
space. Scott was a Managing Director of the Connor Group from January 2014 to August 2019 to where he supported his clients
by providing them accounting and operational consulting services. Mr. Janssen spent six years of his career from January 1993
to November 1999 as an auditor with Ernst & Young and Grant Thornton in the Bay Area and Los Angeles. He was a Managing
Director at Connor Group, a consulting firm from January 2014 to August 2019. Scott received a B.S. in Applied Mathematics
from the University of California, Los Angeles. We believe Scott is qualified to sit on our board due to his long-running
experience in accounting and finance consulting roles.
Number and Terms of Office of Officers and Directors
Upon consummation
of this offering, our board of directors will have 7 members, 4 of whom will be deemed "independent" under SEC and
Nasdaq rules. Our board of directors will be divided into three classes with only one class of directors being elected in each
year and each class serving a three-year term. The term of office of the first class of directors, consisting of Andrew McDonald,
Michael Rice, and David Dobkin will expire at our first annual meeting of stockholders. The term of office of the second class
of directors, consisting of Thomas Wynn, Thomas Mathers, Graham Walmsley, Elizabeth Barrett and Scott Janssen, will expire at the second annual meeting.
We may not hold an annual meeting of stockholders until after we consummate our initial business combination.
Pursuant to an agreement
to be entered into concurrently with the issuance and sale of the securities in this offering, our sponsor, upon consummation of
an initial business combination, will be entitled to nominate three individuals for election to our board of directors.
Our officers are appointed
by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our
board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws
provide that our directors may consist of a chairman of the board, and that our officers may consist of chief executive officer,
president, chief financial officer, executive vice president(s), vice president(s), secretary, treasurer and such other officers
as may be determined by the board of directors.
67
Executive Compensation
No executive officer
has received any cash compensation for services rendered to us. Commencing on the date of this prospectus through the completion
of our initial business combination with a target business, we will pay to LifeSci Holdings LLC a fee of $10,000 per month for
providing us with office space and certain office and secretarial services. However, pursuant to the terms of such agreement, we
may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the
trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue
without interest and be due and payable no later than the date of the consummation of our initial business combination. Other than
the $10,000 per month administrative fee, no compensation or fees of any kind, including finder's fees, consulting fees and
other similar fees, will be paid to our insiders or any of the members of our management team, for services rendered prior to or
in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However,
such individuals will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our
behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business
combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine
their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the
extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts
held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination.
After our initial
business combination, members of our management team who remain with us may be paid consulting, management or other fees from the
combined company with any and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation
materials furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of a stockholder
meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to
determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination
in a Current Report on Form 8-K, as required by the SEC.
Director Independence
Nasdaq listing standards
require that within one year of the listing of our securities on the Nasdaq Capital Market we have at least three independent directors
and that a majority of our board of directors be independent. An "independent director" is defined generally as a person
other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the
opinion of the company's board of directors, would interfere with the director's exercise of independent judgment in
carrying out the responsibilities of a director. Our Board of Directors had determined that Thomas Wynn, Thomas Mathers, Graham
Walmsley, Elizabeth Barrett and Scott Janssen are "independent directors" as defined in the Nasdaq listing standards
and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors
are present.
We will only enter
into a business combination if it is approved by a majority of our independent directors. Additionally, we will only enter into
transactions with our officers and directors and their respective affiliates that are on terms no less favorable to us than could
be obtained from independent parties. Any related-party transactions must be approved by our audit committee and a majority of
disinterested directors.
Audit Committee
Effective as of the
date of this prospectus, we will establish an audit committee of the board of directors, which will consist of Thomas Wynn, Thomas
Mathers and Elizabeth Barrett, each of whom is an independent director. Thomas Wynn will serve as chairman of the audit committee.
The audit committee's duties, which are specified in our Audit Committee Charter, include, but are not limited to:
•
reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K;
•
discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements;
•
discussing with management major risk assessment and risk management policies;
•
monitoring the independence of the independent auditor;
•
verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law;
•
reviewing and approving all related-party transactions;
•
inquiring and discussing with management our compliance with applicable laws and regulations;
•
pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed;
•
appointing or replacing the independent auditor;
•
determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work;
•
establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and
•
approving reimbursement of expenses incurred by our management team in identifying potential target businesses.
68
Financial Experts on Audit Committee
The audit committee
will at all times be composed exclusively of "independent directors" who are "financially literate" as
defined under the Nasdaq listing standards. The Nasdaq listing standards define "financially literate" as being able
to read and understand fundamental financial statements, including a company's balance sheet, income statement and cash flow
statement.
In addition, we must
certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in
finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results
in the individual's financial sophistication. The board of directors has determined that Thomas Wynn qualifies as an "audit
committee financial expert," as defined under rules and regulations of the SEC.
Nominating Committee
Effective as of the
date of this prospectus, we have established a nominating committee of the board of directors, which will consist of Thomas Mathers,
Graham Walmsley and Scott Janssen each of whom is an independent director under Nasdaq's listing standards. Thomas Mathers
is the Chairperson of the nominating committee. The nominating committee is responsible for overseeing the selection of persons
to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management,
stockholders, investment bankers and others.
Guidelines for Selecting Director Nominees
The guidelines for
selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated:
•
should have demonstrated notable or significant achievements
in business, education or public service;
•
should possess the requisite intelligence, education
and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives
and backgrounds to its deliberations; and
•
should have the highest ethical standards, a strong sense
of professionalism and intense dedication to serving the interests of the stockholders.
The nominating committee
will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism
in evaluating a person's candidacy for membership on the board of directors. The nominating committee may require certain
skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and
will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating
committee does not distinguish among nominees recommended by stockholders and other persons.
Compensation Committee
Upon the effectiveness
of the registration statement of which this prospectus forms a part, we will establish a compensation committee of the board of
directors consisting of Scott Janssen, Thomas Wynn and Graham Walmsley, each of whom is an independent director. Scott Janssen
will serve as chairman of the compensation committee. We will adopt a compensation committee charter, which will detail the principal
functions of the compensation committee, including:
•
reviewing and approving on an annual basis the corporate goals and objectives relevant to our President and Chief Executive Officer's compensation, evaluating our President and Chief Executive Officer's performance in light of such goals and objectives and determining and approving the remuneration (if any) of our President and Chief Executive Officer based on such evaluation;
•
reviewing and approving the compensation of all of our other executive officers;
•
reviewing our executive compensation policies and plans;
•
implementing and administering our incentive compensation equity-based remuneration plans;
•
assisting management in complying with our proxy statement and annual report disclosure requirements;
•
approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees;
•
producing a report on executive compensation to be included in our annual proxy statement; and
•
reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.
69
The charter will also
provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant,
legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of
any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other
adviser, the compensation committee will consider the independence of each such adviser, including the factors required by NASDAQ
and the SEC.
Compensation Committee Interlocks and
Insider Participation
We may not have a
compensation committee in place prior to the completion of our initial business combination. Any executive compensation matters
that arise prior to the time we have a compensation committee in place will be determined by our independent directors. None of
our directors who currently serve as members of our compensation committee is, or has at any time in the past been, one of our
officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the compensation
committee of any other entity that has one or more executive officers serving on our board of directors. None of our executive
officers currently serves, or in the past year has served, as a member of the board of directors of any other entity that has one
or more executive officers serving on our compensation committee.
Code of Ethics
Effective upon consummation
of this offering, we will adopt a code of ethics that applies to all of our executive officers, directors and employees. The code
of ethics codifies the business and ethical principles that govern all aspects of our business.
Conflicts of Interest
Investors should be
aware of the following potential conflicts of interest:
•
None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities.
•
In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our officers and directors may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
•
Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company.
•
Unless we consummate our initial business combination, our officers, directors and other insiders will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that such expenses exceed the amount of available proceeds not deposited in the trust account.
•
The insider shares beneficially owned by our officers and directors
will be released from escrow only if our initial business combination is successfully completed. Additionally, if we are unable
to complete an initial business combination within the required time frame, our officers and directors will not be entitled to
receive any amounts held in the trust account with respect to any of their insider shares or private warrants. Furthermore, our sponsor
has agreed that the private warrants will not be sold or transferred by it until after we have completed our initial business combination.
For the foregoing reasons, our board may have a conflict of interest in determining whether a particular target business is an
appropriate business with which to effect our initial business combination.
In general, officers
and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities
to a corporation if:
•
the corporation could financially undertake the opportunity;
•
the opportunity is within the corporation's line of business; and
•
it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.
70
Accordingly, as a
result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting
business opportunities meeting the above-listed criteria to multiple entities. Furthermore, our certificate of incorporation provides
that the doctrine of corporate opportunity will not apply with respect to any of our officers or directors in circumstances where
the application of the doctrine would conflict with any fiduciary duties or contractual obligations they may have. In order to
minimize potential conflicts of interest which may arise from multiple affiliations, our officers and directors (other than our
independent directors) have agreed to present to us for our consideration, prior to presentation to any other person or entity,
any suitable opportunity to acquire a target business, until the earlier of: (1) our consummation of an initial business combination
and (2) 24 months from the date of this prospectus. This agreement is, however, subject to any pre-existing fiduciary and
contractual obligations such officer or director may from time to time have to another entity. Accordingly, if any of them becomes
aware of a business combination opportunity which is suitable for an entity to which he or she has pre-existing fiduciary or contractual
obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity
to such entity, and only present it to us if such entity rejects the opportunity. We do not believe, however, that the pre-existing
fiduciary duties or contractual obligations of our officers and directors will materially undermine our ability to complete our
business combination because in most cases the affiliated companies are closely held entities controlled by the officer or director
or the nature of the affiliated company's business is such that it is unlikely that a conflict will arise.
Three of our officers
and directors, Andrew McDonald, Michael Rice and David Dobkin are officers and directors of LifeSci Acquisition Corp., a special
purpose acquisition company that is seeking a target. LifeSci Acquisition Corp. will have priority over us in connection with potential
target businesses identified by each of them.
The following table
summarizes the current material pre-existing fiduciary or contractual obligations of our officers, directors and director nominees:
Name of Individual
Name of Affiliated
Company
Entity's Business
Affiliation
Andrew McDonald, PhD
LifeSci Capital LLC
LifeSci Advisors LLC
LifeSci Venture Management LLC
LifeSci Index Partners LLC
Attune Pharmaceuticals, Inc.
LifeSci Acquisition Corp.
Healthcare investment bank
Healthcare investor and public relations firm
Healthcare venture capital firm
Index provider of healthcare-based stock market indices
Novel orally administered small molecule
therapeutics for the treatment of rare diseases
Special Purpose Acquisition Company
Co-Founder
Co-Founder
Partner
Member
Co-Founder and Chief Executive Officer
Chairman and Chief Executive Officer
Michael Rice
LifeSci Capital LLC
LifeSci Advisors LLC
LifeSci Venture Management LLC
LifeSci Index Partners LLC
LifeSci Acquisition Corp.
Healthcare investment bank
Healthcare investor and public relations firm
Healthcare venture capital firm
Index provider of healthcare-based stock
        market indices
Special Purpose Acquisition Company
Co-Founder
Co-Founder
Partner
Member
Chief Operating Officer and Director
David Dobkin
LifeSci Capital, LLC
LifeSci Acquisition Corp.
Healthcare investment bank
Special Purpose Acquisition Company
Managing Director
Chief Financial Officer and director
Thomas Wynn
Monashee Investment Management
Investment management
Portfolio Manager
Thomas Mathers
Allievex Corporation
Pappas Ventures V
Neurodegenerative diseases
Venture Capital
President and CEO
General Partner
Graham Walmsley
Logos Global Management, LP
ALX Oncology
Akero Therapeutics
Biotechnology investment
Cancer treatments
Non-alcoholic liver disease treatments
General Partner
Director
Director
Elizabeth Barrett
UroGen Pharma Ltd.
Sage Therapeutics Inc.
Biopharmaceutical company
Biopharmaceutical company
President and
CEO
Director
We
have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our
sponsor. Further,
our insiders, including our officers and directors, have agreed to vote any shares of common stock
held by them in favor of our initial business combination. In addition, they have agreed to waive their respective rights to receive
any amounts held in the trust account with respect to their insider shares and private warrants if we are unable to complete our
initial business combination within the required time frame. If they purchase shares of common stock in this offering or in the
open market, however, they would be entitled to receive their pro rata share of the amounts held in the trust account if we are
unable to complete our initial business combination within the required time frame, but have agreed not to convert such shares
in connection with the consummation of our initial business combination.
All ongoing and future
transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to
be no less favorable to us than are available from unaffiliated third parties. Such transactions will require prior approval by
our audit committee and a majority of our uninterested "independent" directors, or the members of our board who do
not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel.
We will not enter into any such transaction unless our audit committee and a majority of our disinterested "independent"
directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with
respect to such a transaction from unaffiliated third parties.
71
To further minimize
conflicts of interest, we have agreed not to consummate our initial business combination with an entity that is affiliated with
any of our officers, directors or other insiders, unless we have obtained (i) an opinion from an independent investment banking
firm that the business combination is fair to our unaffiliated stockholders from a financial point of view and (ii) the approval
of a majority of our disinterested and independent directors (if we have any at that time). In no event will our insiders or any
of the members of our management team be paid any finder's fee, consulting fee or other similar compensation prior to, or
for any services they render in order to effectuate, the consummation of our initial business combination (regardless of the type
of transaction that it is).
Limitation on Liability and Indemnification
of Directors and Officers
Our certificate of
incorporation provides that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware law
as it now exists or may in the future be amended. In addition, our certificate of incorporation provides that our directors will
not be personally liable for monetary damages to us for breaches of their fiduciary duty as directors, unless they violated their
duty of loyalty to us or our stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful
payments of dividends, unlawful stock purchases or unlawful redemptions, or derived an improper personal benefit from their actions
as directors. Notwithstanding the foregoing, as set forth in our certificate of incorporation, such indemnification will not extend
to any claims our insiders may make to us to cover any loss that they may sustain as a result of their agreement to pay debts and
obligations to target businesses or vendors or other entities that are owed money by us for services rendered or contracted for
or products sold to us as described elsewhere in this prospectus.
Our bylaws also will
permit us to secure insurance on behalf of any officer, director or employee for any liability arising out of his or her actions,
regardless of whether Delaware law would permit indemnification. We will purchase a policy of directors' and officers'
liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment in
some circumstances and insures us against our obligations to indemnify the directors and officers.
These provisions may
discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also
may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action,
if successful, might otherwise benefit us and our stockholders. Furthermore, a stockholder's investment may be adversely
affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these provisions.
We believe that these provisions, the insurance and the indemnity agreements are necessary to attract and retain talented and experienced
directors and officers.
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to
the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public
policy as expressed in the Securities Act and is, therefore, unenforceable.
72
PRINCIPAL STOCKHOLDERS
The following table
sets forth information regarding the beneficial ownership of our shares of common stock as of the date of this prospectus and as
adjusted to reflect the sale of our shares of common stock offered by this prospectus (assuming none of the individuals listed
purchase shares in this offering), by:
•
each person known by us to be the beneficial owner of more than 5% of our issued and outstanding shares of common stock;
•
each of our officers and directors; and
•
all of our officers and directors as a group.
Unless otherwise indicated,
we believe that all persons named in the table have sole voting and investment power with respect to all shares of common stock
beneficially owned by them.
Prior to Offering
After Offering
(2)
Name and Address of Beneficial Owner
(1)
Amount
and Nature of
Beneficial
Ownership
Approximate
Percentage of
Outstanding
Shares of
Common
Stock
Amount
and Nature of
Beneficial
Ownership
Approximate
Percentage of
Outstanding Shares
of Common
Stock
Andrew McDonald Ph.D.
1,910,625
(3)
88.6
%
1,660,500
17.7
%
Michael Rice
1,910,625
(3)
88.6
%
1,660,500
17.7
%
David Dobkin
0
0
0
0
Thomas Wynn
6,000
*
6,000
*
Thomas Mathers
6,000
*
6,000
*
Graham Walmsley
6,000
*
6,000
*
Elizabeth Barrett
6,000
*
6,000
*
Scott Janssen
6,000
*
6,000
*
All officers and directors as a group (7 individuals)
1,940,625
90.0
%
1,690,500
18.0
%
LifeSci Holdings LLC
(4)
1,910,625
88.6
%
1,660,500
17.7
%
Chardan Healthcare Investments LLC
215,625
10.0
%
187,500
2.0
%
*
Less than 1%.
(1)
Unless otherwise indicated, the business address of each of the individuals is c/o LifeSci Acquisition II Corp., 250 W. 55th St., #3401, New York, NY 10019
(2)
Assumes no exercise of the over-allotment option and, therefore, an aggregate of 281,250 shares of common stock held by our initial stockholders are forfeited.
(3)
Consists of shares of common stock owned by LifeSci Holdings
LLC, for which Michael Rice and Andrew McDonald are the managing members.
(4)
Michael Rice and Andrew McDonald are the managing members of
LifeSci Holdings LLC.
Immediately after
this offering, our initial stockholders will beneficially own 20% of the then issued and outstanding shares of common stock (assuming
none of them purchase any shares offered by this prospectus and excluding the private warrants). None of our initial stockholders,
officers and directors has indicated to us that he intends to purchase securities in this offering. Because of the ownership block
held by our initial stockholders, such individuals may be able to effectively exercise control over all matters requiring approval
by our stockholders, including the election of directors and approval of significant corporate transactions other than approval
of our initial business combination.
If the underwriters
do not exercise all or a portion of the over-allotment option, our initial stockholders will have up to an aggregate 281,250 shares
of common stock subject to forfeiture. Only a number of shares necessary to maintain our initial stockholders' collective
20% ownership interest in our shares of common stock after giving effect to the offering and the exercise, if any, of the underwriters'
over-allotment option will be forfeited and excluding the private warrants.
73
All of the insider
shares issued and outstanding prior to the date of this prospectus will be placed in escrow with Continental Stock Transfer &
Trust Company, as escrow agent, until (1) with respect to 50% of the insider shares, the earlier of six months after the date
of the consummation of our initial business combination and the date on which the closing price of our common stock equals or exceeds
$12.50 per share (as adjusted for share splits, share capitalizations, reorganizations and recapitalizations) for any 20 trading
days within any 30-trading day period commencing after our initial business combination and (2) with respect to the remaining
50% of the insider shares, six months after the date of the consummation of our initial business combination, or earlier, in either
case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar
transaction which results in all of our stockholders having the right to exchange their shares for cash, securities or other property.
Up to 281,250 of the insider shares may also be released from escrow earlier than this date for forfeiture and cancellation if
the over-allotment option is not exercised in full as described above.
During the escrow
period, the holders of these shares will not be able to sell or transfer their securities except (i) for transfers to our
officers, directors or their respective affiliates (including for transfers to an entity's members upon its liquidation),
(ii) to relatives and trusts for estate planning purposes, (iii) by virtue of the laws of descent and distribution upon
death, (iv) pursuant to a qualified domestic relations order, (v) by certain pledges to secure obligations incurred in
connection with purchases of our securities, (vi) by private sales made at or prior to the consummation of a business combination
at prices no greater than the price at which the shares were originally purchased or (vii) to us for no value for cancellation
in connection with the consummation of our initial business combination, in each case (except for clause (vii)) where the transferee
agrees to the terms of the escrow agreement, but will retain all other rights as our stockholders, including, without limitation,
the right to vote their shares of common stock and the right to receive cash dividends, if declared. If dividends are declared
and payable in shares of common stock, such dividends will also be placed in escrow. If we are unable to effect a business combination
and liquidate the trust account, none of our initial stockholders will receive any portion of the liquidation proceeds with respect
to their insider shares.
In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants,"
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
If we do not complete our initial business combination within 24 months from the closing of this offering, the proceeds from the
sale of the private warrants will be included in the liquidating distribution to the holders of our public shares. The private
warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the
initial purchasers or their permitted transferees. The private warrants will not be transferable, assignable or saleable until
after the completion of a business combination, subject to the limited exceptions described above. The private warrants purchased
by our sponsor will not be exercisable more than five years from the commencement of sales of this offering in accordance with
FINRA Rule 5110(g)(8)(A), as long as our sponsor or any of its related persons beneficially own these private warrants.
In order to meet our
working capital needs following the consummation of this offering, our initial stockholders, officers and directors or their affiliates
may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their
sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of our initial
business combination, without interest, or, at the lender's discretion, up to $500,000 of the notes may be converted upon
consummation of our business combination into additional private warrants at a conversion price of $0.90 per private warrant. Our
directors have approved the issuance of the private warrants upon conversion of such notes, to the extent the holder wishes to
so convert them at the time of the consummation of our initial business combination. If we do not complete a business combination,
the loans will not be repaid.
LifeSci Holdings LLC
is our "promoter," as that term is defined under the Federal securities laws.
74
CERTAIN TRANSACTIONS
On January 1,
2020, our sponsor purchased 2,156,250 founder shares for an aggregate purchase price of $25,000. On September 30, 2020, LifeSci
Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our sponsor. The founder
shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters' over-allotment
option is not exercised in full or in part.
If the underwriters
do not exercise all or a portion of their over-allotment option, our initial stockholders have agreed that up to an aggregate of
281,250 shares of common stock in proportion to the portion of the over-allotment option that was not exercised are subject to
forfeiture and would be immediately cancelled.
If the underwriters
determine the size of the offering should be increased (including pursuant to Rule 462(b) under the Securities Act) or
decreased, a share capitalizations or a contribution back to capital, as applicable, would be effectuated in order to maintain
our initial stockholder's ownership at 20% of the number of shares issued and outstanding after the closing of this offering.
In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants,"
at $0.90 per warrant for a total purchase price of $2,730,000. Each private warrant is exercisable for one (1) share of common
stock at an exercise price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of
our initial business combination and 12 months from the closing of this offering and will expire five years after the effective
date of the registration statement of which this prospectus forms a part. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
The private warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to
be held by the initial purchasers or their permitted transferees. The private warrants will not be transferable, assignable or
saleable until after the completion of a business combination, subject to the limited exceptions described above. The private warrants
purchased by our sponsor will not be exercisable more than five years from the commencement of sales of this offering in accordance
with FINRA Rule 5110(g)(8)(A), as long as our sponsor or any of its related persons beneficially own these private warrants.
In order to meet our
working capital needs following the consummation of this offering, our initial stockholders, officers and directors and their respective
affiliates may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable
in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of
our initial business combination, without interest, or, at the lender's discretion, up to $500,000 of the notes may be converted
upon consummation of our business combination into additional private warrants at a conversion price of $0.90 per private warrant.
Our directors have approved the issuance of the private warrants upon conversion of such notes, to the extent the holder wishes
to so convert them at the time of the consummation of our initial business combination. If we do not complete a business combination,
the loans would not be repaid.
The holders of our
insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants, will be entitled
to registration and stockholder rights pursuant to an agreement to be signed prior to or on the effective date of this offering.
The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders
of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior
to the date on which these shares of common stock are to be released from escrow. In addition, the holders have certain "piggy-back"
registration rights with respect to registration statements filed subsequent to our consummation of a business combination.
We
will bear the expenses incurred in connection with the filing of any such registration statements.
Our sponsor and its related
persons may not, with respect to the private warrants purchased by it, (i) have more than one demand registration right at
our expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration
statement of which this prospectus forms a part, and (iii) exercise their "piggy-back" registration rights more
than seven (7) years from the commencement of sales of the offering as long as our sponsor or any of its related persons are
beneficial owners of private placement warrants.
Pursuant to the registration
rights and stockholder rights agreement our sponsor will be entitled, upon consummation of our initial business combination, to
nominate three individuals for election to our board of directors, which is described under the section of this prospectus entitled
 "Description of Securities—Registration and Stockholder Rights."
75
We will reimburse
our officers and directors for any reasonable out-of-pocket business expenses incurred by them in connection with certain activities
on our behalf such as identifying and investigating possible target businesses and business combinations. There is no limit on
the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available
proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses
would not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve
all reimbursements and payments made to any initial stockholder or member of our management team, or our or their respective affiliates,
and any reimbursements and payments made to members of our audit committee will be reviewed and approved by our Board of Directors,
with any interested director abstaining from such review and approval.
No compensation or
fees of any kind, including finder's fees, consulting fees or other similar compensation, will be paid to any of our initial
stockholders, officers or directors who owned our shares of common stock prior to this offering, or to any of their respective
affiliates, prior to or with respect to the business combination (regardless of the type of transaction that it is).
All ongoing and future
transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to
be no less favorable to us than are available from unaffiliated third parties. Such transactions, including the payment of any
compensation, will require prior approval by a majority of our uninterested "independent" directors (to the extent
we have any) or the members of our board who do not have an interest in the transaction, in either case who had access, at our
expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our disinterested "independent"
directors (or, if there are no "independent" directors, our disinterested directors) determine that the terms of such
transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated
third parties.
Related Party Policy
Our Code of Ethics,
which we will adopt upon consummation of this offering, will require us to avoid, wherever possible, all related party transactions
that could result in actual or potential conflicts of interests, except under guidelines approved by the board of directors (or
the audit committee). Related-party transactions are defined as transactions in which (1) the aggregate amount involved will
or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries is a participant, and (3) any
(a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner of our common
stock, or (c) immediate family member, of the persons referred to in clauses (a) and (b), has or will have a direct or
indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity).
A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his
or her work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives
improper personal benefits as a result of his or her position.
Our audit committee,
pursuant to its written charter, will be responsible for reviewing and approving related-party transactions to the extent we enter
into such transactions. All ongoing and future transactions between us and any of our officers and directors or their respective
affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such
transactions will require prior approval by our audit committee and a majority of our uninterested "independent" directors,
or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our
attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of
our disinterested "independent" directors determine that the terms of such transaction are no less favorable to us
than those that would be available to us with respect to such a transaction from unaffiliated third parties. Additionally, we require
each of our directors and executive officers to complete a directors' and officers' questionnaire that elicits information
about related party transactions.
These procedures are
intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict
of interest on the part of a director, employee or officer.
To further minimize
potential conflicts of interest, we have agreed not to consummate a business combination with an entity which is affiliated with
any of our initial stockholders unless we obtain an opinion from an independent investment banking firm that the business combination
is fair to our unaffiliated stockholders from a financial point of view. Furthermore, in no event will any of our existing officers,
directors or initial stockholders, or any entity with which they are affiliated, be paid any finder's fee, consulting fee
or other compensation prior to, or for any services they render in order to effectuate, the consummation of a business combination.
76
DESCRIPTION OF SECURITIES
General
Pursuant to our amended
certificate of incorporation, our authorized capital stock consists of 30,000,000 shares of common stock, par value $0.0001, and
1,000,000 shares of preferred stock, par value $0.0001. As of the date of this prospectus, 2,156,250 shares of common stock are
issued and outstanding, held our sponsor, our directors, and affiliates of our management team. No preferred shares are issued
or outstanding.
Common Stock
Our holders of record
of our common stock are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with
any vote held to approve our initial business combination, our insiders, officers and directors, have agreed to vote their respective
shares of common stock owned by them immediately prior to this offering, including both the insider shares and any shares acquired
in this offering or following this offering in the open market, in favor of the proposed business combination.
We will consummate
our initial business combination only if public stockholders do not exercise conversion rights in an amount that would cause our
net tangible assets to be less than $5,000,001 and a majority of the outstanding shares of common stock voted are voted in favor
of the business combination.
Pursuant to our certificate
of incorporation, if we do not consummate our initial business combination within 24 months from the closing of this offering,
we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not
more than ten business days thereafter, redeem 100% of the outstanding public shares, which redemption will completely extinguish
public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our
remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above)
to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our insiders
have agreed to waive their rights to share in any distribution with respect to their insider shares.
Our stockholders have
no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the
shares of common stock, except that public stockholders have the right to sell their shares to us in any tender offer or have their
shares of common stock converted to cash equal to their pro rata share of the trust account if they vote on the proposed business
combination and the business combination is completed.
77
If we hold a stockholder
vote to amend any provisions of our certificate of incorporation relating to stockholder's rights or pre-business combination
activity (including the substance or timing within which we have to complete a business combination), we will provide our public
stockholders with the opportunity to redeem their shares of common stock upon approval of any such amendment at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held
in the trust account and not previously released to us to pay our franchise and income taxes or for working capital purposes, divided
by the number of then outstanding public shares, in connection with any such vote. In either of such events, converting stockholders
would be paid their pro rata portion of the trust account promptly following consummation of the business combination or the approval
of the amendment to the certificate of incorporation. If the business combination is not consummated or the amendment is not approved,
stockholders will not be paid such amounts.
Preferred Stock
There are no shares
of preferred stock outstanding. No shares of preferred stock are being issued or registered in this offering. Accordingly, our
board of directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion,
voting or other rights which could adversely affect the voting power or other rights of the holders of common stock. However, the
underwriting agreement prohibits us, prior to a business combination, from issuing preferred stock which participates in any manner
in the proceeds of the trust account, or which votes as a class with the common stock on our initial business combination. We may
issue some or all of the preferred stock to effect our initial business combination. In addition, the preferred stock could be
utilized as a method of discouraging, delaying or preventing a change in control of us. Although we do not currently intend to
issue any shares of preferred stock, we reserve the right to do so in the future.
Private Warrants
No warrants are currently
outstanding. Each private warrant entitles the registered holder to purchase one share of common stock at a price of $11.50 per
whole share, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of this
offering or the consummation of an initial business combination.
The private warrants
will not be exercisable more than five years from the commencement of sales of this offering in accordance with FINRA Rule 5110(g)(8)(A),
as long as our sponsor or any of its related persons beneficially own these private warrants.
The exercise price
and number of shares of common stock issuable on exercise of the warrants may be adjusted in certain circumstances including in
the event of a share dividend, extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However,
the warrants will not be adjusted for issuances of shares of common stock at a price below their respective exercise prices.
The warrants may be
exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with
the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment
of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant
holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their
warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the warrants, each holder
will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.
Dividends
We have not paid any
cash dividends on our shares of common stock to date and do not intend to pay cash dividends prior to the completion of a business
combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements
and general financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to
a business combination will be within the discretion of our then board of directors. It is the present intention of our board of
directors to retain all earnings, if any, for use in our business operations and, accordingly, our board does not anticipate declaring
any dividends in the foreseeable future.
Our Transfer Agent
The transfer agent
for our shares of common stock is Continental Stock Transfer & Trust Company, 1 State
Street, 30th Floor, New York, New York 10004.
Certain Anti-Takeover Provisions of Delaware Law and our
Certificate of Incorporation and By-Laws
We have opted out
of Section 203 of the Delaware General Corporate Law, or the DGCL. However, our amended and restated certificate of incorporation
contains similar provisions providing that we may not engage in certain "business combinations" with any "interested
stockholder" for a three-year period following the time that the stockholder became an interested stockholder, unless:
•
prior to such time, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
•
upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of our voting stock outstanding at the time the transaction commenced, excluding certain shares; or
•
at or subsequent to that time, the business combination is approved by our board of directors and by the affirmative vote of holders of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.
Generally, a "business
combination" includes a merger, asset or stock sale or certain other transactions resulting in a financial benefit to the
interested stockholder. Subject to certain exceptions, an "interested stockholder" is a person who, together with that
person's affiliates and associates, owns, or within the previous three years owned, 20% or more of our voting stock.
Under certain circumstances,
this provision will make it more difficult for a person who would be an "interested stockholder" to effect various
business combinations with a corporation for a three-year period. This provision may encourage companies interested in acquiring
our company to negotiate in advance with our board of directors because the stockholder approval requirement would be avoided if
our board of directors approves either the business combination or the transaction which results in the stockholder becoming an
interested stockholder. These provisions also may have the effect of preventing changes in our board of directors and may make
it more difficult to accomplish transactions which stockholders may otherwise deem to be in their best interests.
78
Our amended and restated
certificate of incorporation provides that our sponsor and its respective affiliates, any of their respective direct or indirect
transferees of at least 20% of our outstanding common stock and any group as to which such persons are party to, do not constitute
 "interested stockholders" for purposes of this provision.
Special meeting of stockholders
Our bylaws provide
that special meetings of our stockholders may be called only by a majority vote of our board of directors, by our chief executive
officer or by our chairman.
Advance notice requirements for stockholder proposals and
director nominations
Our bylaws provide
that stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as
directors at our annual meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder's
notice will need to be delivered to our principal executive offices not later than the close of business on the 90
th
day nor earlier than the opening of business on the 120
th
day prior to the scheduled date of the annual meeting of stockholders.
Our bylaws also specify certain requirements as to the form and content of a stockholders' meeting. These provisions may
preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors
at our annual meeting of stockholders.
Authorized but unissued shares
Our authorized but
unissued common stock and preferred stock are available for future issuances without stockholder approval and could be utilized
for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit
plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or
discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.
Exclusive forum for certain lawsuits
Our amended and restated
certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative forum, the Court
of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for any (1) derivative
action or proceeding brought on behalf of our company, (2) action asserting a claim of breach of a fiduciary duty owed by
any director, officer, employee or agent of our company to our company or our stockholders, or any claim for aiding and abetting
any such alleged breach, (3) action asserting a claim against our company or any director or officer of our company arising
pursuant to any provision of the DGCL or our amended and restated certificate of incorporation or our bylaws, or (4) action
asserting a claim against us or any director or officer of our company governed by the internal affairs doctrine except for, as
to each of (1) through (4) above, any claim (A) as to which the Court of Chancery determines that there is an indispensable
party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction
of the Court of Chancery within ten days following such determination), (B) which is vested in the exclusive jurisdiction
of a court or forum other than the Court of Chancery, or (C) arising under the federal securities laws, including the Securities
Act as to which the Court of Chancery and the federal district court for the District of Delaware shall concurrently be the sole
and exclusive forums. Notwithstanding the foregoing, the inclusion of such provision in our amended and restated certificate of
incorporation will not be deemed to be a waiver by our stockholders of our obligation to comply with federal securities laws, rules and
regulations, and the provisions of this paragraph will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America shall be the sole and exclusive
forum. Although we believe this provision benefits us by providing increased consistency in the application of Delaware law in
the types of lawsuits to which it applies, the provision may have the effect of discouraging lawsuits against our directors and
officers. Furthermore, the enforceability of choice of forum provisions in other companies' certificates of incorporation
has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable
or unenforceable.
79
SECURITIES ELIGIBLE FOR FUTURE SALE
Immediately
after this offering, we will have 9,375,000 shares of common stock issued and outstanding, or 10,781,250 shares of common
stock if the over-allotment option is exercised in full. Of these shares, the 7,500,000 shares sold in this offering, or
8,625,000 shares if the over-allotment option is exercised in full, will be freely tradable without restriction or further
registration under the Securities Act, except for any shares purchased by one of our affiliates within the meaning of
Rule 144 under the Securities Act. All of the remaining shares are restricted securities under Rule 144, in that
they were issued in private transactions not involving a public offering. All of those shares will not be transferable except
in limited circumstances described elsewhere in this prospectus.
Rule 144
A person who has beneficially
owned restricted shares of common stock for at least six months would be entitled to sell their securities provided that (i) such
person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale
and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale. Persons
who have beneficially owned restricted shares of common stock for at least six months but who are our affiliates at the time of,
or any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would
be entitled to sell within any three-month period a number of shares that does not exceed the greater of either of the following:
•
1% of the number of shares of common stock then issued and outstanding, which will equal 93,750 shares immediately after this offering (or 107,812 shares) if the over-allotment option is exercised in full); and
•
The average weekly trading volume of the shares of common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.
Sales under Rule 144
are also limited by manner of sale provisions and notice requirements and to the availability of current public information about
us.
Restrictions on the Use of Rule 144 by Shell Companies
or Former Shell Companies
Historically, the
SEC staff had taken the position that Rule 144 is not available for the resale of securities initially issued by companies
that are, or previously were, blank check companies, like us. The SEC has codified and expanded this position in the amendments
discussed above by prohibiting the use of Rule 144 for resale of securities issued by any shell companies (other than business
combination related shell companies) or any issuer that has been at any time previously a shell company. The SEC has provided an
important exception to this prohibition, however, if the following conditions are met:
•
the issuer of the securities that was formerly a shell company has ceased to be a shell company;
•
the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
•
the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
•
at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.
As a result, it is
likely that pursuant to Rule 144, our initial stockholders will be able to sell their insider shares freely without registration
one year after we have completed our initial business combination assuming they are not an affiliate of ours at that time.
80
Registration and Stockholder Rights
The holders of our
insider shares issued and outstanding on the date of this prospectus, as well as the holders of the private warrants, will be entitled
to registration and stockholder rights pursuant to an agreement to be signed prior to or on the effective date of this offering.
The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders
of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior
to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the private warrants
can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders
have certain "piggy-back" registration rights with respect to registration statements filed subsequent to our consummation
of a business combination.
We will bear the expenses incurred in connection with the filing of any such registration statements.
Our sponsor and its related persons may not, with respect to the private warrants purchased by it, (i) have more than one
demand registration right at our expense, (ii) exercise their demand registration rights more than five (5) years from
the effective date of the registration statement of which this prospectus forms a part, and (iii) exercise their "piggy-back"
registration rights more than seven (7) years from the effective date of the registration statement of which this prospectus
forms a part, as long as our sponsor or any of its related persons are beneficial owners of private placement warrants.
In addition, pursuant
to the registration and stockholder rights agreement, our sponsor, upon consummation of an initial business combination, will be
entitled to nominate three individuals for election to our board of directors.
81
UNDERWRITING (CONFLICTS OF INTEREST)
We intend to offer
our securities described in this prospectus through the underwriters named below. LifeSci Capital is the representative for the
underwriters. We have entered into an underwriting agreement with the representative. Subject to the terms and conditions of the
underwriting agreement, each of the underwriters has severally agreed to purchase from us the number of shares listed next to its
name in the following table:
Underwriter
Number of
    Shares
LifeSci Capital
[__]
[__]
[__]
Total
7,500,000
A copy of the underwriting
agreement has been filed as an exhibit to the registration statement of which this prospectus forms a part.
Listing of our Securities
Our shares of common
stock will be quoted on Nasdaq under the symbol "LSAQ". Our shares will be listed on Nasdaq on or promptly after the
effective date of the registration statement. We cannot guarantee that our securities will continue to be listed on Nasdaq after
this offering.
Over-allotment Option
We have granted the
underwriters an option to buy up to 1,125,000 additional shares. The underwriters may exercise this option solely for the purpose
of covering over-allotments, if any, made in connection with this offering. The underwriters have 45 days from the date of this
prospectus to exercise this option. If the underwriters exercise this option, they will each purchase additional shares approximately
in proportion to the amounts specified in the table above.
Commissions and Discounts
Shares sold by the
underwriters to the public will initially be offered at the offering price set forth on the cover of this prospectus. The underwriters
will be entitled to a cash underwriting discount of $1,500,000 (or $1,725,000 if the over-allotment option is exercised in full).
[__] will receive $[__], payable out of the cash underwriting discount of $1,500,000 (or $1,725,000 if the over-allotment option
is exercised in full), for acting as a qualified independent underwriter. Any shares sold by the underwriters to securities dealers
may be sold at a discount of up to [$0.08] per share from the public offering price. If all of the shares are not sold at the initial
public offering price, the representative may change the offering price and the other selling terms. Upon execution of the underwriting
agreement, the underwriters will be obligated to purchase the shares at the prices and upon the terms stated therein, and, as a
result, will thereafter bear any risk associated with changing the offering price to the public or other selling terms.
The underwriters have
agreed to reimburse certain of our expenses. We have agreed to reimburse the underwriters for all expenses and fees related to
the review by FINRA, which will not exceed $25,000.
The following table
shows the per share and total underwriting discounts and commissions we will pay to the underwriters assuming both no exercise
and full exercise of the underwriters' over-allotment option to purchase up to an additional 1,125,000 shares.
Business Combination Marketing Agreement
We have engaged LifeSci
Capital as an advisor in connection with our business combination to assist us in holding meetings with our shareholders to discuss
the potential business combination and the target business' attributes, introduce us to potential investors that are interested
in purchasing our securities in connection with our initial business combination, assist us in obtaining shareholder approval for
the business combination and assist us with our press releases and public filings in connection with the business combination.
We will pay LifeSci Capital a cash fee for such services upon the consummation of our initial business combination in an amount
equal to 3.5% of the gross proceeds of this offering (exclusive of any applicable finders' fees which might become payable);
provided that up to 33% of the fee may be allocated in our sole discretion to other third parties who are investment banks or financial
advisory firms not participating in this offering that assist us in identifying and consummating an initial business combination.
Additionally, we will
pay LifeSci Capital a cash fee equal to 1.0% of the total consideration payable in the proposed business combination if it introduces
us to the target business with which we complete a business combination; provided that the foregoing fee will not be paid prior
to the date that is 60 days from the effective date of the registration statement of which this prospectus forms a part, unless
FINRA determines that such payment would not be deemed underwriters' compensation in connection with this offering pursuant
to FINRA Rule 5110.01(b)(2).
Per Share
Without
Over-allotment
With
Over-allotment
Public offering price
$
10.00
$
75,000,000
$
86,250,000
Discount and qualified independent underwriter fees
(1)
$
0.20
$
1,500,000
$
1,725,000
Proceeds before expenses
$
9.80
$
73,500,000
$
84,525,000
(1)
The offering expenses are estimated at $480,000.
82
Pricing of Securities
We have been advised
by the representative that the underwriters propose to offer the shares to the public at the offering price set forth on the cover
page of this prospectus.
Prior to this offering
there has been no public market for any of our securities. The public offering price of the shares was negotiated between us and
the representative. Factors considered in determining the prices and terms of the shares include:
•
the history and prospects of companies whose principal business is the acquisition of other companies;
•
prior offerings of those companies;
•
our prospects for acquiring an operating business at attractive values;
•
our capital structure;
•
the per share amount of net proceeds being placed into the trust account;
•
an assessment of our management and their experience in identifying operating companies;
•
general conditions of the securities markets at the time of the offering; and
•
other factors as were deemed relevant.
However, although
these factors were considered, the determination of our offering price is more arbitrary than the pricing of securities for an
operating company in a particular industry since the underwriters are unable to compare our financial results and prospects with
those of public companies operating in the same industry.
Regulatory Restrictions on Purchase of Securities
Rules of the
SEC may limit the ability of the underwriters to bid for or purchase our shares before the distribution of the shares is completed.
However, the underwriters may engage in the following activities in accordance with the rules:
•
Stabilizing Transactions. The underwriters may make bids or
purchases for the purpose of preventing or retarding a decline in the price of our common stock, as long as stabilizing bids do
not exceed the offering price of $10.00 and the underwriters comply with all other applicable rules.
•
Over-Allotments and Syndicate Coverage Transactions.    The
underwriters may create a short position in our common stock by selling more of our shares than are set forth on the cover page of
this prospectus up to the amount of the over-allotment option. This is known as a covered short position. The underwriters may
also create a short position in our common stock by selling more of our shares than are set forth on the cover page of this
prospectus and the shares allowed by the over-allotment option. This is known as a naked short position. If the underwriters create
a short position during the offering, the representative may engage in syndicate covering transactions by purchasing our shares
in the open market. The representative may also elect to reduce any short position by exercising all or part of the over-allotment
option. Determining what method to use in reducing the short position depends on how the shares trade in the aftermarket following
the offering. If the share price drops following the offering, the short position is usually covered with shares purchased by the
underwriters in the aftermarket. However, the underwriters may cover a short position by exercising the over-allotment option even
if the share price drops following the offering. If the share price rises after the offering, then the over-allotment option is
used to cover the short position. If the short position is more than the over-allotment option, the naked short must be covered
by purchases in the aftermarket, which could be at prices above the offering price.
•
Penalty Bids. The representative may reclaim a selling concession
from a syndicate member when the shares originally sold by the syndicate member are purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions.
83
Stabilization and
syndicate covering transactions may cause the price of our securities to be higher than they would be in the absence of these transactions.
The imposition of a penalty bid might also have an effect on the prices of our securities if it discourages resales of our securities.
Neither we nor the
underwriters make any representation or prediction as to the effect that the transactions described above may have on the price
of our securities. These transactions may occur on Nasdaq, in the over-the-counter market or on any trading market. If any of these
transactions are commenced, they may be discontinued without notice at any time.
Conflicts of Interest
LifeSci Holdings LLC,
our sponsor, is an affiliate of LifeSci Capital LLC, the representative of the underwriters in this offering, and certain of our
officers and directors are affiliated with LifeSci Capital LLC. As a result, LifeSci Capital LLC is deemed to have a "conflict
of interest" within the meaning of Rule 5121.
Accordingly, this
offering is being made in compliance with the applicable requirements of Rule 5121. Rule 5121 requires that a "qualified
independent underwriter," as defined in Rule 5121, participate in the preparation of the registration statement and
prospectus and exercise the usual standards of due diligence with respect thereto. [__] has agreed to act as a "qualified
independent underwriter" for this offering. [__] will receive $[__] for acting as a qualified independent underwriter. We
have agreed to indemnify [__] against certain liabilities incurred in connection with acting as a "qualified independent
underwriter," including liabilities under the Securities Act. In addition, no underwriter with a conflict of interest will
confirm sales to any account over which it exercises discretionary authority without the specific prior written approval of the
account holder.
Other Terms
Except as set forth
above, we are not under any contractual obligation to engage any of the underwriters to provide any services for us after this
offering, and have no present intent to do so. However, any of the underwriters may, among other things, introduce us to potential
target businesses or assist us in raising additional capital, as needs may arise in the future. If any underwriter provides services
to us after this offering, we may pay the underwriter fair and reasonable fees that would be determined at that time in an arm's
length negotiation; provided that no agreement will be entered into with the underwriter and no fees for such services will be
paid to the underwriter prior to the date which is 90 days after the date of this prospectus, unless FINRA determines that such
payment would not be deemed underwriter's compensation in connection with this offering.
In addition, LifeSci
Holdings LLC, our sponsor, has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants,"
at $0.90 per warrant for a total purchase price of $2,730,000. The private warrants will become exercisable on the later of the
completion of our initial business combination and 12 months from the closing of this offering and will expire five years after
the effective date of the registration statement of which this prospectus forms a part. Each private warrant is exercisable for
one (1) share of common stock at an exercise price of $11.50 per warrant. This purchase will take place on a private placement
basis simultaneously with the consummation of this offering. Of the $2,730,000 we will receive from the sale of the private warrants,
$1,980,000 will be used for offering expenses and $750,000 will be used for working capital. Our sponsor has also agreed that
if the over-allotment option is exercised by the underwriters, it will purchase from us at a price of $0.90 per warrant an additional
number of private warrants (up to a maximum of 250,000 private warrants) in an amount that is necessary to maintain in the
trust account $10.00 per share sold to the public in this offering. These additional private warrants will be purchased in a private
placement that will occur simultaneously with the purchase of shares resulting from the exercise of the over-allotment option.
The private warrants
have been deemed compensation by FINRA and are therefore subject to a 360-day lock-up, including the 180-day lock-up pursuant to
Rule 5110(e)(1) of the FINRA Manual from the commencement of sales of the offering. Pursuant to FINRA Rule 5110(e)(1),
these securities will not be sold during the offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject
of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities
by any person for a period of 360 days immediately following the effective date of the registration statement of which this prospectus
forms a part or commencement of sales of the public offering, except to any underwriter and selected dealer participating in the
offering and their bona fide officers, partners, registered persons and affiliates provided that all securities so transferred
remain subject to the lockup restriction above for the remainder of the time period. We have granted the holders of private warrants
the registration rights as described under the section "Securities Eligible for Future Sale — Registration and Stockholder
Rights."
84
Indemnification
We have agreed to
indemnify the underwriters against some liabilities, including civil liabilities under the Securities Act, or to contribute to
payments the underwriters may be required to make in this respect.
Resale Restrictions
We intend to distribute
our securities in the Province of Ontario, Canada (the "Canadian Offering Jurisdiction") by way of a private placement
and exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in such Canadian
Offering Jurisdiction. Any resale of our securities in Canada must be made under applicable securities laws that will vary depending
on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary
exemption granted by the applicable Canadian securities regulatory authority. Canadian resale restrictions in some circumstances
may apply to resales of interests made outside of Canada. Canadian purchasers are advised to seek legal advice prior to any resale
of our securities. We may never be a "reporting issuer", as such term is defined under applicable Canadian securities
legislation, in any province or territory of Canada in which our securities will be offered and there currently is no public market
for any of the securities in Canada, and one may never develop. Canadian investors are advised that we have no intention to file
a prospectus or similar document with any securities regulatory authority in Canada qualifying the resale of the securities to
the public in any province or territory in Canada.
Representations of Purchasers
A Canadian purchaser
will be required to represent to us and the dealer from whom the purchase confirmation is received that:
•
the purchaser is entitled under applicable provincial securities laws to purchase our securities without the benefit of a prospectus qualified under those securities laws;
•
where required by law, that the purchaser is purchasing as principal and not as agent;
•
the purchaser has reviewed the text above under Resale Restrictions; and
•
the purchaser acknowledges and consents to the provision of specified information concerning its purchase of our securities to the regulatory authority that by law is entitled to collect the information.
Rights of Action — Ontario Purchasers Only
Under Ontario securities
legislation, certain purchasers who purchase a security offered by this prospectus during the period of distribution will have
a statutory right of action for damages, or while still the owner of our securities, for rescission against us in the event that
this prospectus contains a misrepresentation without regard to whether the purchaser relied on the misrepresentation. The right
of action for damages is exercisable not later than the earlier of 180 days from the date the purchaser first had knowledge of
the facts giving rise to the cause of action and three years from the date on which payment is made for our securities. The right
of action for rescission is exercisable not later than 180 days from the date on which payment is made for our securities. If a
purchaser elects to exercise the right of action for rescission, the purchaser will have no right of action for damages against
us. In no case will the amount recoverable in any action exceed the price at which our securities were offered to the purchaser
and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, we will have no liability.
In the case of an action for damages, we will not be liable for all or any portion of the damages that are proven to not represent
the depreciation in value of our securities as a result of the misrepresentation relied upon. These rights are in addition to,
and without derogation from, any other rights or remedies available at law to an Ontario purchaser. The foregoing is a summary
of the rights available to an Ontario purchaser. Ontario purchasers should refer to the complete text of the relevant statutory
provisions.
85
Enforcement of Legal Rights
All of our directors
and officers as well as the experts named herein are located outside of Canada and, as a result, it may not be possible for Canadian
purchasers to effect service of process within Canada upon us or those persons. All of our assets and the assets of those persons
are located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada
or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.
Collection of Personal Information
If a Canadian purchaser
is resident in or otherwise subject to the securities laws of the Province of Ontario, the Purchaser authorizes the indirect collection
of personal information pertaining to the Canadian purchaser by the Ontario Securities Commission (the "OSC") and each
Canadian purchaser will be required to acknowledge and agree that the Canadian purchaser has been notified by us (i) of the
delivery to the OSC of personal information pertaining to the Canadian purchaser, including, without limitation, the full name,
residential address and telephone number of the Canadian purchaser, the number and type of securities purchased and the total purchase
price paid in respect of the securities, (ii) that this information is being collected indirectly by the OSC under the authority
granted to it in securities legislation, (iii) that this information is being collected for the purposes of the administration
and enforcement of the securities legislation of Ontario, and (iv) that the title, business address and business telephone
number of the public official in Ontario who can answer questions about the OSC's indirect collection of the information
is the Administrative Assistant to the Director of Corporate Finance, the Ontario Securities Commission, Suite 1903, Box 5520,
Queen Street West, Toronto, Ontario, M5H 3S8, Telephone: (416) 593-8086, Facsimile: (416) 593-8252.
86
LEGAL MATTERS
Loeb & Loeb
LLP, is acting as United States counsel in connection with the registration of our securities under the Securities Act and will
pass on the validity of the securities offered in the prospectus. Ellenoff Grossman & Schole LLP, is acting as counsel
for the underwriters in this offering.
EXPERTS
The financial statements
of LifeSci Acquisition II Corp. as of June 30, 2020, and for the period from December 18, 2019 (inception) through June 30,
2020 appearing in this prospectus have been audited by WithumSmith+Brown, PC, independent registered public accounting firm,
as set forth in their report thereon, appearing elsewhere in this prospectus, and are included in reliance on such report given
on the authority of such firm as an experts in auditing and accounting.
WHERE YOU CAN FIND ADDITIONAL INFORMATION
We have filed with
the SEC a registration statement on Form S-1, which includes exhibits, schedules and amendments, under the Securities Act,
with respect to this offering of our securities. Although this prospectus, which forms a part of the registration statement, contains
all material information included in the registration statement, parts of the registration statement have been omitted as permitted
by rules and regulations of the SEC. We refer you to the registration statement and its exhibits for further information about
us, our securities and this offering. The registration statement and its exhibits, as well as our other reports filed with the
SEC, can be inspected and copied at the SEC's public reference room at 100 F Street, N.E., Washington, D.C. 20549. The public
may obtain information about the operation of the public reference room by calling the SEC at 1-800-SEC-0330. In addition, the
SEC maintains a web site at
http://www.sec.gov
which contains the Form S-1 and other reports, proxy and information
statements and information regarding issuers that file electronically with the SEC.
87
LIFESCI ACQUISITION II CORP.
INDEX TO FINANCIAL STATEMENTS
Page
Report of Independent Registered Public Accounting Firm
F-2
Financial Statements:
Balance Sheet
F-3
Statement of Operations
F-4
Statement of Changes in Stockholder's Equity
F-5
Statement of Cash Flows
F-6
Notes to Financial Statements
F-7
F-
1
REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
To the Stockholder and the Board of Directors
of
LifeSci Acquisition II Corp.
Opinion on the Financial Statements
We have audited the accompanying balance
sheet of LifeSci Acquisition II Corp. (the "Company") as of June 30, 2020, the related statements of operations,
changes in stockholder's equity and cash flows for the period from December 18, 2019 (inception) through June 30,
2020, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the Company as of June 30, 2020, and the results of its
operations and its cash flows for the period from December 18, 2019 (inception) through June 30, 2020, in conformity
with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion.
/s/ WithumSmith+Brown, PC
We have served as the Company's auditor
since 2020.
New York, New York
October 14, 2020
F-
2
LIFESCI ACQUISITION II CORP.
BALANCE SHEET
JUNE 30, 2020
ASSETS
Current asset – cash
$
25,000
Deferred offering costs
28,000
TOTAL ASSETS
$
53,000
LIABILITIES AND STOCKHOLDER'S EQUITY
Current liabilities:
Accrued expenses
$
1,000
Accrued offering costs
28,000
Total Current Liabilities
29,000
Commitments and Contingencies
Stockholder's Equity
Common stock, $0.0001 par value; 5,000,000 shares authorized; 2,156,250 shares issued and outstanding
(1)
216
Additional paid-in capital
24,784
Accumulated deficit
(1,000
)
Total Stockholder's Equity
24,000
TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY
$
53,000
(1)
Includes up to 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.
The accompanying notes are an integral
part of these financial statements.
F-
3
LIFESCI ACQUISITION II CORP.
STATEMENT OF OPERATIONS
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020
Formation and operating costs
$
1,000
Net Loss
$
(1,000
)
Weighted average shares outstanding, basic and diluted
(1)
1,875,000
Basic and diluted net loss per common share
$
(0.00
)
(1)
Excludes an aggregate of up to 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.
The accompanying notes are an integral
part of these financial statements.
F-
4
LIFESCI ACQUISITION II CORP.
STATEMENT OF CHANGES IN STOCKHOLDER'S EQUITY
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020
Common Stock
Additional
Paid-in
Accumulated
Total
Stockholder's
Shares
Amount
Capital
Deficit
Equity
Balance – December 18, 2019 (inception)
—
$
—
$
—
$
—
$
—
Issuance of common stock to Sponsor
(1)
2,156,250
216
24,784
—
25,000
Net loss
—
—
—
(1,000
)
(1,000
)
Balance - June 30, 2020
2,156,250
$
216
$
24,784
$
(1,000
)
$
24,000
(1)
Includes 281,250 shares of common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.
The accompanying notes are an integral
part of these financial statements.
F-
5
LIFESCI ACQUISITION II CORP.
STATEMENT OF CASH FLOWS
FOR THE PERIOD FROM DECEMBER 18, 2019 (INCEPTION) THROUGH JUNE 30, 2020
Cash Flows from Operating Activities:
Net loss
$
(1,000
)
Changes in operating assets and liabilities:
Accrued expenses
1,000
Net cash used in operating activities
—
Cash Flows from Financing Activities:
Proceeds from issuance of common stock to Sponsor
25,000
Net cash provided by financing activities
25,000
Net Change in Cash
25,000
Cash – Beginning of period
—
Cash – End of period
$
25,000
Non-cash investing and financing activities:
Deferred offering costs included in accrued offering costs
$
28,000
The accompanying notes are an integral
part of these financial statements.
F-
6
Note 1 — Description of Organization and Business Operations
LifeSci Acquisition II Corp. (the "Company")
was incorporated in Delaware on December 18, 2019. The Company was formed for the purpose of entering into a merger, share
exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business transaction with one or
more businesses or entities that the Company has not yet identified (a "Business Combination"). Although the Company
is not limited to a particular industry or geographic region for purposes of consummating a Business Combination, the Company intends
to focus on businesses operating in North America in the healthcare industry. The Company is an early stage and emerging growth
company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.
As of June 30, 2020, the Company had
not commenced any operations. All activity through June 30, 2020 relates to the Company's formation and the proposed
initial public offering ("Proposed Public Offering"), which is described below. The Company will not generate any operating
revenues until after the completion of a Business Combination, at the earliest. The Company will generate non-operating income
in the form of interest income from the proceeds derived from the Proposed Public Offering. The Company has selected June 30
as its fiscal year end.
The Company's ability to commence
operations is contingent upon obtaining adequate financial resources through a Proposed Public Offering of 7,500,000 shares of
common stock (or 8,625,000 shares if the underwriters' over-allotment option is exercised in full) (the "Shares")
at $10.00 per Share, which is discussed in Note 3, and the sale of 3,033,333 warrants (or 3,283,333 warrants if the underwriters'
over-allotment option is exercised in full (the "Private Warrants") at a price of $0.90 per warrant in a private placement,
in a private placement to LifeSci Holdings, LLC (the "Sponsor"), an entity affiliated LifeSci Capital LLC, that will
close simultaneously with the Proposed Public Offering.
The Company's management has broad
discretion with respect to the specific application of the net proceeds of the Proposed Public Offering and the sale of the Private
Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
The Company's initial Business Combination must be with one or more target businesses that together have a fair market value
equal to at least 80% of the balance in the Trust Account (as defined below)  (net
of amounts previously released to the Company to pay its tax obligations and for working capital purposes, subject to an annual
limit of $250,000) at the time of the signing an agreement to enter into a Business Combination. The Company will only complete
a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities
of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an
investment company under the Investment Company Act of 1940, as amended, or the Investment Company Act. There is no assurance that
the Company will be able to successfully effect a Business Combination. Upon the closing of the Proposed Public Offering, management
has agreed that $10.00 per Share sold in the Proposed Public Offering and the proceeds from the sale of the Private Warrants will
be held in a trust account ("Trust Account") and invested in U.S. government securities, within the meaning set forth
in Section 2(a)(16) of the Investment Company Act, with a maturity of 183 days or less or in any open-ended investment company
that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined
by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the
funds in the Trust Account as described below.
The Company will provide its stockholders with the opportunity
to redeem all or a portion of their Shares sold in the Proposed Public Offering (the "Public Shares") upon the completion
of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or
(ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination
or conduct a tender offer will be made by the Company, solely in its discretion. The stockholders will be entitled to redeem their
shares for a pro rata portion of the amount then on deposit in the Trust Account (initially approximately $10.00 per share, plus
any pro rata interest earned on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations
or for working capital purposes). The common stock subject
to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Proposed Public
Offering, in accordance with Accounting Standards Codification ("ASC") Topic 480 "Distinguishing Liabilities
from Equity."
F-
7
The Company will proceed with a Business
Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and,
if the Company seeks stockholder approval, a majority of the outstanding shares voted are voted in favor of the Business Combination.
If a stockholder vote is not required by law and the Company does not decide to hold a stockholder vote for business or other legal
reasons, the Company will, pursuant to its Amended and Restated Certificate of Incorporation, conduct the redemptions pursuant
to the tender offer rules of the Securities and Exchange Commission ("SEC"), and file tender offer documents with
the SEC prior to completing a Business Combination. If, however, a stockholder approval of the transaction is required by law,
or the Company decides to obtain stockholder approval for business or other legal reasons, the Company will offer to redeem shares
in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company
seeks stockholder approval in connection with a Business Combination, the Sponsor and other initial stockholders (collectively,
the "Initial Stockholders") have agreed to (a) vote their Founder Shares (as defined in Note 5),  and any Public Shares held by them in favor of a Business Combination and (b) not to convert any shares
(including Founder Shares) in connection with a stockholder vote to approve a Business Combination or sell any such shares to the
Company in a tender offer in connection with a Business Combination. Additionally, each public stockholder may elect to redeem
their Public Shares irrespective of whether they vote for or against the proposed transaction.
Notwithstanding the foregoing, if the Company
seeks stockholder approval of a Business Combination and the Company does not conduct redemptions pursuant to the tender offer
rules, a stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting
in concert or as a "group" (as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act")), will be restricted from redeeming their shares with respect to more than an aggregate of 20%
of the Public Shares.
The Company will have until 24 months from
the closing of the Proposed Public Offering to consummate a Business Combination (the "Combination Period"). If the
Company is unable to complete a Business Combination within the Combination Period, the Company will (i) cease all operations
except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than five business days thereafter,
redeem 100% of the outstanding Public Shares, at a per share price, payable in cash, equal to the aggregate amount then on deposit
in the Trust Account, including interest earned (net of taxes payable), divided by the number of then outstanding Public Shares,
which redemption will completely extinguish public stockholders' rights as stockholders (including the right to receive further
liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of the remaining stockholders and the Company's board of directors, proceed to commence
a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to its obligations to provide for
claims of creditors and the requirements of applicable law. The proceeds deposited in the Trust Account could, however, become
subject to claims of creditors.
The Sponsor and Chardan Healthcare Investments
LLC have agreed to (i) waive their redemption rights with respect to Founder Shares and any Public Shares
they may acquire during or after the Proposed Public Offering in connection with the consummation of a Business Combination, (ii) to
waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares
if the Company fails to consummate a Business Combination within the Combination Period and (iii) not to propose an amendment
to the Company's Amended and Restated Certificate of Incorporation that would affect the substance or timing of the Company's
obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides
the public stockholders an opportunity to redeem their Public Shares in conjunction with any such amendment. However, the Sponsor
will be entitled to liquidating distributions with respect to any Public Shares acquired if the Company fails to consummate a Business
Combination or liquidates within the Combination Period.
In order to protect the amounts held in
the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services
rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into
a transaction agreement, reduce the amount of funds in the Trust Account to below $10.00 per share, except as to any claims by
a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account
or to any claims under the Company's indemnity of the underwriters of the Proposed Public Offering against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the "Securities Act"). Moreover, in the event
that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent
of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify
the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company's
independent registered public accounting firm), prospective target businesses or other entities with which the Company does business,
execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust
Account.
Going Concern Consideration
The Company does not have sufficient liquidity
to meet its anticipated obligations over the next year from the date of the issuance of these financial statements. In connection
with the Company's assessment of going concern considerations in accordance with FASB's Accounting Standards Update
("ASU") 2014-15, "Disclosures of Uncertainties about an Entity's Ability to Continue as a Going Concern,"
management has determined that the Company has access to funds from the Sponsor that are sufficient to fund the working capital
needs of the Company until the earlier of the consummation of the Proposed Public Offering or one year from the issuance of these
financial statements (see Note 3).
F-
8
Note 2 — Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements are
presented in in conformity with accounting principles generally accepted in the United States of America ("GAAP") and
pursuant to the rules and regulations of the SEC.
Emerging Growth Company
The Company is an "emerging growth
company," as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups
Act of 2012 (the "JOBS Act"), and it may take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required
to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved.
Further, Section 102(b)(1) of
the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards
until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not
have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting
standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements
that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt
out of such extended transition period which means that when a standard is issued or revised and it has different application dates
for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time
private companies adopt the new or revised standard. This may make comparison of the Company's financial statements with
another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using
the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of financial statements
in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of expenses during the reporting period.
Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate,
could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly
from those estimates.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents
as of June 30, 2020.
Deferred Offering Costs
Deferred offering costs consist of legal,
accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Proposed
Public Offering and that will be charged to stockholder's equity upon the completion of the Proposed Public Offering. Should
the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will
be charged to operations.
Income Taxes
The Company complies with the accounting
and reporting requirements of ASC Topic 740 "Income Taxes," which requires an asset and liability approach to financial
accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the
financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on
enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation
allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
F-
9
ASC 740 prescribes a recognition threshold
and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken
in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination
by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax
expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2020. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation
from its position.
The Company may be subject to potential
examination by federal, state and city taxing authorities in the areas of income taxes. These potential examinations may include
questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal,
state and city tax laws. The Company's management does not expect that the total amount of unrecognized tax benefits will
materially change over the next twelve months. The Company is subject to income tax examinations by major taxing authorities since
inception.
The provision for income taxes was deemed
to be de minimis for the period from December 18, 2019 (inception) through June 30, 2020.
Net Loss Per Common Share
Net loss per share is computed by dividing
net loss by the weighted average number of shares of common stock outstanding during the period, excluding shares of common stock
subject to forfeiture by the Sponsor. Weighted average shares were reduced for the effect of an aggregate of 281,250 shares of
common stock that are subject to forfeiture if the over-allotment option is not exercised by the underwriters (see Note 7). At
June 30, 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or
converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per share is the
same as basic loss per share for the period presented.
Concentration of Credit Risk
Financial instruments that potentially
subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may
exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account and management
believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments
The fair value of the Company's assets
and liabilities, which qualify as financial instruments under ASC 820, "Fair Value Measurement," approximates the carrying
amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Recent Accounting Pronouncements
Management does not believe that any recently
issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company's
financial statements.
Note 3 — Public Offering
Pursuant to the Proposed Public Offering, the Company will offer
for sale 7,500,000 Shares (or 8,625,000 Shares if the underwriters' over-allotment option is exercised in full), at a purchase
price of $10.00 per Share.
Note 4 — Private Placement
In connection with the Proposed Public
Offering, the Sponsor is expected to purchase an aggregate of 3,033,333 Private Warrants (or 3,283,333 Private Warrants if the
over-allotment option is exercised in full) at a price of $0.90 per Private Warrant for an aggregate purchase price of $2,730,000,
or $2,955,000, in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. Each Private
Warrant is exercisable to purchase  one share of common stock at an exercise price of $11.50 per warrant. per share.
If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private
Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). There will be
no redemption rights or liquidating distributions from the Trust Account with respect to the Private Warrants.
F-
10
Note 5 — Related Party Transactions
Founder Shares
On January 1, 2020, the Company issued
an aggregate of 2,156,250 shares of common stock (the "Founder Shares") to the Sponsor for an aggregate purchase price
of $25,000.  On September 30, 2020, LifeSci Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor in our
sponsor. The founder shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that the underwriters'
over-allotment option is not exercised in full or in part, with LifeSci Holdings LLC to forfeit up to 253,125 shares and Chardan Healthcare
Investments LLC to forfeit up to 28,125 shares. so that the Sponsor will
collectively own approximately 20% of the Company's issued and outstanding shares after the Proposed Public Offering (assuming
the Sponsor does not purchase any Public Shares in the Proposed Public Offering).
The Sponsor and Chardan Healthcare Investments
LLC have agreed that, subject to certain limited exceptions, 50% of the Founder Shares will not be transferred, assigned, sold
or released from escrow until the earlier of (i) six months after the date of the consummation of a Business Combination or
(ii) the date on which the closing price of the Company's shares of common stock equals or exceeds $12.50 per share
(as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading
day period commencing after a Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned,
sold or released from escrow until six months after the date of the consummation of a Business Combination, or earlier, in either
case, if, subsequent to a Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other
similar transaction which results in all of the stockholders having the right to exchange their shares of common stock for cash,
securities or other property.
Promissory Note — Related Party
On June 19, 2020, the Company issued
an unsecured promissory note to the Sponsor (the "Promissory Note"), pursuant to which the Company may borrow up to
an aggregate principal amount of $175,000. The Promissory Note is non-interest bearing and is payable within 15 days of the Sponsor
providing the Company with written notice of demand. As of June 30, 2020, there were no amounts outstanding under the Promissory
Note.
Administrative Support Agreement
The Company intends to enter into an agreement,
commencing on the effective date of the Proposed Public Offering through the earlier of the Company's consummation of a Business
Combination and its liquidation, to pay an affiliate of the Sponsor a total of $10,000 per month for office space, utilities and
secretarial support.
Related Party Loans
In order to finance transaction costs in
connection with a Business Combination, the Sponsor, an affiliate of the Sponsor, or the Company's officers and directors
may, but are not obligated to, loan the Company funds from time to time or at any time, as may be required ("Working Capital
Loans"). Each Working Capital Loan would be evidenced by a promissory note. The Working Capital Loans would be paid upon
consummation of a Business Combination, without interest or, at the lender's discretion, up to $500,000 of such Working Capital
Loans may be converted into shares of the post Business Combination entity at a price of $0.90 per warrant. In the event that a
Business Combination does not close, the Company may use a portion of the proceeds held outside the Trust Account to repay the
Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of June 30,
2020, no Working Capital Loans were outstanding.
Note 6 — Commitments and Contingencies
Risks and Uncertainties
Management is currently evaluating the
impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have
a negative effect on the Company's financial position, results of its operations, close of the Proposed Public Offering and/or
search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty. _
F-
11
Registration and Stockholder Rights
The holders of the Founder Shares and the
Private Warrants and any shares that may be issued upon conversion of Working Capital Loans (and all underlying securities) will
be entitled to registration and stockholder rights pursuant to a registration and stockholder rights agreement to be signed prior
to or on the effective date of the Proposed Public Offering. The holders of a majority of these securities are entitled to make
up to two demands that the Company register such securities. The holders of the majority of the Founders Warrants can elect to exercise
these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be
released from escrow. The holders of a majority of the Private Warrants can elect to exercise these registration rights at any
time after the Company consummates a Business Combination. In addition, the holders have certain "piggy-back" registration
rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will
bear the expenses incurred in connection with the filing of any such registration statements. The Sponsor and its related persons
may not, with respect to the Private Warrants purchased by it, (i) have more than one demand registration right at the Company's
expense, (ii) exercise their demand registration rights more than five (5) years from the effective date of the registration
statement of the Proposed Public Offering, and (iii) exercise their "piggy-back" registration rights more than
seven (7) years from the effective date of the Proposed Public Offering, as long as the Sponsor or any of its related persons
are beneficial owners of Private Warrants.
Underwriting Agreement
The Company will grant the underwriters a 45-day option from
the date of the Proposed Public Offering to purchase up to 1,125,000 additional Shares to cover over-allotments, if any, at the
Proposed Public Offering price less the underwriting discounts and commissions.
The underwriters will be entitled to a cash underwriting discount
of $0.20 per Share, or $1,500,000 in the aggregate (or $1,725,000 if the over-allotment option is exercised in full), payable upon
the closing of the Proposed Public Offering.
Note 7 — Stockholder's Equity
Common
Stock
— The Company is authorized to issue 5,000,000 shares of common stock with a par value of $0.0001 per
share. The Company plans on filing an Amended and Restated Certificate of Incorporation prior to the closing date of the Proposed
Public Offering such that the Company will increase the number of shares of common stock authorized to be issued. Holders of the
Company's common stock are entitled to one vote for each share. At June 30, 2020, there were 2,156,250 shares of common
stock issued and outstanding, of which 281,250 shares are subject to forfeiture to the extent that the underwriters' over-allotment
option is not exercised in full so that the Sponsor will own 20% of the issued and outstanding shares after the Proposed Public
Offering (assuming the Sponsor do not purchase any Public Shares in the Proposed Public Offering).
Warrants
—The Private Warrants will become exercisable at any time commencing on the later of (1) one year after
the closing of the Proposed Public Offering or (2) the consummation of a Business Combination; provided that the Company has
an effective and current registration statement covering the shares of common stock issuable upon the exercise of the Public Warrants
and a current prospectus relating to such shares of common stock.
The Private Warrants purchased by the Sponsor
will be exercisable on a cashless basis and not be exercisable more than five years from the commencement of sales of the Proposed
Public Offering, in accordance with FINRA Rule 5110(g)(8)(A), as long as the Sponsor or any of its related persons beneficially
own these Private Warrants.
Note 8 — Subsequent Events
The Company evaluated subsequent
events and transactions that occurred after the balance sheet date up to October 14, 2020, the date that the financial
statements were available to be issued. Based upon this review, the Company did not identify
any subsequent events, other than described in Note 5, that would have required adjustment or disclosure in the financial statements.
F-
12
Until [·], 2020 (25 days after the
date of this prospectus), all dealers that buy, sell or trade our shares of common stock, whether or not participating in this
offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus
when acting as underwriters and with respect to their unsold allotments or subscriptions.
No dealer, salesperson or any other person
is authorized to give any information or make any representations in connection with this offering other than those contained in
this prospectus and, if given or made, the information or representations must not be relied upon as having been authorized by
us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any security other than the securities
offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by anyone in any jurisdiction
in which the offer or solicitation is not authorized or is unlawful.
$75,000,000
LifeSci Acquisition II Corp.
7,500,000 Shares of Common Stock
PRELIMINARY PROSPECTUS
Sole Book-Running Manager
LifeSci Capital
[__], 2020
The information in this
prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.
PRELIMINARY PROSPECTUS
SUBJECT TO COMPLETION, DATED 
    OCTOBER 14, 2020
$75,000,000
LIFESCI ACQUISITION II CORP.
7,500,000 SHARES OF COMMON STOCK
This prospectus has
been prepared for and will be used by LifeSci Capital ("LifeSci") in connection with offers and sales of our shares
of common stock in certain market making transactions effected from time to time for 30 days following the date of this prospectus.
These transactions may occur in the open market or may be privately negotiated at prevailing market prices at the time of sales,
at prices related thereto or at negotiated prices. We will not receive any proceeds of such transactions. LifeSci has no obligation
to make a market in our shares, and may discontinue such activities at any time without notice, at its sole discretion. All such
transactions with respect to our securities that are made pursuant to a prospectus after the date of this prospectus are being
made solely pursuant to this prospectus, as it may be supplemented from time to time.
There is presently
no public market for our common stock. We intend to apply to have our common stock listed on the Nasdaq Capital Market, or Nasdaq,
under the symbol "LSAQ" on or promptly after the date of this prospectus. We cannot guarantee that our securities will
be approved for listing on Nasdaq. We cannot assure you that our securities will continue to be listed on Nasdaq after this offering.
We are an "emerging
growth company" as defined in the Jumpstart Our Business Startups Act of 2012 and will therefore be subject to reduced public
company reporting requirements.
Investing in our
securities involves a high degree of risk. See "Risk Factors" beginning on page 18 of this prospectus for a discussion
of information that should be considered in connection with an investment in our securities.
Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
Sole Book-Running Manager
LifeSci Capital
[__], 2020
A-
1
LIFESCI ACQUISITION II CORP.
TABLE OF CONTENTS
Page
SUMMARY
1
SUMMARY FINANCIAL DATA
17
RISK FACTORS
18
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
38
USE OF PROCEEDS
39
DIVIDEND POLICY
42
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
45
PROPOSED BUSINESS
49
MANAGEMENT
66
PRINCIPAL STOCKHOLDERS
73
CERTAIN TRANSACTIONS
75
DESCRIPTION OF SECURITIES
77
SECURITIES ELIGIBLE FOR FUTURE SALE
82
PLAN OF DISTRIBUTION
84
LEGAL MATTERS
89
EXPERTS
89
WHERE YOU CAN FIND ADDITIONAL INFORMATION
89
INDEX TO FINANCIAL STATEMENTS
F-1
A-
2
The Offering
In making your decision
on whether to invest in our securities, you should take into account not only the backgrounds of the members of our management
team, but also the special risks we face as a blank check company and the fact that this offering is not being conducted in compliance
with Rule 419 promulgated under the Securities Act. You will not be entitled to protections normally afforded to investors
in Rule 419 blank check offerings. You should carefully consider these and the other risks set forth in the section below
entitled "Risk Factors" beginning on page 18 of this prospectus.
Listing of our securities and proposed symbol
We anticipate that the shares of common stock will be listed on Nasdaq under the symbol "LSAQ".
A-
3
Offering proceeds to be held in trust
$75,000,000 of the net proceeds of
        this offering (or $86,250,000 if the over-allotment option is exercised in full), including $2,730,000 (or $2,955,000 if the
        over-allotment option is exercised in full) we will receive from the sale of the private warrants, or $10.00 per share sold
        to the public in this offering will be placed in a trust account in the United States, maintained by Continental
        Stock Transfer & Trust Company, acting as trustee pursuant to an agreement to be signed on the date of this
        prospectus. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full) we will receive from the sale
        of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) be used for offering
        expenses and $750,000 will be used for working capital.
Except as set forth below, the proceeds
        in the trust account will not be released until the earlier of: (1) the completion of an initial business combination within
        the required time period and (2) our redemption of 100% of the outstanding public shares if we have not completed a business
        combination in the required time period. Therefore, unless and until our initial business combination is consummated, the proceeds
        held in the trust account will not be available for our use for any expenses related to this offering or expenses which we may
        incur related to the investigation and selection of a target business and the negotiation of an agreement to acquire a target business.
Notwithstanding the foregoing, there can be released to us,
from time to time, (i) any interest earned on the funds in the trust account that we may need to pay our tax obligations and
(ii) any remaining interest earned on the funds in the trust account up to $250,000 annually that we need for our working
capital requirements. With this exception, expenses incurred by us may be paid prior to a business combination only from the net
proceeds of this offering not held in the trust account of approximately $750,000 provided, however, that in order to meet our
working capital needs following the consummation of this offering if the funds not held in the trust account are insufficient,
our initial stockholders, officers and directors or their affiliates may, but are not obligated to, loan us funds, from time to
time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory
note. The notes would either be paid upon consummation of our initial business combination, without interest, or, at the lender's
discretion, up to $500,000 of the notes may be converted upon consummation of our business combination into additional private
warrants at a conversion price of $0.90 per private warrant. Such private warrants will be identical to the private warrants to
be issued at the closing of this offering. Our directors have approved the issuance of the private warrants upon conversion of
such notes, to the extent the holder wishes to so convert them at the time of the consummation of our initial business combination.
If we do not complete a business combination, the loans will only be repaid with funds not held in the trust account, to the extent
available.
A-
4
Limited payments to insiders
Prior to the consummation of a
business combination, there will be no fees, reimbursements or other cash payments paid to our initial stockholders, officers,
directors or their affiliates prior to, or for any services they render in order to effectuate, the consummation of a business
combination (regardless of the type of transaction that it is) other than:
•         payment of $10,000 per month to an affiliate of LifeSci Holdings
LLC for office space and related services, subject to deferral as described herein;
•         repayment
        of loans which may be made by our insiders, officers, directors or any of its or their affiliates to finance transaction costs
        in connection with an initial business combination, the terms of which have not been determined;
•         reimbursement
        of out-of-pocket expenses incurred by them in connection with certain activities on our behalf, such as identifying and investigating
        possible business targets and business combinations; and
•         repayment
        upon consummation of our initial business combination of any loans which may be made by our initial stockholders or their affiliates
        or our officers and directors to finance transaction costs in connection with an intended initial business combination.
There is no limit on the amount of out-of-pocket
        expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in
        the trust account and the interest income earned on the amounts held in the trust account available to us, such expenses would
        not be reimbursed by us unless we consummate an initial business combination. Our audit committee will review and approve all reimbursements
        and payments made to any initial stockholder or member of our management team, or their respective affiliates, and any reimbursements
        and payments made to members of our audit committee will be reviewed and approved by our board of directors, with any interested
        director abstaining from such review and approval.
Potential revisions to agreements with insiders
We could seek to amend certain agreements made by our management team disclosed in this prospectus without the approval of stockholders, although we have no intention to do so. For example, restrictions on our executives relating to the voting of securities owned by them, the agreement of our management team to remain with us until the closing of a business combination, the obligation of our management team to not propose certain changes to our organizational documents or the obligation of the management team and its affiliates to not receive any compensation in connection with a business combination could be modified without obtaining stockholder approval. Although stockholders would not be given the opportunity to redeem their shares in connection with such changes, in no event would we be able to modify the redemption or liquidation rights of our stockholders without permitting our stockholders the right to redeem their shares in connection with any such change. We will not agree to any such changes unless we believed that such changes were in the best interests of our stockholders (for example, if such a modification were necessary to complete a business combination).
A-
5
Stockholder approval of, or tender offer in connection with, initial business combination
W
e have agreed not to enter into a definitive agreement regarding an initial business combination without the prior consent of our sponsor.
In connection with any proposed initial business combination, we will either (1) seek stockholder approval of such initial business combination at a meeting called for such purpose at which public stockholders may seek to convert their public shares, regardless of whether they vote for or against the proposed business combination, into their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable) or (2) provide our public stockholders with the opportunity to sell their public shares to us by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the trust account (net of taxes payable), in each case subject to the limitations described herein. Notwithstanding the foregoing, our initial stockholders have agreed, pursuant to written letter agreements with us, not to convert any public shares held by them into their pro rata share of the aggregate amount then on deposit in the trust account. If we determine to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its public shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that we are unable to satisfy any applicable closing condition set forth in the definitive agreement related to our initial business combination, or we are unable to maintain net tangible assets of at least $5,000,001, we will not consummate such initial business combination. The decision as to whether we will seek stockholder approval of a proposed business combination or will allow stockholders to sell their shares to us in a tender offer will be made by us based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval. If we provide stockholders with the opportunity to sell their shares to us by means of a tender offer, we will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial business combination as is required under the SEC's proxy rules. If we seek stockholder approval of our initial business combination, we will consummate the business combination only if a majority of the outstanding shares of common stock voted are
voted in favor of the business combination.
A-
6
We have determined not to consummate any business combination unless we have net tangible assets of at least $5,000,001 upon such consummation in order to avoid being subject to Rule 419 promulgated under the Securities Act. However, if we seek to consummate an initial business combination with a target business that imposes any type of working capital closing condition or requires us to have a minimum amount of funds available from the trust account upon consummation of such initial business combination, our net tangible asset threshold may limit our ability to consummate such initial business combination (as we may be required to have a lesser number of shares redeemed) and may force us to seek third party financing which may not be available on terms acceptable to us or at all. As a result, we may not be able to consummate such initial business combination and we may not be able to locate another suitable target within the applicable time period, if at all.
Our initial stockholders have agreed (A) to vote their
founder shares and any public shares in favor of any proposed business combination, (B) not to propose, or vote in favor of,
prior to and unrelated to an initial business combination, an amendment to our certificate of incorporation that would affect the
substance or timing of our redemption obligation to redeem all public shares if we cannot complete an initial business combination
within 24 months unless we provide public stockholder an opportunity to redeem their public shares in conjunction with any such
amendment, (C) not to convert any shares (including the founder shares) into the right to receive cash from the trust account
in connection with a stockholder vote to approve our proposed initial business combination or sell any shares to us in a tender
offer in connection with our proposed initial business combination, and (D) that the founder shares shall not participate
in any liquidating distribution upon winding up if a business combination is not consummated. None of our initial stockholders
or their affiliates has indicated any intention to purchase public shares in this offering or shares of common stock in the open
market or in private transactions. However, if a significant number of stockholders vote, or indicate an intention to vote, against
a proposed business combination, our initial stockholders, officers, directors or their affiliates could make such purchases in
the open market or in private transactions in order to influence the vote. Our initial stockholders, officers, directors and their
affiliates could purchase sufficient shares so that the initial business combination may be approved without the majority vote
of public shares held by non-affiliates. Notwithstanding the foregoing, our officers, directors, initial stockholders and their
affiliates will not make purchases of shares of common stock if the purchases would violate Section 9(a)(2) or Rule 10b-5
of the Exchange Act, which are rules designed to stop potential manipulation of a company's stock or purchasing shares
when the buyer is in possession of material non-public information about the Company.
A-
7
Conditions to completing our initial business combination
We have agreed not to enter into a definitive
agreement regarding an initial business combination without the prior consent of our sponsor. Further, there is no limitation
on our ability to raise funds privately or through loans in connection with our initial business combination. Our initial business
combination must occur with one or more target businesses that together have an aggregate fair market value of at least 80% of
the value of the trust account (excluding any taxes payable on the income earned on the trust account) at the time of the agreement
to enter into the initial business combination. If we are no longer listed on Nasdaq, we will not be required to satisfy the 80%
test.
If our board is not able to independently
        determine the fair market value of the target business or businesses, we may obtain an opinion from an independent investment banking
        or accounting firm as to the fair market value of the target business. We will complete our initial business combination only if
        the post-transaction company in which our public stockholders own shares will own or acquire 50% or more of the outstanding voting
        securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
        as an investment company under the Investment Company Act. Even if the post-transaction company owns 50% or more of the voting
        securities of the target, our stockholders prior to the business combination may collectively own a minority interest in the post
        business combination company, depending on valuations ascribed to the target and us in the business combination transaction. If
        less than 100% of the equity interests or assets of a target business or businesses are owned or acquired by the post-transaction
        company, the portion of such business or businesses that is owned or acquired is what will be valued for purposes of the 80% test,
        provided that in the event that the business combination involves more than one target business, the 80% test will be based on
        the aggregate value of all of the target businesses.
Conversion rights
In connection with any stockholder meeting
        called to approve a proposed initial business combination, each public stockholder will have the right, regardless of whether he,
        she or it is voting for or against such proposed business combination, to demand that we convert his, her or its public shares
        into a
pro rata
share of the trust account upon consummation of the business combination.
We may require public stockholders wishing
        to exercise conversion rights, whether they are a record holder or hold their shares in "street name," to either tender
        the certificates they are seeking to convert to our transfer agent or to deliver the shares they are seeking to convert to the
        transfer agent electronically using Depository Trust Company's DWAC (Deposit/Withdrawal At Custodian) System, at the holder's
        option, at any time at or prior to the vote on the business combination. There is a nominal cost associated with this tendering
        process and the act of certificating the shares or delivering them through the DWAC System. The transfer agent will typically charge
        the tendering broker $45 and it would be up to the broker whether or not to pass this cost on to the converting holder. However,
        this fee would be incurred regardless of whether or not we require holders to deliver their shares prior to the vote on the business
        combination in order to exercise conversion rights. This is because a holder would need to deliver shares to exercise conversion
        rights regardless of the timing of when such delivery must be effectuated. However, in the event we require stockholders to deliver
        their shares prior to the vote on the proposed business combination and the proposed business combination is not consummated, this
        may result in an increased cost to stockholders. The conversion rights will include the requirement that a beneficial holder must
        identify itself in order to validly redeem its shares.
A-
8
Under Delaware law, we may be required
        to give a minimum of only ten days' notice for each general meeting. As a result, if we require public stockholders who wish
        to convert their shares of common stock into the right to receive a
pro rata
portion of the funds in the trust account to
        comply with the foregoing delivery requirements, holders may not have sufficient time to receive the notice and deliver their shares
        for conversion. Accordingly, investors may not be able to exercise their conversion rights and may be forced to retain our securities
        when they otherwise would not want to.
If we require public stockholders who wish
        to convert their shares of common stock to comply with specific delivery requirements for conversion described above and such proposed
        business combination is not consummated, we will promptly return such certificates to the tendering public stockholders.
Release of funds in trust account upon closing of our initial business combination
On the completion of our initial business combination, all amounts held in the trust account will be released to us. We will use these funds to pay amounts due to any public stockholders who exercise their conversion rights as described above under "— Conversion rights" to pay all or a portion of the consideration payable to the target or targets or owners of the target or targets of our initial business combination and to pay other expenses associated with our initial business combination. If our initial business combination is paid for using stock or debt securities, or not all of the funds released from the trust account are used for payment of the consideration in connection with our initial business combination, we may apply the balance of the cash released to us from the trust account for general corporate purposes, including for maintenance or expansion of operations of post-transaction businesses, the payment of principal or interest due on indebtedness incurred in completing our initial business combination, to fund the purchase of other companies or for working capital.
Liquidation if no business combination
If we are unable to complete our initial business combination
within 24 months from the closing of this offering, we will (i) cease all operations except for the purpose of winding up,
(ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public
shares (including any public shares in this offering or any public shares that our initial stockholders or their affiliates purchased
in this offering or later acquired in the open market or in private transactions), which redemption will completely extinguish
public stockholders' rights as stockholders (including the right to receive further liquidation distributions, if any), subject
to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of our
remaining holders of common stock and our board of directors, proceed to commence a voluntary liquidation and thereby a formal
dissolution of the Company, subject (in the case of (ii) and (iii) above) to our obligations to provide for claims of
creditors and the requirements of applicable law.
A-
9
In connection with our redemption of 100%
        of our outstanding public shares for a portion of the funds held in the trust account, each holder will receive a full pro rata
        portion of the amount then in the trust account, plus any pro rata interest earned on the funds held in the trust account and not
        necessary to pay our taxes payable on such funds.
We may not have funds sufficient to pay
        or provide for all creditors' claims. Although we will seek to have all third parties (including any vendors or other entities
        we engage after this offering) and any prospective target businesses enter into valid and enforceable agreements with us waiving
        any right, title, interest or claim of any kind in or to any monies held in the trust account, there is no guarantee that they
        will execute such agreements. There is also no guarantee that the third parties would not challenge the enforceability of these
        waivers and bring claims against the trust account for monies owed them.
The holders of the founder shares, private warrants will not
participate in any redemption distribution with respect to their founder shares, private warrants, but may have any public shares
redeemed upon liquidation.
If we are unable to conclude our initial
        business combination and we expend all of the net proceeds of this offering not deposited in the trust account, without taking
        into account any interest earned on the trust account, we expect that the initial per-share redemption price will be approximately
        $10.00. The proceeds deposited in the trust account could, however, become subject to claims of our creditors that are in preference
        to the claims of our stockholders. Furthermore, our underwriters may seek recourse against the proceeds in the trust account relating
        to any future claims they may have against us. In addition, if we are forced to file a bankruptcy case or an involuntary bankruptcy
        case is filed against us that is not dismissed, the proceeds held in the trust account could be subject to applicable bankruptcy
        law, and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our
        stockholders. Therefore, the actual per-share redemption price may be less than approximately $10.00. We will pay the costs of
        any subsequent liquidation from our remaining assets outside of the trust account. If such funds are insufficient, our sponsor
        has agreed to pay the funds necessary to complete such liquidation and has agreed not to seek repayment for such expenses. We currently
        do not anticipate that such funds will be insufficient.
Afilliation
LifeSci owns shares of our common stock. Additionally, certain
of our initial stockholders, officers and directors are affiliated with LifeSci.
A-
10
USE OF PROCEEDS
This prospectus is delivered in connection with the offer and
sale of our shares of common stock by LifeSci in certain market making transactions. We will not receive any of the proceeds from
these transactions.
A-
11
PLAN OF DISTRIBUTION
This prospectus has
been prepared for use by LifeSci in connection with offers and sales of our common stock in certain market making transactions
effected from time to time for 30 days following the date of this prospectus. LifeSci may act as principals in these transactions.
These sales will be made at prevailing market prices at the time of sale, at prices related thereto or at negotiated prices. We
will not receive any of the proceeds of these transactions.
LifeSci, through our
sponsor, owns 1,910,625 shares of common stock (88.6% of our outstanding shares of common stock). Additionally officers and directors
of LifeSci own shares of common stock. In addition, LifeSci Holdings LLC, our sponsor, has committed to purchase from us an aggregate
of 3,033,333 warrants (or 3,283,333 warrants if the over-allotment option is exercised in full), or "private warrants,"
at $0.90 per warrant for a total purchase price of $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full).
The private warrants will become exercisable on the later of the completion of our initial business combination and 12 months from
the closing of this offering and will expire five years after the effective date of the registration statement of which this prospectus
forms a part.
We agreed to file
a "market making" prospectus in order to allow LiefSci to engage in market making activities for our shares for 30
days following the date of this prospectus. LifeSci acted as sole book-running manager in our recently completed initial public
offering of securities. Purchases and sales in the open market by LifeSci may include short sales, purchases to cover short positions,
which may include purchases pursuant to the over-allotment option and stabilizing purchases, in accordance with Regulation M under
the Exchange Act. Purchases to cover short positions and stabilizing purchases, as well as other purchases by LifeSci for its own
account, may have the effect of preventing or retarding a decline in the market price of the shares. It may also cause the price
of the shares to be higher than the price that would otherwise exist in the open market in the absence of these transactions. LifeSci
may conduct these transactions in the over-the-counter market or otherwise. If LifeSci commences any of these transactions, it
may discontinue them at any time.
We have been advised by LifeSci that, following our initial
public offering, it intends to engage in market making transactions for our common stock as permitted by applicable laws and regulations.
However, LifeSci is not obligated to do so and LifeSci may discontinue its market making activities at any time without notice.
In addition, such market making activity will be subject to the limits imposed by the Securities Act and the Exchange Act. Accordingly,
no assurance can be given as to the liquidity of the trading market for our common stock, that you will be able to sell any of
our shares held by you at a particular time or that the prices that you receive when you sell will be favorable. See "Risk
Factors — There is currently no market for our securities and a market for our securities may not develop, which
would adversely affect the liquidity and price of our securities."
We have agreed to
indemnify LifeSci in our initial public offering against certain liabilities, including liabilities under the Securities Act, or
to contribute to payments LifeSci may be required to make because of any of those liabilities.
We are not under any
contractual obligation to engage LifeSci to provide any services for us after our initial public offering, and have no present
intent to do so. However, LifeSci may introduce us to potential target businesses or assist us in raising additional capital in
the future. If LifeSci provides services to us in the future, we may pay LifeSci fair and reasonable fees that would be determined
at that time in an arm's length negotiation; provided that no agreement will be entered into with LifeSci and no fees for
such services will be paid to LifeSci prior to the date that is 90 days from the date of this prospectus, unless FINRA determines
that such payment would not be deemed underwriters' compensation in connection with our initial public offering and we may
pay LifeSci or any entity with which it is affiliated a finder's fee or other compensation for services rendered to us in
connection with the completion of an initial business combination.
LifeSci and its affiliates
may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our
affiliates, for which it may in the future receive, customary fees and commissions for any such transactions.
In addition, in the
ordinary course of its business activities, LifeSci and its affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for its own
account and for the accounts of its customers. Such investments and securities activities may involve securities and/or instruments
of ours or our affiliates. LifeSci and its affiliates may also make investment recommendations and/or publish or express independent
research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.
A-
12
Until
[
·
], 2020 (25 days after the date of this prospectus), all dealers that
buy, sell or trade our shares of common stock, whether or not participating in this offering, may be required to deliver a prospectus.
This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their
unsold allotments or subscriptions.
No dealer, salesperson
or any other person is authorized to give any information or make any representations in connection with this offering other than
those contained in this prospectus and, if given or made, the information or representations must not be relied upon as having
been authorized by us. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any security other
than the securities offered by this prospectus, or an offer to sell or a solicitation of an offer to buy any securities by anyone
in any jurisdiction in which the offer or solicitation is not authorized or is unlawful.
$75,000,000
LifeSci Acquisition II Corp.
7,500,000
Shares of Common Stock
PRELIMINARY PROSPECTUS
Sole Book-Running Manager
LifeSci Capital
[__], 2020
A-
13
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 13. Other Expenses of Issuance and Distribution.
The estimated expenses
payable by us in connection with the offering described in this registration statement (other than the underwriting discount and
commissions) will be as follows:
Initial Trustees' fee
$
6,500
SEC Registration Fee
9,410
FINRA filing fee
13,438
Accounting fees and expenses
40,000
Nasdaq listing fees
50,000
Printing and engraving expenses
20,000
Legal fees and expenses
225,000
Miscellaneous
115,652
Total
$
480,000
Item 14. Indemnification of Directors and Officers.
Our certificate of
incorporation provides that all directors, officers, employees and agents of the registrant shall be entitled to be indemnified
by us to the fullest extent permitted by Section 145 of the Delaware General Corporation Law.
Section 145 of
the Delaware General Corporation Law concerning indemnification of officers, directors, employees and agents is set forth below.
Section 145.
Indemnification of officers, directors, employees and agents; insurance.
(a) A corporation
shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the
right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership,
joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid
in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted
in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation,
and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person's conduct was unlawful.
The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere
or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the
person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal
action or proceeding, had reasonable cause to believe that the person's conduct was unlawful.
(b) A corporation
shall have power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or
completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the
person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against
expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement
of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed
to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of
Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication
of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery or such other court shall deem proper.
II-
1
(c) To the extent
that a present or former director or officer of a corporation has been successful on the merits or otherwise in defense of any
action, suit or proceeding referred to in subsections (a) and (b) of this section, or in defense of any claim, issue
or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably
incurred by such person in connection therewith.
(d) Any indemnification
under subsections (a) and (b) of this section (unless ordered by a court) shall be made by the corporation only as authorized
in the specific case upon a determination that indemnification of the present or former director, officer, employee or agent is
proper in the circumstances because the person has met the applicable standard of conduct set forth in subsections (a) and
(b) of this section. Such determination shall be made, with respect to a person who is a director or officer at the time of
such determination, (1) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though
less than a quorum, or (2) by a committee of such directors designated by majority vote of such directors, even though less
than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written
opinion, or (4) by the stockholders.
(e) Expenses
(including attorneys' fees) incurred by an officer or director in defending any civil, criminal, administrative or investigative
action, suit or proceeding may be paid by the corporation in advance of the final disposition of such action, suit or proceeding
upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined
that such person is not entitled to be indemnified by the corporation as authorized in this section. Such expenses (including attorneys'
fees) incurred by former officers and directors or other employees and agents may be so paid upon such terms and conditions, if
any, as the corporation deems appropriate.
(f) The indemnification
and advancement of expenses provided by, or granted pursuant to, the other subsections of this section shall not be deemed exclusive
of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement,
vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as
to action in another capacity while holding such office. A right to indemnification or to advancement of expenses arising under
a provision of the certificate of incorporation or a bylaw shall not be eliminated or impaired by an amendment to such provision
after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative action,
suit or proceeding for which indemnification or advancement of expenses is sought, unless the provision in effect at the time of
such act or omission explicitly authorizes such elimination or impairment after such action or omission has occurred.
(g) A corporation
shall have power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent
of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred
by such person in any such capacity, or arising out of such person's status as such, whether or not the corporation would
have the power to indemnify such person against such liability under this section.
(h) For purposes
of this section, references to "the corporation" shall include, in addition to the resulting corporation, any constituent
corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence
had continued, would have had power and authority to indemnify its directors, officers, and employees or agents, so that any person
who is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or
other enterprise, shall stand in the same position under this section with respect to the resulting or surviving corporation as
such person would have with respect to such constituent corporation if its separate existence had continued.
(i) For purposes
of this section, references to "other enterprises" shall include employee benefit plans; references to "fines"
shall include any excise taxes assessed on a person with respect to any employee benefit plan; and references to "serving
at the request of the corporation" shall include any service as a director, officer, employee or agent of the corporation
which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit
plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to
be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner
 "not opposed to the best interests of the corporation" as referred to in this section.
II-
2
(j) The indemnification
and advancement of expenses provided by, or granted pursuant to, this section shall, unless otherwise provided when authorized
or ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit
of the heirs, executors and administrators of such a person.
(k) The Court
of Chancery is hereby vested with exclusive jurisdiction to hear and determine all actions for advancement of expenses or indemnification
brought under this section or under any bylaw, agreement, vote of stockholders or disinterested directors, or otherwise. The Court
of Chancery may summarily determine a corporation's obligation to advance expenses (including attorneys' fees).
Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant
to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection
with the securities being registered, we will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by it is against public policy
as expressed in the Securities Act and will be governed by the final adjudication of such issue.
In accordance with
Section 102(b)(7) of the DGCL, our certificate of incorporation, will provide that no director shall be personally liable
to us or any of our stockholders for monetary damages resulting from breaches of their fiduciary duty as directors, except to the
extent such limitation on or exemption from liability is not permitted under the DGCL unless they violated their duty of loyalty
to the Company or its stockholders, acted in bad faith, knowingly or intentionally violated the law, authorized unlawful payments
of dividends, unlawful stock purchases or unlawful redemptions, or derived improper personal benefit from their actions as directors.
The effect of this provision of our certificate of incorporation is to eliminate our rights and those of our stockholders (through
stockholders' derivative suits on our behalf) to recover monetary damages against a director for breach of the fiduciary
duty of care as a director, including breaches resulting from negligent or grossly negligent behavior, except, as restricted by
Section 102(b)(7) of the DGCL. However, this provision does not limit or eliminate our rights or the rights of any stockholder
to seek non-monetary relief, such as an injunction or rescission, in the event of a breach of a director's duty of care.
If the DGCL is amended
to authorize corporate action further eliminating or limiting the liability of directors, then, in accordance with our certificate
of incorporation, the liability of our directors to us or our stockholders will be eliminated or limited to the fullest extent
authorized by the DGCL, as so amended. Any repeal or amendment of provisions of our certificate of incorporation limiting or eliminating
the liability of directors, whether by our stockholders or by changes in law, or the adoption of any other provisions inconsistent
therewith, will (unless otherwise required by law) be prospective only, except to the extent such amendment or change in law permits
us to further limit or eliminate the liability of directors on a retroactive basis.
Our certificate of
incorporation will also provide that we will, to the fullest extent authorized or permitted by applicable law, indemnify our current
and former officers and directors, as well as those persons who, while directors or officers of our corporation, are or were serving
as directors, officers, employees or agents of another entity, trust or other enterprise, including service with respect to an
employee benefit plan, in connection with any threatened, pending or completed proceeding, whether civil, criminal, administrative
or investigative, against all expense, liability and loss (including, without limitation, attorney's fees, judgments, fines,
ERISA excise taxes and penalties and amounts paid in settlement) reasonably incurred or suffered by any such person in connection
with any such proceeding. Notwithstanding the foregoing, a person eligible for indemnification pursuant to our certificate of incorporation
will be indemnified by us in connection with a proceeding initiated by such person only if such proceeding was authorized by our
board of directors, except for proceedings to enforce rights to indemnification.
The right to indemnification
conferred by our certificate of incorporation is a contract right that includes the right to be paid by us the expenses incurred
in defending or otherwise participating in any proceeding referenced above in advance of its final disposition, provided, however,
that if the DGCL requires, an advancement of expenses incurred by our officer or director (solely in the capacity as an officer
or director of our corporation) will be made only upon delivery to us of an undertaking, by or on behalf of such officer or director,
to repay all amounts so advanced if it is ultimately determined that such person is not entitled to be indemnified for such expenses
under our certificate of incorporation or otherwise.
II-
3
The rights to indemnification
and advancement of expenses will not be deemed exclusive of any other rights which any person covered by our certificate of incorporation
may have or hereafter acquire under law, our certificate of incorporation, our bylaws, an agreement, vote of stockholders or disinterested
directors, or otherwise.
Any repeal or amendment
of provisions of our certificate of incorporation affecting indemnification rights, whether by our stockholders or by changes in
law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective only,
except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive basis,
and will not in any way diminish or adversely affect any right or protection existing at the time of such repeal or amendment or
adoption of such inconsistent provision with respect to any act or omission occurring prior to such repeal or amendment or adoption
of such inconsistent provision. Our certificate of incorporation will also permit us, to the extent and in the manner authorized
or permitted by law, to indemnify and to advance expenses to persons other that those specifically covered by our certificate of
incorporation.
Our bylaws, which
we intend to adopt immediately prior to the closing of this offering, include the provisions relating to advancement of expenses
and indemnification rights consistent with those set forth in our certificate of incorporation. In addition, our bylaws provide
for a right of indemnity to bring a suit in the event a claim for indemnification or advancement of expenses is not paid in full
by us within a specified period of time. Our bylaws also permit us to purchase and maintain insurance, at our expense, to protect
us and/or any director, officer, employee or agent of our corporation or another entity, trust or other enterprise against any
expense, liability or loss, whether or not we would have the power to indemnify such person against such expense, liability or
loss under the DGCL.
Any repeal or amendment
of provisions of our bylaws affecting indemnification rights, whether by our board of directors, stockholders or by changes in
applicable law, or the adoption of any other provisions inconsistent therewith, will (unless otherwise required by law) be prospective
only, except to the extent such amendment or change in law permits us to provide broader indemnification rights on a retroactive
basis, and will not in any way diminish or adversely affect any right or protection existing thereunder with respect to any act
or omission occurring prior to such repeal or amendment or adoption of such inconsistent provision.
We will enter into
indemnity agreements with each of our officers and directors a form of which is filed as Exhibit 10.6 to this Registration
Statement. These agreements will require us to indemnify these individuals to the fullest extent permitted under Delaware law and
to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.
Pursuant to the Underwriting
Agreement filed as Exhibit 1.1 to this Registration Statement, we have agreed to indemnify the Underwriters and the Underwriters
have agreed to indemnify us against certain civil liabilities that may be incurred in connection with this offering, including
certain liabilities under the Securities Act.
Item 15. Recent Sales of Unregistered Securities.
•
On January 1, 2020, our sponsor purchased 2,156,250 shares,
which we refer to herein as "founder shares" or "insider shares," for an aggregate purchase price of $25,000.
On September 30, 2020, LifeSci Holdings LLC transferred 215,625 founder shares to Chardan Healthcare Investments LLC, an investor
in our sponsor. The founder shares include an aggregate of up to 281,250 shares that are subject to forfeiture to the extent that
the underwriters' over-allotment option is not exercised in full or in part. Because these offers and sales were made to
a single purchaser in a transaction not involving a public offering, the shares were issued in reliance on the exemption from registration
contained in Section 4(a)(2) of the Securities Act.
•
LifeSci Holdings LLC, our sponsor,
has committed to purchase from us an aggregate of 3,033,333 warrants, or "private warrants," at $0.90 per warrant for
a total purchase price of $2,730,000.
Each private warrant is exercisable for one (1) share of common stock at an exercise
price of $11.50 per warrant. The private warrants will become exercisable on the later of the completion of our initial business
combination and 12 months from the closing of this offering and will expire five years after the effective date of the registration
statement of which this prospectus forms a part. This purchase will take place on a private placement basis simultaneously with
the consummation of this offering. Our sponsor has also agreed that if the over-allotment option is exercised by the underwriters,
it will purchase from us at a price of $0.90 per warrant an additional number of private warrants (up to a maximum of 250,000 private
warrants) in an amount that is necessary to maintain in the trust account $10.00 per share sold to the public in this offering.
These additional private warrants will be purchased in a private placement that will occur simultaneously with the purchase of
shares resulting from the exercise of the over-allotment option. Because this offer and sale is being made to a single purchaser,
the sale does not involve a public offering and is being made in reliance on the exemption from registration contained in Section 4(a)(2) of
the Securities Act. Of the $2,730,000 (or $2,955,000 if the over-allotment option is exercised in full) we will receive from the
sale of the private warrants, $1,980,000 (or $2,205,000 if the over-allotment option is exercised in full) will be used for offering
expenses and $750,000 will be used for working capital.
No underwriting discounts
or commissions were paid with respect to such sales.
II-
4
Item 16. Exhibits and Financial Statement Schedules.
(a)     The
following exhibits are filed as part of this Registration Statement:
Exhibit No.
Description
1.1*
Form of Underwriting Agreement.
1.2*
Form of Business Combination Marketing Agreement.
3.1*
Certificate of Incorporation.
3.2*
Form of Amended and Restated Certificate of Incorporation.
3.3*
Bylaws.
4.1*
Specimen Common Stock Certificate.
4.2*
Form of Warrant Agreement.
5.1*
Form of Opinion of Loeb & Loeb LLP.
10.1*
Form of Letter Agreement among the Registrant, LifeSci Holdings LLC and the Company's officers, directors and stockholders.
10.2*
Form of Investment Management Trust Agreement between Continental Stock Transfer & Trust Company and the Registrant.
10.3*
Form of Escrow Agreement between the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders.
10.4*
Form of Registration Rights Agreement among the Registrant and the Initial Stockholders and Continental Stock Transfer & Trust Company.
10.5*
Subscription Agreement, dated January 1, 2020, between the Registrant and LifeSci Holdings LLC.
10.6*
Form of Private Placement Warrant Subscription Agreement between the Registrant and LifeSci Holdings LLC.
10.7*
Form of Administrative Support Agreement.
14*
Form of Code of Ethics.
23.1
Consent of WithumSmith+Brown, P.C.
23.2*
Consent of Loeb & Loeb LLP (included in Exhibit 5.2).
24*
Power of Attorney (included on the signature page of the original filing hereof).
99.1*
Form of Audit Committee Charter.
99.2*
Form of Nominating Committee Charter.
99.3*
Form of Compensation Committee Charter.
99.4*
Consent of Thomas Wynn.
99.5*
Consent of Thomas Mathers.
99.6*
Consent of Graham Walmsley.
99.7*
Consent of Elizabeth Barrett.
99.8*
Consent of Scott Janssen.
*        To be filed
by amendment.
Item 17. Undertakings.
(a)
The undersigned registrant hereby undertakes to provide
to the underwriters at the closing specified in the underwriting agreements, certificates in such denominations and registered
in such names as required by the underwriter to permit prompt delivery to each purchaser.
(b)
Insofar as indemnification for liabilities arising under
the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such
issue.
II-
5
(c)     The
undersigned registrant hereby undertakes that:
(1) For the purpose
of determining liability under the Securities Act of 1933 to any purchaser, if the registrant is subject to Rule 430C, each
prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration
statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or
deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will,
as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior
to such date of first use.
(2) For the purpose
of determining liability of a registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities,
the undersigned registrant undertakes that in a primary offering of securities of an undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or
sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser
and will be considered to offer or sell such securities to such purchaser:
(i) Any preliminary
prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
(ii) Any free writing
prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by an undersigned
registrant;
(iii) The portion
of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and
(iv) Any other communication
that is an offer in the offering made by the undersigned registrant to the purchaser.
(d)     The
undersigned registrant hereby undertakes that:
(1)
For purposes of determining any liability under the Securities
Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon
Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or
497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared
effective.
(2)
For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
II-
6
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of New York, on the 14th day of October, 2020.
LIFESCI ACQUISITION II CORP.
By:
/s/ Andrew McDonald
Name:
Andrew McDonald
Title:
Chief Executive Officer
POWER OF ATTORNEY
KNOW ALL MEN BY THESE
PRESENTS, that each person whose signature appears below constitutes and appoints Andrew McDonald his or her true and lawful attorney-in-fact,
with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities
to sign any and all amendments including post-effective amendments to this registration statement, and to file the same, with all
exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and
confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the
dates indicated.
Name
Position
Date
/s/ Andrew McDonald
Chairman and Chief Operating Officer
October 14, 2020
Andrew McDonald
(Principal executive officer) and Director
/s/ David Dobkin
Chief Financial Officer (Principal financial and
October 14, 2020
David Dobkin
accounting officer), Head of Strategy and Director
/s/ Michael Rice
Chief Operating Officer (Principal financial and Director
October 14, 2020
Michael Rice
II-
7